

GenCore version 5.1.4.p5.4578
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: February 14, 2003, 07:50:34 ; Search time 621.5 Seconds

(without alignments)
4354.885 Million cell updates/sec

Title: US-09-091-605-2

Sequence: 1 CATGCTGAGAGGACCTTTAC.....GGCTGGTGAAGGCCGAGGA 93

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapept 1.0

Searched: 2054640 seqs, 14551402878 residues

Total number of hits satisfying chosen parameters: 4109280

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Database :

Listing first 45 summaries

GenEmbl:*

1: gb_da:*

2: gb_htg:*

3: gb_in:*

4: gb_om:*

5: gb_ov:*

6: gb_pat:*

7: gb_ph:*

8: gb_pl:*

9: gb_pr:*

10: gb_ro:*

11: gb_sts:*

12: gb_sy:*

13: gb_un:*

14: gb_vi:*

15: em_ba:*

16: em_fun:*

17: em_hum:*

18: em_in:*

19: em_mu:*

20: em_om:*

21: em_or:*

22: em_ov:*

23: em_pat:*

24: em_ph:*

25: em_pl:*

26: em_ro:*

27: em_sts:*

28: em_un:*

29: em_vi:*

30: em_htg_hum:*

31: em_htg_inv:*

32: em_htg_other:*

33: em_htg_mus:*

34: em_htg_pln:*

35: em_htg_rnd:*

36: em_htg_mam:*

37: em_htg_vrt:*

38: em_sy:*

39: em_htgo_hum:*

40: em_htgo_mus:*

41: em_htgo_other:*

Pred. No. is the number of results predicted by chance to have a

score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	93	100.0	396	6 AX147675	AX147675 Sequence
2	93	100.0	528	6 AR030615	AR030615 Sequence
3	93	100.0	528	6 AR168153	AR168153 Sequence
4	93	100.0	528	6 E05860	E05860 DNA encodin
5	93	100.0	559	6 AF529185	AF529185 Ovis arie
6	93	100.0	955	6 AR108107	AR108107 Sequence
7	93	100.0	955	6 AR108109	AR108109 Sequence
8	93	100.0	1062	9 HUMGLUC	J04040 Human gluc
9	93	100.0	1108	4 B005278	K00107 Bovine panc
10	93	100.0	1154	6 BC005278	BC005278 Homo sapi
11	93	100.0	2356	6 AR108119	AR108119 Sequence
12	93	100.0	6455	9 HSGIUC	V01515 Human gene
13	93	100.0	10050	9 HSGIUCG2	X03991 Human gluc
14	93	100.0	163681	9 AC007750	AC007750 Homo sapi
15	91.4	98.3	528	6 AR030614	AR030614 Sequence
16	91.4	98.3	528	6 AR168152	AR168152 Sequence
17	91.4	98.3	1123	4 AF308439	AF308439 Canis fam
18	88.8	95.5	1053	10 GPIGG	D00014 Cavia porce
19	86.6	93.1	1104	10 OC0GLU	M57688 Octodon deg
20	83.4	89.7	277	10 RATGLU4	K02811 Rat glucago
21	83.4	89.7	895	6 AR108106	AR108106 Sequence
22	83.4	89.7	1034	6 A31421	A31421 H.sapiens m
23	83.4	89.7	1102	10 BC012975	BC012975 Mus muscu
24	83.4	89.7	182906	2 AC111919	AC111919 Rattus no
25	83.4	89.7	210317	2 AC115074	AC115074 Mus muscu
26	83.4	89.7	219014	2 AC024141	AC024141 Mus muscu
27	81.8	88.0	668	10 NMPPROGLG	Z46845 M.musculus
28	81.8	88.0	1116	10 AF276754	AF276754 Mus muscu
29	80.8	86.9	144	6 AR030619	AR030619 Sequence
30	80.8	86.9	144	6 AR168157	AR168157 Sequence
31	79	84.9	106	11 GA2680	G42680 GCG Bovine
32	78.6	84.5	1118	10 HAMGG	J00059 Syrian hams
33	72.2	77.6	1186	5 S78477	S78477 proglucagon
34	72.2	77.6	1576	5 GEPPEG	Y07539 Chicken mRN
35	72.2	77.6	1576	6 E03593	E03593 DNA encodin
36	65.8	70.8	1050	5 HSU7612	U77612 Heloderma s
37	65.8	70.8	1196	5 HSU7611	U77611 Heloderma s
38	63.2	68.0	315	6 I07551	I07551 Sequence 40
39	50	53.8	1408	5 AF004432	AF004432 Xenopus 1
40	49.8	51.2	1290	5 AR077755	AR077755 Sequence
41	47.6	51.2	1290	5 AF004433	AF004433 Xenopus 1
42	46	49.5	1300	5 AF324209	AF324209 Hoplobatr
43	45.6	49.0	493	5 LAGI01	V00632 Lophius ame
44	41.4	44.5	383	5 OMU19913	U19913 Oncorhynch
45	41.4	44.5	383	5 OTU19920	U19920 Oncorhynch

ALIGNMENTS

RESULT 1
AX147675
LOCUS AX147675
DEFINITION Sequence 2 from Patent WO0136643.
ACCESSION AX147675
VERSION AX147675.1 GI:14346730
KEYWORDS
SOURCE
ORGANISM
synthetic construct.
synthetic construct
artificial sequences.
REFERENCE
Trecu,D.A., Concio,M.F. and Dugway,S.J.
1 (bases 1 to 396)
TITLE Nucleic acid construct for optimized production of products
JOURNAL Patent: WO 0136643-A 2 25-MAY-2001.
TRANSMARKOTIC THERAPIES, INC. (US)

FEATURES
source

Location/Qualifiers
1..396
/organism="synthetic construct"
/db_xref="taxon:32630"
/note="synthesized nucleotide"

BASE COUNT
81 a 111 c 121 g 83 t

ORIGIN

Query Match
Best Local Similarity 100.0%; Score 93; DB 6; Length 396;
Matches 93; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CATGCTGAAGGACCTTTACCAAGTATGTTCTTATTGGAAGGCCAAGCTGCCAAG 60
|||||
DB 286 CATGCTGAAGGACCTTTACCAAGTATGTTCTTATTGGAAGGCCAAGCTGCCAAG 345
|||||

QY 61 GAATTCATTGCTTGGCTGTGAAGGCCGAGGA 93
|||||

DB 346 GAATTCATTGCTTGGCTGTGAAGGCCGAGGA 378
|||||

RESULT 2
AR030615
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source

AR030615
Sequence 8 from patent US 5861284.
AR030615
AR030615.1 GI:5943829
Unknown.
Unknown.
Unclassified.
1 (bases 1 to 528)
Nishimura,O., Kuriyama,M., Koyama,N. and Fukuda,T.
Method for producing a biologically active recombinant
cysteine-free parathyroid hormone (1-34)
Patent: US 5861284-A 8 19-JAN-1999;
Location/Qualifiers
1..528
/organism="unknown"

BASE COUNT
142 a 121 c 143 g 122 t

ORIGIN

Query Match
Best Local Similarity 100.0%; Score 93; DB 6; Length 528;
Matches 93; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CATGCTGAAGGACCTTTACCAAGTATGTTCTTATTGGAAGGCCAAGCTGCCAAG 60
|||||
DB 1 CATGCTGAAGGACCTTTACCAAGTATGTTCTTATTGGAAGGCCAAGCTGCCAAG 60
|||||

QY 61 GAATTCATTGCTTGGCTGTGAAGGCCGAGGA 93
|||||

DB 61 GAATTCATTGCTTGGCTGTGAAGGCCGAGGA 93
|||||

RESULT 3
AR168153
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source

AR168153
Sequence 8 from patent US 6287806.
AR168153
AR168153.1 GI:17903977
Unknown.
Unknown.
Unclassified.
1 (bases 1 to 528)
Nishimura,O., Kuriyama,M., Koyama,N. and Fukuda,T.
Method for producing a biologically active recombinant
cysteine-free peptide
Patent: US 6287806-A 8 11-SEP-2001;
Location/Qualifiers
1..528
/organism="unknown"

BASE COUNT
142 a 121 c 143 g 122 t

ORIGIN

Query Match
Best Local Similarity 100.0%; Score 93; DB 6; Length 528;
Matches 93; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CATGCTGAAGGACCTTTACCAAGTATGTTCTTATTGGAAGGCCAAGCTGCCAAG 60
|||||
DB 1 CATGCTGAAGGACCTTTACCAAGTATGTTCTTATTGGAAGGCCAAGCTGCCAAG 60
|||||

QY 61 GAATTCATTGCTTGGCTGTGAAGGCCGAGGA 93
|||||

DB 61 GAATTCATTGCTTGGCTGTGAAGGCCGAGGA 93
|||||

RESULT 4
E05860
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT

E05860
DNA encoding fusion protein comprising glucagon-like peptide 1 and
fibroblast growth factor.
E05860
E05860.1 GI:2174047
JP 1993304976-A/3.
synthetic construct.
synthetic construct.
artificial sequences.
1 (bases 1 to 528)
Nishimura,T., Koyama,N., Kuriyama,M. and Fukuda,T.
PRODUCTION OF PEPTIDE
Patent: JP 1993304976-A 3 19-NOV-1993;
TAKEDA CHEM IND LTD
OS Artificial gene
OC Artificial sequence; Genes.
OS Homo sapiens (human)
PN JP 1993304976-A/3
PD 19-NOV-1993
PF 18-FEB-1992 JP 1992030635
PR 19-FEB-1991 JP 91P 24841, 18-OCT-1991 JP 91P 271438, PR
24-OCT-1991 JP 91P 277724
PI NISHIMURA TADASHI, KOYAMA NOBUYUKI, KURIYAMA MASARO, PI
FUKUDA TSUNEHIKO
PC C12P21/00,C07K15/00,C12N15/00//C12N15/18,C12N15/62,C12P21/02,
PC C12P21/00,
PC C12R1:19),(C12P21/02,C12R1:19);
CC strandedness: Double;
CC topology: Linear;
CC hypothetical: No;
CC anti-sense: No;
FH Key
FH Location/Qualifiers
FT CDS
FT 1..528
FT /product="fusion protein comprising internal
FT fragment of
FT glucagon-like peptide 1 and partial fragment
FT of fibroblast
FT growth factor"
FT replace(96,'T')
FT /product="internal fragment of glucagon-like
FT peptide 1"
FT 97..528
FT /product="partial fragment of fibroblast FT
FT growth factor".
FT Location/Qualifiers

source 1..528
/organism="synthetic construct"
/db_xref="taxon:32630"
BASE COUNT 142 a 122 c 143 g 121 t
ORIGIN

Query Match 100.0%; Score 93; DB 6; Length 528;
Best Local Similarity 100.0%; Pred. No. 1.2e-21;
Matches 93; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CATGCTGAAGGACCTTACAGTATGTTCTTATTGGAAGGCCAAGTGCAG 60
|||||
Db 1 CATGCTGAAGGACCTTACAGTATGTTCTTATTGGAAGGCCAAGTGCAG 60
QY 61 GAATTCATTGCTTGGCTGTGTAAGGCCGAGGA 93
|||||
Db 61 GAATTCATTGCTTGGCTGTGTAAGGCCGAGGA 93

RESULT 5
AF529185 559 bp mRNA linear MAM 13-AUG-2002
LOCUS AF529185
DEFINITION Ovis aries preproglucagon mRNA, partial cds.
ACCESSION AF529185
VERSION AF529185.1 GI:22212831
KEYWORDS
SOURCE sheep.
ORGANISM Ovis aries
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
Bovidae; Caprinae; Ovis.
1 (bases 1 to 559)
Characterization of the endocrine pancreas in an ovine placental
insufficiency IUGR fetus

REFERENCE
AUTHORS Limesand, S.W. and Hay, W.W. Jr.
TITLE Unpublished
JOURNAL 2 (bases 1 to 559)
AUTHORS Limesand, S.W. and Hay, W.W. Jr.
TITLE Direct Submission
JOURNAL Submitted (15-JUL-2002) Pediatrics, University of Colorado Health
Sciences Center, 4200 E 9th Ave, Denver, CO 80262, USA
FEATURES
source location/Qualifiers
1..559
/organism="Ovis aries"
/db_xref="taxon:9940"
/tissue_type="pancreas"
/dev_stage="fetal"
1..30
31..>559
/codon_start=1
/product="preproglucagon"
/protein_id="AA04409.1"
/db_xref="GI:22212831"
/translation="MKSLEYVAGLLVLAAGSQWHSLONTSEKSSFPAPOTDPLGDP
DOISEDKRHSQGFSTSDYSKLDSRRADQFVOMNTKRNKNNIAKRHDEFERHAECT
FTSDVSSYLEGOAKERFTLAVLKGRGRDRPEEVNIVEELRRRHADGSFDEMTVLD
SLATRDFNLMLQTKI"

BASE COUNT 160 a 137 c 138 g 124 t
ORIGIN

Query Match 100.0%; Score 93; DB 4; Length 559;
Best Local Similarity 100.0%; Pred. No. 1.2e-21;
Matches 93; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CATGCTGAAGGACCTTACAGTATGTTCTTATTGGAAGGCCAAGTGCAG 60
|||||
Db 322 CATGCTGAAGGACCTTACAGTATGTTCTTATTGGAAGGCCAAGTGCAG 381
QY 61 GAATTCATTGCTTGGCTGTGTAAGGCCGAGGA 93
|||||
Db 382 GAATTCATTGCTTGGCTGTGTAAGGCCGAGGA 414

RESULT 6
AR108107 955 bp DNA linear PAT 14-FEB-2001
LOCUS AR108107
DEFINITION Sequence 57 from patent US 6110707.
ACCESSION AR108107
VERSION AR108107.1 GI:12823594
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
AUTHORS 1 (bases 1 to 955)
Newgard, C.B., Halban, P., Normington, K.D., Clark, S.A., Thigpen, A.E.,
Quade, C., Kruse, F. and McGarry, D.
TITLE Recombinant expression of proteins from secretory cell lines
JOURNAL Patent: US 6110707-A 57 29-AUG-2000;
FEATURES
source location/Qualifiers
1..955
/organism="unknown"

BASE COUNT 301 a 181 c 203 g 270 t
ORIGIN
Query Match 100.0%; Score 93; DB 6; Length 955;
Best Local Similarity 100.0%; Pred. No. 1.2e-21;
Matches 93; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CATGCTGAAGGACCTTACAGTATGTTCTTATTGGAAGGCCAAGTGCAG 60
|||||
Db 318 CATGCTGAAGGACCTTACAGTATGTTCTTATTGGAAGGCCAAGTGCAG 377
QY 61 GAATTCATTGCTTGGCTGTGTAAGGCCGAGGA 93
|||||
Db 378 GAATTCATTGCTTGGCTGTGTAAGGCCGAGGA 410

RESULT 7
AR108109 955 bp DNA linear PAT 14-FEB-2001
LOCUS AR108109
DEFINITION Sequence 60 from patent US 6110707.
ACCESSION AR108109
VERSION AR108109.1 GI:12823596
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
AUTHORS 1 (bases 1 to 955)
Newgard, C.B., Halban, P., Normington, K.D., Clark, S.A., Thigpen, A.E.,
Quade, C., Kruse, F. and McGarry, D.
TITLE Recombinant expression of proteins from secretory cell lines
JOURNAL Patent: US 6110707-A 60 29-AUG-2000;
FEATURES
source location/Qualifiers
1..955
/organism="unknown"

BASE COUNT 302 a 180 c 202 g 271 t
ORIGIN
Query Match 100.0%; Score 93; DB 6; Length 955;
Best Local Similarity 100.0%; Pred. No. 1.2e-21;
Matches 93; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CATGCTGAAGGACCTTACAGTATGTTCTTATTGGAAGGCCAAGTGCAG 60
|||||
Db 318 CATGCTGAAGGACCTTACAGTATGTTCTTATTGGAAGGCCAAGTGCAG 377
QY 61 GAATTCATTGCTTGGCTGTGTAAGGCCGAGGA 93
|||||
Db 378 GAATTCATTGCTTGGCTGTGTAAGGCCGAGGA 410

RESULT 8
HUMGLUC 1062 bp mRNA linear PRI 08-NOV-1994
LOCUS HUMGLUC
DEFINITION Human glucagon mRNA, complete cds.
ACCESSION J04040

VERSION J04040.1 GI:183269
 KEYWORDS glucocorticoid
 SOURCE Human (neonate) brainstem, cDNA to mRNA, clones BS13,A,B].
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
 REFERENCE 1 (bases 1 to 1062)
 AUTHORS Drucker,D.J. and Asa,S.
 TITLE Glucagon gene expression in vertebrate brain
 JOURNAL J. Biol. Chem. 263 (27), 13475-13478 (1988)
 MEDLINE 88330860
 PUBMED 2901414
 FEATURES
 source
 location/Qualifiers
 1..1062
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /map="2q36-q37"
 1..1062
 /gene="GCG"
 /gene="GCG"
 <1..1062
 /gene="GCG"
 /product="GCG mRNA"
 38..580
 /gene="GCG"
 /note="preproglucagon"
 /codon_start=1
 /protein_id="AA52567.1"
 /db_xref="GI:183270"
 /db_xref="GDB:G00-119-265"
 /translation="MKSIFYVAGLFYMLVQGSNQRSIQNTTEKSSSFPAQOTPLDLP
 DQINDEKRRHSGQFTSDYSKYLDNRADPFVQWLMNTRNNINAKRHDEPERHAEGT
 FTSVSSYLEGQAAKEFLIWLKGRGRDPPEEVAIVEELRRHADGSPSDENMTYLD
 NLARDFINMLIQTKITDRK"
 38..97
 /gene="GCG"
 /note="glucagon signal peptide"
 98..304
 /gene="GCG"
 /product="glucocorticoid"
 194..280
 /gene="GCG"
 /product="glucagon"
 287..304
 /gene="GCG"
 /product="glucagon"
 311..421
 /product="intervening peptide I"
 /gene="GCG"
 /product="glucagon-like peptide I"
 428..466
 /gene="GCG"
 /product="glucagon-like peptide II"
 473..571
 /gene="GCG"
 /product="glucagon-like peptide II"
 200 c 215 g 307 t
 BASE COUNT 340 a
 ORIGIN 81 bp upstream of RsaI site; chromosome 2q36-q37.
 Query Match 100.0%; Score 93; DB 9; Length 1062;
 Best Local Similarity 100.0%; Pred. No. 1.2e-21;
 Matches 93; Conservativity 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 CATGCTGAAGGACCTTTACCACTGATGTAAGTTCTATTGGAGGCCAAGCTGCCAAG 60
 DB 329 CATGCTGAAGGACCTTTACCACTGATGTAAGTTCTATTGGAGGCCAAGCTGCCAAG 388
 QY 61 GAATTCATTGCTGCTGGCTGGAAGGCCGAGGA 93
 DB 389 GAATTCATTGCTGCTGGCTGGAAGGCCGAGGA 421
 RESULT 9
 BOYGG BOYGG 1108 bp mRNA linear MAR 27-APR-1993

DEFINITION Bovine pancreas preproglucagon mRNA.
 ACCESSION K00107
 VERSION K00107.1 GI:163081
 KEYWORDS glucocorticoid; glucagon; hormone.
 SOURCE Bovine cDNA to pancreatic mRNA.
 ORGANISM Bos taurus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
 Bovidae; Bovinae; Bos.
 REFERENCE 1 (bases 1 to 1108)
 AUTHORS Lopez,L.C., Frazier,M.L., Su,C.J., Kumar,A. and Saunders,G.F.
 TITLE Mammalian pancreatic preproglucagon contains three glucagon-related
 peptides
 JOURNAL Proc. Natl. Acad. Sci. U.S.A. 80 (18), 5485-5489 (1983)
 MEDLINE 8329996
 PUBMED 6577439
 FEATURES
 source
 location/Qualifiers
 1..1108
 /organism="Bos taurus"
 /db_xref="taxon:9913"
 91..633
 /gene="GCG"
 /note="preproglucagon"
 /codon_start=1
 /protein_id="AAA30538.1"
 /db_xref="GI:163082"
 /translation="MKSIFYVAGLFYMLVQGSNQRSIQNTTEKSSSFPAQOTPLDLP
 DQINDEKRRHSGQFTSDYSKYLDNRADPFVQWLMNTRNNINAKRHDEPERHAEGT
 FTSVSSYLEGQAAKEFLIWLKGRGRDPPEEVAIVEELRRHADGSPSDENMTYLD
 SLATRDFINMLIQTKITDRK"
 232 c 213 g 307 t
 BASE COUNT 356 a
 ORIGIN 232 c 213 g 307 t
 Query Match 100.0%; Score 93; DB 4; Length 1108;
 Best Local Similarity 100.0%; Pred. No. 1.2e-21;
 Matches 93; Conservativity 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 CATGCTGAAGGACCTTTACCACTGATGTAAGTTCTATTGGAGGCCAAGCTGCCAAG 60
 DB 382 CATGCTGAAGGACCTTTACCACTGATGTAAGTTCTATTGGAGGCCAAGCTGCCAAG 441
 QY 61 GAATTCATTGCTGCTGGCTGGAAGGCCGAGGA 93
 DB 442 GAATTCATTGCTGCTGGCTGGAAGGCCGAGGA 474
 RESULT 10
 BC005278
 LOCUS BC005278 1154 bp mRNA linear PRI 12-JUL-2001
 DEFINITION Homo sapiens, glucagon, clone MGC:12325 IMAGE:3950435, mRNA,
 complete cds.
 ACCESSION BC005278
 VERSION BC005278.1 GI:13528971
 KEYWORDS MGC.
 SOURCE Homo sapiens.
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
 REFERENCE 1 (bases 1 to 1154)
 AUTHORS Strausberg,R.
 TITLE Direct Submission
 JOURNAL Submitted (27-MAR-2001) National Institutes of Health, Mammalian
 Gene Collection (MGC), Cancer Genomics Office, National Cancer
 Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590,
 USA
 REMARK NIH-MGC Project URL: <http://mgc.nci.nih.gov>
 CONTACT Contact: MGC help desk
 EMAIL Email: cgapbs-remail.nih.gov
 TISSUE Tissue Procurement: CLOUTRECH
 CDNA CDNA Library Preparation: CLOUTRECH Laboratories, Inc.
 DNA DNA Sequencing by: Sequencing Group at the Stanford Human Genome
 Center, Stanford University School of Medicine, Stanford, CA 94305
 WEB Web site: <http://www.shgc.stanford.edu>

Contact: (Dickson, Mark) mcdexpi1.stanford.edu
Dickson, M., Schmutz, J., Grimwood, J., Rodriguez, A., and Myers, R. M.

Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LINL at: <http://image.lnl.gov>
Series: IRAL Plate: 16 Row: k Column: 10
This clone was selected for full length sequencing because it passed the following selection criteria: matched mRNA gi: 4503944.

FEATURES

source

1..1154

CDS

/organism="Homo sapiens"
/db_xref="taxon:9606"
/db_xref="locusID:2641"
/clone="MGC:12325 IMAGE:3950435"
/tissue_type="Pancreas"
/clone_lib="NIH_MGC_78"
/lab_host="DH10B"
/note="Vector: pDNR-LIB"
100..642
/codon_start=1
/product="glucagon"
/protein_id="AAH05278.1"
/db_xref="GI:13528972"
/translation="MKSIFYVAGLFVWLVOGWSORSLQDTEKSRFSASQADPLSDP
DOMNEDKRHSQGTFTSDYSKYLDSRRADFPQWMTNKKRNRIAKRHDEPERHAGT
FTSDVSSYLEGQAAKEFTLAVKGRGRDRPDEVALVEELGRHAGDSFDEMTIILD
NLARDFTNMLIQRTIDR"

BASE COUNT

391 a 218 c 226 g 319 t

ORIGIN

Query Match 100.0%; Score 93; DB 9; Length 1154;
Best Local Similarity 100.0%; Pred. No. 1.2e-21;
Matches 93; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY

1 CATGCTGAAGGACCTTTACAGTATGATTTCTTATTGGAAGGCCAAGTCCCAAG 60

DB

391 CATGCTGAAGGACCTTTACAGTATGATTTCTTATTGGAAGGCCAAGTCCCAAG 450

QY

61 GAATTCATTGCTTGGCTGTGAAGGCCGAGGA 93

DB

451 GAATTCATTGCTTGGCTGTGAAGGCCGAGGA 483

RESULT 11

ARI08119

LOCUS

DEFINITION

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

TITLE

JOURNAL

FEATURES

SOURCE

BASE COUNT

ORIGIN

Query Match

Best Local Similarity

Matches

93; Conservative

0; Mismatches

0; Indels

0; Gaps

0;

QY

1 CATGCTGAAGGACCTTTACAGTATGATTTCTTATTGGAAGGCCAAGTCCCAAG 60

DB

1704 CATGCTGAAGGACCTTTACAGTATGATTTCTTATTGGAAGGCCAAGTCCCAAG 1763

QY 61 GAATTCATTGCTTGGCTGTGAAGGCCGAGGA 93
DB 1764 GAATTCATTGCTTGGCTGTGAAGGCCGAGGA 1796

RESULT 12

HSGIUC

LOCUS

DEFINITION

KEYWORDS

SOURCE

ORGANISM

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

TITLE

JOURNAL

MEDLINE

PUBMED

COMMENT

FEATURES

SOURCE

CDS

QY

1 CATGCTGAAGGACCTTTACAGTATGATTTCTTATTGGAAGGCCAAGTCCCAAG 60

DB

3698 CATGCTGAAGGACCTTTACAGTATGATTTCTTATTGGAAGGCCAAGTCCCAAG 3757

QY

61 GAATTCATTGCTTGGCTGTGAAGGCCGAGGA 93

DB

3758 GAATTCATTGCTTGGCTGTGAAGGCCGAGGA 3790

RESULT 13

HSGIUCG2

Query Match

Best Local Similarity

Matches

93; Conservative

0; Mismatches

0; Indels

0; Gaps

0;

QY

1 CATGCTGAAGGACCTTTACAGTATGATTTCTTATTGGAAGGCCAAGTCCCAAG 60

DB

3698 CATGCTGAAGGACCTTTACAGTATGATTTCTTATTGGAAGGCCAAGTCCCAAG 3757

QY

61 GAATTCATTGCTTGGCTGTGAAGGCCGAGGA 93

DB

3758 GAATTCATTGCTTGGCTGTGAAGGCCGAGGA 3790

RESULT 13

HSGIUCG2

Query Match

Best Local Similarity

Matches

93; Conservative

0; Mismatches

0; Indels

0; Gaps

0;

QY

1 CATGCTGAAGGACCTTTACAGTATGATTTCTTATTGGAAGGCCAAGTCCCAAG 60

DB

3698 CATGCTGAAGGACCTTTACAGTATGATTTCTTATTGGAAGGCCAAGTCCCAAG 3757

QY

61 GAATTCATTGCTTGGCTGTGAAGGCCGAGGA 93

DB

3758 GAATTCATTGCTTGGCTGTGAAGGCCGAGGA 3790

RESULT 13

HSGIUCG2

Query Match

Best Local Similarity

Matches

93; Conservative

0; Mismatches

0; Indels

0; Gaps

0;

LOCUS HSLGUCG2 10050 bp DNA linear PRI 20-APR-1995
 DEFINITION Human glucagon gene.
 ACCESSION X03991
 VERSION X03991.1 GI:31786
 KEYWORDS glucagon; glucagon-like peptide; hormone; preproglucagon;
 preprohormone; signal peptide.
 SOURCE Homo sapiens.
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
 REFERENCE 1 (bases 1 to 10050)
 AUTHORS White,J.W. and Saunders,G.F.
 TITLE Structure of the human glucagon gene
 JOURNAL Nucleic Acids Res. 14 (12), 4719-4730 (1986)
 MEDLINE 86259053
 PUBMED 3725587
 COMMENT See also <HSLGUC; V01515> which is derived from the same library.
 Sequence discrepancies may indicate that the two clones represent
 different alleles or may be due to cloning artefacts. pos. 3516 in
 <X03991> corresponds to pos. 9 in <V01515> (the first eight
 nucleotides of which are probably a cloning artefact).
 FEATURES
 source
 location/Qualifiers
 1..10050
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /clone-lib="fetal liver genomic DNA"
 complement(535..538)
 /note="CAAT-box (complementary strand)"
 577..581
 /note="TATA-box"
 603..698
 /note="exon 1; untranslated leader (5' UT-region)"
 699..3665
 /note="intron I"
 3666..3766
 /note="exon 2"
 join(3675..3766,5339..5500,7177..7314,8683..8826,
 9481..9487)
 /note="prepro-glucagon"
 /codon_start=1
 /protein_id="CAA27627.1"
 /db_xref="GI:762941"
 /db_xref="SWISS-PROT:P01275"
 /translation="MKSIFYVAGLFVMLVQGSWORSLODTEEKSRFSASQADPLSDP
 DQNEDEKRRHSGCTFTSDYSKYDSRAQDFVOMLNTNNRNRIAKRHDEFEHAEGT
 FTSVSSYLEGQAAKEFLAMLYKGRGRNRPPEVAIVELGRHADSGSPDEMTILD
 NLAARDFIWLQITKIDPK"
 3675..3734
 /note="intron II"
 3767..5338
 /note="intron II"
 5339..5500
 /note="exon 3"
 5339..5396
 /note="glucicentin related pancreatic peptide (AA 12-30)
 (5339 is 3rd base in codon)"
 5397..5402
 /note="spacer (AA 31-32; 2AA)"
 5403..5489
 /note="glucagon (AA 33-61; 29AA)"
 5490..5500
 /note="spacer (AA 61-65; 4AA) (5500 is 2nd base in codon)"
 5501..7176
 /note="intron III"
 7177..7314
 /note="exon 4"
 7177..7195
 /note="spacer (AA 66-71; 6AA) (7177 is 3rd base in codon)"
 7196..7306
 /note="glucagon-like peptide 1 (AA 72-108; 37AA)"
 7307..7314
 /note="spacer (AA 109-111; 3AA) (7314 is 2nd base in
 codon)"

intron 7315..8682
 /note="intron IV"
 exon 8683..8826
 /note="exon 5"
 misc-feature 8683..8826
 /note="pro-glucagon (AA 112-159) (8683 is 3rd base in
 codon) (8826 is 2nd base in codon)"
 misc-feature 8683..8725
 /note="spacer (AA 112-125; 14AA) (8683 is 3rd base in
 codon)"
 misc-feature 8726..8826
 /note="glucagon-like peptide 2 (AA 126-159) (8826 is 2nd
 base in codon)"
 intron 8827..9480
 /note="intron V"
 exon 9481..9487
 /note="exon 6"
 misc-feature 9481..9484
 /note="glucagon-like peptide 2 (AA 159-160; 35AA total)
 (9481 is 3rd base in codon)"
 misc-feature 9481..9484
 /note="pro-glucagon (AA 159-160) (9481 is 3rd base in
 codon)"
 misc-feature 9950..9956
 /note="pot. polyA signal"
 misc-feature 9965..9974
 /note="region of pot. polyA sites"
 BASE COUNT 3397 a 1698 c 1746 g 3209 t
 ORIGIN

Query Match 100.0%; Score 93; DB 9; Length 10050;
 Best Local Similarity 100.0%; Pred. NO. 1.3e-21;
 Matches 93; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CATGCTGAAGGACCTTACAGTATGATGTTCTTATTTGAAGCCAGCTGCCAAG 60
 Db 7214 CATGCTGAAGGACCTTACAGTATGATGTTCTTATTTGAAGCCAGCTGCCAAG 7273
 Qy 61 GAATTCATTGCTTGCTGCTGTGAAGCGCAGAGA 93
 Db 7274 GAATTCATTGCTTGCTGCTGTGAAGCGCAGAGA 7306

RESULT 14
 AC007750/c 163681 bp DNA linear PRI 02-OCT-2000
 LOCUS AC007750
 DEFINITION Homo sapiens BAC clone Rpl1-576116 from 2, complete sequence.
 ACCESSION AC007750
 VERSION AC007750.3 GI:6094634
 KEYWORDS HTG.
 SOURCE Homo sapiens.
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
 REFERENCE 1 (bases 1 to 163681)
 AUTHORS Sulston,J.E. and Waterston,R.
 TITLE Toward a complete human genome sequence
 JOURNAL Genome Res. 8 (11), 1097-1108 (1998)
 MEDLINE 99063792
 PUBMED 9847074
 2 (bases 1 to 163681)
 REFERENCE Colton,M., Maupin,R., Hawkins,M. and Harkins,R.
 AUTHORS The sequence of Homo sapiens BAC clone Rpl1-576116
 TITLE Unpublished
 JOURNAL 3 (bases 1 to 163681)
 REFERENCE Waterston,R.H.
 AUTHORS Direct Submission
 TITLE Submitted (05-JUN-1999) Genome Sequencing Center, Washington
 JOURNAL University School of Medicine, 4444 Forest Park Parkway, St. Louis,
 MO 63108, USA
 4 (bases 1 to 163681)
 REFERENCE Waterston,R.H.
 AUTHORS Direct Submission
 TITLE

JOURNAL

REFERENCE

Submitted (22-OCT-1999) Genome Sequencing Center, Washington University School of Medicine, 4444 Forest Park Parkway, St. Louis, MO 63108, USA
5 (bases 1 to 163681)

AUTHORS

Waterston, R.
Direct Submission

COMMENT

Submitted (02-OCT-2000) Department of Genetics, Washington University, 4444 Forest Park Avenue, St. Louis, Missouri 63108, USA
On Oct 22, 1999 this sequence version replaced g1:5103889.

----- Genome Center
Center: Washington University Genome Sequencing Center
Center code: WUGSC
Web site: <http://genome.wustl.edu/gsc>
Contact: sapiens@wustl.wustl.edu
----- Summary Statistics
Center project name: H_NH0576116

NOTICE: This sequence may not represent the entire insert of this clone. It may be shorter because we only sequence overlapping clone sections once, or longer because we provide a small overlap between neighboring data submissions.

This sequence was finished as follows unless otherwise noted:
all regions were double stranded, sequenced with an alternate chemistry, or covered by high quality data (i.e., phred quality >= 30); an attempt was made to resolve all sequencing problems, such as compressions and repeats; all regions were covered by sequence from more than one subclone; and the assembly was confirmed by restriction digest.

MAPPING INFORMATION:

Mapping information for this clone was provided by Dr. John D. Mpherson, Department of Genetics, Washington University, St. Louis MO. For additional information about the map position of this sequence, see <http://genome.wustl.edu/gsc>

SOURCE INFORMATION:

The RPCI-11 human BAC library was made from the blood of one male donor, as described by Osoegawa, K., Moon, P.Y., Zhao, B., Frengen, E., Teleno, M., Catanesi, J.J. and de Jong, P.J. (1998) An improved approach for construction of bacterial artificial chromosome libraries. Genomics 51:1-8. The clone may be obtained either from Research Genetics, Inc. (<http://www.resgen.com>) or Pieter de Jong and coworkers at the Roswell Park Cancer Institute (<http://bacpac.med.buffalo.edu>)
VECTOR: pBACe3.6

NEIGHBORING SEQUENCE INFORMATION:

The clone sequenced to the left is RP11-178A14. Actual start of this clone is at base position 1 of RP11-576116; actual end is at base position 163681 of RP11-576116.
Location/Qualifiers

FEATURES

1. 163681

/organism="Homo sapiens"

/db_xref="taxon:9606"

/chromosome="2"

/map="2"

/clone="RP11-576116"

/clone_lib="RPCI-11"

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

5263..5299

/rpt_family="(CA)n"

5417..5648

/rpt_family="L1"

7093..7556

/rpt_family="L2"

8702..9187

/rpt_family="MaLR"

9386..9586

/rpt_family="MIR"

10580..10739

/rpt_family="L2"

10792..11064

/rpt_family="Alu"

11136..12912

/rpt_family="L1"

12894..12899

/note="match to EST A1077564 (NID:93411972) cz33g05.x1"

12982..13011

/rpt_family="(TTG)n"

13109..13133

/rpt_family="(TTA)n"

13134..13419

/rpt_family="Alu"

13833..14130

/rpt_family="Alu"

14437..14573

/rpt_family="MER1_type"

14742..14887

/rpt_family="L1"

15098..15234

/rpt_family="L1"

15444..15460

/note="match to EST A1922427 (NID:95658391) w006b10.x1"

15449..15475

/rpt_family="(T)n"

15476..15695

/rpt_family="L1"

15713..15993

/rpt_family="Alu"

15994..16013

/rpt_family="(TAA)n"

16039..16131

/rpt_family="L1"

16140..16281

16284..16327

/rpt_family="(TG)n"

16328..16394

/rpt_family="(CAT)n"

16396..16576

/rpt_family="L1"

16625..16997

/rpt_family="L1"

17020..17274

/rpt_family="L1"

17270..17603

/rpt_family="L1"

17644..18442

/rpt_family="L1"

18444..20187

/rpt_family="L1"

20260..20562

/rpt_family="MER2_type"

20563..20850

/rpt_family="Alu"

20851..20910

/rpt_family="MER2_type"

21194..21218

/rpt_family="(T)n"

21204..21219

/note="match to EST A1582416 (NID:94568313) tr97d11.x1"

21204..21219

misc_feature

misc_feature

misc_feature

misc_feature

misc_feature

misc_feature

misc_feature

misc_feature

misc_feature

misc_feature

misc_feature

misc_feature

misc_feature

misc_feature

misc_feature

misc_feature

misc_feature

misc_feature

GenCore version 5.1.4.p5.4578
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: February 14, 2003, 07:57:09 : Search time 1184 Seconds
(without alignments)
1272.112 Million cell updates/sec

Title: US-09-091-605-2

Perfect score: 93
Sequence: 1 CATGCTGAGGACGACTTAC.....GGCTGCTGAAGGCCGAGCA 93

Scoring table: IDENTITY_NUC
Gapop 10.0, Gapext 1.0

Searched: 16154066 seqs, 8097743376 residues

Total number of hits satisfying chosen parameters: 32308132

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :

EST:*
1: em_estba:*
2: em_esthum:*
3: em_estlin:*
4: em_estmu:*
5: em_estov:*
6: em_estpl:*
7: em_estro:*
8: em_hlc:*
9: gb_est1:*
10: gb_est2:*
11: gb_hlc:*
12: gb_est3:*
13: gb_est4:*
14: gb_est5:*
15: em_estfun:*
16: em_estom:*
17: gb_gss:*
18: em_gss_hum:*
19: em_gss_hum:*
20: em_gss_hum:*
21: em_gss_hum:*
22: em_gss_vrt:*
23: em_gss_mam:*
24: em_gss_mus:*
25: em_gss_other:*
26: em_gss_pro:*
27: em_gss_rtd:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match Length	ID	Description
1	93	100.0	359	13 B1715164
2	93	100.0	382	14 BM313323
3	93	100.0	389	14 BM313323
4	93	100.0	394	12 BM313323
5	93	100.0	419	14 BM313323
6	93	100.0	427	13 BM313323

RESULT 1	LOCUS	DEFINITION	ACCESSION	VERSION	KEYWORDS	SOURCE	ORGANISM	REFERENCE	AUTHORS	TITLE	JOURNAL	COMMENT
B1715164	B1715164	359 bp mRNA linear EST 19-SEP-2001	B1715164	B1715164	GI:15690859	human.	Homo sapiens	1 (bases 1 to 359)	Melton, D., Brown, J., Kenty, G., Permutt, A., Lee, C., Kaestner, K., Lemishka, I., Scarce, M., Brestelli, J., Gradwohl, G., Clifton, S., Hillier, L., Marra, M., Pape, D., Wylie, T., Martin, J., Blaisdell, A., Schmitt, A., Theising, B., Ritter, E., Ronko, I., Bennett, J., Cardenas, M., Gibbons, M., McCann, R., Cole, R., Tsagaris, R., Williams, T., Jackson, Y., and Bowers, K.	Unpublished (2000)	Endocrine Pancreas Consortium	Harvard University, Howard Hughes Medical Institute Dept of Molecular and Cellular Biology, 7 Divinity Ave, Cambridge, MA 02138
B1715164	B1715164	359 bp mRNA linear EST 19-SEP-2001	B1715164	B1715164	GI:15690859	human.	Homo sapiens	1 (bases 1 to 359)	Melton, D., Brown, J., Kenty, G., Permutt, A., Lee, C., Kaestner, K., Lemishka, I., Scarce, M., Brestelli, J., Gradwohl, G., Clifton, S., Hillier, L., Marra, M., Pape, D., Wylie, T., Martin, J., Blaisdell, A., Schmitt, A., Theising, B., Ritter, E., Ronko, I., Bennett, J., Cardenas, M., Gibbons, M., McCann, R., Cole, R., Tsagaris, R., Williams, T., Jackson, Y., and Bowers, K.	Unpublished (2000)	Endocrine Pancreas Consortium	Harvard University, Howard Hughes Medical Institute Dept of Molecular and Cellular Biology, 7 Divinity Ave, Cambridge, MA 02138

ALIGNMENTS

RESULT 1
LOCUS B1715164
DEFINITION B1715164
ACCESSION B1715164
VERSION B1715164
KEYWORDS B1715164
SOURCE B1715164
ORGANISM B1715164

REFERENCE B1715164
AUTHORS B1715164
TITLE B1715164
JOURNAL B1715164
COMMENT B1715164

EST. B1715164
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
1 (bases 1 to 359)
Melton, D., Brown, J., Kenty, G., Permutt, A., Lee, C., Kaestner, K., Lemishka, I., Scarce, M., Brestelli, J., Gradwohl, G., Clifton, S., Hillier, L., Marra, M., Pape, D., Wylie, T., Martin, J., Blaisdell, A., Schmitt, A., Theising, B., Ritter, E., Ronko, I., Bennett, J., Cardenas, M., Gibbons, M., McCann, R., Cole, R., Tsagaris, R., Williams, T., Jackson, Y., and Bowers, K.
Unpublished (2000)
Endocrine Pancreas Consortium
Contact: Douglas Melton, Klaus H. Kaestner, & Hiroshi Inoue
Harvard University, Howard Hughes Medical Institute
Dept of Molecular and Cellular Biology, 7 Divinity Ave, Cambridge, MA 02138
Tel: 617-495-1812
Fax: 617-495-8557
Email: dmelton@biohp.harvard.edu

Library was constructed by Dr. Hiroshi Inoue DNA sequencing by:
Washington University Genome Sequencing Center for information on
obtaining a clone please contact: Dr. Hiroshi Inoue
(hinoue@im.wustl.edu)
Seq primer: -40RP from Gibco

High quality sequence stop: 277.
Location/Qualifiers

FEATURES

source
1..359
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone_id="HR85 islet"
/tissue_type="Purified pancreatic islet"
/lab_host="DH10B"
/note="Organ: Pancreas; Vector: pBluescript SK(-); Site_1:
NotI; Site_2: XhoI; cDNA made by oligo-dT priming.
Size-selected on agarose gel. Average insert size ~1kb. 5'
XhoI site was destroyed after directional cloning.
Amplified once. Contact Information: Hiroshi Inoue, MD,
Metabolism Div. (Alan Permutt Lab), Washington University
School of Medicine, Box 8127, 660 South Euclid Ave., St.
Louis, MO 63110, E-mail: hinoue@imgate.wustl.edu, Tel:
314-362-1916, Fax: 314-747-2692."

BASE COUNT 103 a 74 c 92 g 90 t

ORIGIN

Query Match 100.0%; Score 93; DB 13; Length 359;
Best Local Similarity 100.0%; Pred. No. 1.5e-21;
Matches 93; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CATGCTGAAGGACCTTACAGTGATGTTCTTATTGGAGGCCAAGTCCCAAG 60
|||||
Db 126 CATGCTGAAGGACCTTACAGTGATGTTCTTATTGGAGGCCAAGTCCCAAG 185

QY 61 GAATTCATTGCTTGGCTGGTGAAGGCCGAGGA 93
|||||
Db 186 GAATTCATTGCTTGGCTGGTGAAGGCCGAGGA 218

RESULT 2 382 bp mRNA linear EST 03-JAN-2002
BM313323
LOCUS 1982f07.y1 HR85 islet Homo sapiens cDNA 5' similar to SW:GLUC_HUMAN
DEFINITION P01275 GLUCAGON PRECURSOR. [1] ; mRNA sequence.
ACCESSION BM313323
VERSION BM313323.1 GI:18047668
KEYWORDS EST.
SOURCE human.
ORGANISM Homo sapiens

REFERENCE
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
1 (bases 1 to 382)
Melton,D., Brown,J., Kenty,G., Permutt,A., Lee,C., Kaestner,K.,
Lemshka,I., Searce,M., Brestelli,J., Gradwohl,G., Clifton,S.,
Hillier,L., Marra,M., Pape,D., Wylie,T., Martin,J., Blistain,A.,
Schmitt,A., Theising,B., Ritter,E., Ronko,I., Bennett,J., Cardenas
, M., Gibbons,M., McCann,R., Cole,R., Tsagarisvilli,R., Williams,T.,
Jackson,Y. and Bowers,Y.
Endocrine Pancreas Consortium
Unpublished (2000)
Other ESTs: 1982f07.x1

TITLE
JOURNAL
COMMENT

Contact: Douglas Melton, Klaus H. Kaestner, & Hiroshi Inoue
Endocrine Pancreas Consortium
Harvard University, Howard Hughes Medical Institute
Dept of Molecular and Cellular Biology, 7 Divinity Ave, Cambridge,
MA 02138
Tel: 617-495-1812
Fax: 617-495-8557
Email: dmelton@biochem.harvard.edu
Library was constructed by Dr. Hiroshi Inoue DNA sequencing by:
Washington University Genome Sequencing Center for information on
obtaining a clone please contact: Dr. Hiroshi Inoue
(hinoue@im.wustl.edu)
Seq primer: -40RP from Gibco.

FEATURES

source

Location/Qualifiers
1..382
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone_id="HR85 islet"
/tissue_type="Purified pancreatic islet"
/lab_host="DH10B"
/note="Organ: Pancreas; Vector: pBluescript SK(-); Site_1:
NotI; Site_2: XhoI; cDNA made by oligo-dT priming.
Size-selected on agarose gel. Average insert size ~1kb. 5'
XhoI site was destroyed after directional cloning.
Amplified once. Contact Information: Hiroshi Inoue, MD,
Metabolism Div. (Alan Permutt Lab), Washington University
School of Medicine, Box 8127, 660 South Euclid Ave., St.
Louis, MO 63110, E-mail: hinoue@imgate.wustl.edu, Tel:
314-362-1916, Fax: 314-747-2692."

BASE COUNT 110 a 79 c 98 g 95 t

ORIGIN

Query Match 100.0%; Score 93; DB 13; Length 382;
Best Local Similarity 100.0%; Pred. No. 1.5e-21;
Matches 93; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CATGCTGAAGGACCTTACAGTGATGTTCTTATTGGAGGCCAAGTCCCAAG 60
|||||
Db 135 CATGCTGAAGGACCTTACAGTGATGTTCTTATTGGAGGCCAAGTCCCAAG 194

QY 61 GAATTCATTGCTTGGCTGGTGAAGGCCGAGGA 93
|||||
Db 195 GAATTCATTGCTTGGCTGGTGAAGGCCGAGGA 227

RESULT 3 389 bp mRNA linear EST 02-JUN-2002
B0632756
LOCUS 1127e09.y1 HR85 islet Homo sapiens cDNA clone IMAGE:6031216 5'
DEFINITION similar to SW:GLUC_HUMAN P01275 GLUCAGON PRECURSOR. [1] ; mRNA
sequence.
ACCESSION B0632756
VERSION B0632756.1 GI:21684274
KEYWORDS EST.
SOURCE human.
ORGANISM Homo sapiens

REFERENCE
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
1 (bases 1 to 389)
Melton,D., Brown,J., Kenty,G., Permutt,A., Lee,C., Kaestner,K.,
Lemshka,I., Searce,M., Brestelli,J., Gradwohl,G., Clifton,S.,
Hillier,L., Marra,M., Pape,D., Wylie,T., Martin,J., Blistain,A.,
Schmitt,A., Theising,B., Ritter,E., Ronko,I., Bennett,J., Cardenas
, M., Gibbons,M., McCann,R., Cole,R., Tsagarisvilli,R., Williams,T.,
Jackson,Y. and Bowers,Y.
Endocrine Pancreas Consortium
Unpublished (2000)
Other ESTs: 1127e09.x1

TITLE
JOURNAL
COMMENT

Contact: Douglas Melton, Klaus H. Kaestner, & Hiroshi Inoue
Endocrine Pancreas Consortium
Harvard University, Howard Hughes Medical Institute
Dept of Molecular and Cellular Biology, 7 Divinity Ave, Cambridge,
MA 02138
Tel: 617-495-1812
Fax: 617-495-8557
Email: dmelton@biochem.harvard.edu
Library was constructed by Dr. Hiroshi Inoue DNA sequencing by:
Washington University Genome Sequencing Center for information on
obtaining a clone please contact: Dr. Hiroshi Inoue
(hinoue@im.wustl.edu)
Seq primer: -40RP from Gibco
High quality sequence stop: 361.
Location/Qualifiers
1..389
/organism="Homo sapiens"
/db_xref="taxon:9606"

```

/clone="IMAGE:6031216"
/clone_lib="HR85 islet"
/tissue_type="Purified pancreatic islet"
/lab_host="DH10B"
/Note="Organ: Pancreas; Vector: pBluescript SK(-); Site_1:
NotI; Site_2: XhoI; cDNA made by oligo-dT priming.
Size-selected on agarose gel. Average insert size
-1kb. 5'
XhoI site was destroyed after directional cloning.
Amplified once. Contact information: Hiroshi Inoue, MD,
Metabolism Div. (Alan Permutt Lab), Washington University
School of Medicine, Box 8127, 660 South Euclid Ave., St.
Louis, MO 63110, E-mail: hinoue@imgate.wustl.edu, Tel:
314-362-1916, Fax: 314-747-2692."
BASE COUNT      116 a      76 c      94 g      103 t
ORIGIN
Query Match      100.0%; Score 93; DB 14; Length 389;
Best Local Similarity 100.0%; Pred. No. 1.5e-21;
Matches 93; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 CATGCTGAAGGACCTTACAGTATGTAAGTTCTTATTGGAAGGCCAAGTCCCAAG 60
|||||
DB 72 CATGCTGAAGGACCTTACAGTATGTAAGTTCTTATTGGAAGGCCAAGTCCCAAG 131
|||||

OY 61 GAATTCATTGCTGCTGCTGCTGGAAGGCCGAGGA 93
|||||
DB 132 GAATTCATTGCTGCTGCTGCTGGAAGGCCGAGGA 164
|||||

RESULT 4
LOCUS      BG654963      394 bp      mRNA      linear      EST 05-JUL-2001
DEFINITION BG654963.1 HR85 islet Homo sapiens cDNA 5' similar to SW:GLUC_HUMAN
P01275 GLOCACON PRECURSOR. [1] ;, mRNA sequence.
ACCESSION  BG654963
VERSION     BG654963.1  GI:13792372
KEYWORDS    EST.
SOURCE      human.
ORGANISM    Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE   1 (bases 1 to 394)
AUTHORS    Melton,D., Brown,J., Kenty,G., Permutt,A., Lee,C., Kaestner,K.,
            Lemishka,I., Scearce,M., Brestelli,J., Gradwohl,G., Clifton,S.,
            Hillier,L., Marra,M., Pape,D., Wylie,T., Martin,J., Bilstain,A.,
            Schmitt,A., Theising,B., Ritter,E., Ronko,I., Bennett,D., Cardenas
            M., Gibbons,M., McCann,R., Cole,R., Tsagarisshvili,R., Williams,T.,
            Jackson,Y. and Bowers,Y.
            Endocrine Pancreas Consortium
            Unpublished (2000)
            Contact: Douglas Melton, Klaus H. Kaestner, & Hiroshi Inoue
            Endocrine Pancreas Consortium
            Harvard University, Howard Hughes Medical Institute
            Dept of Molecular and Cellular Biology, 7 Divinity Ave, Cambridge,
            MA 02138
            Tel: 617-495-1812
            Fax: 617-495-8557
            Email: dmelton@biochem.harvard.edu
            Library was constructed by Dr. Hiroshi Inoue DNA sequencing by:
            Washington University Genome Sequencing Center For information on
            obtaining a clone please contact: Dr. Hiroshi Inoue
            (hinoue@img.wustl.edu)
            Seq primer: -40RP from Gibco
            High quality sequence stop: 350.
            Location/Qualifiers
                1..394
                /organism="Homo sapiens"
                /db_xref="taxon:9606"
                /clone_lib="HR85 islet"
                /tissue_type="Purified pancreatic islet"
                /lab_host="DH10B"
                /Note="Organ: Pancreas; Vector: pBluescript SK(-); Site_1:
                NotI; Site_2: XhoI; cDNA made by oligo-dT priming.
                Size-selected on agarose gel. Average insert size -1kb. 5'
                XhoI site was destroyed after directional cloning.
                Amplified once. Contact information: Hiroshi Inoue, MD,
                Metabolism Div. (Alan Permutt Lab), Washington University
                School of Medicine, Box 8127, 660 South Euclid Ave., St.
                Louis, MO 63110, E-mail: hinoue@imgate.wustl.edu, Tel:
                314-362-1916, Fax: 314-747-2692."
                BASE COUNT      119 a      74 c      90 g      110 t
                ORIGIN
                Query Match      100.0%; Score 93; DB 12; Length 394;
                Best Local Similarity 100.0%; Pred. No. 1.6e-21;
                Matches 93; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

                OY 1 CATGCTGAAGGACCTTACAGTATGTAAGTTCTTATTGGAAGGCCAAGTCCCAAG 60
                |||||
                DB 58 CATGCTGAAGGACCTTACAGTATGTAAGTTCTTATTGGAAGGCCAAGTCCCAAG 117
                |||||

                OY 61 GAATTCATTGCTGCTGCTGCTGGAAGGCCGAGGA 93
                |||||
                DB 118 GAATTCATTGCTGCTGCTGCTGGAAGGCCGAGGA 150
                |||||

                RESULT 5
                LOCUS      BM836042      419 bp      mRNA      linear      EST 06-MAR-2002
                DEFINITION BM836042.1 S55N0484s1 Homo sapiens cDNA clone S55N0484s1-18-G08
                5', mRNA sequence.
                ACCESSION  BM836042
                VERSION     BM836042.1  GI:19192451
                KEYWORDS    EST.
                SOURCE      human.
                ORGANISM    Homo sapiens
                Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
                Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
                REFERENCE   1 (bases 1 to 419)
                AUTHORS    Kim,N.S., Hahn,Y., Oh,J.H., Lee,J.Y., Ahn,H.Y., Chu,M.Y., Kim,M.R.,
                Oh,K.J., Cheong,J.E., Sohn,H.Y., Kim,D.M., Park,H.S., Kim,S. and
                Kim,Y.S.
                21C Frontier Korean EST Project 2001
                Unpublished (2002)
                Contact: Kim YS
                Genome Research Center
                Korea Research Institute of Bioscience & Biotechnology
                52 Eoeun-dong Yuseong-gu, Daejeon 305-333, South Korea
                Tel: +82-42-860-4470
                Fax: +82-42-860-4409
                Email: yongsung@mail.kribb.re.kr
                Plate: 18 row: 6 column: 08
                High quality sequence stop: 419.
                Location/Qualifiers
                    1..419
                    /organism="Homo sapiens"
                    /db_xref="taxon:9606"
                    /clone="S55N0484s1-18-G08"
                    /clone_lib="S55N0484s1"
                    /sex="M"
                    /tissue_type="Stomach"
                    /cell_type="Epithelial"
                    /lab_host="Top10F"
                    /Note="Organ: Stomach; Vector: pTZ18RP1; Site_1: EcoRI;
                    Site_2: NotI; The poly (A)+ RNA was decapped with tabacco
                    acid pyrophosphatase (TAP) and ligated with DNA-RNA linker
                    including EcoRI site by treatment of T4 RNA ligase. The
                    first strand cDNA was synthesized from oligo dT-selected
                    mRNA by priming with dT-tailed vector. The dT-tailed
                    vector was adjusted to have about 60nt. The cDNA vector
                    was circularized with E. coli DNA ligase after digestion
                    of EcoRI which site is also included in vector. An RNA
                    strand converted to a DNA strand by Okayama-Berg method.
                    The obtained cDNA vectors were used for transformation of
                    competent cells E. coli Top10F by electroporation method.

```

After analyzing and sequencing about 2,000 - 3,000 colonies in original cDNA library, the abundant cDNAs were selected and amplified by PCR reaction using vector region 3' primer. The PCR products were used as template for synthesis of biotinylated single stranded RNA by in vitro transcription reaction. The synthesized RNA probes were hybridized with antisense single stranded cDNAs prepared from original library and incubated with avidin-gel. After removing DNA-RNA hybrids by centrifuge, the subtracted cDNA libraries were constructed by transformation of the remaining DNA into competent cells E. coli Top10F' with electroporation method."

BASE COUNT 122 a 82 c 94 g 121 t

ORIGIN

Query Match 100.0%; Score 93; DB 14; Length 419;
Best Local Similarity 100.0%; Pred. No. 1.6e-21;
Matches 93; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CATGCTGAAGGACCTTTACCACTGATGTAAGTCTTATTTGGAAGCCCAAGCTGCCAAG 60
Db 30 CATGCTGAAGGACCTTTACCACTGATGTAAGTCTTATTTGGAAGCCCAAGCTGCCAAG 89
QY 61 GAATTCATTGCTTGGCTGGTGAAGGCCGAGGA 93
Db 90 GAATTCATTGCTTGGCTGGTGAAGGCCGAGGA 122

RESULT 6
BI466966 427 bp mRNA linear EST 22-AUG-2001
LOCUS ic17d08.y3 HR85 islet Homo sapiens cDNA 5' similar to SW:GLUC_HUMAN
ACCESSION P01275 GLUCAGON PRECURSOR. [1] ; mRNA sequence.
VERSION BI466966
KEYWORDS EST
SOURCE human.
ORGANISM Homo sapiens

REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo. 1 (bases 1 to 427)
AUTHORS Melton, D., Brown, J., Keny, G., Permutt, A., Lee, C., Kaestner, K., Lemishka, I., Scarsee, M., Brestelli, J., Gradwohl, G., Clifton, S., Hillier, L., Marra, M., Pape, D., Wylie, T., Martin, J., Bliststein, A., Schmitt, A., Theising, B., Ritter, E., Ronko, I., Bennett, J., Cardenas, M., Gibbons, M., McCann, R., Cole, R., Tsagaris, R., Williams, T., Jackson, Y., and Bowers, Y.
TITLE Endocrine Pancreas Consortium
JOURNAL Unpublished (2000)
COMMENT Other ESTs: ic17d08.x3
Contact: Douglas Melton, Klaus H. Kaestner, & Hiroshi Inoue
Endocrine Pancreas Consortium
Harvard University, Howard Hughes Medical Institute
Dept of Molecular and Cellular Biology, 7 Divinity Ave, Cambridge, MA 02138
Tel: 617-495-1812
Fax: 617-495-8557
Email: dmelton@hmp.harvard.edu
Library was constructed by Dr. Hiroshi Inoue DNA sequencing by: Washington University Genome Sequencing Center For information on obtaining a clone please contact: Dr. Hiroshi Inoue (hinoue@im.wustl.edu)
Trace considered overall poor quality
High quality sequence stop: 1.
Location/Qualifiers
1. 427

FEATURES

source
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone_id="HR85 islet"
/tissue_type="Purified pancreatic islet"
/lab_host="DH10B"
/note="Organ: Pancreas; Vector: pBluescript SK(-); Site_1:

NOT1; Site_2: XhoI; cDNA made by oligo-dT priming. Size-selected on agarose gel. Average insert size -1kb. 5' XhoI site was destroyed after directional cloning. Amplified once. Contact information: Hiroshi Inoue, MD, Metabolism Div. (Alan Permutt Lab), Washington University School of Medicine, Box 8127, 660 South Euclid Ave., St. Louis, MO 63110, E-mail: hinoue@imgate.wustl.edu, Tel: 314-362-1916, Fax: 314-747-2692."

BASE COUNT 123 a 94 c 111 g 99 t

ORIGIN

Query Match 100.0%; Score 93; DB 13; Length 427;
Best Local Similarity 100.0%; Pred. No. 1.6e-21;
Matches 93; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CATGCTGAAGGACCTTTACCACTGATGTAAGTCTTATTTGGAAGCCCAAGCTGCCAAG 60
Db 290 CATGCTGAAGGACCTTTACCACTGATGTAAGTCTTATTTGGAAGCCCAAGCTGCCAAG 349
QY 61 GAATTCATTGCTTGGCTGGTGAAGGCCGAGGA 93
Db 350 GAATTCATTGCTTGGCTGGTGAAGGCCGAGGA 382

RESULT 7
BI0271272 443 bp mRNA linear EST 07-MAY-2002
LOCUS ik11g04.y1 HR85 islet Homo sapiens cDNA clone IMAGE: 5780910 5' similar to SW:GLUC_HUMAN P01275 GLUCAGON PRECURSOR. [1] ; mRNA sequence.
ACCESSION BI0271272
VERSION BI0271272.1 GI:20496338
KEYWORDS EST.
SOURCE human.
ORGANISM Homo sapiens

REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo. 1 (bases 1 to 443)
AUTHORS Melton, D., Brown, J., Keny, G., Permutt, A., Lee, C., Kaestner, K., Lemishka, I., Scarsee, M., Brestelli, J., Gradwohl, G., Clifton, S., Hillier, L., Marra, M., Pape, D., Wylie, T., Martin, J., Bliststein, A., Schmitt, A., Theising, B., Ritter, E., Ronko, I., Bennett, J., Cardenas, M., Gibbons, M., McCann, R., Cole, R., Tsagaris, R., Williams, T., Jackson, Y., and Bowers, Y.
TITLE Endocrine Pancreas Consortium
JOURNAL Unpublished (2000)
COMMENT Contact: Douglas Melton, Klaus H. Kaestner, & Hiroshi Inoue
Endocrine Pancreas Consortium
Harvard University, Howard Hughes Medical Institute
Dept of Molecular and Cellular Biology, 7 Divinity Ave, Cambridge, MA 02138
Tel: 617-495-1812
Fax: 617-495-8557
Email: dmelton@hmp.harvard.edu
Library was constructed by Dr. Hiroshi Inoue DNA sequencing by: Washington University Genome Sequencing Center For information on obtaining a clone please contact: Dr. Hiroshi Inoue (hinoue@im.wustl.edu)
Seq primer: -40RP from Gibco.

FEATURES

source
Location/Qualifiers
1. 443
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone_id="HR85 islet"
/tissue_type="Purified pancreatic islet"
/lab_host="DH10B"
/note="Organ: Pancreas; Vector: pBluescript SK(-); Site_1: Not1; Site_2: XhoI; cDNA made by oligo-dT priming. Size-selected on agarose gel. Average insert size -1kb. 5' XhoI site was destroyed after directional cloning. Amplified once. Contact information: Hiroshi Inoue, MD, Metabolism Div. (Alan Permutt Lab), Washington University

School of Medicine, Box 8127, 660 South Euclid Ave., St. Louis, MO 63110, E-mail: hinoue@imgate.wustl.edu, Tel: 314-362-1916, Fax: 314-747-2692."

BASE COUNT 132 a 99 c 110 g 101 t 1 others

ORIGIN

Query Match 100.0%; Score 93; DB 14; Length 443;
Best Local Similarity 100.0%; Pred. No. 1.7e-21;
Matches 93; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 CATGCTGAAGGACCTTACCACTGATGATGTTCTTATTTGGAAGCCCAAGTGCAG 60
|||||
Db 335 CATGCTGAAGGACCTTACCACTGATGATGTTCTTATTTGGAAGCCCAAGTGCAG 394

OY 61 GAATTCATTGCTTGGCTGGTGAAGCCGAGCA 93
|||||
Db 395 GAATTCATTGCTTGGCTGGTGAAGCCGAGCA 427

RESULT 8
BM503895 451 bp mRNA linear EST 14-FEB-2002
LOCUS 1997b05.y1 HR85 islet Homo sapiens cDNA 5' similar to SW:GLUC_HUMAN
DEFINITION P01275 GLUCAGON PRECURSOR. [1] ; mRNA sequence.

ACCESSION BM503895.1 GI:18666121
VERSION
KEYWORDS
SOURCE EST.
ORGANISM human.

REFERENCE Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

AUTHORS Melton,D., Brown,J., Kenty,G., Permutt,A., Lee,C., Kaestner,K., Lemishka,I., Searce,M., Brestelli,J., Gradwohl,G., Clifton,S., Hillier,L., Marra,M., Pape,D., Wylie,T., Martin,J., Blistein,A., Schmitt,A., Theising,B., Rittler,E., Ronko,I., Bennett,J., Cardenas,M., Gibbons,M., McCann,R., Cole,R., Tsagarishvili,R., Williams,T., Jackson,Y. and Bowers,Y.
Endocrine Pancreas Consortium
Unpublished (2000)
Other-ESTs: 1997b05.x1
Contact: Douglas Melton, Klaus H. Kaestner, & Hiroshi Inoue
Endocrine Pancreas Consortium
Harvard University, Howard Hughes Medical Institute
Dept of Molecular and Cellular Biology, 7 Divinity Ave, Cambridge, MA 02138
Tel: 617-495-1812
Fax: 617-495-8557
Email: dmelton@bioh.p.harvard.edu
Library was constructed by Dr. Hiroshi Inoue DNA sequencing by: Washington University Genome Sequencing Center For information on obtaining a clone please contact: Dr. Hiroshi Inoue (hinoue@im.wustl.edu)
Seq primer: -40RP from Gibco
High quality sequence stop: 440.
Location/Qualifiers

FEATURES

1. 451
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone_lib="HR85 islet"
/tissue_type="Purified pancreatic islet"
/lab_host="DH10B"
/note="Organ: Pancreas; Vector: pBluescript SK(-); Site: 1;
Noti: Site: 2; XhoI: cDNA made by oligo-dT priming.
Size-selected on agarose gel. Average insert size -1kb. 5'
XhoI site was destroyed after directional cloning.
Amplified once. Contact information: Hiroshi Inoue, MD,
Metabolism Div. (Alan Permutt Lab), Washington University
School of Medicine, Box 8127, 660 South Euclid Ave., St.
Louis, MO 63110, E-mail: hinoue@imgate.wustl.edu, Tel:
314-362-1916, Fax: 314-747-2692."

BASE COUNT 135 a 86 c 106 g 123 t 1 others

Query Match 100.0%; Score 93; DB 13; Length 451;
Best Local Similarity 100.0%; Pred. No. 1.7e-21;
Matches 93; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 CATGCTGAAGGACCTTACCACTGATGATGTTCTTATTTGGAAGCCCAAGTGCAG 60
|||||
Db 74 CATGCTGAAGGACCTTACCACTGATGATGTTCTTATTTGGAAGCCCAAGTGCAG 133

OY 61 GAATTCATTGCTTGGCTGGTGAAGCCGAGCA 93
|||||
Db 134 GAATTCATTGCTTGGCTGGTGAAGCCGAGCA 166

RESULT 9
B0776591/c 451 bp mRNA linear EST 26-JUL-2002
LOCUS 1134g04.x1 HR85 islet Homo sapiens cDNA clone IMAGE:6032047 3'
DEFINITION similar to SW:GLUC_HUMAN P01275 GLUCAGON PRECURSOR. [1] ; mRNA sequence.

ACCESSION B0776591.1 GI:21985063
VERSION B0776591
KEYWORDS
SOURCE EST.
ORGANISM human.

REFERENCE Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

AUTHORS Melton,D., Brown,J., Kenty,G., Permutt,A., Lee,C., Kaestner,K., Lemishka,I., Searce,M., Brestelli,J., Gradwohl,G., Clifton,S., Hillier,L., Marra,M., Pape,D., Wylie,T., Martin,J., Blistein,A., Schmitt,A., Theising,B., Rittler,E., Ronko,I., Bennett,J., Cardenas,M., Gibbons,M., McCann,R., Cole,R., Tsagarishvili,R., Williams,T., Jackson,Y. and Bowers,Y.
Endocrine Pancreas Consortium
Unpublished (2000)
Contact: Douglas Melton, Klaus H. Kaestner, & Hiroshi Inoue
Endocrine Pancreas Consortium
Harvard University, Howard Hughes Medical Institute
Dept of Molecular and Cellular Biology, 7 Divinity Ave, Cambridge, MA 02138
Tel: 617-495-1812
Fax: 617-495-8557
Email: dmelton@bioh.p.harvard.edu
Library was constructed by Dr. Hiroshi Inoue DNA sequencing by: Washington University Genome Sequencing Center For information on obtaining a clone please contact: Dr. Hiroshi Inoue (hinoue@im.wustl.edu)
Seq primer: -40UP from Gibco.

FEATURES

1. 451
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone_lib="IMAGE:6032047"
/tissue_type="Purified pancreatic islet"
/lab_host="DH10B"
/note="Organ: Pancreas; Vector: pBluescript SK(-); Site: 1;
Noti: Site: 2; XhoI: cDNA made by oligo-dT priming.
Size-selected on agarose gel. Average insert size -1kb. 5'
XhoI site was destroyed after directional cloning.
Amplified once. Contact information: Hiroshi Inoue, MD,
Metabolism Div. (Alan Permutt Lab), Washington University
School of Medicine, Box 8127, 660 South Euclid Ave., St.
Louis, MO 63110, E-mail: hinoue@imgate.wustl.edu, Tel:
314-362-1916, Fax: 314-747-2692."

BASE COUNT 132 a 96 c 82 g 141 t

Query Match 100.0%; Score 93; DB 14; Length 451;
Best Local Similarity 100.0%; Pred. No. 1.7e-21;
Matches 93; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CATGCTGAAGGACCTTTACAGTATGATGATTTCTATTATTGGAAGCCCAAGTCCCAAG 60
 |||||||
 Db 451 CATGCTGAAGGACCTTTACAGTATGATGATTTCTATTATTGGAAGCCCAAGTCCCAAG 392
 |||||||
 QY 61 GAATTCATTGCTTGGCTGTGTAAGGCCGAGGA 93
 |||||||
 Db 391 GAATTCATTGCTTGGCTGTGTAAGGCCGAGGA 359
 |||||||

RESULT 10
 BG656237 458 bp mRNA linear EST 05-JUL-2001
 LOCUS 1b38904.y1 HR85 islet Homo sapiens cDNA 5' similar to SW:GLUC_HUMAN
 DEFINITION P01275 GLUCAGON PRECURSOR. [1] ; mRNA sequence.
 ACCESSION BG656237
 VERSION BG656237.1 GI:13793646
 KEYWORDS EST.
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
 REFERENCE 1 (bases 1 to 458)
 AUTHORS Lemisha, I., Scaer, M., Brestelli, J., Gradwohl, G., Clifton, S.,
 Hillier, L., Marra, M., Pape, D., Wylie, T., Martin, J., Blistain, A.,
 Schmitt, A., Theising, B., Rittler, E., Ronko, I., Bennett, J., Cardenas,
 M., Gibbons, M., McCann, R., Cole, R., Tsagarisvill, R., Williams, T.,
 Jackson, Y. and Bowers, Y.
 Endocrine Pancreas Consortium
 Unpublished (2000)
 CONTACT: Douglas Melton, Klaus H. Kaestner, & Hiroshi Inoue
 Endocrine Pancreas Consortium
 Harvard University, Howard Hughes Medical Institute
 Dept of Molecular and Cellular Biology, 7 Divinity Ave, Cambridge,
 MA 02138
 Tel: 617-495-1812
 Fax: 617-495-8557
 Email: dmelton@biohp.harvard.edu
 Library was constructed by Dr. Hiroshi Inoue DNA sequencing by:
 Washington University Genome Sequencing Center For information on
 obtaining a clone please contact: Dr. Hiroshi Inoue
 (hinoue@im.wustl.edu)
 Seq primer: -40RP from Gibco
 High quality sequence stop: 452.
 FEATURES
 source
 Location/Qualifiers
 1..458
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /clone_lib="HR85 islet"
 /tissue_type="Purified pancreatic islet"
 /lab_host="DH10B"
 /note="Organ: Pancreas; Vector: pBluescript SK(-); Site_1:
 NotI; Site_2: XhoI; cDNA made by oligo-dT priming.
 Size-selected on agarose gel. Average insert size ~1kb. 5'
 XhoI site was destroyed after directional cloning.
 Amplified once. Contact information: Hiroshi Inoue, MD,
 Metabolism Div. (Alan Permutt Lab), Washington University
 School of Medicine, Box 8127, 660 South Euclid Ave., St.
 Louis, MO 63110, E-mail: hinoue@imgate.wustl.edu, Tel:
 314-362-1916, Fax: 314-747-2692."

BASE COUNT 134 a 106 c 111 g 107 t
 ORIGIN
 Query Match 100.0%; Score 93; DB 12; Length 458;
 Best Local Similarity 100.0%; Pred. No. 1.7e-21;
 Matches 93; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CATGCTGAAGGACCTTTACAGTATGATGATTTCTATTATTGGAAGCCCAAGTCCCAAG 60
 |||||||
 Db 348 CATGCTGAAGGACCTTTACAGTATGATGATTTCTATTATTGGAAGCCCAAGTCCCAAG 407
 |||||||
 QY 61 GAATTCATTGCTTGGCTGTGTAAGGCCGAGGA 93
 |||||||

Db 408 GAATTCATTGCTTGGCTGTGTAAGGCCGAGGA 440
 |||||||
 RESULT 11
 BQ286311 459 bp mRNA linear EST 14-MAY-2002
 LOCUS 1k28604.y1 HR85 islet Homo sapiens cDNA clone IMAGE:5782351 5'
 DEFINITION similar to SW:GLUC_HUMAN P01275 GLUCAGON PRECURSOR. [1] ; mRNA
 sequence.
 ACCESSION BQ286311
 VERSION BQ286311.1 GI:20655687
 KEYWORDS EST.
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
 REFERENCE 1 (bases 1 to 459)
 AUTHORS Lemisha, I., Scaer, M., Brestelli, J., Gradwohl, G., Clifton, S.,
 Hillier, L., Marra, M., Pape, D., Wylie, T., Martin, J., Blistain, A.,
 Schmitt, A., Theising, B., Rittler, E., Ronko, I., Bennett, J., Cardenas,
 M., Gibbons, M., McCann, R., Cole, R., Tsagarisvill, R., Williams, T.,
 Jackson, Y. and Bowers, Y.
 Endocrine Pancreas Consortium
 Unpublished (2000)
 CONTACT: Douglas Melton, Klaus H. Kaestner, & Hiroshi Inoue
 Endocrine Pancreas Consortium
 Harvard University, Howard Hughes Medical Institute
 Dept of Molecular and Cellular Biology, 7 Divinity Ave, Cambridge,
 MA 02138
 Tel: 617-495-1812
 Fax: 617-495-8557
 Email: dmelton@biohp.harvard.edu
 Library was constructed by Dr. Hiroshi Inoue DNA sequencing by:
 Washington University Genome Sequencing Center For information on
 obtaining a clone please contact: Dr. Hiroshi Inoue
 (hinoue@im.wustl.edu)
 Seq primer: -40RP from Gibco
 High quality sequence stop: 440.
 FEATURES
 source
 Location/Qualifiers
 1..459
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /clone="IMAGE:5782351"
 /clone_lib="HR85 islet"
 /tissue_type="Purified pancreatic islet"
 /lab_host="DH10B"
 /note="Organ: Pancreas; Vector: pBluescript SK(-); Site_1:
 NotI; Site_2: XhoI; cDNA made by oligo-dT priming.
 Size-selected on agarose gel. Average insert size ~1kb. 5'
 XhoI site was destroyed after directional cloning.
 Amplified once. Contact information: Hiroshi Inoue, MD,
 Metabolism Div. (Alan Permutt Lab), Washington University
 School of Medicine, Box 8127, 660 South Euclid Ave., St.
 Louis, MO 63110, E-mail: hinoue@imgate.wustl.edu, Tel:
 314-362-1916, Fax: 314-747-2692."

BASE COUNT 135 a 105 c 109 g 110 t
 ORIGIN
 Query Match 100.0%; Score 93; DB 14; Length 459;
 Best Local Similarity 100.0%; Pred. No. 1.7e-21;
 Matches 93; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CATGCTGAAGGACCTTTACAGTATGATGATTTCTATTATTGGAAGCCCAAGTCCCAAG 60
 |||||||
 Db 366 CATGCTGAAGGACCTTTACAGTATGATGATTTCTATTATTGGAAGCCCAAGTCCCAAG 425
 |||||||
 QY 61 GAATTCATTGCTTGGCTGTGTAAGGCCGAGGA 93
 |||||||
 Db 426 GAATTCATTGCTTGGCTGTGTAAGGCCGAGGA 458
 |||||||

RESULT 12

BM312520 461 bp mRNA linear EST 03-JAN-2002
 LOCUS 1975612.y1 HR85 islet Homo sapiens cDNA 5' similar to SW:GLUC_HUMAN
 DEFINITION P01275 GLUCAGON PRECURSOR. [1] ; mRNA sequence.
 ACCESSION BM312520
 VERSION BM312520.1 GI:18046865
 KEYWORDS EST.
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
 REFERENCE 1 (bases 1 to 461)
 AUTHORS Melton,D., Brown,J., Kenty,G., Permutt,A., Lee,C., Kaestner,K.,
 Lemishka,I., Scaer,M., Brestelli,J., Gradwohl,G., Clifton,S.,
 Hillier,L., Marra,M., Pape,D., Wylie,T., Martin,J., Blistain,A.,
 Schmitt,A., Theising,B., Rittler,E., Ronko,I., Bennett,J., Cardenas
 ,M., Gibbons,M., McCann,R., Cole,R., Tsagarisvilli,R., Williams,T.,
 Jackson,Y. and Bowers,Y.
 TITLE Endocrine Pancreas Consortium
 JOURNAL Unpublished (2000)
 COMMENT Contact: Douglas Melton, Klaus H. Kaestner, & Hiroshi Inoue
 Endocrine Pancreas Consortium
 Harvard University, Howard Hughes Medical Institute
 Dept of Molecular and Cellular Biology, 7 Divinity Ave, Cambridge,
 MA 02138
 Tel: 617-495-1812
 Fax: 617-495-8557
 Email: dmelton@bioh.harvard.edu
 Library was constructed by Dr. Hiroshi Inoue DNA sequencing by:
 Washington University Genome Sequencing Center For information on
 obtaining a clone please contact: Dr. Hiroshi Inoue
 (hinoue@im.wustl.edu)
 Seq primer: -40RP from Gibco
 High quality sequence stop: 401.
 FEATURES
 source
 1..461
 Location/Qualifiers
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /clone_lib="HR85 islet"
 /tissue_type="Purified pancreatic islet"
 /lab_host="DH10B"
 /note="Organ: Pancreas; Vector: pBluescript SK(-); Site:1:
 NotI; Site:2: XhoI; cDNA made by oligo-dT priming.
 Size selected on agarose gel. Average insert size ~1kb. 5'
 XhoI site was destroyed after directional cloning.
 Amplified once. Contact Information: Hiroshi Inoue, MD,
 Metabolism Div. (Alan Permutt Lab), Washington University
 School of Medicine, Box 8127, 660 South Euclid Ave., St.
 Louis, MO 63110, E-mail: hinoue@im.wustl.edu, Tel:
 314-362-1916, Fax: 314-747-2692."
 BASE COUNT 128 a 102 c 118 g 113 t
 ORIGIN
 Query Match 100.0%; Score 93; DB 13; Length 461;
 Best Local Similarity 100.0%; Pred. No. 1.7e-21;
 Matches 93; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Oy 1 CATGCTGAAGGACCTTACCAAGATGATTAAGTTCTTATTGGAAGCCCAAGCTGCCAAG 60
 Db 265 CATGCTGAAGGACCTTACCAAGATGATTAAGTTCTTATTGGAAGCCCAAGCTGCCAAG 324
 Oy 61 GAATTCATTGCTGCTGGCTGTAAGAGCCGAGGA 93
 Db 325 GAATTCATTGCTGCTGGCTGTAAGAGCCGAGGA 357
 RESULT 13 463 bp mRNA linear EST 07-MAY-2002
 LOCUS BQ271456
 DEFINITION iK14b08.y1 HR85 islet Homo sapiens cDNA clone IMAGE: 5780703 5'
 similar to SW:GLUC_HUMAN P01275 GLUCAGON PRECURSOR. [1] ; mRNA
 sequence.
 ACCESSION BQ271456

VERSION BQ271456.1 GI:20496522
 KEYWORDS EST.
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
 REFERENCE 1 (bases 1 to 463)
 AUTHORS Melton,D., Brown,J., Kenty,G., Permutt,A., Lee,C., Kaestner,K.,
 Lemishka,I., Scaer,M., Brestelli,J., Gradwohl,G., Clifton,S.,
 Hillier,L., Marra,M., Pape,D., Wylie,T., Martin,J., Blistain,A.,
 Schmitt,A., Theising,B., Rittler,E., Ronko,I., Bennett,J., Cardenas
 ,M., Gibbons,M., McCann,R., Cole,R., Tsagarisvilli,R., Williams,T.,
 Jackson,Y. and Bowers,Y.
 TITLE Endocrine Pancreas Consortium
 JOURNAL Unpublished (2000)
 COMMENT Other ESTs: iK14b08.x1
 Contact: Douglas Melton, Klaus H. Kaestner, & Hiroshi Inoue
 Endocrine Pancreas Consortium
 Harvard University, Howard Hughes Medical Institute
 Dept of Molecular and Cellular Biology, 7 Divinity Ave, Cambridge,
 MA 02138
 Tel: 617-495-1812
 Fax: 617-495-8557
 Email: dmelton@bioh.harvard.edu
 Library was constructed by Dr. Hiroshi Inoue DNA sequencing by:
 Washington University Genome Sequencing Center For information on
 obtaining a clone please contact: Dr. Hiroshi Inoue
 (hinoue@im.wustl.edu)
 Seq primer: -40RP from Gibco.
 FEATURES
 source
 1..463
 Location/Qualifiers
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /clone_image="5780703"
 /clone_lib="HR85 islet"
 /tissue_type="Purified pancreatic islet"
 /lab_host="DH10B"
 /note="Organ: Pancreas; Vector: pBluescript SK(-); Site:1:
 NotI; Site:2: XhoI; cDNA made by oligo-dT priming.
 Size selected on agarose gel. Average insert size ~1kb. 5'
 XhoI site was destroyed after directional cloning.
 Amplified once. Contact Information: Hiroshi Inoue, MD,
 Metabolism Div. (Alan Permutt Lab), Washington University
 School of Medicine, Box 8127, 660 South Euclid Ave., St.
 Louis, MO 63110, E-mail: hinoue@im.wustl.edu, Tel:
 314-362-1916, Fax: 314-747-2692."
 BASE COUNT 135 a 107 c 115 g 106 t
 ORIGIN
 Query Match 100.0%; Score 93; DB 14; Length 463;
 Best Local Similarity 100.0%; Pred. No. 1.7e-21;
 Matches 93; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Oy 1 CATGCTGAAGGACCTTACCAAGATGATTAAGTTCTTATTGGAAGCCCAAGCTGCCAAG 60
 Db 361 CATGCTGAAGGACCTTACCAAGATGATTAAGTTCTTATTGGAAGCCCAAGCTGCCAAG 420
 Oy 61 GAATTCATTGCTGCTGGCTGTAAGAGCCGAGGA 93
 Db 421 GAATTCATTGCTGCTGGCTGTAAGAGCCGAGGA 453
 RESULT 14 466 bp mRNA linear EST 23-MAY-2002
 LOCUS BQ416911
 DEFINITION iK39c06.y1 HR85 islet Homo sapiens cDNA clone IMAGE: 5783410 5'
 similar to SW:GLUC_HUMAN P01275 GLUCAGON PRECURSOR. [1] ; mRNA
 sequence.
 ACCESSION BQ416911
 VERSION BQ416911.1 GI:21122112
 KEYWORDS EST.
 SOURCE human.
 ORGANISM Homo sapiens

REFERENCE
AUTHORS

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
1 (bases 1 to 466)

TITLE
JOURNAL
COMMENT

Unpublished (2000)
Other-ESTs: IK39C06.x1
Contact: Douglas Melton, Klaus H. Kaestner, & Hiroshi Inoue
Endocrine Pancreas Consortium
Harvard University, Howard Hughes Medical Institute
Dept of Molecular and Cellular Biology, 7 Divinity Ave, Cambridge,
MA 02138
Tel: 617-495-1812
Fax: 617-495-8557
Email: dmelton@biohpc.harvard.edu
Library was constructed by Dr. Hiroshi Inoue DNA sequencing by:
Washington University Genome Sequencing Center For information on
obtaining a clone please contact: Dr. Hiroshi Inoue
(hinoue@im.wustl.edu)
Seq primer: -40RP from Gibco.
Location/Qualifiers

FEATURES
source

1..466
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="IMAGE: 5783410"
/clone_1lb="HR85 islet"
/tissue_type="Purified pancreatic islet"
/lab_host="DH10B"
/note="Organ: Pancreas; Vector: pBluescript SK(-); Site_1:
NotI; Site_2: XhoI; cDNA made by oligo-dT priming.
Size selected on agarose gel. Average insert size ~1kb. 5'
XhoI site was destroyed after directional cloning.
Amplified once. Contact information: Hiroshi Inoue, MD,
Metabolism Div. (Alan Permut Lab), Washington University
School of Medicine, Box 8127, 660 South Euclid Ave., St.
Louis, MO 63110, E-mail: hinoue@imgate.wustl.edu, Tel:
314-362-1916, Fax: 314-747-2692."

BASE COUNT
ORIGIN

139 a 108 c 113 g 106 t

Query Match 100.0%; Score 93; DB 14; Length 466;
Best Local Similarity 100.0%; Pred. No. 1.7e-21;
Matches 93; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 CATGCTGAAGGACCTTACGAGTGTAGTCTTATTGGAAAGCCAGCTGCCAAG 60
|||||
DB 370 CATGCTGAAGGACCTTACGAGTGTAGTCTTATTGGAAAGCCAGCTGCCAAG 429
OY 61 GAATTCATTGCTTGGCTGGTGAAGGCCGAGGA 93
|||||
DB 430 GAATTCATTGCTTGGCTGGTGAAGGCCGAGGA 462

RESULT 15
BQ271361 468 bp mRNA linear EST 07-MAY-2002
LOCUS BQ271361
DEFINITION ik12h07.y1 HR85 islet Homo sapiens cDNA clone IMAGE: 5780965 5'
similar to SM:GLUC_HUMAN P01275 GLUCAGON PRECURSOR. [1] ;, mRNA
sequence.

ACCESSION BQ271361
VERSION BQ271361.1 GI:20496427
KEYWORDS EST.

SOURCE human.
ORGANISM Homo sapiens

REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
1 (bases 1 to 468)
AUTHORS Melton,D., Brown,J., Kenty,G., Permut,A., Lee,C., Kaestner,K.,

TITLE
JOURNAL
COMMENT

Unpublished (2000)
Other-ESTs: ik12h07.x1
Contact: Douglas Melton, Klaus H. Kaestner, & Hiroshi Inoue
Endocrine Pancreas Consortium
Harvard University, Howard Hughes Medical Institute
Dept of Molecular and Cellular Biology, 7 Divinity Ave, Cambridge,
MA 02138
Tel: 617-495-1812
Fax: 617-495-8557
Email: dmelton@biohpc.harvard.edu
Library was constructed by Dr. Hiroshi Inoue DNA sequencing by:
Washington University Genome Sequencing Center For information on
obtaining a clone please contact: Dr. Hiroshi Inoue
(hinoue@im.wustl.edu)
Seq primer: -40RP from Gibco.
Location/Qualifiers

FEATURES
source

1..468
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="IMAGE: 5780965"
/clone_1lb="HR85 islet"
/tissue_type="Purified pancreatic islet"
/lab_host="DH10B"
/note="Organ: Pancreas; Vector: pBluescript SK(-); Site_1:
NotI; Site_2: XhoI; cDNA made by oligo-dT priming.
Size selected on agarose gel. Average insert size ~1kb. 5'
XhoI site was destroyed after directional cloning.
Amplified once. Contact information: Hiroshi Inoue, MD,
Metabolism Div. (Alan Permut Lab), Washington University
School of Medicine, Box 8127, 660 South Euclid Ave., St.
Louis, MO 63110, E-mail: hinoue@imgate.wustl.edu, Tel:
314-362-1916, Fax: 314-747-2692."

BASE COUNT
ORIGIN

140 a 108 c 114 g 106 t

Query Match 100.0%; Score 93; DB 14; Length 468;
Best Local Similarity 100.0%; Pred. No. 1.7e-21;
Matches 93; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 CATGCTGAAGGACCTTACGAGTGTAGTCTTATTGGAAAGCCAGCTGCCAAG 60
|||||
DB 370 CATGCTGAAGGACCTTACGAGTGTAGTCTTATTGGAAAGCCAGCTGCCAAG 429
OY 61 GAATTCATTGCTTGGCTGGTGAAGGCCGAGGA 93
|||||
DB 430 GAATTCATTGCTTGGCTGGTGAAGGCCGAGGA 462

Search completed: February 14, 2003, 09:05:34
Job time : 1189 secs

us-09-091-605-4.rge

Thu Feb 27 13:12:08 2003

GenCore version 5.1.4-p5-4578
Copyright (c) 1993 - 2003 Compen Ltd.

OM nucleic - nucleic search, using sw model
February 14, 2003, 07:50:34 ; Search time 621.5 Seconds
(without alignments)
Run on: 4354.885 Million cell updates/sec

US-09-091-605-4
1 CATGTTGAAGGACCTTAC.....GGCTGTCGAAGCGCCGAGA 93

Title: Perfect score: 1
Sequence: IDENTITY_NUC
Gapop 10.0, Gapext 1.0

Scoring table: Gapop 10.0, Gapext 1.0

Searched: 2054640 seqs, 14551402878 residues 4109280

Total number of hits satisfying chosen parameters:

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : GenEmbl :
1: gb.ba :
2: gb.hcg :
3: gb.in :
4: gb.om :
5: gb.ov :
6: gb.pat :
7: gb.ph :
8: gb.pl :
9: gb.pr :
10: gb.ro :
11: gb.sts :
12: gb.sy :
13: gb.un :
14: gb.vi :
15: em.ba :
16: em.fun :
17: em.hum :
18: em.in :
19: em.mu :
20: em.mu :
21: em.or :
22: em.ov :
23: em.pat :
24: em.ph :
25: em.pl :
26: em.ro :
27: em.sts :
28: em.un :
29: em.vi :
30: em.hcg.hum :
31: em.hcg.lnv :
32: em.hcg.other :
33: em.hcg.mus :
34: em.hcg.pln :
35: em.hcg.rod :
36: em.hcg.man :
37: em.hcg.vrt :
38: em.sy :
39: em.hcgo.hum :
40: em.hcgo.mus :
41: em.hcgo.other :

score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Match	Length	DB	ID	Description
1	91.4	98.3	396	6	AX147675	AX147675 Sequence
2	91.4	98.3	528	6	AR030615	AR030615 Sequence
3	91.4	98.3	528	6	AR168153	AR168153 Sequence
4	91.4	98.3	528	6	E05860	E05860 DNA encodin
5	91.4	98.3	528	6	AF529185	AF529185 Ovis arie
6	91.4	98.3	528	6	AR108107	AR108107 Sequence
7	91.4	98.3	528	6	AR108109	AR108109 Sequence
8	91.4	98.3	528	6	HUMGLUC	HUMGLUC
9	91.4	98.3	528	6	BOVGLC	BOVGLC
10	91.4	98.3	528	6	BC005278	BC005278
11	91.4	98.3	528	6	AR108119	AR108119 Sequence
12	91.4	98.3	528	6	HSGLUCG2	HSGLUCG2
13	91.4	98.3	528	6	AC007750	AC007750
14	91.4	98.3	528	6	AR030614	AR030614
15	91.4	98.3	528	6	AR168152	AR168152
16	91.4	98.3	528	6	AR168152	AR168152
17	91.4	98.3	528	6	AR168152	AR168152
18	91.4	98.3	528	6	AR168152	AR168152
19	91.4	98.3	528	6	AR168152	AR168152
20	91.4	98.3	528	6	AR168152	AR168152
21	91.4	98.3	528	6	AR168152	AR168152
22	91.4	98.3	528	6	AR168152	AR168152
23	91.4	98.3	528	6	AR168152	AR168152
24	91.4	98.3	528	6	AR168152	AR168152
25	91.4	98.3	528	6	AR168152	AR168152
26	91.4	98.3	528	6	AR168152	AR168152
27	91.4	98.3	528	6	AR168152	AR168152
28	91.4	98.3	528	6	AR168152	AR168152
29	91.4	98.3	528	6	AR168152	AR168152
30	91.4	98.3	528	6	AR168152	AR168152
31	91.4	98.3	528	6	AR168152	AR168152
32	91.4	98.3	528	6	AR168152	AR168152
33	91.4	98.3	528	6	AR168152	AR168152
34	91.4	98.3	528	6	AR168152	AR168152
35	91.4	98.3	528	6	AR168152	AR168152
36	91.4	98.3	528	6	AR168152	AR168152
37	91.4	98.3	528	6	AR168152	AR168152
38	91.4	98.3	528	6	AR168152	AR168152
39	91.4	98.3	528	6	AR168152	AR168152
40	91.4	98.3	528	6	AR168152	AR168152
41	91.4	98.3	528	6	AR168152	AR168152
42	91.4	98.3	528	6	AR168152	AR168152
43	91.4	98.3	528	6	AR168152	AR168152
44	91.4	98.3	528	6	AR168152	AR168152
45	91.4	98.3	528	6	AR168152	AR168152

ALIGNMENTS

RESULT 1
AX147675 396 bp DNA
LOCUS AX147675
DEFINITION AX147675
ACCESSION AX147675
VERSION AX147675.1 GI:14346730
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1 (bases 1 to 396)
TRECIO, D.A., CONCINO, M.F. and DUGUAY, S.J.
Nucleic acid construct for optimized production of products
Patent: WO 0136643-A-2 25-MAY-2001;
TRANSMUTANTIC THERAPIES, INC. (US)

Pred. No. is the number of results predicted by chance to have a

source 1..528
/organism="synthetic construct"
/db_xref="taxon:32630"
BASE COUNT 142 a 122 c 143 g 121 t
ORIGIN

Query Match 98.3%; Score 91.4; DB 6; Length 528;
Best Local Similarity 98.9%; Pred. No. 5.2e-21;
Matches 92; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 CATGTTGAAGGACCTTACAGTATGATGTTCTTATTGGAAGGCCAAGCTCCCAAG 60
|||||
DB 1 CATGCTGAAGGACCTTACAGTATGATGTTCTTATTGGAAGGCCAAGCTCCCAAG 60

QY 61 GAATTCATTGCTTGGCTGCTGAAGGCCGAGGA 93
|||||
DB 61 GAATTCATTGCTTGGCTGCTGAAGGCCGAGGA 93

RESULT 5
AF529185 559 bp mRNA linear MAM 13-AUG-2002
LOCUS AF529185
DEFINITION Ovis aries preproglucagon mRNA, partial cds.
ACCESSION AF529185
VERSION AF529185.1 GI:22212831
KEYWORDS
SOURCE sheep.
ORGANISM Ovis aries
REFERENCE 1 (bases 1 to 559)
AUTHORS Limesand, S.W. and Hay, W.W. Jr.
TITLE Characterization of the endocrine pancreas in an ovine placental
JOURNAL Unpublished
REFERENCE 2 (bases 1 to 559)
AUTHORS Limesand, S.W. and Hay, W.W. Jr.
TITLE Direct Submission
JOURNAL Submitted (15-JUL-2002) Pediatrics, University of Colorado Health
Sciences Center, 4200 E 9th Ave, Denver, CO 80262, USA

FEATURES
source
1..559
/organism="Ovis aries"
/db_xref="taxon:9940"
/tissue_type="pancreas"
/dev_stage="fetal"
1..30
31..>559
/codon_start=1
/product="preproglucagon"
/protein_id="AA094A09.1"
/translation="MKSILFVAGLVLMALQSGWQSLQNTKSSSPAPQDPLGDP
DOISDKRHSQGFSTSDYKSLDSRRADQFVQMLNKTNNKNNIAKHDFERRHAGT
FISDVSSYLEGQAAKEFIAMLVKGRGRDPEPVNIVEELRRRRHADGSPSDMNTVLD
SLATRDFIMVLOTIR"

BASE COUNT 160 a 137 c 138 g 124 t
ORIGIN

Query Match 98.3%; Score 91.4; DB 4; Length 559;
Best Local Similarity 98.9%; Pred. No. 5.3e-21;
Matches 92; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 CATGTTGAAGGACCTTACAGTATGATGTTCTTATTGGAAGGCCAAGCTCCCAAG 60
|||||
DB 322 CATGCTGAAGGACCTTACAGTATGATGTTCTTATTGGAAGGCCAAGCTCCCAAG 381

QY 61 GAATTCATTGCTTGGCTGCTGAAGGCCGAGGA 93
|||||
DB 382 GAATTCATTGCTTGGCTGCTGAAGGCCGAGGA 414

RESULT 6
AR108107 955 bp DNA linear PAT 14-FEB-2001
LOCUS AR108107
DEFINITION Sequence 57 from patent US 6110707.
ACCESSION AR108107
VERSION AR108107.1 GI:12823594
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

REFERENCE 1 (bases 1 to 955)
AUTHORS Newgard, C.B., Halban, P., Normington, K.D., Clark, S.A., Thigpen, A.E.,
Quade, C., Kruse, F., and McGarry, D.
TITLE Recombinant expression of proteins from secretory cell lines
JOURNAL Patent: US 6110707-A 57 29-AUG-2000;
FEATURES location/Qualifiers
source 1..955
/organism="unknown"

BASE COUNT 301 a 181 c 203 g 270 t
ORIGIN

Query Match 98.3%; Score 91.4; DB 6; Length 955;
Best Local Similarity 98.9%; Pred. No. 5.4e-21;
Matches 92; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 CATGTTGAAGGACCTTACAGTATGATGTTCTTATTGGAAGGCCAAGCTCCCAAG 60
|||||
DB 318 CATGCTGAAGGACCTTACAGTATGATGTTCTTATTGGAAGGCCAAGCTCCCAAG 377

QY 61 GAATTCATTGCTTGGCTGCTGAAGGCCGAGGA 93
|||||
DB 378 GAATTCATTGCTTGGCTGCTGAAGGCCGAGGA 410

RESULT 7
AR108109 955 bp DNA linear PAT 14-FEB-2001
LOCUS AR108109
DEFINITION Sequence 60 from patent US 6110707.
ACCESSION AR108109
VERSION AR108109.1 GI:12823596
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

REFERENCE 1 (bases 1 to 955)
AUTHORS Newgard, C.B., Halban, P., Normington, K.D., Clark, S.A., Thigpen, A.E.,
Quade, C., Kruse, F., and McGarry, D.
TITLE Recombinant expression of proteins from secretory cell lines
JOURNAL Patent: US 6110707-A 60 29-AUG-2000;
FEATURES location/Qualifiers
source 1..955
/organism="unknown"

BASE COUNT 302 a 180 c 202 g 271 t
ORIGIN

Query Match 98.3%; Score 91.4; DB 6; Length 955;
Best Local Similarity 98.9%; Pred. No. 5.4e-21;
Matches 92; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 CATGTTGAAGGACCTTACAGTATGATGTTCTTATTGGAAGGCCAAGCTCCCAAG 60
|||||
DB 318 CATGCTGAAGGACCTTACAGTATGATGTTCTTATTGGAAGGCCAAGCTCCCAAG 377

QY 61 GAATTCATTGCTTGGCTGCTGAAGGCCGAGGA 93
|||||
DB 378 GAATTCATTGCTTGGCTGCTGAAGGCCGAGGA 410

RESULT 8
HUMGLUC 1062 bp mRNA linear PRI 08-NOV-1994
LOCUS HUMGLUC
DEFINITION Human glucagon mRNA, complete cds.
ACCESSION J04040

```

VERSION      J04040.1 GI:183269
KEYWORDS     glucenlin; glucagon.
SOURCE       Human (neonate) brainstem, cDNA to mRNA, clones BS13.A,B].
ORGANISM     Homo sapiens
              Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE    1 (bases 1 to 1062)
AUTHORS      Drucker,D.J. and Asa,S.
TITLE        Glucagon gene expression in vertebrate brain
JOURNAL      J. Biol. Chem. 263 (27), 13475-13478 (1988)
MEDLINE      88330860
PUBMED       2901414
FEATURES     source
              location/Qualifiers
              1..1062
              /organism="Homo sapiens"
              /db_xref="taxon:9606"
              /map="2q36-q37"
              1..1062
              /gene="GCG"
              <1..1062
              /gene="GCG"
              /product="GCG mRNA"
              38..580
              /gene="GCG"
              /note="preproglucagon"
              /codon_start=1
              /protein_id="AA52567.1"
              /db_xref="GI:183270"
              /db_xref="GDB:G00-119-265"
              /translation="MKSIFVAGLFVNLVQSGWRSIQTEKSRFSASQADPLSDP
              DOMEDKRHSOCTFTSDYSKYIDSRADDFVQMLNTRNNRIAKRHDEFERHAGT
              FTSVSSYLEGQAKEFTLAWLVKGRGRDPPEVNIYELRRRHADGSFSDENMTILD
              NLAARDFINMLIQTKITDRK"
              38..97
              /gene="GCG"
              /note="glucagon signal peptide"
              98..304
              /gene="GCG"
              /product="glucenlin"
              194..280
              /gene="GCG"
              /product="glucagon"
              287..304
              /gene="GCG"
              /product="intervening peptide I"
              311..421
              /gene="GCG"
              /product="glucagon-like peptide I"
              428..466
              /gene="GCG"
              /product="intervening peptide II"
              473..571
              /gene="GCG"
              /product="glucagon-like peptide II"
              200 c 215 g 307 t
BASE COUNT   81 bp upstream of RsaI site; chromosome 2q36-q37.
ORIGIN
Query Match 98.3%; Score 91.4; DB 9; Length 1062;
Best Local Similarity 98.9%; Pred. No. 5,4e-21;
Matches 92; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1 CATGTGAAGGACCTTACCATGATGATGATTTATTATTTGGAAGCCCAAGCTGCCAAG 60
DB 329 CATGCTGAAGGACCTTACCATGATGATGATTTATTATTTGGAAGCCCAAGCTGCCAAG 388
QY 61 GAATTCATTGCTTGGCTGTGTAAGGCCGAGGA 93
DB 389 GAATTCATTGCTTGGCTGTGTAAGGCCGAGGA 421
RESULT 9
BOVGG BOVGG 1108 bp mRNA linear MAM 27-APR-1993
LOCUS

```

```

DEFINITION   Bovine pancreas preproglucagon mRNA.
ACCESSION   K00107
VERSION      K00107.1 GI:163081
KEYWORDS     glucenlin; glucagon; hormone.
SOURCE       Bovine cDNA to pancreatic mRNA.
ORGANISM     Bos taurus
              Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
              Bovidae; Bos.
REFERENCE    1 (bases 1 to 1108)
AUTHORS      Lopez,L.C., Frazier,M.L., Su,C.J., Kumar,A. and Saunders,G.F.
TITLE        Mammalian pancreatic preproglucagon contains three glucagon-related
              peptides
JOURNAL      Proc. Natl. Acad. Sci. U.S.A. 80 (18), 5485-5489 (1983)
MEDLINE      83299996
PUBMED       6577439
FEATURES     source
              location/Qualifiers
              1..1108
              /organism="Bos taurus"
              /db_xref="taxon:9913"
              91..633
              /note="preproglucagon"
              /codon_start=1
              /protein_id="AAA30538.1"
              /db_xref="GI:163082"
              /translation="MKSIFVAGLFVNLVQSGWRSIQTEKSRFSASQADPLSDP
              DOMEDKRHSOCTFTSDYSKYIDSRADDFVQMLNTRNNRIAKRHDEFERHAGT
              FTSVSSYLEGQAKEFTLAWLVKGRGRDPPEVNIYELRRRHADGSFSDENMTILD
              SLATRDFINMLIQTKITDRK"
              232 c 213 g 307 t
BASE COUNT   356 a 232 c 213 g 307 t
ORIGIN
Query Match 98.3%; Score 91.4; DB 4; Length 1108;
Best Local Similarity 98.9%; Pred. No. 5,4e-21;
Matches 92; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1 CATGTGAAGGACCTTACCATGATGATGATTTATTATTTGGAAGCCCAAGCTGCCAAG 60
DB 382 CATGCTGAAGGACCTTACCATGATGATGATTTATTATTTGGAAGCCCAAGCTGCCAAG 441
QY 61 GAATTCATTGCTTGGCTGTGTAAGGCCGAGGA 93
DB 442 GAATTCATTGCTTGGCTGTGTAAGGCCGAGGA 474
RESULT 10
BOVGG BOVGG 1154 bp mRNA linear PRI 12-JUL-2001
LOCUS
ACCESSION   BC005278
VERSION      BC005278
KEYWORDS     complete cds.
SOURCE       Homo sapiens.
ORGANISM     Homo sapiens
              Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE    1 (bases 1 to 1154)
AUTHORS      Strausberg,R.
TITLE        Direct Submission
JOURNAL      Submitted (27-MAR-2001) National Institutes of Health, Mammalian
              Gene Collection (MGC), Cancer Genomics Office, National Cancer
              Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590,
              USA
REMARK       NIH-MGC Project URL: http://mgc.nci.nih.gov
              Contact: MGC help desk
              Email: cgapbs-retail.nih.gov
              Tissue Procurement: CLOMTECH
              CDNA Library Preparation: CLOMTECH Laboratories, Inc.
              CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LNL)
              DNA Sequencing by: Sequencing Group at the Stanford Human Genome
              Center, Stanford University School of Medicine, Stanford, CA 94305
              Web site: http://www.shgc.stanford.edu

```


Contact: (Dickson, Mark) mcdepaxil.stanford.edu
Dickson, M., Schmutz, J., Grimwood, J., Rodriguez, A., and Myers, R. M.

Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at: <http://image.llnl.gov>
Series: IRAL Plate: 16 Row: k Column: 10
This clone was selected for full length

Location/Qualifiers: matched mRNA gi: 4503944

FEATURES

SOURCE

```

/organism="Homo sapiens"
/db_xref="taxon:9606"
/db_xref="locusID:2641"
/clone="MGC:12325 IMAGE:3950435"
/tissue_type="Pancreas"
/clone_lib="NH_MGC_78"
/lab_host="DH10B"
/notes="Vector: pDNR-LIB"
100..642
CDS

```

BASE COUNT	ORIGIN
391 a	218 c
	226 g
	319 t

Query Match	98.3%	Score 91.4;	DB 9;	Length 1154;
Best Local Similarity	98.9%	Pred. No. 5.4e-21;		
Matches	92;	Conservative	0;	Mismatches 1.

QY	QY	QY
1	CAATGTAAGAGGGACCTTTACCGAGTATGTAAAGTTCTTATTTTGAAGGCCAAGCTGCCAAG	60
391	CATGCTGAAGGACCTTTACCGAGTATGTAAAGTTCTTATTTTGAAGGCCAAGCTGCCAAG	450
61	GAATTCATTGCTTGGCTGGTGAAGAGGCCGAGGA	93
451	GAATTCATTGCTTGGCTGGTGAAGAGGCCGAGGA	483

RESULT 11
AR108119

Accession	AJ018119.1	
Definition	Sequence 72 from patent US 6110707.	DNA
Accession	AR108119.1	GI:12823606
Version		
Keywords		

SOURCE	ORGANISM	REFERENCE
Unknown.	Unknown.	1 (bases 1 to 2356)
Unknown.	Unclassified.	

NOTES	TITLE	JOURNAL	REFERENCES
	Recombinant expression of proteins from secretory cell lines	US 6110707-A 72 29-AUG-2000;	Quade, C., Kruse, F. and McGarry, D.
			Wengert, C., B., Halban, P., Normington, K. D., Clark, S. A., Thigpen, A. E.,

SOURCE	1. .2356	/organism="unknown"
BASE COUNT	614 a	600 c 581 g 561 t
ORIGIN		

Query Match	98.38;	Score 91.4;	DB 6;	Length 2356;
Best Local Similarity	98.9%;	Pred. No. 5.5e-21;		
Matches	92;	Conservative	0;	Mismatches 1;
			Indels	0;
			Gaps	0.

[illegible][illegible]

RESULT 12			
LOCUS	HSGLUC		
DEFINITION	Human gene encoding preproglucagon. Glucagon is a 29-amino acid		
	6455 bp	DNA	linear
			PR1 09-FEB-1999

action of insulin by stimulating hepatic glycogenolysis and gluconeogenesis. Also included in the proglucagon sequence are two regions (GIP-1 and GIP-2) which are homologous to glucagon itself but not identical.

ACCESSION	V01515
VERSION	V01515.1
KEYWORDS	GI:31777
ORGANISM	glucagon; signal peptide.
SOURCE	Homo sapiens.
ORGANISM	Homo sapiens

REFERENCE
AUTHORS

Bell, G.I., Sanchez-Pescador, R., Iaybourn, P.J. and Natarian, B. C.
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 6455)

TITLE	Exon duplication and divergence in the human preproglucagon gene
JOURNAL	Nature 304 (5924), 368-371 (1985)
MEDLINE	83271477
PUBMED	6877358
COMMENT	Data kindly provided by Dr. G. L. Smith

FEATURES	DATE
Location/Qualifiers	20-SEP-1983
1. 6455	by G.I. Bell.
/organism="Homo sapiens"	
/db_xref="taxon:9606"	

```

CDS
    join(168..229,1832..1993,3661..3798,5168..5315)
        /codon_start=1
        /product="precursor"
        /protein_id="CAA24759.1"
        /db_xref="db_xref"

```

```

/od_xref="SMISS-PROT:P01275"
/translation="KSIYFVAGLEVMIVQGSWORSIQDNEEKSRSFASQADPLSD
DQNEEDKSYSGFTSDYSKIDSRADDVQIMLIMLRNNINLAKRDEEHKAGST
FTIDVSSYLEGQAEFTMIYKGRGRDPEFVAIDPEIAPKADKDEEPPNMAV"

```

```
MAAREIIMLIQTITDR"
168. .227
sig_peptide
mat_peptide
/product="glucagon"
```

```
mac_peptide      3680.  .3790  
                  /product="GLP-1"  
mat_peptide      5211.  .5312  
                  /product="GLP-2"  
intron           260.   .1831
```

intron	/number=1 1994. .3660
intron	/number=2 3799. .5167

Query Match	BASE COUNT	ORIGIN	/number=3
98.3%	2167	a	1107
Score 91.4		c	1121
nb 9.1		g	2060
1000th call		t	

1 CATGTTGAGGACGACCTTTACCAAGTATGTAAAGTCTTATTTGGAAGGCCAAGTCGCAAG 60
Best Local Similarity 98.98%; Predicted Length 6455;
Matches 92; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

3698 CATGCTGAAGGAGCCTTTCACAGTATGTAAGTTCTTATTTTGGAAAGGCCAAGTGGCAAG 3757

```

b      3758  GAATTCATTGCTTTGGCTGCTGTAAGGCCGAGGA 3790
RESULT 13

```

LOCUS	DEFINITION	ACCESSION	VERSION	KEYWORDS	SOURCE	ORGANISM	REFERENCE	AUTHORS	TITLE	JOURNAL	MEDLINE	PUBMED	COMMENT	FEATURES
HSGLUCG2	Human glucagon gene.	X03991	X03991.1	gi:31786	glucagon; glucagon-like peptide; hormone; preproglucagon; preprohormone; signal peptide.	Homo sapiens.	Homo sapiens	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.	1 (bases 1 to 10050)	White, J.W. and Saunders, G.F.	Structure of the human glucagon gene	Nucleic Acids Res. 14 (12), 4719-4730 (1986)	See also <HSGLUC; V01515> which is derived from the same library. Sequence discrepancies may indicate that the two clones represent different alleles or may be due to cloning artefacts. pos. 3516 in <X03991> corresponds to pos. 9 in <V01515> (the first eight nucleotides of which are probably a cloning artefact).	Location/Qualifiers 1..10050 /organism="Homo sapiens" /db_xref="taxon:9606" /clone="lambdaHCCG1" /clone_lib="fetal liver genomic DNA" complement(535..538) /note="CAAT-box (complementary strand)" 577..581 /note="TATA-box" 603..698 /note="exon 1; untranslated leader (5' UT-region)" 699..3665 /note="intron 1" 3666..3766 /note="exon 2" join(3675..3766,5339..5500,7177..7314,8683..8826,9481..9487) /note="prepro-glucagon" /codon_start=1 /protein_id="CAA27627.1" /db_xref="GI:762941" /db_xref="SWISS-PROT:P01275" /translation="MKSIFYVAGLEFVMIYVGGSKORSLDIEFKSRSSASQADPLSPDMDNKRHSQCTFSDYSKYLDSRRADFPQWMNTRNNITAKRDEERRAEETFSDDVSLGCGAAKEFTIAMVKGGRDRPFEVAIVELGRRHADSFSDEMTILDNIAADFNIMLIQTKITDRK" 3675..3734 3767..5338 /note="intron II" 5339..5500 /note="exon 3" 5339..5396 /note="glucinin related pancreatic peptide (AA 12-30) (5339 is 3rd base in codon)" 5397..5402 /note="spacer (AA 31-32; 2AA)" 5403..5489 /note="glucagon (AA 33-61; 29AA)" 5490..5500 /note="spacer (AA 61-65; 4AA) (5500 is 2nd base in codon)" 5501..7176 /note="intron III" 7177..7314 /note="exon 4" 7177..7195 /note="spacer (AA 66-71; 6AA) (7177 is 3rd base in codon)" 7196..7306 /note="glucagon-like peptide 1 (AA 72-108; 37AA)" 7307..7314 /note="spacer (AA 109-111; 3AA) (7314 is 2nd base in codon)"

intron	7315..8682	/note="intron IV"
exon	8683..8826	/note="exon 5"
misc_feature	8683..8826	/note="pro-glucagon (AA 112-159) (8683 is 3rd base in codon) (8826 is 2nd base in codon)"
misc_feature	8683..8725	/note="spacer (AA 112-125; 14AA) (8683 is 3rd base in codon)"
misc_feature	8726..8826	/note="glucagon-like peptide 2 (AA 126-159) (8826 is 2nd base in codon)"
intron	8827..9480	/note="intron V"
exon	9481..95487	/note="exon 6"
misc_feature	9481..9484	/note="glucagon-like peptide 2 (AA 159-160; 35AA total) (9481 is 3rd base in codon)"
misc_feature	9481..9484	/note="pro-glucagon (AA 159-160) (9481 is 3rd base in codon)"
misc_feature	9950..9956	/note="pot. polyA signal"
misc_feature	9956..9974	/note="region of pot. polyA sites"
BASE COUNT	3397 a 1698 c 1746 g 3209 t	
ORIGIN		
Query Match	98.34	Score 91.4; DB 9; Length 10050;
Best local Similarity	98.98	Pred. No. 5.8e-21;
Matches	92; Conservative	0; Mismatches 1; Indels 0; Gaps 0;
OY	1	CATGTTGAAGGACCTTTACACATGATGATAGTTCTTATTGGAGGCCAAGCTGCCAAG 60
Db	7214	CATGCTGAAGGACCTTTACACATGATGATAGTTCTTATTGGAGGCCAAGCTGCCAAG 7273
OY	61	GAATTCATTGCTTGCGCTGGTGAAGGCCGAGGA 93
Db	7274	GAATTCATTGCTTGCGCTGGTGAAGGCCGAGGA 7306
RESULT 14		
AC007750/c		163681 bp DNA linear PRI 02-OCT-2000
LOCUS	AC007750	
DEFINITION	Homo sapiens BAC clone RP11-576116 from 2, complete sequence.	
ACCESSION	AC007750	
VERSION	AC007750.3	GI:6094634
KEYWORDS	HTG.	
SOURCE	Homo sapiens.	
ORGANISM	Homo sapiens.	
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;	
AUTHORS	Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.	
TITLE	1 (bases 1 to 163681)	
JOURNAL	Suiston,J.E. and Waterston,R.	
REFERENCE	Toward a complete human genome sequence	
AUTHORS	Genome Res. 8 (11), 1097-1108 (1998)	
JOURNAL	99063792	
MEDLINE	9847074	
PUBMED	2 (bases 1 to 163681)	
REFERENCE	Cotton,M., Maupin,R., Hawkins,M. and Harkins,R.	
AUTHORS	The sequence of Homo sapiens BAC clone RP11-576116	
TITLE	Unpublished	
JOURNAL	3 (bases 1 to 163681)	
REFERENCE	Waterston,R.H.	
AUTHORS	Direct Submission	
JOURNAL	Submitted (05-JUN-1999) Genome Sequencing Center, Washington	
REFERENCE	University School of Medicine, 4444 Forest Park Parkway, St. Louis	
AUTHORS	MO 63108, USA	
TITLE	4 (bases 1 to 163681)	
REFERENCE	Waterston,R.H.	
AUTHORS	Direct Submission	
TITLE		

JOURNAL

Submitted (22-OCT-1999) Genome Sequencing Center, Washington University School of Medicine, 4444 Forest Park Parkway, St. Louis, MO 63108, USA
5 (bases 1 to 163681)
Waterston, R.

REFERENCE

AUTHORS

TITLE

JOURNAL

COMMENT

Submitted (02-OCT-2000) Department of Genetics, Washington University, 4444 Forest Park Avenue, St. Louis, Missouri 63108, USA
On Oct 22, 1999 this sequence version replaced g1:5103889.

----- Genome Center

Center: Washington University Genome Sequencing Center

Center code: WUGSC

Web site: <http://genome.wustl.edu/gsc>

Contact: sapiens@watson.wustl.edu

----- Summary Statistics

Center project name: H_NH0576116

NOTICE: This sequence may not represent the entire insert of this clone. It may be shorter because we only sequence overlapping clone sections once, or longer because we provide a small overlap between neighboring data submissions.

This sequence was finished as follows unless otherwise noted:
all regions were double stranded, sequenced with an alternate chemistry, or covered by high quality data (i.e., phred quality >= 30); an attempt was made to resolve all sequencing problems, such as compressions and repeats; all regions were covered by sequence from more than one subclone; and the assembly was confirmed by restriction digest.

MAPPING INFORMATION:

Mapping information for this clone was provided by Dr. John D. McPherson, Department of Genetics, Washington University, St. Louis MO. For additional information about the map position of this sequence, see <http://genome.wustl.edu/gsc>

SOURCE INFORMATION:

The RPCI-11 human BAC library was made from the blood of one male donor, as described by Osoegawa, K., Moon, P.Y., Zhao, B., Frengen, E., Tatenno, M., Catanesi, J.J. and de Jong, P.J. (1998) An improved approach for construction of bacterial artificial chromosome libraries. Genomics 51:1-8. The clone may be obtained either from Research Genetics, Inc. (<http://www.resgen.com>) or Pieter de Jong and coworkers at the Roswell Park Cancer Institute (<http://bacpac.med.buffalo.edu>)

VECTOR: pBACe3.6

NEIGHBORING SEQUENCE INFORMATION:

The clone sequenced to the left is RP11-178A14. Actual start of this clone is at base position 1 of RP11-576116; actual end is at base position 163681 of RP11-576116.

Location/Qualifiers

1. 163681

/organism="Homo sapiens"

/db_xref="taxon:9606"

/chromosome="2"

/map="2"

/clone="RP11-576116"

/clone_lib="RPCI-11"

216. 322

/rpt_family="MER81"

/rpt_family="(CACGT)n"

1536. 1694

/rpt_family="MIR"

2098. 3518

/rpt_family="L2"

3614. 3902

/rpt_family="Alu"

4090. 4568

/rpt_family="MER1_type"

5128. 5148

/rpt_family="AT-rich"

repeat_region

5263. 5299

/rpt_family="(CA)n"

repeat_region

5417. 5648

/rpt_family="L1"

repeat_region

7093. 7556

/rpt_family="L2"

repeat_region

8702. 9187

/rpt_family="MaLR"

repeat_region

9386. 9586

/rpt_family="MIR"

repeat_region

10580. 10739

/rpt_family="L2"

repeat_region

10792. 11064

/rpt_family="Alu"

repeat_region

11136. 12912

/rpt_family="L1"

misc_feature

12894. 12899

/note="match to EST AI077564 (NID:93411972) OZ33905.X1"

repeat_region

12982. 13011

/rpt_family="(TTG)n"

repeat_region

13109. 13133

/rpt_family="(TTA)n"

repeat_region

13134. 13419

/rpt_family="Alu"

repeat_region

13833. 14130

/rpt_family="Alu"

repeat_region

14437. 14573

/rpt_family="MER1_type"

repeat_region

14742. 14887

/rpt_family="L1"

repeat_region

15098. 15234

/rpt_family="L1"

misc_feature

15444. 15460

/note="match to EST AI922427 (NID:95658391) WO06D10.X1"

repeat_region

15449. 15475

/rpt_family="(T)n"

repeat_region

15476. 15695

/rpt_family="L1"

repeat_region

15713. 15993

/rpt_family="Alu"

repeat_region

15994. 16013

/rpt_family="(TAAA)n"

repeat_region

16039. 16131

/rpt_family="L1"

repeat_region

16140. 16281

/rpt_family="L1"

repeat_region

16284. 16327

/rpt_family="(TG)n"

repeat_region

16328. 16394

/rpt_family="(CATA)n"

repeat_region

16396. 16576

/rpt_family="L1"

repeat_region

16625. 16997

/rpt_family="L1"

repeat_region

17020. 17274

/rpt_family="L1"

repeat_region

17270. 17603

/rpt_family="L1"

repeat_region

17644. 18442

/rpt_family="L1"

repeat_region

18444. 20187

/rpt_family="L1"

repeat_region

20260. 20562

/rpt_family="MER1_type"

repeat_region

20563. 20850

/rpt_family="Alu"

repeat_region

20851. 20910

/rpt_family="MER2_type"

repeat_region

21194. 21218

/rpt_family="(T)n"

misc_feature

21204. 21219

/note="match to EST AI582416 (NID:94566313) tr97d11.x1"

misc_feature

21204. 21219

Search completed: February 14, 2003, 08:25:24
 JOD time : 662.5 secs

misc_feature /note="match to EST AI583407 (NID:94569304) ts09d01.xl"
 21204. .21219
 /note="match to EST AI589439 (NID:94598487) tr76a08.xl"
 21204. .21219
 /note="match to EST AI865901 (NID:95530008) wk88p06.xl"
 21618. .21730
 /rpt_family="MERL_type"
 21800. .21840
 /rpt_family="AT_rich"
 21991. .22290
 /rpt_family="Alu"
 21991. .22205
 /note="match to EST AI682812 (NID:944892994) wc66f03.xl"
 22464. .22658
 /rpt_family="MALR"
 22756. .23030
 /rpt_family="MALR"
 23343. .23397
 /rpt_family="(CA)n"
 23919. .23983
 /rpt_family="MIR"
 24424. .24581
 /rpt_family="MERL_type"
 24728. .24983
 /note="match to EST T10929 (NID:9391083)"
 24730. .25234
 misc_feature

Query Match 98.3%; Score 91.4; DB 9; Length 163681;
 Best Local Similarity 98.9%; Pred. No. 6.5e-21;
 Matches 92; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1 CATGCTGAAGGACCTTACCGATGATGAAGTCTTATTGGAGGCCCAAGCTGCCAAG 60
 |||||
 Db 27495 CATGCTGAAGGACCTTACCGATGATGAAGTCTTATTGGAGGCCCAAGCTGCCAAG 27436
 OY 61 GAATTCATTCCTGGCTGCTGAAGGCCGAGGA 93
 |||||
 Db 27435 GAATTCATTCCTGGCTGCTGAAGGCCGAGGA 27403

RESULT 15
 AR030614
 LOCUS AR030614 528 bp DNA linear PAT 29-SEP-1999
 DEFINITION Sequence 7 from patent US 5861284.
 ACCESSION AR030614
 VERSION AR030614.1 GI:5943828
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 Unclassified.
 REFERENCE 1 (bases 1 to 528)
 AUTHORS Nishimura, O., Kuriyama, M., Koyama, N. and Fukuda, T.
 TITLE Method for producing a biologically active recombinant
 cysteine-free parathyroid hormone (1-34)
 JOURNAL Patent: US 5861284-A 7 19-JAN-1999;
 FEATURES
 source 1..528
 /organism="unknown"
 BASE COUNT 142 a 121 c 144 g 121 t
 ORIGIN

Query Match 96.6%; Score 89.8; DB 6; Length 528;
 Best Local Similarity 97.8%; Pred. No. 1.9e-20;
 Matches 91; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1 CATGCTGAAGGACCTTACCGATGATGAAGTCTTATTGGAGGCCCAAGCTGCCAAG 60
 |||||
 Db 1 CATGCTGAAGGACCTTACCGATGATGAAGTCTTATTGGAGGCCCAAGCTGCCAAG 60
 OY 61 GAATTCATTCCTGGCTGCTGAAGGCCGAGGA 93
 |||||
 Db 61 GAATTCATTCCTGGCTGCTGAAGGCCGAGGA 93

GenCore version 5.1.4_p5.4578
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: February 14, 2003, 08:25:59 ; Search time 67 Seconds
(without alignments)
706,972 Million cell updates/sec

Title: US-09-091-605-4

Perfect score: 93
Sequence: 1 CATGTTGAGGACCTTAC.....GGCTGGGAAGGCCGAGCA 93

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 424239 segs, 254661826 residues

Total number of hits satisfying chosen parameters: 848478

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

Published Applications_NA:*

- 1: /cgn2_6/prodata/1/pubpna/US07_PUBCOMB.seq:*
- 2: /cgn2_6/prodata/1/pubpna/PCOT_NEW_PUB.seq:*
- 3: /cgn2_6/prodata/1/pubpna/US06_NEW_PUB.seq:*
- 4: /cgn2_6/prodata/1/pubpna/US06_PUBCOMB.seq:*
- 5: /cgn2_6/prodata/1/pubpna/US07_NEW_PUB.seq:*
- 6: /cgn2_6/prodata/1/pubpna/PCOTUS_PUBCOMB.seq:*
- 7: /cgn2_6/prodata/1/pubpna/US08_NEW_PUB.seq:*
- 8: /cgn2_6/prodata/1/pubpna/US08_PUBCOMB.seq:*
- 9: /cgn2_6/prodata/1/pubpna/US09_NEW_PUB.seq:*
- 10: /cgn2_6/prodata/1/pubpna/US09_PUBCOMB.seq:*
- 11: /cgn2_6/prodata/1/pubpna/US10_NEW_PUB.seq:*
- 12: /cgn2_6/prodata/1/pubpna/US10_PUBCOMB.seq:*
- 13: /cgn2_6/prodata/1/pubpna/US60_NEW_PUB.seq:*
- 14: /cgn2_6/prodata/1/pubpna/US60_PUBCOMB.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	91.4	98.3	1174	9 US-09-981-353-169	Sequence 169, App
2	27.4	29.5	2000	9 US-09-938-842A-4681	Sequence 4681, App
3	27.4	29.5	2002	10 US-09-887-576-22	Sequence 22, Appl
4	27.2	29.2	490	9 US-09-864-761-345	Sequence 445, Appl
5	27.2	29.2	495	9 US-10-076-622-461	Sequence 461, App
6	27.2	29.2	495	10 US-09-604-287A-461	Sequence 461, App
7	27.2	29.2	495	12 US-10-007-805-461	Sequence 395, App
8	27.2	29.2	1856	10 US-09-925-301-395	Sequence 1, Appl1
9	27.2	29.0	29921	9 US-10-083-853-1	Sequence 94, Appl
10	26.6	28.4	5140	12 US-10-044-090-34	Sequence 325, Appl
11	26.4	28.4	2316	10 US-09-801-368-325	Sequence 29, Appl
12	26.2	28.2	436	10 US-09-925-297-29	Sequence 20, Appl
13	25.8	27.7	2048	9 US-09-771-208-20	Sequence 633, App
14	25.8	27.7	2717	12 US-10-044-090-633	Sequence 484, App
15	25.8	27.7	23822	10 US-10-044-090-484	Sequence 572, App
16	25.6	27.5	171	10 US-09-964-824A-572	Sequence 572, A
17	25.6	27.5	353	10 US-09-864-761-19284	Sequence 19284, A
18	25.6	27.5	483	10 US-09-867-701-6056	Sequence 6056, App
19	25.6	27.5	483	10 US-09-864-761-2558	Sequence 2558, App

20	25.6	27.5	1878	10 US-09-925-300-373	Sequence 373, App
21	25.4	27.3	1194	9 US-09-938-842A-264	Sequence 264, App
22	25.4	27.3	7970	9 US-09-764-868-1357	Sequence 1357, App
23	25	26.9	1368	10 US-09-942-845-4	Sequence 4, Appl1
24	25	26.9	1368	10 US-09-986-441-4	Sequence 267, Appl
25	25	26.9	9543	10 US-09-764-877-2677	Sequence 2678, App
26	25	26.9	26591	10 US-09-764-877-2678	Sequence 238, App
27	25	26.9	32729	10 US-09-764-869-2017	Sequence 2017, App
28	25	26.9	32195	10 US-09-764-869-2016	Sequence 2016, App
29	25	26.9	197496	9 US-09-877-177-10	Sequence 10, Appl
30	24.8	26.7	607	10 US-09-770-149-902	Sequence 902, App
31	24.2	26.0	982	12 US-10-062-254-337	Sequence 337, App
32	24.2	26.0	2206	12 US-10-062-254-339	Sequence 339, App
33	24.2	26.0	65608	10 US-09-954-531-180	Sequence 180, App
34	24.2	26.0	65608	10 US-09-962-436-292	Sequence 292, App
35	24.2	26.0	65608	10 US-09-962-832-119	Sequence 119, App
36	24.2	26.0	65608	10 US-09-328-130-6	Sequence 6, Appl1
37	24	25.8	54	9 US-09-960-352-7411	Sequence 7411, App
38	24	25.8	369	10 US-09-960-352-8269	Sequence 8269, App
39	24	25.8	378	10 US-09-960-352-8269	Sequence 457, App
40	24	25.8	503	9 US-09-796-692-4557	Sequence 1781, App
41	24	25.8	1242	9 US-09-938-842A-1781	Sequence 459, App
42	24	25.8	1337	9 US-10-028-072-459	Sequence 459, App
43	24	25.8	1337	9 US-10-121-049-459	Sequence 459, App
44	24	25.8	1337	9 US-10-123-904-459	Sequence 459, App
45	24	25.8	1337	9 US-10-140-470-459	Sequence 459, App

ALIGNMENTS

RESULT 1
US-09-981-353-169
Sequence 169, Application US/09981353
Patent No. US20020160382A1
GENERAL INFORMATION:
APPLICANT: Laeek, Amy M.
TITLE OF INVENTION: GENES EXPRESSED IN COLON CANCER
FILE REFERENCE: PA-0038 US
CURRENT APPLICATION NUMBER: US/09/981, 353
CURRENT FILING DATE: 2001-10-11
NUMBER OF SEQ ID NOS: 194
SOFTWARE: PERL Program
SEQ ID NO 169
LENGTH: 1174
TYPE: DNA
ORGANISM: Homo sapiens
FEATURE:
NAME/KEY: misc.feature
OTHER INFORMATION: Inocyte ID No. US20020160382A1 1075717.1
US-09-981-353-169

Query Match 98.3%; Score 91.4; DB 9; Length 1174;
Best local similarity 98.9%; Pred. No. 4.1e-24;
Matches 92; Conservative 1; Indels 0; Gaps 0;

OY 1 CATGTTGAGGACCTTACCGATGATGTTGTTGAAGGCCAGCTGCCAAG 60
DB 427 CATGCTGAGGACCTTACCGATGATGTTGTTGAAGGCCAGCTGCCAAG 486
OY 61 GAATTCATTCCTGCTGCTGTTGAAGGCCAGCA 93
DB 487 GAATTCATTCCTGCTGCTGTTGAAGGCCAGCA 519

RESULT 2
US-09-938-842A-4681
Sequence 4681, Application US/09938842A
Patent No. US20020160378A1
GENERAL INFORMATION:
APPLICANT: Harper, Jeff
APPLICANT: Kreps, Joel

APPLICANT: Wang, Xun
APPLICANT: Zhu, Tong
TITLE OF INVENTION: STRESS-REGULATED GENES OF PLANTS, TRANSGENIC PLANTS CONTAINING
TITLE OF INVENTION: SAME, AND METHODS OF USE
FILE REFERENCE: SCRI1300-3
CURRENT APPLICATION NUMBER: US/09/938,842A
PRIOR FILING DATE: 2001-08-24
PRIOR APPLICATION NUMBER: US 60/227,866
PRIOR FILING DATE: 2000-08-24
PRIOR APPLICATION NUMBER: US 60/264,647
PRIOR FILING DATE: 2001-01-16
PRIOR APPLICATION NUMBER: US 60/300,111
PRIOR FILING DATE: 2001-06-22
NUMBER OF SEQ ID NOS: 5379
SEQ ID NO 4681
LENGTH: 2000
TYPE: DNA
ORGANISM: Arabidopsis thaliana
US-09-938-842A-4681

Query Match 29.5%; Score 27.4; DB 9; Length 2000;
Best Local Similarity 59.7%; Pred. No. 1.9;
Matches 46; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

QY 2 ATGTGAAGGACCTTACCAGTGATGTTATTGGAAGCCAGTCGCAAG 61
DB 1495 AGCTTAAGTGAAGCTTTACCGATGAGAGGAATGTGTGCAGATGATTCGTAGG 1554
QY 62 AATTCATGCTTGGCTG 78
DB 1555 AATCTCTTCTTTCTG 1571

RESULT 3
US-09-887-576-22
Sequence 22, Application US/09887576
Patent No. US20020144047A1
GENERAL INFORMATION:
APPLICANT: Budworth, P.
APPLICANT: Brown, D.
APPLICANT: Chang, H.
APPLICANT: Zhu, T.
APPLICANT: Han, B.
APPLICANT: Cooper, X.
APPLICANT: Cooper, Bret
TITLE OF INVENTION: Promoters for regulation of plant expression
FILE REFERENCE: 1360 001US1
CURRENT APPLICATION NUMBER: US/09/887,576
PRIOR FILING DATE: 2001-06-25
PRIOR APPLICATION NUMBER: US 60/213,848
PRIOR FILING DATE: 2000-06-23
PRIOR APPLICATION NUMBER: US 60/214,087
PRIOR FILING DATE: 2000-06-23
PRIOR APPLICATION NUMBER: US 60/258,692
PRIOR FILING DATE: 2000-12-29
NUMBER OF SEQ ID NOS: 875
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 22
LENGTH: 2002
TYPE: DNA
ORGANISM: Arabidopsis thaliana
US-09-887-576-22

Query Match 29.5%; Score 27.4; DB 10; Length 2002;
Best Local Similarity 59.7%; Pred. No. 1.9;
Matches 46; Conservative 0; Mismatches 31; Indels 0; Gaps 0;
QY 2 ATGTGAAGGACCTTACCAGTGATGTTATTGGAAGCCAGTCGCAAG 61
DB 1491 AGCTTAAGTGAAGCTTTACCGATGAGAGGAATGTGTGCAGATGATTCGTAGG 1550
QY 62 AATTCATGCTTGGCTG 78
DB 1555 AATCTCTTCTTTCTG 1571

DB 1551 AATCTCTTCTTTCTG 1567

RESULT 4
US-09-864-761-345/C
Sequence 345, Application US/09864761
Patent No. US20020048763A1
GENERAL INFORMATION:
APPLICANT: Penn, Sharon G.
APPLICANT: Rank, David R.
APPLICANT: Hanzel, David K.
APPLICANT: Chen, Wensheng
TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR
FILE REFERENCE: Aecmics-X-1
CURRENT APPLICATION NUMBER: US/09/864,761
PRIOR FILING DATE: 2001-05-23
PRIOR APPLICATION NUMBER: US 60/180,312
PRIOR FILING DATE: 2000-02-04
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: US 09/632,366
PRIOR FILING DATE: 2000-08-03
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00662
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00661
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00670
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: US 60/234,687
PRIOR FILING DATE: 2000-09-21
PRIOR APPLICATION NUMBER: US 09/608,408
PRIOR FILING DATE: 2000-06-30
PRIOR APPLICATION NUMBER: US 09/774,203
PRIOR FILING DATE: 2001-01-29
NUMBER OF SEQ ID NOS: 49117
SOFTWARE: Annomax Sequence Listing Engine vers. 1.1
SEQ ID NO 345
LENGTH: 490
TYPE: DNA
ORGANISM: Homo sapiens
FEATURE:
OTHER INFORMATION: MAP TO 293930.10
OTHER INFORMATION: EXPRESSED IN BT474, SIGNAL = 43
OTHER INFORMATION: EXPRESSED IN HELLO, SIGNAL = 11
OTHER INFORMATION: EXPRESSED IN RETAL LAYER, SIGNAL = 20
OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 8.8
OTHER INFORMATION: EXPRESSED IN HEART, SIGNAL = 3.8
OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL = 4.6
OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 3.1
OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL = 1.7
OTHER INFORMATION: EXPRESSED IN HELA, SIGNAL = 22
OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 25
US-09-864-761-345

Query Match	29.2%;	Score 27.2;	DB 10;	Length 495
Best Local Similarity	56.8%;	Pred. No. 1.3;		

```

; TYPE: DNA
; ORGANISM: Homo sapiens

```

FEATURE:
NAME/KEY: misc_feature
LOCATION: (1851)
OTHER INFORMATION: n equals a,t,g, or c
US-09-925-301-395

Query Match 29.2%; Score 27.2; DB 10; Length 1856;
Best Local Similarity 56.8%; Pred. No. 2.1;
Matches 50; Conservative 0; Mismatches 38; Indels 0; Gaps 0;

QY 6 TGAAGGACCTTTACAGTGAAGTCTTATTGGAGGCCAGCTGCCAAGGAATT 65
DB 1107 TGACATGCTCTCTGCTGCTGGTGAACCACTTTGGCAGTAAGT 1166

QY 66 CATTCCTGGCTGTGAAGGCCGAGA 93
DB 1167 CTTCCCGAGCTGATTACTGTCTAAGA 1194

RESULT 9
US-10-083-853-1/c
Sequence 1, Application US/10083853
Patent No. US20020164709A1
GENERAL INFORMATION:
APPLICANT: Affymetrix, Inc
APPLICANT: Shigeta, Ron T
APPLICANT: Shani-Rose, Michael A
TITLE OF INVENTION: Nucleic Acid Encoding Growth Factor Protein
FILE REFERENCE: 3385.1
CURRENT APPLICATION NUMBER: US/10/083.853
CURRENT FILING DATE: 2002-02-26
PRIOR APPLICATION NUMBER: USSN 60/272.663
NUMBER OF SEQ ID NOS: 2
SOFTWARE: PatentIn version 3.1
SEQ ID NO 1
LENGTH: 29921
TYPE: DNA
ORGANISM: Homo Sapiens
US-10-083-853-1

Query Match 29.0%; Score 27; DB 9; Length 29921;
Best Local Similarity 60.0%; Pred. No. 7.7;
Matches 45; Conservative 0; Mismatches 30; Indels 0; Gaps 0;

QY 9 AGGACCTTTACAGTGAAGTCTTATTGGAGGCCAGCTGCCAAGGAATTCAAT 68
DB 24405 AAGAACTCTTGGCTGATTAAGTTGTTGTAACCAAGTGTAAATGTTTTTAT 24346

QY 69 TGGTGGCTGTGA 83
DB 24345 TCTTTAGATGTAAA 24331

RESULT 10
US-10-044-090-94
Sequence 94, Application US/10044090
Patent No. US20020137081A1
GENERAL INFORMATION:
APPLICANT: Olga Bandman
TITLE OF INVENTION: GENES DIFFERENTIALLY EXPRESSED IN VASCULAR TISSUE ACTIVATION
FILE REFERENCE: PA-0028 US
CURRENT APPLICATION NUMBER: US/10/044.090
CURRENT FILING DATE: 2002-01-09
NUMBER OF SEQ ID NOS: 850
SOFTWARE: PERL Program
SEQ ID NO 94
LENGTH: 5140
TYPE: DNA
ORGANISM: Homo sapiens
FEATURE:
NAME/KEY: misc_feature
OTHER INFORMATION: Incyte ID No. US20020137081A1 109653.1

US-10-044-090-94

Query Match 28.6%; Score 26.6; DB 12; Length 5140;
Best Local Similarity 63.1%; Pred. No. 5.4;
Matches 41; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 7 CAAGGACCTTTACAGTGAAGTCTTATTGGAGGCCAGCTGCCAAGGAATTG 66
DB 1380 GAGGACGATTTTCATGTGTGACAGTGTGTGTAGACCAAGGCCAAGGAATTC 1439

QY 67 ATTGC 71
DB 1440 ATTCC 1444

RESULT 11
US-09-801-368-325/c
Sequence 325, Application US/09801368
Patent No. US20020128250A1
GENERAL INFORMATION:
APPLICANT: Busby, Robert
APPLICANT: Call, Brian
APPLICANT: Hecht, Peter
APPLICANT: Holtzman, Doug
APPLICANT: Madden, Kevin
APPLICANT: Maxon, Mary
APPLICANT: Milne, Todd
APPLICANT: No. US20020128250A1man, Thea
APPLICANT: Royer, John
APPLICANT: Salama, Sofie
APPLICANT: Sherman, Amir
APPLICANT: Silva, Jeff
APPLICANT: Summers, Eric
TITLE OF INVENTION: Methods for Improving Secondary Metabolite Production in Fungi
FILE REFERENCE: 109272.147
CURRENT APPLICATION NUMBER: US/09/801.368
CURRENT FILING DATE: 2001-03-07
PRIOR APPLICATION NUMBER: US 09/487.558
PRIOR FILING DATE: 2000-01-19
PRIOR APPLICATION NUMBER: US 60/160.587
NUMBER OF SEQ ID NOS: 440
SOFTWARE: PatentIn version 3.0
SEQ ID NO 325
LENGTH: 2316
TYPE: DNA
ORGANISM: Saccharomyces cerevisiae
US-09-801-368-325

Query Match 28.4%; Score 26.4; DB 10; Length 2316;
Best Local Similarity 57.1%; Pred. No. 4.6;
Matches 48; Conservative 0; Mismatches 36; Indels 0; Gaps 0;

QY 1 CATGTTGAAGGACCTTTACAGTGAAGTCTTATTGGAGGCCAGCTGCCAAG 60
DB 1853 CATGTTACATTTAAAGTGATTAATGCTGACAGCTTGTGAAGGCCACAGCGTAA 1794
QY 61 GAATTCATTGCTGGCTGTGA 84
DB 1793 GTATTCATAGTGTGTGTGA 1770

RESULT 12
US-09-925-297-29
Sequence 29, Application US/09925297
Patent No. US20020081659A1
GENERAL INFORMATION:
APPLICANT: Rosen et al.
TITLE OF INVENTION: Nucleic Acids, Proteins and Antibodies
FILE REFERENCE: PA105
CURRENT APPLICATION NUMBER: US/09/925.297
CURRENT FILING DATE: 2001-08-10
PRIOR APPLICATION NUMBER: PCT/US00/05989

PRIOR FILING DATE: 2000-03-08
PRIOR APPLICATION NUMBER: 60/124,270
PRIOR FILING DATE: 1999-03-12
NUMBER OF SEQ ID NOS: 928
SOFTWARE: Patentln Ver. 2.0
SEQ ID NO 29
LENGTH: 436
TYPE: DNA
ORGANISM: Homo sapiens
FEATURE:
NAME/KEY: misc feature
LOCATION: (664)
OTHER INFORMATION: n equals a,t,g, or c
NAME/KEY: misc feature
LOCATION: (372)
OTHER INFORMATION: n equals a,t,g, or c
NAME/KEY: misc feature
LOCATION: (410)
OTHER INFORMATION: n equals a,t,g, or c
US-09-925-297-29

Query Match
Best Local Similarity 80.6%; Score 26.2; DB 10; Length 436;
Matches 54; Conservative 0; Mismatches 10; Indels 3; Gaps 2;

QY 10 GGGACCTTACCACTGATGTAATT--CTATTGGAAGGCCAAGCTG-CCAGGAATTC 66
Db 370 GGNCCTTTACCACTGATGTAATTCTTATTGGGAAGGCCAAGCTGCGCAAGGATTC 429
QY 67 ATTGCTT 73
Db 430 ATTGCTT 436

RESULT 13
US-09-771-208-20/c
Sequence 20, Application US/09771208
Patent No. US2002015564A1
GENERAL INFORMATION:
APPLICANT: MEDRANO, JUAN
APPLICANT: BRADFORD, ERIC
APPLICANT: HORVAT, SIMON
TITLE OF INVENTION: CLONING OF A HIGH-GROWTH GENE
FILE REFERENCE: 4077-92371005
CURRENT APPLICATION NUMBER: US/09/771,208
CURRENT FILING DATE: 2001-01-26
PRIOR APPLICATION NUMBER: US 08/999,477
PRIOR FILING DATE: 1997-12-29
NUMBER OF SEQ ID NOS: 20
SOFTWARE: Patentln version 3.0
SEQ ID NO 20
LENGTH: 659158
TYPE: DNA
ORGANISM: Mus musculus
FEATURE:
NAME/KEY: misc feature
LOCATION: (123459)..(123478)
OTHER INFORMATION: n is unidentified a, c, g, or t
NAME/KEY: misc feature
LOCATION: (602466)..(602485)
OTHER INFORMATION: n is unidentified a, c, g, or t
NAME/KEY: misc feature
LOCATION: (546998)..(547017)
OTHER INFORMATION: n is unidentified a, c, g, or t
NAME/KEY: misc feature
LOCATION: (494715)..(494814)
OTHER INFORMATION: n is unidentified a, c, g, or t
NAME/KEY: misc feature
LOCATION: (390986)..(391005)
OTHER INFORMATION: n is unidentified a, c, g, or t
NAME/KEY: misc feature
LOCATION: (346860)..(346823)
OTHER INFORMATION: n is unidentified a, c, g, or t

NAME/KEY: misc feature
LOCATION: (317174)..(317193)
OTHER INFORMATION: n is unidentified a, c, g, or t
NAME/KEY: misc feature
LOCATION: (280353)..(280373)
OTHER INFORMATION: n is unidentified a, c, g, or t
NAME/KEY: misc feature
LOCATION: (271829)..(271848)
OTHER INFORMATION: n is unidentified a, c, g, or t
NAME/KEY: misc feature
LOCATION: (183872)..(183891)
OTHER INFORMATION: n is unidentified a, c, g, or t
NAME/KEY: misc feature
LOCATION: (170625)..(170645)
OTHER INFORMATION: n is unidentified a, c, g, or t
NAME/KEY: misc feature
LOCATION: (132680)..(132700)
OTHER INFORMATION: n is unidentified a, c, g, or t
NAME/KEY: misc feature
OTHER INFORMATION: n is a, c, g, or t
US-09-771-208-20

Query Match
Best Local Similarity 28.0%; Score 26; DB 9; Length 659158;
Matches 47; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 2 ATGTGAAGGACCTTACCACTGATGTAATTCTTATTGGAAGGCCAAGCTGCGCAG 61
Db 298435 ATGTTGAAGGACCTTGGCATTGGACACAGTGTGTGTTAAGGCAAGGCAAGT 298376
QY 62 AATTCAATGCTTGGCTGTGA 83
Db 298375 GTTAAGAGCCTTACAGGCCA 298354

RESULT 14
US-10-044-090-633/c
Sequence 633, Application US/10044090
Patent No. US20020137081A1
GENERAL INFORMATION:
APPLICANT: Olga Bandman
TITLE OF INVENTION: GENES DIFFERENTIALLY EXPRESSED IN VASCULAR TISSUE ACTIVATION
FILE REFERENCE: PA-0028 US
CURRENT APPLICATION NUMBER: US/10/044,090
CURRENT FILING DATE: 2002-01-09
NUMBER OF SEQ ID NOS: 850
SOFTWARE: PERL Program
SEQ ID NO 633
LENGTH: 2048
TYPE: DNA
ORGANISM: Homo sapiens
FEATURE:
NAME/KEY: misc feature
OTHER INFORMATION: Incyte ID No. US20020137081A1 1097794.3
NAME/KEY: unsure
LOCATION: 934, 936
OTHER INFORMATION: a, t, c, g, or other
US-10-044-090-633

Query Match
Best Local Similarity 27.7%; Score 25.8; DB 12; Length 2048;
Matches 45; Conservative 0; Mismatches 32; Indels 0; Gaps 0;

QY 15 CTTTCCAGTGAATGTAAGTCTTATTGGAAGGCCAAGCTGCCAAGATTCATTCCTG 74
Db 365 CTTGAGGCGGACCTTAGATTCTTAAGTGAAGTTAAGAGATCAATCCAGCTCTG 306
QY 75 CCTGTGAAGGCCGAG 91
Db 305 CCTTCAGAAAGGCCAAG 289

RESULT 15

Thu Feb 27 13:12:09 2003

us-09-091-605-4.rnpb

Page 6

```

US-10-044-090-484/c
: Sequence 484, Application US/10044090
: Patent No. US20020137081A1
: GENERAL INFORMATION:
: APPLICANT: Olga Bandman
: TITLE OF INVENTION: GENES DIFFERENTIALLY EXPRESSED IN VASCULAR TISSUE ACTIVATION
: FILE REFERENCE: PA-0028 US
: CURRENT APPLICATION NUMBER: US/10/044,090
: CURRENT FILING DATE: 2002-01-09
: NUMBER OF SEQ. ID NOS: 850
: SOFTWARE: PERL Program
: SEQ. ID NO 484
: LENGTH: 2717
: TYPE: DNA
: ORGANISM: Homo sapiens
: FEATURE:
: NAME/KEY: misc_feature
: OTHER INFORMATION: Incyte ID No. US20020137081A1 1097750.1
: NAME/KEY: unsure
: LOCATION: 1603-1604
: OTHER INFORMATION: a, t, c, g, or other
US-10-044-090-484

```

	Query Match	27.7%	Score 25.8	DB 12	Length 2717	
	Best Local Similarity	56.4%	Pred. No. 8.2			
	Matches	45	Conservative	0	Mismatches	32
					Indels	0
					Gaps	0
OY	15	CCTTACCAAGTGATGTAAGTTCTTATTGGAGCCCAAGTCGCAGAAGATTCATGGCTTG	74			
Db	1027	CTTAGAGGGCGCACCTAGATTCTTAACTGAAGATTAAAGATGATGCCAATCCCAAGCTTGG	968			
OY	75	GCTGTGAANAAGCCGAG	91			
Db	967	CCTTCAGAAAAGGCCAAG	951			

```
Search completed: February 14, 2003, 10:24:13
Job time : 238 secs
```

GenCore version 5.1.3
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: February 13, 2003, 11:03:17 : Search time 30 seconds

(without alignments)
26,401 Million cell updates/sec

Title: US-09-091-605-1

Perfect score: 141
Sequence: 1 HXEGFTSDVSYLXGQAXXFIAMLVKGR 31

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 140259 seqs, 2554876 residues

Total number of hits satisfying chosen parameters: 140259

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Database : Published_Applications_AA:*

1: /cgn2_6/ptodata/2/pubpaa/US08_NEW_PUB.pep:*
2: /cgn2_6/ptodata/2/pubpaa/US06_NEW_PUB.pep:*
3: /cgn2_6/ptodata/2/pubpaa/US06_PUB.pep:*
4: /cgn2_6/ptodata/2/pubpaa/US07_NEW_PUB.pep:*
5: /cgn2_6/ptodata/2/pubpaa/US07_PUB.pep:*
6: /cgn2_6/ptodata/2/pubpaa/US07_PUBCOMB.pep:*
7: /cgn2_6/ptodata/2/pubpaa/US07_PUBCOMB.pep:*
8: /cgn2_6/ptodata/2/pubpaa/US08_PUBCOMB.pep:*
9: /cgn2_6/ptodata/2/pubpaa/US09_NEW_PUB.pep:*
10: /cgn2_6/ptodata/2/pubpaa/US09_PUBCOMB.pep:*
11: /cgn2_6/ptodata/2/pubpaa/US10_NEW_PUB.pep:*
12: /cgn2_6/ptodata/2/pubpaa/US10_PUBCOMB.pep:*
13: /cgn2_6/ptodata/2/pubpaa/US60_NEW_PUB.pep:*
14: /cgn2_6/ptodata/2/pubpaa/US60_PUBCOMB.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	133	94.3	30	9	US-10-125-255-1
2	133	94.3	30	9	US-09-834-229A-5
3	133	94.3	30	10	US-09-851-738-2
4	133	94.3	30	10	US-09-805-507-4
5	133	94.3	30	10	US-09-859-804-4
6	133	94.3	30	10	US-09-982-978-4
7	133	94.3	30	10	US-09-953-021B-4
8	133	94.3	30	12	US-10-072-540A-4
9	133	94.3	31	9	US-09-834-229A-1
10	133	94.3	31	10	US-09-754-723-1
11	133	94.3	31	10	US-09-420-785A-3
12	133	94.3	31	10	US-09-876-388-2
13	133	94.3	31	10	US-09-876-388-17
14	133	94.3	31	10	US-09-876-388-27
15	133	94.3	31	10	US-09-876-388-28
16	133	94.3	31	10	US-09-851-738-3
17	133	94.3	31	10	US-09-805-507-3
18	133	94.3	31	10	US-09-859-804-3
19	133	94.3	31	10	US-09-982-978-3

20	133	94.3	31	10	US-09-953-021B-3	Sequence 3, Appl1
21	133	94.3	31	12	US-10-072-540A-1	Sequence 1, Appl1
22	133	94.3	36	10	US-09-851-738-2	Sequence 2, Appl1
23	133	94.3	36	10	US-09-805-507-2	Sequence 2, Appl1
24	133	94.3	36	10	US-09-859-804-2	Sequence 2, Appl1
25	133	94.3	36	10	US-09-982-978-2	Sequence 2, Appl1
26	133	94.3	36	10	US-09-953-021B-2	Sequence 2, Appl1
27	133	94.3	37	10	US-09-420-785A-2	Sequence 2, Appl1
28	133	94.3	37	10	US-09-876-388-1	Sequence 1, Appl1
29	133	94.3	37	10	US-09-876-388-16	Sequence 16, Appl1
30	133	94.3	37	10	US-09-876-388-25	Sequence 25, Appl1
31	133	94.3	37	10	US-09-876-388-26	Sequence 26, Appl1
32	133	94.3	37	10	US-09-851-738-1	Sequence 1, Appl1
33	133	94.3	37	10	US-09-805-507-1	Sequence 1, Appl1
34	133	94.3	37	10	US-09-859-804-1	Sequence 1, Appl1
35	133	94.3	37	10	US-09-982-978-1	Sequence 1, Appl1
36	133	94.3	37	10	US-09-953-021B-1	Sequence 1, Appl1
37	132	93.6	31	10	US-09-876-388-29	Sequence 29, Appl1
38	132	93.6	31	10	US-09-876-388-30	Sequence 30, Appl1
39	132	93.6	31	12	US-10-072-540A-5	Sequence 5, Appl1
40	125	88.7	28	10	US-09-851-738-6	Sequence 6, Appl1
41	125	88.7	28	10	US-09-805-507-6	Sequence 6, Appl1
42	125	88.7	28	10	US-09-859-804-6	Sequence 6, Appl1
43	125	88.7	28	10	US-09-982-978-6	Sequence 6, Appl1
44	125	88.7	28	10	US-09-953-021B-6	Sequence 6, Appl1
45	125	88.7	29	10	US-09-851-738-5	Sequence 5, Appl1

ALIGNMENTS

RESULT 1
US-10-125-255-1
; Sequence 1, Application US/10125255
; Patent No. US20020165342A1
; GENERAL INFORMATION:
; APPLICANT: Gallows, John A
; APPLICANT: Hoffmann, James A
; TITLE OF INVENTION: Glucagon-Like Insulinotropic Peptides, Compositions and Method
; FILE REFERENCE: X-9332E
; CURRENT APPLICATION NUMBER: US/10/125,255
; CURRENT FILING DATE: 2002-04-17
; PRIOR APPLICATION NUMBER: 09/573,809
; PRIOR FILING DATE: 2000-05-18
; NUMBER OF SEQ ID NOS: 1
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 1
; LENGTH: 30
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: MOD.RES
; LOCATION: (30)..(30)
; OTHER INFORMATION: The arginine residue at position 30 is modified so as to replace the terminal carboxyl group with an amine.
US-10-125-255-1

Query Match 94.3%; Score 133; DB 9; Length 30;
Best Local Similarity 86.7%; Pred. No. 5.3e-15;
Matches 26; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1 HXEGFTSDVSYLXGQAXXFIAMLVKGR 30
Db 1 HXEGFTSDVSYLXGQAXXFIAMLVKGR 30

RESULT 2
US-09-834-229A-5
; Sequence 5, Application US/09834229A
; Publication No. US20030022823A1
; GENERAL INFORMATION:
; APPLICANT: Eftendic, Sued
; TITLE OF INVENTION: USE OF GLP-1 OR ANALOGS IN TREATMENT OF MYOCARDIAL INFARCTION

```

RESULT 6
US-09-982-978-4
Sequence 4: Application us/09982978
Patent No. US20020146405A1
GENERAL INFORMATION:
APPLICANT: COOLIDGE, THOMAS R.
APPLICANT: EHLERS, MARIO
FILE OF INVENTION: TREATMENT OF ACUTE CORONARY SYNDROME WITH GLP-1
FILE REFERENCE: 089187/0395
CURRENT APPLICATION NUMBER: US/09/982,978
CURRENT FILING DATE: 2001-10-22
PRIOR APPLICATION NUMBER: 09/859,804
PRIOR FILING DATE: 2001-05-16
PRIOR APPLICATION NUMBER: 60/205,239
PRIOR FILING DATE: 2000-05-19
NUMBER OF SEQ ID NOS: 13
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 4
LENGTH: 30
TYPE: PRT
ORGANISM: Unknown Organism
FEATURE:
OTHER INFORMATION: Description of Unknown Organism: Mammalian GLP

```

OTHER INFORMATION: peptide
US-09-982-978-4

Query Match 94.3%; Score 133; DB 10; Length 30;
Best Local Similarity 86.7%; Pred. No. 5.3e-15;
Matches 26; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1 HXEGFTSDVSSYLXGQAAKFIAMLVKGR 30
DB 1 HXEGFTSDVSSYLEGQAAKEFIAMLVKGR 30

RESULT 7
US-09-953-021B-4

; Sequence 4, Application US/09953021B
; Patent No. US20020147131A1
; GENERAL INFORMATION:
; APPLICANT: Coolidge, Thomas L.
; APPLICANT: Ehlers, Mario R.W.
; TITLE OF INVENTION: Metabolic intervention with GLP-1 to improve the function of Isch
; TITLE OF INVENTION: Reperitised Skeletal Muscle Tissue
; FILE REFERENCE: P03660US6
; CURRENT APPLICATION NUMBER: US/09/953,021B
; CURRENT FILING DATE: 2001-09-11
; PRIOR APPLICATION NUMBER: 09/302,596
; PRIOR FILING DATE: 1999-04-30
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 4
; LENGTH: 30
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-953-021B-4

Query Match 94.3%; Score 133; DB 10; Length 30;
Best Local Similarity 86.7%; Pred. No. 5.3e-15;
Matches 26; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1 HXEGFTSDVSSYLXGQAAKFIAMLVKGR 30
DB 1 HXEGFTSDVSSYLEGQAAKEFIAMLVKGR 30

RESULT 8
US-10-072-540A-4

; Sequence 4, Application US/10072540A
; Patent No. US20020123466A1
; GENERAL INFORMATION:
; APPLICANT: Hoffmann, James
; TITLE OF INVENTION: GLP-1 FORMULATIONS
; FILE REFERENCE: X-11368A
; CURRENT APPLICATION NUMBER: US/10/072,540A
; CURRENT FILING DATE: 2002-02-08
; PRIOR APPLICATION NUMBER: US 60/067,600
; PRIOR FILING DATE: 1997-12-05
; NUMBER OF SEQ ID NOS: 5
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 4
; LENGTH: 30
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: MOD_RES
; LOCATION: (30)..(30)
; OTHER INFORMATION: AMIDATION
US-10-072-540A-4

Query Match 94.3%; Score 133; DB 12; Length 30;
Best Local Similarity 86.7%; Pred. No. 5.3e-15;
Matches 26; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1 HXEGFTSDVSSYLXGQAAKFIAMLVKGR 30
DB 1 HXEGFTSDVSSYLEGQAAKEFIAMLVKGR 30

DB 1 HXEGFTSDVSSYLEGQAAKEFIAMLVKGR 30

RESULT 9
US-09-834-229A-1
; Sequence 1, Application US/09834229A
; Publication No. US20030022823A1
; GENERAL INFORMATION:
; APPLICANT: Efendic, Sued
; TITLE OF INVENTION: USE OF GLP-1 OR ANALOGS IN TREATMENT OF MYOCARDIAL INFARCTION
; FILE REFERENCE: X-10822A
; CURRENT APPLICATION NUMBER: US/09/834,229A
; CURRENT FILING DATE: 2001-04-12
; PRIOR APPLICATION NUMBER: US 08/915,918
; PRIOR FILING DATE: 1997-08-21
; PRIOR APPLICATION NUMBER: US 06/024,980
; PRIOR FILING DATE: 1995-08-30
; NUMBER OF SEQ ID NOS: 6
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 1
; LENGTH: 31
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-834-229A-1

Query Match 94.3%; Score 133; DB 9; Length 31;
Best Local Similarity 86.7%; Pred. No. 5.5e-15;
Matches 26; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1 HXEGFTSDVSSYLXGQAAKFIAMLVKGR 30
DB 1 HXEGFTSDVSSYLEGQAAKEFIAMLVKGR 30

RESULT 10
US-09-754-723-1
; Sequence 1, Application US/09754723
; Patent No. US20010002394A1
; GENERAL INFORMATION:
; APPLICANT: EPENDIC, Sued
; APPLICANT: GUTINAK, Mark
; APPLICANT: KIRK, Ole
; TITLE OF INVENTION: Use of A Peptide
; FILE REFERENCE: 3745,234-US
; CURRENT APPLICATION NUMBER: US/09/754,723
; CURRENT FILING DATE: 2001-06-21
; PRIOR APPLICATION NUMBER: US 08/842,121
; PRIOR FILING DATE: 1997-04-23
; PRIOR APPLICATION NUMBER: US 08/295,913
; PRIOR FILING DATE: 1994-10-13
; PRIOR APPLICATION NUMBER: PCT/DK93/00099
; PRIOR FILING DATE: 1993-03-19
; PRIOR APPLICATION NUMBER: DK 0363/92
; PRIOR FILING DATE: 1992-03-19
; NUMBER OF SEQ ID NOS: 1
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1
; LENGTH: 31
; TYPE: PRT
; ORGANISM: Homo sapien
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (1)..(31)
; OTHER INFORMATION: Xaa = Any Amino Acid
US-09-754-723-1

Query Match 94.3%; Score 133; DB 10; Length 31;
Best Local Similarity 86.7%; Pred. No. 5.5e-15;
Matches 26; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1 HXEGFTSDVSSYLXGQAAKFIAMLVKGR 30
DB 1 HXEGFTSDVSSYLEGQAAKEFIAMLVKGR 30

```
RESULT 11
US-09-420-785A-3
; Sequence 3, Application US/09420785A
; Patent No. US20010010923A1
; GENERAL INFORMATION:
; APPLICANT: MORTENSEN, UFFE
; APPLICANT: OLESEN, KJELD
; APPLICANT: STENNICKE, HENNING
; APPLICANT: SORESEN, STEEN B.
; APPLICANT: BREDDAM, KLAUS
; TITLE OF INVENTION: MODIFIED CARBOXYPEPTIDASE
; FILE REFERENCE: 089187/0109
; CURRENT APPLICATION NUMBER: US/09/420,785A
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 3
; LENGTH: 31
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (31)
; OTHER INFORMATION: C-terminal amino acid which serves as a leaving
; OTHER INFORMATION: group, typically, an uncharged amino acid side
; OTHER INFORMATION: chain, preferably alanine
US-09-420-785A-3

Query Match          94.3%; Score 133; DB 10; Length 31;
Best Local Similarity 86.7%; Pred. No. 5.5e-15;
Matches 26; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1 HXEGFTSDVSSYLXGQAAXXFIAMLVKGR 30
DB 1 HAEFTSDVSSYLEGQAAXEFLAMLVKGR 30

RESULT 12
US-09-876-388-2
; Sequence 2, Application US/09876388
; Patent No. US20020049153A1
; GENERAL INFORMATION:
; APPLICANT: Bridon, Dominique P.
; APPLICANT: L'Archeveque, Benoit
; APPLICANT: Ezrin, Alan M.
; APPLICANT: Holmes, Darren L.
; APPLICANT: Leblanc, Anouk
; APPLICANT: St. Pierre, Serge
; TITLE OF INVENTION: LONG LASTING INSULINOTROPIC PEPTIDES
; FILE REFERENCE: 500862001610
; CURRENT APPLICATION NUMBER: US/09/876,388
; PRIOR FILING DATE: 2001-09-24
; PRIOR APPLICATION NUMBER: 09/623,618
; PRIOR FILING DATE: 2000-09-05
; PRIOR APPLICATION NUMBER: PCT/US00/13563
; PRIOR FILING DATE: 2000-05-17
; PRIOR APPLICATION NUMBER: 60/159,783
; PRIOR FILING DATE: 1999-10-15
; PRIOR APPLICATION NUMBER: 60/134,406
; PRIOR FILING DATE: 1999-05-17
; NUMBER OF SEQ ID NOS: 35
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 31
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-876-388-2
```

```
Query Match          94.3%; Score 133; DB 10; Length 31;
Best Local Similarity 86.7%; Pred. No. 5.5e-15;
Matches 26; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1 HXEGFTSDVSSYLXGQAAXXFIAMLVKGR 30
DB 1 HAEFTSDVSSYLEGQAAXEFLAMLVKGR 30

RESULT 13
US-09-876-388-17
; Sequence 17, Application US/09876388
; Patent No. US20020049153A1
; GENERAL INFORMATION:
; APPLICANT: Bridon, Dominique P.
; APPLICANT: L'Archeveque, Benoit
; APPLICANT: Ezrin, Alan M.
; APPLICANT: Holmes, Darren L.
; APPLICANT: Leblanc, Anouk
; APPLICANT: St. Pierre, Serge
; TITLE OF INVENTION: LONG LASTING INSULINOTROPIC PEPTIDES
; FILE REFERENCE: 500862001610
; CURRENT APPLICATION NUMBER: US/09/876,388
; PRIOR FILING DATE: 2001-09-24
; PRIOR APPLICATION NUMBER: 09/623,618
; PRIOR FILING DATE: 2000-09-05
; PRIOR APPLICATION NUMBER: PCT/US00/13563
; PRIOR FILING DATE: 2000-05-17
; PRIOR APPLICATION NUMBER: 60/159,783
; PRIOR FILING DATE: 1999-10-15
; NUMBER OF SEQ ID NOS: 35
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 17
; LENGTH: 31
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-876-388-17

Query Match          94.3%; Score 133; DB 10; Length 31;
Best Local Similarity 86.7%; Pred. No. 5.5e-15;
Matches 26; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1 HXEGFTSDVSSYLXGQAAXXFIAMLVKGR 30
DB 1 HAEFTSDVSSYLEGQAAXEFLAMLVKGR 30

RESULT 14
US-09-876-388-27
; Sequence 27, Application US/09876388
; Patent No. US20020049153A1
; GENERAL INFORMATION:
; APPLICANT: Bridon, Dominique P.
; APPLICANT: L'Archeveque, Benoit
; APPLICANT: Ezrin, Alan M.
; APPLICANT: Holmes, Darren L.
; APPLICANT: Leblanc, Anouk
; APPLICANT: St. Pierre, Serge
; TITLE OF INVENTION: LONG LASTING INSULINOTROPIC PEPTIDES
; FILE REFERENCE: 500862001610
; CURRENT APPLICATION NUMBER: US/09/876,388
; PRIOR FILING DATE: 2001-09-24
; PRIOR APPLICATION NUMBER: 09/623,618
; PRIOR FILING DATE: 2000-09-05
; PRIOR APPLICATION NUMBER: PCT/US00/13563
; PRIOR FILING DATE: 2000-05-17
; PRIOR APPLICATION NUMBER: 60/159,783
; PRIOR FILING DATE: 1999-10-15
```


GenCore version 5.1.4.p5_4578
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: February 14, 2003, 08:25:59 ; Search time 67 Seconds
(without alignments)
706.972 Million cell updates/sec

Title: US-09-091-605-2

Perfect score: 93
Sequence: 1 CATGCTGAAGGAGCCTTAC.....GGCTGTGAAGGCCGAGCA 93

Scoring table:
IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 424239 seqs, 254661826 residues

Total number of hits satisfying chosen parameters: 848478

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :

Published Applications_NA:*

- 1: /cgn2_6/ptodata/1/pubpna/US07_PUBCOMB.seq:*
- 2: /cgn2_6/ptodata/1/pubpna/PCRT_NEM_PUB.seq:*
- 3: /cgn2_6/ptodata/1/pubpna/US06_NEM_PUB.seq:*
- 4: /cgn2_6/ptodata/1/pubpna/US06_PUBCOMB.seq:*
- 5: /cgn2_6/ptodata/1/pubpna/US07_NEM_PUB.seq:*
- 6: /cgn2_6/ptodata/1/pubpna/US08_PUBCOMB.seq:*
- 7: /cgn2_6/ptodata/1/pubpna/US08_NEM_PUB.seq:*
- 8: /cgn2_6/ptodata/1/pubpna/US08_PUBCOMB.seq:*
- 9: /cgn2_6/ptodata/1/pubpna/US09_NEM_PUB.seq:*
- 10: /cgn2_6/ptodata/1/pubpna/US09_PUBCOMB.seq:*
- 11: /cgn2_6/ptodata/1/pubpna/US10_NEM_PUB.seq:*
- 12: /cgn2_6/ptodata/1/pubpna/US10_PUBCOMB.seq:*
- 13: /cgn2_6/ptodata/1/pubpna/US60_NEM_PUB.seq:*
- 14: /cgn2_6/ptodata/1/pubpna/US60_PUBCOMB.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length DB	ID	Description
1	93	100.0	1174	9	US-09-981-353-169
2	27.2	29.2	490	10	US-09-864-761-345
3	27.2	29.2	495	9	US-10-076-622-461
4	27.2	29.2	495	10	US-09-604-287A-461
5	27.2	29.2	495	12	US-10-007-805-461
6	27.2	29.2	1856	10	US-09-925-301-395
7	27.2	29.0	436	10	US-09-925-297-29
8	27.2	29.0	29921	9	US-10-083-853-1
9	26.6	28.6	5140	12	US-10-044-090-94
10	25.8	27.7	2000	9	US-09-938-842A-681
11	25.8	27.7	2002	10	US-09-887-576-22
12	25.8	27.7	2048	12	US-10-044-090-633
13	25.8	27.7	2717	12	US-10-044-090-484
14	25.8	27.7	23822	10	US-09-964-824A-572
15	25.6	27.5	54	9	US-09-328-130-6
16	25.6	27.5	171	10	US-09-864-761-19284
17	25.6	27.5	353	10	US-09-867-701-6056
18	25.6	27.5	483	10	US-09-864-761-2558
19	25.6	27.5	1878	10	US-09-925-300-373

20	25.4	27.3	1194	9	US-09-938-842A-264	Sequence 264, App
21	25.4	27.3	1614	10	US-09-923-246-7	Sequence 7, Appl1
22	25.4	27.3	1614	10	US-09-825-561A-1	Sequence 1, Appl1
23	25.4	27.3	1707	10	US-09-758-664-3	Sequence 3, Appl1
24	25.4	27.3	1707	10	US-09-825-561A-64	Sequence 64, Appl1
25	25.4	27.3	1740	10	US-09-758-664-1	Sequence 1, Appl1
26	25.4	27.3	2343	9	US-09-965-313-1	Sequence 1, Appl1
27	25.4	27.3	7970	10	US-09-764-868-1357	Sequence 1357, App
28	25.4	27.3	1368	10	US-09-942-845-4	Sequence 4, Appl1
29	25.4	27.3	1368	10	US-09-986-441-4	Sequence 2677, App
30	25.4	27.3	9543	10	US-09-764-877-2677	Sequence 2678, App
31	25.4	27.3	26591	10	US-09-764-877-2678	Sequence 238, App
32	25.4	27.3	29729	10	US-09-070-927A-238	Sequence 3, Appl1
33	25.4	27.3	2316	10	US-09-801-368-345	Sequence 20, Appl1
34	25.4	27.3	659158	9	US-09-771-208-20	Sequence 902, App
35	25.4	27.3	26.0	10	US-09-770-149-902	Sequence 337, App
36	25.4	27.3	982	12	US-10-062-254-337	Sequence 339, App
37	25.4	27.3	2206	12	US-10-062-254-339	Sequence 180, App
38	25.4	27.3	65608	10	US-09-954-531-180	Sequence 192, App
39	25.4	27.3	65608	10	US-09-962-436-292	Sequence 119, App
40	25.4	27.3	65608	10	US-09-962-832-119	Sequence 3, Appl1
41	25.4	27.3	34	9	US-09-328-130-3	Sequence 5, Appl1
42	25.4	27.3	54	9	US-09-328-130-5	Sequence 7411, App
43	25.4	27.3	359	10	US-09-960-352-7411	Sequence 8259, App
44	25.4	27.3	378	10	US-09-960-352-8259	Sequence 4557, App
45	25.4	27.3	503	9	US-09-796-692-4557	

ALIGNMENTS

RESULT 1
US-09-981-353-169
Sequence 169, Application US/09981353
Patent No. US20020160382A1
GENERAL INFORMATION:
APPLICANT: Lasek, Amy W.
TITLE OF INVENTION: GENES EXPRESSED IN COLON CANCER
FILE REFERENCE: PA-0038 US
CURRENT APPLICATION NUMBER: US/09/981,353
CURRENT FILING DATE: 2001-10-11
NUMBER OF SEQ ID NOS: 194
SOFTWARE: PERL Program
SEQ ID NO 169
LENGTH: 1174
TYPE: DNA
ORGANISM: Homo sapiens
FEATURE:
NAME/KEY: misc-feature
OTHER INFORMATION: Incyte ID No. US20020160382A1 1075717.1
US-09-981-353-169

Query Match 100.0%; Score 93; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 1.1e-24;
Matches 93; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CATGCTGAAGGAGCCTTACAGTGTAGTCTTATTGGAAGGCCAAGCTGCCAAG 60
DB 427 CATGCTGAAGGAGCCTTACAGTGTAGTCTTATTGGAAGGCCAAGCTGCCAAG 486
QY 61 GAATTCATTGCTTGGCTGTGAAGGCCGAGCA 93
DB 487 GAATTCATTGCTTGGCTGTGAAGGCCGAGCA 519

RESULT 2
US-09-864-761-345/c
Sequence 345, Application US/09864761
Patent No. US2002048763A1
GENERAL INFORMATION:
APPLICANT: Penn, Sharon G.
APPLICANT: Rank, David R.

APPLICANT: Hanzel, David K.
 APPLICANT: Chen, Wensheng
 TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR
 FILE REFERENCE: Aecmice-X-1
 CURRENT APPLICATION NUMBER: US/09/864,761
 PRIOR FILING DATE: 2001-05-23
 PRIOR APPLICATION NUMBER: US 60/180,312
 PRIOR FILING DATE: 2000-02-04
 PRIOR APPLICATION NUMBER: US 60/207,456
 PRIOR FILING DATE: 2000-05-26
 PRIOR APPLICATION NUMBER: US 09/632,366
 PRIOR FILING DATE: 2000-08-03
 PRIOR APPLICATION NUMBER: GB 24263,6
 PRIOR FILING DATE: 2000-10-04
 PRIOR APPLICATION NUMBER: US 60/236,359
 PRIOR FILING DATE: 2000-09-27
 PRIOR APPLICATION NUMBER: PCT/US01/00666
 PRIOR FILING DATE: 2001-01-30
 PRIOR APPLICATION NUMBER: PCT/US01/00667
 PRIOR FILING DATE: 2001-01-30
 PRIOR APPLICATION NUMBER: PCT/US01/00664
 PRIOR FILING DATE: 2001-01-30
 PRIOR APPLICATION NUMBER: PCT/US01/00669
 PRIOR FILING DATE: 2001-01-30
 PRIOR APPLICATION NUMBER: PCT/US01/00665
 PRIOR FILING DATE: 2001-01-30
 PRIOR APPLICATION NUMBER: PCT/US01/00668
 PRIOR FILING DATE: 2001-01-30
 PRIOR APPLICATION NUMBER: PCT/US01/00663
 PRIOR FILING DATE: 2001-01-30
 PRIOR APPLICATION NUMBER: PCT/US01/00662
 PRIOR FILING DATE: 2001-01-30
 PRIOR APPLICATION NUMBER: PCT/US01/00661
 PRIOR FILING DATE: 2001-01-30
 PRIOR APPLICATION NUMBER: PCT/US01/00670
 PRIOR FILING DATE: 2001-01-30
 PRIOR APPLICATION NUMBER: US 60/234,687
 PRIOR FILING DATE: 2000-09-21
 PRIOR APPLICATION NUMBER: US 09/608,408
 PRIOR FILING DATE: 2000-06-30
 PRIOR APPLICATION NUMBER: US 09/774,203
 PRIOR FILING DATE: 2001-01-29
 NUMBER OF SEQ ID NOS: 49117
 SOFTWARE: Anomax Sequence Listing Engine vers. 1.1
 SEQ ID NO 345
 LENGTH: 490
 TYPE: DNA
 ORGANISM: Homo sapiens
 FEATURE:
 OTHER INFORMATION: MAP TO Z93930.10
 OTHER INFORMATION: EXPRESSED IN BT474, SIGNAL = 43
 OTHER INFORMATION: EXPRESSED IN HBL100, SIGNAL = 11
 OTHER INFORMATION: EXPRESSED IN FETAL LIVER, SIGNAL = 20
 OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 8
 OTHER INFORMATION: EXPRESSED IN HEART, SIGNAL = 3.8
 OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL = 4.6
 OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 3.1
 OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL = 1.7
 OTHER INFORMATION: EXPRESSED IN HELA, SIGNAL = 22
 OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 25
 US-09-864-761-345

Query Match 29.2%; Score 27.2; DB 10; Length 490;
 Best Local Similarity 56.8%; Pred. No. 1.3;
 Matches 50; Conservative 0; Mismatches 38; Indels 0; Gaps 0;

QY 6 TGAAGGACCTTACACGATGTAGTCTTATTGGAAGGCCAAGCTGCCAAGGAATT 65
 DB 146 TGACATGTCTCTCTCTGTTGGTAAACCATTTCTGGAGGACACTTTTGCAATGAAGT 87
 QY 66 CATTCCTTGCTGGTGAAGGCCGAGGA 93

DB 86 CTTTCCCGACGCTGATTAAGTGTCTAAGGA 59
 RESULT 3
 US-10-076-622-461/c
 Sequence 461, Application US/10076622
 Publication No. US20030023036A1
 GENERAL INFORMATION:
 APPLICANT: Houghton, Raymond L.
 APPLICANT: Sleath, Paul R.
 APPLICANT: Persing, David H.
 TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE THERAPY
 FILE REFERENCE: 210121.470C11
 CURRENT APPLICATION NUMBER: US/10/076,622
 CURRENT FILING DATE: 2002-02-13
 NUMBER OF SEQ ID NOS: 627
 SOFTWARE: FastSeq for Windows Version 4.0
 SEQ ID NO 461
 LENGTH: 495
 TYPE: DNA
 ORGANISM: Homo sapiens
 US-10-076-622-461

Query Match 29.2%; Score 27.2; DB 9; Length 495;
 Best Local Similarity 56.8%; Pred. No. 1.3;
 Matches 50; Conservative 0; Mismatches 38; Indels 0; Gaps 0;

QY 6 TGAAGGACCTTACACGATGTAGTCTTATTGGAAGGCCAAGCTGCCAAGGAATT 65
 DB 158 TGACATGTCTCTCTCTGTTGGTAAACCATTTCTGGAGGACACTTTTGCAATGAAGT 99
 QY 66 CATTCCTTGCTGGTGAAGGCCGAGGA 93
 DB 98 CTTTCCCGACGCTGATTAAGTGTCTAAGGA 71

RESULT 4
 US-09-604-287A-461/c
 Sequence 461, Application US/09604287A
 Patent No. US20020064872A1
 GENERAL INFORMATION:
 APPLICANT: Jiang, Yugu
 APPLICANT: Dillon, Davin C.
 APPLICANT: Mitcham, Jennifer L.
 APPLICANT: Xu, Jiangchun
 APPLICANT: Harlocker, Susan L.
 APPLICANT: Hepler, William T.
 TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE THERAPY AND
 FILE REFERENCE: 210121.470C7
 CURRENT APPLICATION NUMBER: US/09/604,287A
 CURRENT FILING DATE: 2000-06-22
 NUMBER OF SEQ ID NOS: 489
 SOFTWARE: FastSeq for Windows Version 3.0
 SEQ ID NO 461
 LENGTH: 495
 TYPE: DNA
 ORGANISM: Homo sapiens
 US-09-604-287A-461

Query Match 29.2%; Score 27.2; DB 10; Length 495;
 Best Local Similarity 56.8%; Pred. No. 1.3;
 Matches 50; Conservative 0; Mismatches 38; Indels 0; Gaps 0;

QY 6 TGAAGGACCTTACACGATGTAGTCTTATTGGAAGGCCAAGCTGCCAAGGAATT 65
 DB 158 TGACATGTCTCTCTCTGTTGGTAAACCATTTCTGGAGGACACTTTTGCAATGAAGT 99
 QY 66 CATTCCTTGCTGGTGAAGGCCGAGGA 93
 DB 98 CTTTCCCGACGCTGATTAAGTGTCTAAGGA 71

RESULT 5
US-10-007-805-461/c

; Sequence 461, Application US/10007805
; Patent No. US20020150581A1
; GENERAL INFORMATION:

APPLICANT: Jiang, Yuguo
APPLICANT: Dillon, Davin C.
APPLICANT: Mitcham, Jennifer L.
APPLICANT: Xu, Jlangchun
APPLICANT: Harlocker, Susan L.
APPLICANT: Hepler, William T.
APPLICANT: Henderson, Robert A.
APPLICANT: Fanger, Gary R.
APPLICANT: Vedyick, Thomas S.
APPLICANT: McNeill, Patricia D.
APPLICANT: Durham, Margareta
TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE THERAPY
TITLE OF INVENTION: AND DIAGNOSIS OF BREAST CANCER
FILE REFERENCE: 210121.470C10
CURRENT APPLICATION NUMBER: US/10/007.805
CURRENT FILING DATE: 2001-12-07
NUMBER OF SEQ ID NOS: 593
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 461
LENGTH: 495
TYPE: DNA
ORGANISM: Homo sapiens
US-10-007-805-461

Query Match 29.2%; Score 27.2; DB 12; Length 495;
Best Local Similarity 56.8%; Pred. No. 1.3;
Matches 50; Conservative 0; Mismatches 38; Indels 0; Gaps 0;

QY 6 TGAAGGACCTTTACCGATGATGTTCTTATTGGAAGCCCAAGCTGCCAGGAATT 65
DB 158 TGACATGCTCTCTCTGCTTGTGTTAAACCATTTCTGGAGGACACTTTGCCAATGAACT 99
QY 66 CATTCCTGGCTGTGTGAAGCCCGAGA 93
DB 98 CTTTCCCGAGCTGATGTAGTCTTAAGGA 71

RESULT 6
US-09-925-301-395

; Sequence 395, Application US/09925301
; Patent No. US20020052308A1
; GENERAL INFORMATION:

APPLICANT: Rosen et al.
TITLE OF INVENTION: Nucleic Acids, Proteins and Antibodies
FILE REFERENCE: PA106
CURRENT APPLICATION NUMBER: US/09/925.301
CURRENT FILING DATE: 2001-08-10
PRIOR APPLICATION NUMBER: PCT/US00/05882
PRIOR FILING DATE: 2000-03-08
PRIOR APPLICATION NUMBER: 60/1124,270
PRIOR FILING DATE: 1999-03-12
NUMBER OF SEQ ID NOS: 1694
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 395
LENGTH: 1856
TYPE: DNA
ORGANISM: Homo sapiens
FEATURE:
NAME/KEY: misc-feature
LOCATION: (1851)
OTHER INFORMATION: n equals a,t,g, or c
US-09-925-301-395

Query Match 29.2%; Score 27.2; DB 10; Length 1856;
Best Local Similarity 56.8%; Pred. No. 2.2;
Matches 50; Conservative 0; Mismatches 38; Indels 0; Gaps 0;

QY 6 TGAAGGACCTTTACCGATGATGTTCTTATTGGAAGCCCAAGCTGCCAGGAATT 65
DB 1107 TGACATGCTCTCTCTGCTTGTGTTAAACCATTTCTGGAGGACACTTTGCCAATGAACT 1166
QY 66 CATTCCTGGCTGTGTGAAGCCCGAGA 93
DB 1167 CTTTCCCGAGCTGATGTAGTCTTAAGGA 1194

RESULT 7
US-09-925-297-29

; Sequence 29, Application US/09925297
; Patent No. US20020081659A1
; GENERAL INFORMATION:

APPLICANT: Rosen et al.
TITLE OF INVENTION: Nucleic Acids, Proteins and Antibodies
FILE REFERENCE: PA105
CURRENT APPLICATION NUMBER: US/09/925.297
CURRENT FILING DATE: 2001-08-10
PRIOR APPLICATION NUMBER: PCT/US00/05989
PRIOR FILING DATE: 2000-03-08
PRIOR APPLICATION NUMBER: 60/1124,270
PRIOR FILING DATE: 1999-03-12
NUMBER OF SEQ ID NOS: 928
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 29
LENGTH: 436
TYPE: DNA
ORGANISM: Homo sapiens
FEATURE:
NAME/KEY: misc feature
LOCATION: (64)
OTHER INFORMATION: n equals a,t,g, or c
NAME/KEY: misc feature
LOCATION: (372)
OTHER INFORMATION: n equals a,t,g, or c
NAME/KEY: misc feature
LOCATION: (410)
OTHER INFORMATION: n equals a,t,g, or c
US-09-925-297-29

Query Match 29.0%; Score 27; DB 10; Length 436;
Best Local Similarity 57.8%; Pred. No. 1.5;
Matches 48; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 1 CATCTGAAGGACCTTTACCGATGATGTTCTTATTGGAAGCCCAAGCTGCCAG 60
DB 222 CATTCACAGGCGACATTCACAGTACTACAGCAAGTATCTGACTCCAGCGGCGCCAA 281
QY 61 GAATTCATGCTGTGTGGA 83
DB 282 GATTTGTGAGTGTGATGA 304

RESULT 8
US-10-083-853-1/c

; Sequence 1, Application US/10083853
; Patent No. US20020164709A1
; GENERAL INFORMATION:

APPLICANT: Affymetrix, Inc
APPLICANT: Shigeta, Ron T
APPLICANT: Shani-Rose, Michael A
TITLE OF INVENTION: Nucleic Acid Encoding Growth Factor Protein
FILE REFERENCE: 3385.1
CURRENT APPLICATION NUMBER: US/10/083.853
CURRENT FILING DATE: 2002-02-26
PRIOR APPLICATION NUMBER: USSN 60/272.663
PRIOR FILING DATE: 2001-03-01
NUMBER OF SEQ ID NOS: 2
SOFTWARE: PatentIn version 3.1
SEQ ID NO 1
LENGTH: 29921
TYPE: DNA


```

; LENGTH: 2048
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc.feature
; OTHER INFORMATION: Incyte ID No. US20020137081A1 1097794.3
; LOCATION: 934, 936
; OTHER INFORMATION: a, t, c, g, or other
US-10-044-090-633

Query Match
Best Local Similarity 27.7%; Score 25.8; DB 12; Length 2048;
Matches 45; Conservative 0; Mismatches 32; Indels 0; Gaps 0;

Qy 15 CTTACCAAGTATGATGTTCTTATTTGGAAGGCCAGCTGCCAAGAAATTCATTGCTTG 74
Db 365 CTTAGAGCGGACCTAGATCTTACTGGAAGTTTAAAGAGTCAATCCAGTCTTG 306
Qy 75 GCTGTGAAGGCCGAG 91
Db 305 CCTTCAGAAAGGCCAAG 289

RESULT 13
US-10-044-090-484/c
; Sequence 484, Application US/10044090
; Patent No. US20020137081A1
; GENERAL INFORMATION:
; APPLICANT: Oliga Bandman
; TITLE OF INVENTION: GENES DIFFERENTIALLY EXPRESSED IN VASCULAR TISSUE ACTIVATION
; FILE REFERENCE: PA-0028 US
; CURRENT APPLICATION NUMBER: US/10/044, 090
; CURRENT FILING DATE: 2002-01-09
; NUMBER OF SEQ ID NOS: 850
; SOFTWARE: PERL Program
; SEQ ID NO 484
; LENGTH: 2717
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc.feature
; OTHER INFORMATION: Incyte ID No. US20020137081A1 1097750.1
; LOCATION: 1603-1604
; OTHER INFORMATION: a, t, c, g, or other
US-10-044-090-484

Query Match
Best Local Similarity 27.7%; Score 25.8; DB 12; Length 2717;
Matches 45; Conservative 0; Mismatches 32; Indels 0; Gaps 0;

Qy 15 CTTACCAAGTATGATGTTCTTATTTGGAAGGCCAGCTGCCAAGAAATTCATTGCTTG 74
Db 1027 CTTGAGCGCGACCTAGATCTTACTGGAAGTTTAAAGAGTCAATCCAGTCTTG 968
Qy 75 GCTGTGAAGGCCGAG 91
Db 967 CCTTCAGAAAGGCCAAG 951

RESULT 14
US-09-964-824A-572/c
; Sequence 572, Application US/09964824A
; Patent No. US20020102531A1
; GENERAL INFORMATION:
; APPLICANT: Horrigan, Stephen
; TITLE OF INVENTION: Cancer Gene Determination and Therapeutic Screening Using Signatu
; FILE REFERENCE: 689290-73
; CURRENT APPLICATION NUMBER: US/09/964, 824A
; CURRENT FILING DATE: 2001-09-27
; PRIOR APPLICATION NUMBER: US/60/236, 033
```

```

; PRIOR FILING DATE: 2000-09-28
; PRIOR APPLICATION NUMBER: US/60/236, 032
; PRIOR FILING DATE: 2000-09-28
; PRIOR APPLICATION NUMBER: US/60/236, 028
; PRIOR FILING DATE: 2000-09-28
; NUMBER OF SEQ ID NOS: 583
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 572
; LENGTH: 23822
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-964-824A-572

Query Match
Best Local Similarity 27.7%; Score 25.8; DB 10; Length 23822;
Matches 45; Conservative 0; Mismatches 32; Indels 0; Gaps 0;

Qy 15 CTTACCAAGTATGATGTTCTTATTTGGAAGGCCAGCTGCCAAGAAATTCATTGCTTG 74
Db 21710 CTTGAGCGCGACCTAGATCTTACTGGAAGTTTAAAGAGTCAATCCAGTCTTG 21651
Qy 75 GCTGTGAAGGCCGAG 91
Db 21650 CCTTCAGAAAGGCCAAG 21634

RESULT 15
US-09-328-130-6/c
; Sequence 6, Application US/09328130
; Patent No. US2002015597A1
; GENERAL INFORMATION:
; APPLICANT: Selden, Richard F
; APPLICANT: Treco, Douglas
; APPLICANT: Heartlein, Michael W
; TITLE OF INVENTION: In Vivo Production and Delivery of
; FILE REFERENCE: Erythropoietin or Insulinotropin for Gene Therapy
; CURRENT APPLICATION NUMBER: US/09/328, 130
; CURRENT FILING DATE: 1999-06-08
; PRIOR APPLICATION NUMBER: US 08/334,455
; PRIOR FILING DATE: 1994-11-04
; PRIOR APPLICATION NUMBER: US 07/911,533
; PRIOR FILING DATE: 1992-07-10
; PRIOR APPLICATION NUMBER: US 07/787,840
; PRIOR FILING DATE: 1991-11-05
; PRIOR APPLICATION NUMBER: US 07/789,188
; PRIOR FILING DATE: 1991-11-05
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 54
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-328-130-6

Query Match
Best Local Similarity 27.5%; Score 25.6; DB 9; Length 54;
Matches 28; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 1 CATGCTGAAGGACCTTTACAGATGATGAG 32
Db 34 CATGCTGAAGGACCTTTACAGTGAATATG 3

Search completed: February 14, 2003, 10:21:22
Job time : 77 secs
```


GenCore version 5.1.3
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: February 13, 2003, 11:02:01 ; Search time 16 seconds
(without alignments)
186.260 Million cell updates/sec

Title: US-09-091-605-1

Perfect score: 141
Sequence: 1 HXEGFTSDVSYLXGQAAAXFIAMLVKGRX 31

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 283224 seqs, 96134422 residues

Total number of hits satisfying chosen parameters: 283224

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%

Listing first 45 summaries

Database : PIR.73:*

1: pir1:.*
2: pir2:.*
3: pir3:.*
4: pir4:.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB ID	Description
1	133	94.3	158	1 GCRG	glucagon precursor
2	133	94.3	180	1 GCHU	glucagon precursor
3	133	94.3	180	1 GCEP	glucagon precursor
4	133	94.3	180	1 GCRTDU	glucagon precursor
5	133	94.3	180	1 GCRT	glucagon precursor
6	133	94.3	180	1 GCHY	glucagon precursor
7	133	94.3	180	1 GCBO	glucagon precursor
8	133	94.3	180	2 A57294	glucagon precursor
9	121	85.8	151	1 GCCH	glucagon precursor
10	121	85.8	206	2 I51301	proglucagon - chic
11	107	75.9	30	2 B61125	glucagon-like pept
12	107	75.9	30	2 C61125	glucagon-like pept
13	107	75.9	101	1 GCRFB	glucagon precursor
14	104	73.8	122	1 GCAFE	glucagon 2 precurs
15	102	72.3	66	2 I51093	glucagon - chinook
16	102	72.3	178	2 I51058	glucagon I precurs
17	101	71.6	63	1 GCIDC	glucagon precursor
18	101	71.6	72	1 GCGXA	glucagon precursor
19	98	69.5	30	2 S44473	glucagon-like pept
20	97	68.8	60	1 GCNC	glucagon precursor
21	97	68.8	178	2 I51057	glucagon II precur
22	89	63.1	87	1 GCFTS	glucagon precursor
23	84	59.6	29	2 S07211	glucagon - marbler
24	82	58.2	29	1 GCDP	glucagon - smaler
25	81	57.4	29	1 GCOPI	glucagon - North A
26	81	57.4	29	2 A91740	glucagon - turkey
27	81	57.4	29	2 A91741	glucagon - rabbit
28	81	57.4	29	2 A91742	glucagon - Arabian
29	81	57.4	29	2 C39258	glucagon - common

ALIGNMENTS

30	81	57.4	69	1 GCDG69	glucagon-69 - dog
31	81	57.4	124	1 GCAF	glucagon I precurs
32	80	56.7	29	1 GCEN	glucagon - elephant
33	79	56.0	29	1 GCDK	glucagon - duck
34	79	56.0	29	1 A61583	glucagon - ostrich
35	79	56.0	29	1 GCTTS	glucagon - slider
36	77	54.6	31	2 HWGH4G	glucagon-4 - Gila m
37	77	54.6	31	2 S44472	glucagon G2 - Nort
38	77	54.6	39	1 HWGH3Z	glucagon I - Europ
39	76	53.9	29	2 C60840	glucagon - Chinchi
40	75	53.2	29	1 GCBP	glucagon G1 - Nort
41	75	53.2	31	2 S44471	glucagon - Europea
42	74	52.5	29	1 GCFL	glucagon - bigeye
43	74	52.5	29	2 A61135	glucagon - bowfin
44	74	52.5	29	2 S39018	glucagon - bowfin
45	67	47.5	36	1 GCPI	glucagon-36 - spot

RESULT 1

GCPE
glucagon precursor - pig (fragment)
N:Alternate names: glidentin; oxyntomodulin
N:Contains: glidentin-related peptide; glucagon; glucagon-37 (oxyntomodulin); glucago
C:Species: Sus scrofa domestica (domestic pig)
C:Date: 17-Dec-1982 #sequence, revision 31-Mar-1993 #text_change 20-Mar-1998
C:Accession: A01540; A60312; A91781; B32614; A28064
R:Thim, L.; Moody, A.J.
Regul. Pept. 2, 139-150, 1981
A:Title: The primary structure of porcine glidentin (proglucagon).
A:Reference number: A94233; MUID:81248172; PMID:6894800
A:Accession: A01540
A:Molecule type: protein
A:Residues: 1-69 <TH>
R:Thim, L.; Moody, A.J.
Regul. Pept. Suppl. 2, S33, 1983
A:Title: Primary structure of a possible porcine proglucagon fragment.
A:Reference number: A60312
A:Accession: A60312
A:Molecule type: protein
A:Residues: 1-30 <TH>
A:Note: this peptide is co-secreted with glucagon from the pancreas
R:Bromer, W.W.; Sinn, L.G.; Behrens, O.K.
J. Am. Chem. Soc. 79, 2807-2810, 1957
A:Title: The amino acid sequence of glucagon. V. Location of amide groups, acid degra
A:Reference number: A91781
A:Accession: A91781
A:Molecule type: protein
A:Residues: 33-61 <BRO>
R:Orskov, C.; Bersani, M.; Johnsen, A.H.; Hojrup, P.; Holst, J.J.
J. Biol. Chem. 264, 12826-12829, 1989
A:Title: Complete sequences of glucagon-like peptide-1 from human and pig small intes
A:Reference number: A92732; MUID:69327238; PMID:2753890
A:Accession: B32614
A:Molecule type: protein
A:Residues: 78-107 <ORS>
R:Buhl, T.; Thim, L.; Kofod, H.; Orskov, C.; Harling, H.; Holst, J.J.
J. Biol. Chem. 263, 8621-8624, 1988
A:Title: Naturally occurring products of proglucagon 111-160 in the porcine and human
A:Reference number: A28064; MUID:88243712; PMID:3379036
A:Accession: A28064
A:Molecule type: protein
A:Residues: 111-158 <BRO>
C:Comment: X's represent missing amino acids, mostly basic, that are predicted to ext
C:Superfamily: glucagon
C:Keywords: amidated carboxyl end; carbohydrate metabolism; duplication; hormone; int
F:1-69/Product: glucagon-69 #status experimental <G69>
F:1-30/Region: glidentin-related peptide #status experimental
F:33-69/Product: glucagon-37 #status predicted <G37>
F:33-61/Product: glucagon #status experimental <GCN>
F:78-107/Product: glucagon-like peptide 1 #status experimental <GLI>

F:126-158/Product: glucagon-like peptide 2 #status experimental <GL2>
F:107/Modified site: amidated carboxyl end (Arg) (amide in mature form from following gl

Query Match 94.3%; Score 133; DB 1; Length 156;
Best Local Similarity 86.7%; Pred. No. 5.5e-14;
Matches 26; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 1 HXEGFTSDVSSYLXGQAAAXXFIAMLVKGR 30
Db 78 HAEGETSDVSSYLEGQAAKEFIAMLVKGR 107

RESULT 2

glucagon precursor [validated] - human

N:Contains: glicentin; glicentin-related polypeptide (GRP); glucagon; glucagon-like peptide 1 (tGLP1)

C:Species: Homo sapiens (man)

C:Date: 24-Apr-1984 #sequence_revision 31-Mar-1993 #text_change 08-Dec-2000

C:Accession: A24377; A44197; A30875; A32614; A01541; S23309

R:White, J.W.; Saunders, G.F.

Nucleic Acids Res. 14, 4719-4730, 1986

A:Title: Structure of the human glucagon gene.

A:Reference number: A24377; MUID:86259053; PMID:3725587

A:Accession: A24377

A:Molecule type: DNA

A:Residues: 1-180 <MHI>

A:Cross-references: GB:X03991

R:Bell, G.I.; Sanchez-Pescador, R.; Laybourn, P.J.; Najarian, R.C.

Nature 304, 368-371, 1983

A:Title: Exon duplication and divergence in the human preproglucagon gene.

A:Reference number: A44197; MUID:83271477; PMID:6877358

A:Accession: A44197

A:Molecule type: DNA

A:Residues: 1-179 <BED>

A:Cross-references: GB:V01515; NID:g31777; PIDN:CAA24759.1; PID:g31778

R:Drucker, D.J.; Asa, S.

J. Biol. Chem. 263, 13475-13478, 1988

A:Title: Glucagon gene expression in vertebrate brain.

A:Reference number: A30875; MUID:88330860; PMID:2901414

A:Accession: A30875

A:Molecule type: mRNA

A:Residues: 1-180 <DRU>

A:Cross-references: GB:J04040; NID:g183269; PIDN:AAA52567.1; PID:g183270

R:Orskov, C.; Bersani, M.; Johnsen, A.H.; Hojrup, P.; Holst, J.J.

J. Biol. Chem. 264, 12826-12829, 1989

A:Title: Complete sequences of glucagon-like peptide-1 from human and pig small intestine

A:Reference number: A92732; MUID:89327238; PMID:2753890

A:Accession: A32614

A:Molecule type: protein

A:Residues: 98-127 <ORS>

R:Thomsen, J.; Kristiansen, K.; Brunfeldt, K.; Sundby, F.

FEBS Lett. 21, 315-319, 1972

A:Title: The amino acid sequence of human glucagon.

A:Reference number: A91373

A:Accession: A01541

A:Molecule type: protein

A:Residues: 53-81 <THO>

R:Tsugita, A.; Takamoto, K.; Kamo, M.; Iwagata, H.

Eur. J. Biochem. 206, 691-696, 1992

A:Title: C-terminal sequencing of protein. A novel partial acid hydrolysis and analysis

A:Reference number: S23309; MUID:9228996; PMID:1606566

A:Accession: S23309

A:Molecule type: protein

A:Residues: 53-81 <TSU>

C:Comment: In pancreatic alpha-cells, proglucagon is processed to glicentin-related polypeptide 1, glucagon-like peptide 1, glucagon-like peptide 2, and glucagon-like peptide 3.

A:Gene: GDB:GCG

A:Cross-references: GDB:119265; OMIM:138030

A:Map position: 2q36-2q37

A:Introns: 31/2; 85/2; 131/2; 179/2

C:Superfamily: glucagon

C:Keywords: amidated carboxyl end; carbohydrate metabolism; duplication; hormone; int

F:1-20/Domain: signal sequence #status predicted <SIG>

F:21-180/Product: proglucagon #status experimental <PGC>

F:21-89/Product: glicentin #status experimental <GLN>

F:21-50/Product: glicentin-related polypeptide #status predicted <GRPP>

F:53-89/Product: oxyntomodulin #status experimental <ONX>

F:53-81/Product: glucagon #status experimental <GNC>

F:92-178/Product: major proglucagon fragment #status experimental <MPGF>

F:92-127/Product: glucagon-like peptide 1 #status experimental <GL1>

F:98-127/Product: truncated glucagon-like peptide 1 #status experimental <TGL>

F:146-178/Product: glucagon-like peptide 2 #status predicted <GL2>

F:127/Modified site: amidated carboxyl end (Arg) (amide in mature form from following

Query Match

Best Local Similarity 94.3%; Score 133; DB 1; Length 180;

Matches 26; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 1 HXEGFTSDVSSYLXGQAAAXXFIAMLVKGR 30

Db 98 HAEGETSDVSSYLEGQAAKEFIAMLVKGR 127

RESULT 3

glucagon precursor - guinea pig

N:Alternate names: oxyntomodulin

C:Contains: glicentin-related peptide; glucagon; glucagon-37 (oxyntomodulin); glucagon

C:Species: Cavia porcellus (guinea pig)

C:Date: 30-Sep-1987 #sequence_revision 31-Dec-1992 #text_change 16-Jun-2000

C:Accession: A24856; A23849; A60323

R:Seino, S.; Welsh, M.; Bell, G.I.; Chan, S.J.; Steiner, D.F.

FEBS Lett. 203, 25-30, 1986

A:Title: Mutations in the guinea pig preproglucagon gene are restricted to a specific

A:Reference number: A24856; MUID:86248118; PMID:375107

A:Accession: A24856

A:Molecule type: mRNA

A:Residues: 1-180 <SEI>

A:Cross-references: DDBJ:D00014; GB:N00014; NID:g220288; PIDN:BA00010.1; PID:g220289

R:Huang, C.G.; Eng, J.; Pan, Y.C.E.; Holmes, J.D.; Yalow, R.S.

Diabetes 35, 508-512, 1986

A:Title: Guinea pig glucagon differs from other mammalian glucagons.

A:Reference number: A23849; MUID:86165412; PMID:3956884

A:Accession: A23849

A:Molecule type: protein

A:Residues: 53-81 <HUA>

R:Conlon, J.M.; Hansen, H.F.; Schwartz, T.W.

Regul. Pept. 11, 309-320, 1985

A:Title: Primary structure of glucagon and a partial sequence of oxyntomodulin (gluca

A:Reference number: A60323; MUID:86017849; PMID:4048553

A:Accession: A60323

A:Molecule type: protein

A:Residues: 53-81 <CON>

A:Note: glucagon-37 was not completely sequenced

C:Superfamily: glucagon

C:Keywords: amidated carboxyl end; carbohydrate metabolism; duplication; hormone; pan

F:1-20/Domain: signal sequence #status predicted <SIG>

F:21-180/Product: proglucagon #status predicted <PGC>

F:21-50/Product: glicentin-related polypeptide #status predicted <GRPP>

F:53-89/Product: oxyntomodulin #status experimental <ONX>

F:53-81/Product: glucagon #status experimental <GNC>

F:98-127/Product: glucagon-like peptide 1 #status predicted <GL1>

F:146-178/Product: glucagon-like peptide 2 #status predicted <GL2>

F:127/Modified site: amidated carboxyl end (Arg) (amide in mature form from following

Query Match

Best Local Similarity 94.3%; Score 133; DB 1; Length 180;

Matches 26; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 1 HXEGFTSDVSSYLXGQAAAXXFIAMLVKGR 30

Db 98 HAEGETSDVSSYLEGQAAKEFIAMLVKGR 127

RESULT 4

GCRRDU glucagon precursor - degu
 N:Contains: glucentin-related peptide; glucagon; glucagon-like peptide 1; glucagon-like
 C:Species: Octodon degus (degu)
 C>Date: 31-Mar-1993 #sequence_revision 31-Mar-1993 #text_change 18-Jun-1999
 C:Accession: C36118
 R:Nishi, M.; Steiner, D.F.
 Mol. Endocrinol. 4, 1192-1198, 1990
 A:Title: Cloning of complementary DNAs encoding islet amyloid polypeptide, insulin, and
 A:Reference number: A36118; MUID:91155952; PMID:2293024
 A:Accession: C36118
 A:Molecule type: mRNA
 A:Residues: 1-180 <NTS>
 A:Cross-references: GB:M57688; NID:g202467; PIDN:AAA0588.1; PID:g202468
 C:Superfamily: glucagon
 C:Keywords: amidated carboxyl end; carbohydrate metabolism; duplication; hormone; pancre
 F:1-20/Domain: signal sequence #status predicted <SIG>
 F:21-180/Product: proglucagon #status predicted <PGC>
 F:21-50/Region: glucentin-related peptide #status predicted
 F:53-81/Product: glucagon #status predicted <GCN>
 F:98-127/Product: glucagon-like peptide 1 #status predicted <GL1>
 F:146-178/Product: glucagon-like peptide 2 #status predicted <GL2>
 F:127/Modified site: amidated carboxyl end (Arg) (amide in mature form from following gl

Query Match 94.3%; Score 133; DB 1; Length 180;
 Best Local Similarity 86.7%; Pred. No. 6.3e-14;
 Matches 26; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1 HXEGFTSDVSSYLXGQAAKXFIAMLVKGR 30
 Db 98 HAEFTSDVSSYLEGOAKKFIAMLVKGR 127

RESULT 5

GCRT glucagon precursor - rat
 N:Contains: glucentin-related peptide; glucagon; glucagon-like peptide 1; glucagon-like
 C:Species: Rattus norvegicus (Norway rat)
 C>Date: 30-Sep-1987 #sequence_revision 30-Sep-1987 #text_change 26-Feb-1999
 C:Accession: A22655; A25190; A44198
 R:Heinrich, G.; Gros, P.; Habener, J.F.
 J. Biol. Chem. 259, 14082-14087, 1984
 A:Title: Glucagon gene sequence: four of six exons encode separate functional domains of
 A:Reference number: A22655; MUID:85054855; PMID:6094559
 A:Accession: A22655
 A:Molecule type: DNA
 A:Residues: 1-180 <HEI>
 A:Cross-references: EMBL:K02809
 A:Note: The authors translated the codon TNG for residue 10 as Glu and ACC for residue 5
 R:Mojsos, S.; Heinrich, G.; Wilson, I.B.; Ravazzola, M.; Orci, L.; Habener, J.F.
 J. Biol. Chem. 261, 11880-11889, 1986
 A:Title: Preproglucagon gene expression in pancreas and intestine diversifies at the lev
 A:Reference number: A25190; MUID:86304324; PMID:3528148
 A:Accession: A25190
 A:Status: not compared with conceptual translation
 A:Molecule type: mRNA
 A:Residues: 1-180 <MOC>
 R:Heinrich, G.; Gros, P.; Lund, P.K.; Bentley, R.C.; Habener, J.F.
 Endocrinology 115, 2176-2181, 1984
 A:Title: Pre-proglucagon messenger ribonucleic acid: nucleotide and encoded amino acid s
 A:Reference number: A44198; MUID:85051023; PMID:6548696
 A:Accession: A44198
 A:Status: preliminary
 A:Molecule type: mRNA
 A:Residues: 1-180 <HE2>
 A:Cross-references: GB:K02809; GB:K02810; GB:K02811; GB:K02812
 C:Genetics:
 A:Introns: 31/2; 85/2; 131/2; 179/2
 C:Superfamily: glucagon
 C:Keywords: amidated carboxyl end; carbohydrate metabolism; duplication; hormone; pancre
 F:1-20/Domain: signal sequence #status predicted <SIG>

F:21-180/Product: proglucagon #status predicted <PGC>
 F:21-50/Region: glucentin-related peptide #status predicted
 F:53-81/Product: glucagon #status predicted <GCN>
 F:98-127/Product: glucagon-like peptide 1 #status predicted <GL1>
 F:146-178/Product: glucagon-like peptide 2 #status predicted <GL2>
 F:127/Modified site: amidated carboxyl end (Arg) (amide in mature form from following

Query Match 94.3%; Score 133; DB 1; Length 180;
 Best Local Similarity 86.7%; Pred. No. 6.3e-14;
 Matches 26; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1 HXEGFTSDVSSYLXGQAAKXFIAMLVKGR 30
 Db 98 HAEFTSDVSSYLEGOAKKFIAMLVKGR 127

RESULT 6

GCHY glucagon precursor - golden hamster
 N:Contains: glucentin-related peptide; glucagon; glucagon-like peptide 1; glucagon-11
 C:Species: Mesocricetus auratus (golden hamster)
 C>Date: 13-Jun-1983 #sequence_revision 13-Jun-1983 #text_change 20-Mar-1998
 C:Accession: A01539
 R:Bell, G.I.; Santerre, R.F.; Mullenbach, G.T.
 Nature 302, 716-718, 1983
 A:Title: Hamster preproglucagon contains the sequence of glucagon and two related pep
 A:Reference number: A01539; MUID:83167563; PMID:6835407
 A:Accession: A01539
 A:Molecule type: mRNA
 A:Residues: 1-180 <BEL>
 A:Cross-references: EMBL:J00059
 C:Superfamily: glucagon
 C:Keywords: amidated carboxyl end; carbohydrate metabolism; duplication; hormone; pan
 F:1-20/Domain: signal sequence #status predicted <SIG>
 F:21-180/Product: proglucagon #status predicted <PGC>
 F:21-50/Region: glucentin-related peptide #status predicted
 F:53-81/Product: glucagon #status predicted <GCN>
 F:98-127/Product: glucagon-like peptide 1 #status predicted <GL1>
 F:146-180/Product: glucagon-like peptide 2 #status predicted <GL2>
 F:127/Modified site: amidated carboxyl end (Arg) (amide in mature form from following

Query Match 94.3%; Score 133; DB 1; Length 180;
 Best Local Similarity 86.7%; Pred. No. 6.3e-14;
 Matches 26; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1 HXEGFTSDVSSYLXGQAAKXFIAMLVKGR 30
 Db 98 HAEFTSDVSSYLEGOAKKFIAMLVKGR 127

RESULT 7

GCBO glucagon precursor - bovine
 N:Contains: glucentin-related peptide; glucagon; glucagon-like peptide 1; glucagon-11
 C:Species: Bos primigenius taurus (cattle)
 C>Date: 14-Nov-1983 #sequence_revision 14-Nov-1983 #text_change 20-Mar-1998
 C:Accession: A93970; A92081; A01538
 R:Lopez, L.C.; Frazier, M.L.; Su, C.J.; Kumar, A.; Saunders, G.F.
 Proc. Natl. Acad. Sci. U.S.A. 80, 5485-5489, 1983
 A:Title: Mammalian pancreatic preproglucagon contains three glucagon-related peptides
 A:Reference number: A93970; MUID:83299966; PMID:8577439
 A:Accession: A93970
 A:Molecule type: mRNA
 A:Residues: 1-180 <LOP>
 A:Cross-references: EMBL:K00107
 R:Brumer, W.W.; Boucher, M.E.; Koffenberger Jr., J.E.
 J. Biol. Chem. 246, 2822-2827, 1971
 A:Title: Amino acid sequence of bovine glucagon.
 A:Reference number: A92081; MUID:71166445; PMID:5102927
 A:Accession: A92081
 A:Molecule type: protein
 A:Residues: 53-81 <BO>
 C:Superfamily: glucagon

C:Keywords: amidated carboxyl end; carboxylate metabolism; duplication; hormone; pancreas; signal sequence
F:1-20/Domain: signal sequence #status predicted <SIG>
E:21-180/Product: proglucagon #status predicted <PGC>
E:21-50/Region: glucocorticoid-related peptide #status predicted
E:53-81/Product: glucagon #status experimental <GCN>
E:98-127/Product: glucagon-like peptide 1 #status experimental <GL1>
E:146-178/Product: glucagon-like peptide 2 #status predicted <GL2>
F:127/Modified site: amidated carboxyl end (Arg) (amide in mature form from following gl

Query Match	94.3%	Score 133;	DB 1;	Length 180;
Best Local Similarity	86.7%;	Pred. No. 6.3e-14;		
Matches 26;	Conservative 0;	Mismatches 4;	Indels 0;	Gaps 0;

QY 1 HXEGFTSDVSSYLXGQAAXFIAMLVKGR 30
 | | | | | | | | | | | | | | | |
Db 98 HAEGFTSDVSSYLEGQAKEFIAMLVKGR 127

RESULT 8
A57294
glucagon precursor - mouse
C:Species: Mus musculus (house mouse)
C:Date: 01-Dec-1995 #sequence_revision 01-Dec-1995 #text_change 16-Jul-1999
C:Accession: A57294; S49303
R:Rothenberg, M.E.; Ellertson, C.D.; Klein, K.; Zhou, Y.; Lindberg, I.; McDonald, J.K.;
J. Biol. Chem. 270, 10136-10146, 1995
A:Title: Processing of mouse proglucagon by recombinant prohormone convertase 1 and immu
A:Reference number: A57294; MUID:95247722; PMID:7730317
A:Accession: A57294
A:Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-180 <ROT>
A:Cross-references: EMBL:Z46845; NID:g599880; PIDN:CA86902.1; PID:g599881
C:Superfamily: glucagon
C:Keywords: carbohydrate metabolism; duplication; hormone; pancreas

	94.3%	Score 133	DB 2:	Length 180;
Query Match	86.7%	Pred. No.	6,3e-14;	
Best Local Similarity		Mismatches	4;	Gaps 0;
Matches	26;	Conservative	0;	Indels 0;
OY	1 HXECTFTSDVSSYLXGQAAAXFIANLVNKR	30		
	I I I I I I I I I I I I I I I I I I I I			
	98 HAEGTFTSDVSSYLEGQAARFIANLVNKR	127		

RESULT 9
GCCH
glucagon precursor - chicken
N:Contains: glucagon; glucagon-like peptide 1
C:Species: Gallus gallus (chicken)
C:Date: 31-Dec-1991 #sequence,revision 31-Mar-1993 #text_change 18-Jun-1999
C:Accession: S09992; A92189; A60836; A01542
FEBS Lett. 264, 117-120, 1990
A:Title: Nucleotide sequence determination of chicken glucagon precursor cDNA. Chicken F
A:Reference number: S09992; MWID:90249492; PMID:2338135
A:Accession: S09992
A:Molecule type: mRNA
A:Residues: 1-151 <NAS>
A:Cross-References: EMBL:Y07539; NID:g63749; PIDN:CAA68827.1; PID:g63750
R:Pollock, H.G.; Kimmel, J.R.
J. Biol. Chem. 250, 9337-9380, 1975
A:Title: Chicken glucagon. Isolation and amino acid sequence studies.
A:Reference number: A92189; MWID:76069271; PMID:1194290
A:Accession: A92189
A:Molecule type: protein
A:Residues: 55-83 <POL>
R:Huang, J.; Eng, J.; Yalow, R.S.
Horm. Metab. Res. 19, 542-544, 1987
A:Title: Chicken glucagon: sequence and potency in receptor assay.
A:Reference number: A60836; MWID:88113418; PMID:2828209
A:Accession: A60836
A:Molecule type: protein

A:Residues: 55-83 <HDA>
C:Superfamily: glucagon
C:Keywords: amidated carboxyl end; carbohydrate metabolism; duplication; hormone; pan
F:1-22/Domain: signal sequence #status predicted <SIG>
F:23-151/Product: proglucagon #status predicted <PC>
F:55-83/Product: glucagon #status experimental <GCN>
F:118-147/Product: glucagon-like peptide 1 #status predicted <GL1>
F:147/Modified site: amidated carboxyl end (Arg) (amide in mature form from following

Query Match	85.8%;	Score 121;	DB 1;	Length 151;
Best Local Similarity	73.3%;	Pred. No. 4.5e-12;		
Matches 22;	Conservative 3;	Mismatches 5;	Indels 0;	Gaps 0;

QY 1 HXEGFTSDVSSYLXGQAAAXFIAMLVKGR 30
| |||:|||| ||| ||||| ||
Db 118 HAEGTYSDTISYLEGQAAKEFIAMLVNGR 147

```

RESULT 10
I51301
proglucagon - chicken
C:Species: Gallus gallus (chicken)
C:Date: 13-Sep-1996 #sequence_revision 13-Sep-1996 #text_change 16-Jul-1999
C:Accession: I51301
R:Irwin, D.M.; Wong, J.
MOL. Endocrinol. 9, 267-277, 1995
A:Title: Trout and chicken proglucagon: alternative splicing generates mRNA transcrip
A:Reference number: A55895; M01D:95295739; PMID:7776976
A:Accession: I51301
A:Status: preliminary; translated from GB/EMBL/DBJ
A:Molecule type: rRNA
A:Residues: 1-206 <IRW>
A:Cross-references: GB:S78477; NID:g999386; PIDN:AAAB34506.1; PID:g999387
C:Superfamily: glucagon
C:Keywords: duplication

```

	Query Match	85.8%	Score 121	DB 2	Length 206;
	Best Local Similarity	73.3%	Pred.	No. 6.2e-12;	
	Matches 22;	Conservative 3;	Mismatches 5;	Indels 0;	Gaps 0;
OY	I HXEGFTSDVSSYLKGQAAXXFIAWLNVGR	30			
b	118 HAEGFTSDITSYLEGOAKKEFIAMLNVR	147			

```

RESULT 11
B61125      glucagon-like peptide - American eel
C:Species: Anguilla rostrata (American eel)
C:Date: 10-Mar-1994 #sequence_revision 10-Mar-1994 #text_change 21-Nov-1997
C:Accession: B61125
R:Conlon, J.M.; Andrews, P.C.; Thim, L.; Moon, T.W.
Gen. Comp. Endocrinol. 82, 23-32, 1991
A:Title: The primary structure of glucagon-like peptide but not insulin has been cons
A:Reference number: A61125; M0ID:91340068; PMID:1674385
A:Accession: B61125
A:Molecule type: protein
A:Residues: 1-30 <CON>
C:Superfamily: glucagon
C:Keywords: amidated carboxyl end; duplication
F:1-30/Product: glucagon-like peptide #status experimental <GLP>
F:30/Modified site: amidated carboxyl end (Arg) #status predicted

Query Match          75.9%; Score 107; DB 2: Length 30;
Best Local Similarity 66.7%; Pred. 0.1,5e-10;
Matches 20; Conservative 3; Mismatches 7; Indels 0; Gaps 0;

QY      1 HXEGFTSDVSYLXGQAAXXFIAMLVKGR 30
      1 |||:||||||| ||| 1::|| 1|
Db      1 HAEGTYSDVSYLQDQAAKEFVSWLKTGR 30

RESULT 12

```

```
QY      1 HXEGFTTSDVSSYLXGQAAXXFIAWLVKGR   30  
        | :| |:| |:| |:| |:| |:| |:| |:|  
Db      1 HAEGTYTSDVSSYLQDQAAKEFVSWLKTGR   30
```

RESULT 12

```

C61125
glucagon-like peptide - European eel
C:Species: Anguilla anguilla (European eel)
C>Date: 10-Mar-1994 #sequence_revision 10-Mar-1994 #text_change 21-Nov-1997
C:Accession: C61125
R:Conlon, J.M.; Andrews, P.C.; Thim, L.; Moon, T.W.
Gen. Comp. Endocrinol. 82, 23-32, 1991
A:Title: The primary structure of glucagon-like peptide but not insulin has been conserv
A:Reference number: A61125; MUID:91340068; PMID:1874385
A:Accession: C61125
A:Molecule type: protein
A:Residues: 1-30 <CON>
C:Superfamily: glucagon
C:Keywords: amidated carboxyl end; duplication
F:1-30/Product: glucagon-like peptide #status experimental <GLP>
F:30/Modified site: amidated carboxyl end (Arg) #status experimental

Query Match
Best Local Similarity 75.9%; Score 107; DB 2; Length 30;
Matches 20; Conservative 3; Mismatches 7; Indels 0; Gaps 0;

QY 1 HXEGFTSDVSSYLXGQAAXXFIAMLVKGR 30
| :||:|||||  |||  ||:  ||
Db 1 HADGTYTSDVSSYLDQQAKEFVSWLKTGR 30

RESULT 13
GCRCB
glucagon precursor - bullfrog (fragments)
N:Alternate names: oxyntomodulin
C:Species: glucagon; glucagon-36 (oxyntomodulin); glucagon-like peptide 1; glucagon-like
C:Species: Rana catesbeiana (bullfrog)
C>Date: 31-Mar-1993 #sequence_revision 31-Mar-1993 #text_change 20-Mar-1998
C:Accession: B28091; C28091; D28091
R:Pollock, H.G.; Hamilton, J.W.; Rouse, J.B.; Ebner, K.E.; Rawlitch, A.B.
J. Biol. Chem. 263, 9746-9751, 1988
A:Title: Isolation of peptide hormones from the pancreas of the bullfrog (Rana catesbeiana)
A:Reference number: A92730; MUID:88257102; PMID:3260236
A:Accession: B28091
A:Molecule type: protein
A:Residues: 1-36 <P02>
A:Accession: C28091
A:Molecule type: protein
A:Residues: 37-68 <POL>
A:Accession: D28091
A:Molecule type: protein
A:Residues: 69-101 <P03>
C:Superfamily: glucagon
C:Keywords: carbohydrate metabolism; duplication; hormone; pancreas
F:1-36/Product: glucagon-36 (oxyntomodulin) #status experimental <G36>
F:1-29/Product: glucagon #status predicted <GCN>
F:37-67/Product: glucagon-like peptide 1 #status experimental <GL1>
F:69-101/Product: glucagon-like peptide 2 #status experimental <GL2>

Query Match
Best Local Similarity 75.9%; Score 107; DB 1; Length 101;
Matches 19; Conservative 5; Mismatches 6; Indels 0; Gaps 0;

QY 1 HXEGFTSDVSSYLXGQAAXXFIAMLVKGR 30
| :|||||:|||||  |||  ||:  ||
Db 37 HADGTFSDMSYLEKAKAFVDMLIKGR 66

RESULT 14
GCAF2
glucagon 2 precursor - American gooselish
N:Contains: glucagon; glucagon-like peptide 1
C:Species: Lophius americanus (American gooselish)
C>Date: 31-Mar-1993 #sequence_revision 31-Mar-1993 #text_change 21-Jul-2000
C:Accession: A05150
R:Lund, P.K.; Goodman, R.H.; Montminy, M.R.; Dee, P.C.; Habener, J.F.
J. Biol. Chem. 258, 3280-3284, 1983
A:Title: Anglerfish islet pre-proglucagon II. Nucleotide and corresponding amino acid se

```

```

A:Reference number: A05150; MUID:83135785; PMID:6338015
A:Accession: A05150
A:Molecule type: mRNA
A:Residues: 1-122 <LUN>
A:Cross-references: GB:J00933; NID:964021; PIDN:CAA23905.1; PID:964022
C:Superfamily: glucagon
C:Keywords: carbohydrate metabolism; duplication; hormone; pancreas
F:1-21/Domain: signal sequence #status predicted <SIG>
F:22-122/Product: proglucagon 2 #status predicted <PGC2>
F:52-80/Product: glucagon #status predicted <GCN>
F:89-119/Product: glucagon-like peptide 1 #status predicted <GL1>

Query Match
Best Local Similarity 73.8%; Score 104; DB 1; Length 122;
Matches 19; Conservative 4; Mismatches 7; Indels 0; Gaps 0;

QY 1 HXEGFTSDVSSYLXGQAAXXFIAMLVKGR 30
| :|||||:|||||  |||  ||:  ||
Db 89 HADGTYTSDVSSYLDQQAADVSWLKAGR 118

RESULT 15
I51093
glucagon - chinook salmon (fragment)
C:Species: Oncorhynchus tshawytscha (chinook salmon)
C>Date: 13-Sep-1996 #sequence_revision 13-Sep-1996 #text_change 16-Jul-1999
C:Accession: I51093
R:Irwin, D.M.; Wong, J.
Mol. Endocrinol. 9, 267-277, 1995
A:Title: Trout and chicken proglucagon: alternative splicing generates mRNA transcript
A:Reference number: A55895; MUID:95295739; PMID:7776976
A:Accession: I51093
A:Status: preliminary; translated from GB/EMBL/DBJ
A:Molecule type: mRNA
A:Residues: 1-66 <IRW>
A:Cross-references: EMBL:U19920; NID:9736366; PIDN:AAC59670.1; PID:9736367
C:Superfamily: glucagon
C:Keywords: duplication

Query Match
Best Local Similarity 72.3%; Score 102; DB 2; Length 66;
Matches 18; Conservative 5; Mismatches 7; Indels 0; Gaps 0;

QY 1 HXEGFTSDVSSYLXGQAAXXFIAMLVKGR 30
| :|||||:|||||  |||  ||:  ||
Db 33 HADGTYTSDVSSYLDQQAADVSWLKAGR 62

Search completed: February 13, 2003, 11:03:32
Job time : 17 secs

```

1

2

3

4

5

GenCore version 5.1.3
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: February 13, 2003, 10:58:31 ; Search time 11 Seconds
(without alignments)
116.888 Million cell updates/sec

Title: US-09-091-605-1
Sequence: 141
1 HXEGFTSDVSSYLXGQAXXFIAMLVKGRX 31

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 112892 seqs, 41476328 residues
Total number of hits satisfying chosen parameters: 112892

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database: SwissProt_40:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match Length	ID	Description
1	133	94.3	158 1	GLUC_PIG
2	133	94.3	180 1	GLUC_BOVIN
3	133	94.3	180 1	GLUC_CAVPO
4	133	94.3	180 1	GLUC_HUMAN
5	133	94.3	180 1	GLUC_MESAU
6	133	94.3	180 1	GLUC_MOUSE
7	133	94.3	180 1	GLUC_OCTDE
8	133	94.3	180 1	GLUC_RAT
9	121	85.8	151 1	GLUC_CHICK
10	107	75.9	30 1	GLUC_RANCA
11	107	75.9	103 1	GLUC_ANGAN
12	104	73.8	122 1	GLUC_LOPAM
13	102	72.3	121 1	GLUC_CARAU
14	101	71.6	78 1	GLUC_LEPSP
15	100	70.9	71 1	GLUC_ICTPU
16	98	69.5	71 1	GLUC_PIRAME
17	97	68.8	68 1	GLUC_ORENI
18	94	66.7	33 1	GLUC_ONCKI
19	89	63.1	96 1	GLUC_MYOSC
20	84	59.6	29 1	GLUC_TORMA
21	82	58.2	29 1	GLUC_SCYCA
22	81	57.4	29 1	GLUC_DIDMA
23	81	57.4	29 1	GLUC_RABIT
24	81	57.4	29 1	GLUC_CANFA
25	81	57.4	124 1	GLUC_LOPAM
26	80	56.7	29 1	GLUC_CALMI
27	79	56.0	29 1	GLUC_ANAPL
28	79	56.0	87 1	EXE4_HELLO
29	78	55.3	36 1	GLUC_ORENI
30	77	54.6	29 1	GLUC_LAMFL
31	77	54.6	29 1	EXE3_HELLO
32	75	53.2	29 1	GLUC_CHIBR
33	74	52.5	29 1	GLUC_PLAFB

34	74	52.5	75 1	GLUC_AMICA	P33528 amia calva
35	67	47.5	36 1	GLUC_HYDGO	P09682 hydrogous
36	49	34.8	42 1	GIP_BOVIN	P09680 bos taurus
37	49	34.8	42 1	GIP_PIG	P01281 sus scrofa
38	49	34.8	144 1	GIP_MOUSE	P48756 mus musculus
39	49	34.8	144 1	GIP_RAT	O06145 ratius norv
40	48.5	34.4	326 1	UPK_SYNY3	Q35684 synecocyst
41	48	34.0	72 1	VIP_BOVIN	P81401 bos taurus
42	48	34.0	72 1	VIP_CAVPO	P04566 cavia porce
43	48	34.0	72 1	VIP_PIG	P01284 sus scrofa
44	48	34.0	72 1	VIP_RABIT	P32649 oryctolagus
45	48	34.0	153 1	GIP_HUMAN	P09681 homo sapien

ALIGNMENTS

RESULT 1	ID	GLUC_PIG	STANDARD:	PRT:	158 AA.
AC	P01274:				
DT	21-JUN-1986 (Rel. 01, Created)				
DT	01-NOV-1990 (Rel. 16, Last sequence update)				
DT	16-OCT-2001 (Rel. 40, Last annotation update)				
DE	Glucagon precursor [Contains: Glucentin, Glucicentin-related polypeptide (GRP); Glucagon; Glucagon-like peptide 1 (GLP1); Glucagon-like peptide 2 (GLP2)] (Fragment).				
GN	GCG.				
OS	Sus scrofa (Pig).				
OC	Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;				
OC	Mammalia; Eutheria; Cetartiodactyla; Suina; Suidae; Sus.				
OX	NCBI_TaxID=9823;				
RN	[1]				
RX	SEQUENCE OF 1-69.				
RA	MEDLINE=81248172; PubMed=6894800;				
RT	Thim L., Moody A.J.;				
RL	"The primary structure of porcine glucicentin (proglucagon).";				
RN	Regul. Pept. 2:139-150(1981).				
RP	[2]				
RX	SEQUENCE OF 1-69.				
RA	MEDLINE=82221776; PubMed=7045833;				
RT	Thim L., Moody A.J.;				
RL	"The amino acid sequence of porcine glucicentin.";				
RN	Peptides 2 Suppl. 2:37-39(1981).				
RP	[3]				
RX	SEQUENCE OF 33-61.				
RA	Bromer W.W., Sinn L.G., Behrens O.K.;				
RT	"The amino acid sequence of glucagon. V. Location of amide groups, acid degradation studies and summary of sequential evidence.";				
RL	J. Am. Chem. Soc. 79:2807-2810(1957).				
RN	[4]				
RP	SEQUENCE OF 78-107.				
RX	MEDLINE=89327238; PubMed=2753890;				
RA	Orskov C., Bersani M., Johnsen A.H., Hoejrup P., Holst J.J.;				
RT	"Complete sequences of glucagon-like peptide-1 from human and pig small intestine.";				
RL	J. Biol. Chem. 264:12826-12829(1989).				
RN	[5]				
RP	SEQUENCE OF 111-158.				
RX	MEDLINE=88243712; PubMed=3379036;				
RA	Buhl T., Thim L., Kotof H., Orskov C., Harling H., Holst J.J.;				
RT	"Naturally occurring products of proglucagon 111-160 in the porcine and human small intestine.";				
RL	J. Biol. Chem. 263:8621-8624(1988).				
RN	[6]				
RP	X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS).				
RX	MEDLINE=76051297; PubMed=171582;				
RA	Sasaki K., Dockerill S., Adamiak D.A., Tickle I.J., Blundell T.L.;				
RT	"X-ray analysis of glucagon and its relationship to receptor binding.";				
RL	Nature 257:751-757(1975).				
CC	-1- FUNCTION: GLUCAGON PROMOTES HYDROLYSIS OF GLYCOGEN AND LIPIDS, AND RAISES THE BLOOD SUGAR LEVEL.				

CC -1- FUNCTION: GLP2 STIMULATES INTESTINAL GROWTH AND UPREGULATES VILLOS
 CC HEIGHT IN THE SMALL INTESTINE, CONCOMITANT WITH INCREASED CRYPT
 CC CELL PROLIFERATION AND DECREASED ENTEROCYTE APOPTOSIS.
 CC -1- INDUCTION: PRODUCED IN THE A CELLS OF THE ISLETS OF LANGERHANS
 CC IN RESPONSE TO A DROP IN BLOOD SUGAR CONCENTRATION.
 CC -1- MISCELLANEOUS: X'S IN THE SEQUENCE WERE INCLUDED BY HOMOLOGY WITH
 CC HUMAN SEQUENCE.
 CC -1- SIMILARITY: BELONGS TO THE GLUCAGON FAMILY.
 DR PIR: A01540; GCPG.
 DR PDB: 1GCM; 30-SEP-83.
 DR InterPro: IPR000532; Glucagon.
 DR Pfam: PF00123; hormone2; 3.
 DR SMART: SM00070; GLUCA; 3.
 DR PROSITE: PS00260; GLUCAGON; 3.
 KW Glucagon family; Hormone; Cleavage on pair of basic residues;
 KW 3D-structure.
 FT PEPTIDE 1 1
 FT PEPTIDE 1 69 GLICENTIN.
 FT PEPTIDE 1 30 GLICENTIN-RELATED POLYPEPTIDE.
 FT PEPTIDE 33 61 GLUCAGON.
 FT PEPTIDE 78 107 GLUCAGON-LIKE PEPTIDE 1.
 FT PEPTIDE 126 158 GLUCAGON-LIKE PEPTIDE 2.
 FT HELIX 39 42
 FT TURN 43 45
 FT HELIX 46 55
 FT TURN 56 57
 SQ SEQUENCE 158 AA; 18212 MW; 28C6FCF257F33B2 CRC64;
 Query Match 94.3%; Score 133; DB 1; Length 158;
 Best Local Similarity 86.7%; Pred. No. 2.6e-14;
 Matches 26; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
 OY 1 HXGFTSDVSSYLXGQAAXXFIAMLVKGR 30
 Db 78 HXGFTSDVSSYLXGQAAXXFIAMLVKGR 107
 RESULT 2
 ID GLUC_BOVIN STANDARD; PRT; 180 AA.
 AC P01272;
 DT 21-JUL-1986 (Rel. 01, Created)
 DT 13-AUG-1987 (Rel. 05, Last sequence update)
 DT 15-JUN-2002 (Rel. 41, Last annotation update)
 DE Glucagon precursor [Contains: Glucocentriin-related polypeptide (GRPP);
 DE Glucagon; Glucagon-like peptide 1 (GLP1); Glucagon-like peptide 2
 DE (GLP2)].
 GN GCG.
 OS Bos taurus (Bovine).
 OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
 OC Bovidae; Bovinae; Bos.
 OX NCBI_TaxID=9913;
 RN [1]
 RP SEQUENCE FROM N.A.
 RA MEDLINE=8329996; PubMed=6577439;
 RA Lopez L.C., Frazier M.L., Su C.-J., Kumar A., Saunders G.F.;
 RA "Mammalian pancreatic preproglucagon contains three glucagon-related
 RA peptides";
 RA Proc. Natl. Acad. Sci. U.S.A. 80:5485-5489(1983).
 RN [2]
 RP SEQUENCE OF 53-81.
 RA MEDLINE=7116645; PubMed=5102927;
 RA Bremer W.W., Boucher M.E., Koffenberger J.E. Jr.;
 RA "Amino acid sequence of bovine glucagon";
 RA J. Biol. Chem. 246:2822-2827(1971).
 RN [3]
 RP STRUCTURE BY NMR OF 53-81.
 RA MEDLINE=7116645; PubMed=6631957;
 RA Braun W., Wider G., Lee K.H., Wuthrich K.;
 RA "Confirmation of glucagon in a lipid-water interphase by 1H nuclear
 RA magnetic resonance";
 RA J. Mol. Biol. 169:921-948(1983).

CC -1- FUNCTION: GLUCAGON PROMOTES HYDROLYSIS OF GLYCOGEN AND LIPIDS, AND
 CC RAISES THE BLOOD SUGAR LEVEL.
 CC -1- FUNCTION: GLP2 STIMULATES INTESTINAL GROWTH AND UPREGULATES VILLOS
 CC HEIGHT IN THE SMALL INTESTINE, CONCOMITANT WITH INCREASED CRYPT
 CC CELL PROLIFERATION AND DECREASED ENTEROCYTE APOPTOSIS.
 CC -1- INDUCTION: PRODUCED IN THE A CELLS OF THE ISLETS OF LANGERHANS
 CC IN RESPONSE TO A DROP IN BLOOD SUGAR CONCENTRATION.
 CC -1- SIMILARITY: BELONGS TO THE GLUCAGON FAMILY.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC -----
 DR EMBL: K00107; AAA30538.1; -
 DR PIR: A01538; GCOB.
 DR PDB: 1KX6; 13-FEB-02.
 DR InterPro: IPR000532; Glucagon.
 DR Pfam: PF00123; hormone2; 3.
 DR PRINTS: PR00275; GLUCAGON.
 DR SMART: SM00070; GLUCA; 3.
 DR PROSITE: PS00260; GLUCAGON; 4.
 KW Glucagon family; Hormone; Cleavage on pair of basic residues; Signal;
 KW 3D-structure.
 FT SIGNAL 1 20
 FT PEPTIDE 21 50 GLICENTIN-RELATED POLYPEPTIDE.
 FT PEPTIDE 53 81 GLUCAGON.
 FT PEPTIDE 92 128 GLUCAGON-LIKE PEPTIDE 1.
 FT PEPTIDE 146 178 GLUCAGON-LIKE PEPTIDE 2.
 SQ SEQUENCE 180 AA; 20944 MW; 8D9BAFF05B9F15FF CRC64;
 Query Match 94.3%; Score 133; DB 1; Length 180;
 Best Local Similarity 86.7%; Pred. No. 3e-14;
 Matches 26; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
 OY 1 HXGFTSDVSSYLXGQAAXXFIAMLVKGR 30
 Db 98 HXGFTSDVSSYLXGQAAXXFIAMLVKGR 127
 RESULT 3
 ID GLUC_CAVPO STANDARD; PRT; 180 AA.
 AC P05110;
 DT 13-AUG-1987 (Rel. 05, Created)
 DT 13-AUG-1987 (Rel. 05, Last sequence update)
 DT 16-OCT-2001 (Rel. 40, Last annotation update)
 DE Glucagon precursor [Contains: Glucocentriin-related polypeptide (GRPP);
 DE Glucagon; Glucagon-37 (Oxyntomodulin); Glucagon-like peptide 1 (GLP1);
 DE Glucagon-like peptide 2 (GLP2)].
 GN GCG.
 OS Cavia porcellus (Guinea pig).
 OC Eukaryota; Metazoa; Chordata; Cranialia; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Hystriocognathi; Caviidae; Cavia.
 OX NCBI_TaxID=10141;
 RN [1]
 RP SEQUENCE FROM N.A.
 RA MEDLINE=86248118; PubMed=3755107;
 RA Seino S., Welsh M., Bell G.I., Chan S.J., Steiner D.F.;
 RA "Mutations in the guinea pig preproglucagon gene are restricted to a
 RA specific portion of the prohormone sequence";
 RA FEBS Lett. 203:25-30(1986).
 RN [2]
 RP SEQUENCE OF 53-81.
 RA MEDLINE=86165412; PubMed=3956884;
 RA Huang C.G., Eng J., Pan Y.-C.E., Hulmes J.D., Yalow R.S.;
 RA "Guinea pig glucagon differs from other mammalian glucagons";
 RA Diabetes 35:508-512(1986).
 RN [3]
 RP PARTIAL SEQUENCE OF 53-89.

RA MEDLINE=86017849; PubMed=4048553;
 RA Conlon J.M., Hansen H.F., Schwartz T.W.;
 RA "Primary structure of glucagon and a partial sequence of
 RA oxyntomodulin (glucagon-37) from the guinea pig.";
 RL Regul. Pept. 11:309-320(1985).
 CC -1- FUNCTION: GLUCAGON PROMOTES HYDROLYSIS OF GLYCOGEN AND LIPIDS, AND
 CC RAISES THE BLOOD SUGAR LEVEL.
 CC -1- FUNCTION: GLIP2 STIMULATES INTESTINAL GROWTH AND UPREGULATES VILLOS
 CC HEIGHT IN THE SMALL INTESTINE, CONCOMITANT WITH INCREASED CRYPT
 CC CELL PROLIFERATION AND DECREASED ENTEROCYTE APOPTOSIS.
 CC -1- INDUCTION: PRODUCED IN THE A CELLS OF THE ISLETS OF LANGERHANS
 CC IN RESPONSE TO A DROP IN BLOOD SUGAR CONCENTRATION.
 CC -1- SIMILARITY: BELONGS TO THE GLUCAGON FAMILY.
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL Outstation
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (see <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC
 CC EMBL: D00014; BAA0010.1; -
 DR PIR: A24656; GCGP.
 DR HSP: P01274; IGCN.
 DR InterPro: IPR000532; Glucagon.
 DR Pfam: PF00123; hormone2; 3.
 DR PRINTS: PR00275; GLUCAGON.
 DR SMART: SM00070; GLUCA; 3.
 DR PROSITE: PS00260; GLUCAGON; 4.
 DR Glucagon family; Hormone; Cleavage on pair of basic residues; Signal.
 KW SIGNAL 1 20 GLUCENTIN-RELATED POLYPEPTIDE.
 FT SIGNAL 1 20
 FT PEPTIDE 21 50
 FT PEPTIDE 53 81 GLUCAGON.
 FT PEPTIDE 53 89 GLUCAGON-37.
 FT PEPTIDE 92 128 GLUCAGON-LIKE PEPTIDE 1.
 FT PEPTIDE 146 178 GLUCAGON-LIKE PEPTIDE 2.
 FT PEPTIDE 160 20972 MW: 702PB181161D2776 CRC64;
 SQ SEQUENCE 180 AA; 20972 MW: 702PB181161D2776 CRC64;
 Query Match 94.3%; Score 133; DB 1; Length 180;
 Best local Similarity 86.7%; Pred. No. 3e-14;
 Matches 26; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
 QY 1 HXGFTSDVSSYLXGQAAXXFIAMLVKGR 30
 DB 98 HXGFTSDVSSYLXGQAAXXFIAMLVKGR 127
 RESULT 4
 GLUC_HUMAN STANDARD; PRT; 180 AA.
 ID GLUC_HUMAN
 AC P01275;
 DT 21-JUL-1986 (Rel. 01, created)
 DT 13-AUG-1987 (Rel. 05, last sequence update)
 DT 15-JUN-2002 (Rel. 41, last annotation update)
 DE Glucagon precursor [Contains: Glucocentrin-related polypeptide (GRP)];
 DE Glucagon; Glucagon-like peptide 1 (GLP1); Glucagon-like peptide 2
 DE (GLP2)].
 GN GCG.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
 OC NCBI_Taxid=9606;
 RX NCB1_Taxid=9606;
 RN [1]
 RP SEQUENCE FROM N.A. PubMed=2901414;
 RX MEDLINE=88330860;
 RA Drucker D.J., Asa S.;
 RT "Glucagon gene expression in vertebrate brain.";
 RL J. Biol. Chem. 263:13475-13478(1988).
 RN [2]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=86259053; PubMed=3725587;
 RA White J.W., Saunders G.F.;

RT RT
 RL "Structure of the human glucagon gene.";
 RL Nucleic Acids Res. 14:4719-4730(1986).
 RN [3]
 RP SEQUENCE FROM N.A.
 RC TISSUE=Liver;
 RA MEDLINE=83271477; PubMed=6877358;
 RX Bell G.I., Sanchez-Pescador R., Laybourn P.J., Najarian R.C.;
 RT "Exon duplication and divergence in the human preproglucagon gene.";
 RL Nature 304:368-371(1983).
 RN [4]
 RP SEQUENCE FROM N.A.
 RC TISSUE=Pancreas;
 RA Straussberg R.;
 RL Submitted (MAR-2001) to the EMBL/GenBank/DBJ databases.
 RN [5]
 RP SEQUENCE OF 53-81.
 RA Thomsen J., Kristiansen K., Sundby F.;
 RT "The amino acid sequence of human glucagon.";
 RL FEBS Lett. 21:315-319(1972).
 RN [6]
 RP SEQUENCE OF 98-127.
 RA MEDLINE=89327238; PubMed=2753890;
 RX Orskov C., Bersani M., Johnsen A.H., Hoejrup P., Holst J.J.;
 RT "Complete sequences of glucagon-like peptide-1 from human and pig
 RT small intestine.";
 RL J. Biol. Chem. 264:12826-12829(1989).
 RN [7]
 RP X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF 53-81.
 RX MEDLINE=98334683; PubMed=9667960;
 RA Sturm N.S., Lin Y., Burley S.K., Kristiansky J.L., Ahn J.M.,
 RA Azharenko B.Y., Trivedi D., Hruby V.J.;
 RT "Structure-function studies on positions 17, 18, and 21 replacement
 RT analogues of glucagon: the importance of charged residues and salt
 RT bridges in glucagon biological activity.";
 RL J. Med. Chem. 41:2693-2700(1998)
 CC -1- FUNCTION: GLUCAGON PROMOTES HYDROLYSIS OF GLYCOGEN AND LIPIDS, AND
 CC RAISES THE BLOOD SUGAR LEVEL.
 CC -1- FUNCTION: GLIP2 STIMULATES INTESTINAL GROWTH AND UPREGULATES VILLOS
 CC HEIGHT IN THE SMALL INTESTINE, CONCOMITANT WITH INCREASED CRYPT
 CC CELL PROLIFERATION AND DECREASED ENTEROCYTE APOPTOSIS.
 CC -1- INDUCTION: PRODUCED IN THE A CELLS OF THE ISLETS OF LANGERHANS
 CC IN RESPONSE TO A DROP IN BLOOD SUGAR CONCENTRATION.
 CC -1- PHARMACEUTICAL: Available under the names Glucagon (Eli Lilly) and
 CC Glucagon or Glucagon Novo Nordisk (Novo Nordisk). Used to treat
 CC severe hypoglycemia in insulin-dependent diabetics.
 CC -1- SIMILARITY: BELONGS TO THE GLUCAGON FAMILY.
 CC -1- DATABASE: NAME=Glucagon at Eli Lilly;
 CC NOTE=Clinical information on Eli Lilly glucagon products;
 CC WWW="http://www.lillydiabetes.com/Products/PatientInfo.cfm".
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL Outstation
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (see <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC
 CC EMBL: J04040; AAS2567.1; -
 CC EMBL: X03991; CAA27627.1; -
 CC EMBL: V01515; CAA24759.1; -
 CC EMBL: BC005278; AAH05278.1; -
 DR PIR: A24377; GCHU.
 DR PIR: A24309; S23309.
 DR PDB: 1BHO; 1B-NOV-98.
 DR Genew: HGNC:4191; GCG.
 DR MIM: 138030; -
 DR MIM: 231530; -
 DR InterPro: IPR000532; Glucagon.
 DR Pfam: PF00123; hormone2; 3.
 DR PRINTS: PR00275; GLUCAGON.
 DR SMART: SM00070; GLUCA; 3.
 DR PROSITE: PS00260; GLUCAGON; 4.

KW Glucagon family; Hormone; Cleavage on pair of basic residues; Signal;
KW Pharmaceutical; 3D-structure.

FT SIGNAL 1 20
FT PEPTIDE 21 50 GLUCENTIN-RELATED POLYPEPTIDE.
FT PEPTIDE 53 81 GLUCAGON.
FT PEPTIDE 98 127 GLUCAGON-LIKE PEPTIDE 1.
FT PEPTIDE 146 178 GLUCAGON-LIKE PEPTIDE 2.
FT CONFLICT 82 82
SQ SEQUENCE 180 AA; 20909 MW; 7A99EC629B2862C CRC64;

Query Match 94.3%; Score 133; DB 1; Length 180;
Best Local Similarity 86.7%; Pred. No. 3e-14;
Matches 26; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1 HXEGFTSDVSYLXGQAAAXFIAMLVKGR 30
DB 98 HAEFTSDVSYLXGQAAKEFIAMLVKGR 127

RESULT 5
GLUC_MESAU
ID GLUC_MESAU STANDARD; PRT; 180 AA.

AC P01273;
DT 21-JUL-1986 (Rel. 01, Created)
DT 01-FEB-1996 (Rel. 33, Last sequence update)
DT 16-OCT-2001 (Rel. 40, Last annotation update)
DE Glucagon precursor [Contains: Glucocentin-related polypeptide (GRP);
DE Glucagon; Glucagon-like peptide 1 (GLP1); Glucagon-like peptide 2
DE (GLP2)].
GN GCG.
OS Mesocricetus auratus (Golden hamster).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Cricetinae;
OX Mesocricetus.
RN NCBI_TaxID=10036;
[1]
RP SEQUENCE FROM N.A.
RA MEDLINE=83167563; PubMed=6835407;
RA Bell G.I., Santerre R.F., Mullenbach G.T.;
RT "Hamster preproglucagon contains the sequence of glucagon and two
RT related peptides.";
RL Nature 302:716-718(1983).
RN [2]
RP REVISIONS TO 12-15.

RA Bell G.I.;
CC Submitted (xxx-1985) to the EMBL/GenBank/DBJ databases.
CC -1- FUNCTION: GLUCAGON PROMOTES HYDROLYSIS OF GLYCOCEN AND LIPIDS, AND
CC -1- RAISES THE BLOOD SUGAR LEVEL.
CC -1- FUNCTION: GLP2 STIMULATES INTESTINAL GROWTH AND UPREGULATES VILLOS
CC HEIGHT IN THE SMALL INTESTINE, CONCOMITANT WITH INCREASED CRYPT
CC CELL PROLIFERATION AND DECREASED ENTEROCYTE APOPTOSIS.
CC -1- INDUCTION: PRODUCED IN THE A CELLS OF THE ISLETS OF LANGERHANS
CC IN RESPONSE TO A DROP IN BLOOD SUGAR CONCENTRATION.
CC -1- SIMILARITY: BELONGS TO THE GLUCAGON FAMILY.

CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (see <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).

DR EMBL; J00059; AAA37074.1; -;
DR PIR; A01539; GCHY.
DR HSSP; P01274; 1GCH.
DR InterPro; IPR000532; Glucagon.
DR Pfam; PF00123; hormone2; 3.
DR PRINTS; PR00275; GLUCAGON.
DR SMART; SM00070; GLUCA; 3.
DR PROSITE; PS00260; GLUCAGON; 4.
KW Glucagon family; Hormone; Cleavage on pair of basic residues; Signal.
FT SIGNAL 1 20
FT PEPTIDE 21 50
GLUCENTIN-RELATED POLYPEPTIDE.

FT PEPTIDE 21 50
FT PEPTIDE 53 81 GLUCAGON.
FT PEPTIDE 92 128 GLUCAGON-LIKE PEPTIDE 1.
FT PEPTIDE 146 178 GLUCAGON-LIKE PEPTIDE 2.
SQ SEQUENCE 180 AA; 20954 MW; 02791849D7AADD4B CRC64;

Query Match 94.3%; Score 133; DB 1; Length 180;
Best Local Similarity 86.7%; Pred. No. 3e-14;
Matches 26; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1 HXEGFTSDVSYLXGQAAAXFIAMLVKGR 30
DB 98 HAEFTSDVSYLXGQAAKEFIAMLVKGR 127

RESULT 6

GLUC_MOUSE
ID GLUC_MOUSE STANDARD; PRT; 180 AA.
AC P55095;
DT 01-OCT-1996 (Rel. 34, Created)
DT 01-OCT-1996 (Rel. 34, Last sequence update)
DT 15-JUN-2002 (Rel. 41, Last annotation update)
DE Glucagon precursor [Contains: Glucocentin-related polypeptide (GRP);
DE Glucagon; Glucagon-like peptide 1 (GLP1); Glucagon-like peptide 2
DE (GLP2)].
GN GCG.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RA TISUE-Pancreatic islets;
RA MEDLINE=95247722; PubMed=7730317;
RA Rothenberg M.E., Ellertson C.D., Klein K., Zhou Y., Linberg I.,
RA McDonald J.K., Mackin R.B., Noe B.D.;
RT "Processing of mouse proglucagon by recombinant prohormone convertase
RT 1 and immunopurified prohormone convertase 2 in vitro.";
RL J. Biol. Chem. 270:10136-10146(1995).
RN [2]
RP SEQUENCE FROM N.A.
RA Shamsadin R., Knepel W.;
RT "Mouse glucagon full length cDNA.";
RL Submitted (JUN-2000) to the EMBL/GenBank/DBJ databases.
CC -1- FUNCTION: GLUCAGON PROMOTES HYDROLYSIS OF GLYCOCEN AND LIPIDS, AND
CC -1- RAISES THE BLOOD SUGAR LEVEL.
CC -1- FUNCTION: GLP2 STIMULATES INTESTINAL GROWTH AND UPREGULATES VILLOS
CC HEIGHT IN THE SMALL INTESTINE, CONCOMITANT WITH INCREASED CRYPT
CC CELL PROLIFERATION AND DECREASED ENTEROCYTE APOPTOSIS.
CC -1- INDUCTION: PRODUCED IN THE A CELLS OF THE ISLETS OF LANGERHANS
CC IN RESPONSE TO A DROP IN BLOOD SUGAR CONCENTRATION.
CC -1- SIMILARITY: BELONGS TO THE GLUCAGON FAMILY.

CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (see <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).

DR EMBL; Z46845; CA86902.1; -;
DR HSSP; AF276754; AAK96898.1; -;
DR HSSP; P01274; 1GCH.
DR MGI; MGI:95674; Gcg.
DR InterPro; IPR000532; Glucagon.
DR Pfam; PF00123; hormone2; 3.
DR PRINTS; PR00275; GLUCAGON.
DR SMART; SM00070; GLUCA; 3.
DR PROSITE; PS00260; GLUCAGON; 4.
KW Glucagon family; Hormone; Cleavage on pair of basic residues; Signal.
FT SIGNAL 1 20
FT PEPTIDE 21 50
GLUCENTIN-RELATED POLYPEPTIDE.

FT PEPTIDE 53 81 GLUCAGON.
FT PEPTIDE 92 128 GLUCAGON-LIKE PEPTIDE 1.
FT PEPTIDE 146 178 GLUCAGON-LIKE PEPTIDE 2.
SQ SEQUENCE 180 AA; 20906 MW; 595AA6DD9A589950 CRC64;

Query Match 94.3%; Score 133; DB 1; Length 180;
Best Local Similarity 86.7%; Pred. No. 3e-14;
Matches 26; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1 HXEGFTSDVSSYLXGQAAKXFIAMLVKGR 30
Db 98 HAEFTSDVSSYLEGQAKFIAMLVKGR 127

RESULT 7
ID GLUC_OCTDE STANDARD; PRT; 180 AA.
AC P22890;
DT 01-AUG-1991 (Rel. 19, Created)
DT 01-AUG-1991 (Rel. 19, Last sequence update)
DT 16-OCT-2001 (Rel. 40, Last annotation update)
DE Glucagon precursor [contains: Glucagon-related polypeptide (GRP);
DE Glucagon; Glucagon-like peptide 1 (GLP1); Glucagon-like peptide 2
DE (GRP2)].
GN GCG.
OS Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Hystriognathi; Octodontidae; Octodon.
OX NCBI_TaxID=10160;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=91155952; PubMed=2293024;
RA Nishi M., Steiner D.F.;
RT "Cloning of complementary DNAs encoding islet amyloid polypeptide,
RT insulin, and glucagon precursors from a New World rodent, the degu,
RT Octodon degus.";
RT Mol. Endocrinol. 4:1192-1198(1990).
RL
CC -1- FUNCTION: GLUCAGON PROMOTES HYDROLYSIS OF GLYCOGEN AND LIPIDS, AND
CC -1- RAISES THE BLOOD SUGAR LEVEL.
CC -1- FUNCTION: GLP2 STIMULATES INTESTINAL GROWTH AND UPREGULATES VILLUS
CC HEIGHT IN THE SMALL INTESTINE, CONCOMITANT WITH INCREASED CRYPT
CC CELL PROLIFERATION AND DECREASED ENTEROCYTE APOPTOSIS.
CC -1- INDUCTION: PRODUCED IN THE A CELLS OF THE ISLETS OF LANGERHANS
CC IN RESPONSE TO A DROP IN BLOOD SUGAR CONCENTRATION.
CC -1- SIMILARITY: BELONGS TO THE GLUCAGON FAMILY.

CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).
CC -----
CC EMBL: M57688; AAA40588.1; -;
CC PIR: C36118; GCRTDU.
CC HSSP: P01274; 1GCN.
CC InterPro: IPR000532; Glucagon.
CC Pfam: PF00123; hormone2; 3.
CC PRINTS: PR00275; GLUCAGON.
CC SMART: SM00070; GLUCA. 3.
CC PROSITE: PS00260; GLUCAGON; 4.
CC Glucagon family; Hormone; Cleavage on pair of basic residues; Signal;
KW Amidation.
FT SIGNAL 1 20
FT PEPTIDE 21 50 GLUCENTIN-RELATED POLYPEPTIDE.
FT PEPTIDE 53 81
FT PEPTIDE 92 127 GLUCAGON-LIKE PEPTIDE 1.
FT PEPTIDE 146 178 GLUCAGON-LIKE PEPTIDE 2.
FT MOD_RES 127 127 AMIDATION (G-128 PROVIDE AMIDE GROUP).
SQ SEQUENCE 180 AA; 21165 MW; 6E8836160A9A3051 CRC64;

Query Match 94.3%; Score 133; DB 1; Length 180;

Best Local Similarity 86.7%; Pred. No. 3e-14;
Matches 26; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1 HXEGFTSDVSSYLXGQAAKXFIAMLVKGR 30
Db 98 HAEFTSDVSSYLEGQAKFIAMLVKGR 127

RESULT 8
ID GLUC_RAT STANDARD; PRT; 180 AA.
AC P06863;
DT 01-JAN-1988 (Rel. 06, Created)
DT 01-JAN-1988 (Rel. 06, Last sequence update)
DT 16-OCT-2001 (Rel. 40, Last annotation update)
DE Glucagon precursor [contains: Glucagon-related polypeptide (GRP);
DE Glucagon; Glucagon-like peptide 1 (GLP1); Glucagon-like peptide 2
DE (GRP2)].
GN GCG.
OS Rattus norvegicus (Rat).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
OX NCBI_TaxID=10116;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=85054853; PubMed=6094539;
RA Heinrich G., Gros P., Habener J.F.;
RT "Glucagon gene sequence. Four of six exons encode separate functional
RT domains of rat pre-proglucagon.";
RT J. Biol. Chem. 259:14082-14087(1984).
RL
CC -1- FUNCTION: GLUCAGON PROMOTES HYDROLYSIS OF GLYCOGEN AND LIPIDS, AND
CC -1- RAISES THE BLOOD SUGAR LEVEL.
CC -1- FUNCTION: GLP2 STIMULATES INTESTINAL GROWTH AND UPREGULATES VILLUS
CC HEIGHT IN THE SMALL INTESTINE, CONCOMITANT WITH INCREASED CRYPT
CC CELL PROLIFERATION AND DECREASED ENTEROCYTE APOPTOSIS.
CC -1- INDUCTION: PRODUCED IN THE A CELLS OF THE ISLETS OF LANGERHANS
CC IN RESPONSE TO A DROP IN BLOOD SUGAR CONCENTRATION.
CC -1- SIMILARITY: BELONGS TO THE GLUCAGON FAMILY.

CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).
CC -----
CC EMBL: K02813; AAA41235.1; -;
CC EMBL: K02809; AAA41235.1; JOINED.
CC EMBL: K02810; AAA41235.1; JOINED.
CC EMBL: K02811; AAA41235.1; JOINED.
CC EMBL: K02812; AAA41235.1; JOINED.
CC PIR: A22655; GCRT.
CC PIR: A44198; A44198.
CC HSSP: P01274; 1GCN.
CC InterPro: IPR000532; Glucagon.
CC Pfam: PF00123; hormone2; 3.

DR PRINTS: PR00275; GLUCAGON.
 DR SMART: SM00070; GLUCA; 3.
 DR PROSITE: PS00260; GLUCAGON; 4.
 KW GLUCAGON family; Hormone; Cleavage on pair of basic residues; Signal.
 FT SIGNAL 1 20
 FT PEPTIDE 21 50 GLICENTIN-RELATED POLYPEPTIDE.
 FT PEPTIDE 53 81 GLUCAGON.
 FT PEPTIDE 92 128 GLUCAGON-LIKE PEPTIDE 1.
 FT PEPTIDE 146 178 GLUCAGON-LIKE PEPTIDE 2.
 SQ SEQUENCE 180 AA; 20846 MW; 76931409D03C7978 CRC64;

Query Match 94.3%; Score 133; DB 1; Length 180;
 Best Local Similarity 86.7%; Pred. No. 3e-14;
 Matches 26; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1 HXEGFTSDVSSYLXGQAXXFIAMLVKGR 30
 DB 98 HAEGFTSDVSSYLEGQAKKEFIAMLVKGR 127

RESULT 9
 ID GLUC_CHICK STANDARD; PRT: 151 AA.
 AC P01277;
 DT 21-JUL-1986 (Rel. 01, Created)
 DT 01-AUG-1990 (Rel. 15, Last sequence update)
 DT 15-JUL-1999 (Rel. 38, Last annotation update)
 DE Glucagon precursor.
 OS Gallus gallus (Chicken), and
 OS Meleagris gallopavo (Common turkey).
 CC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 CC Archosauria; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae;
 CC Gallus.
 OC NCBI_TaxID=9031, 9103;
 RN [1]
 RP SEQUENCE FROM N. A.
 RC SPECIES=Chicken; TISSUE=Pancreas;
 RX MEDLINE=90249492; PubMed=2338135;
 RA Hasegawa S., Terazono K., Nata K., Takada T., Yamamoto H.,
 RA Okamoto H.;
 RT "Nucleotide sequence determination of chicken glucagon precursor
 RT cDNA. Chicken preproglucagon does not contain glucagon-like peptide
 RT I.";
 RL FEBS Lett. 264:117-120(1990).
 RN [2]
 RP SEQUENCE OF 55-83.
 RC SPECIES=Chicken;
 RX MEDLINE=76069271; PubMed=1194290;
 RA Pollock H.G., Kimmel J.R.;
 RT "Chicken glucagon. Isolation and amino acid sequence studies.";
 RL J. Biol. Chem. 250:9377-9380(1975).
 RN [3]
 RP COMPOSITION, AND SEQUENCE OF 55-83.
 RC SPECIES=M.gallipavo;
 RX MEDLINE=73074118; PubMed=4645932;
 RA Mathiesen J., Frandsen E.K., Hedting L.G., Sundby F.;
 RT "Turkey glucagon: crystallization, amino acid composition and
 RT immunology.";
 RL Horm. Metab. Res. 4:360-363(1972).
 CC -1- FUNCTION: PROMOTES HYDROLYSIS OF GLYCOGEN AND LIPIDS, AND RAISES
 CC THE BLOOD SUGAR LEVEL.
 CC -1- INDUCTION: PRODUCED IN THE A CELLS OF THE ISLETS OF LANGERHANS
 CC IN RESPONSE TO A DROP IN BLOOD SUGAR CONCENTRATION.
 CC -1- MISCELLANEOUS: THE COMPOSITION OF TURKEY GLUCAGON APPEARS TO BE
 CC IDENTICAL WITH CHICKEN.
 CC -1- MISCELLANEOUS: CHICKEN PREPROGLUCAGON DOES NOT CONTAIN
 CC GLUCAGON-LIKE PEPTIDE II.
 CC -1- SIMILARITY: BELONGS TO THE GLUCAGON FAMILY.
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL Outstation-
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way

CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (see <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC -----
 DR EMBL: Y07539; CAA68827.1; -.
 DR PIR: S09992; GCCH.
 DR PIR: A91740; A91740.
 DR HSSP: P01274; IGCN.
 DR InterPro: IPR000532; Glucagon.
 DR Pfam: PF00123; hormone2; 2.
 DR PRINTS: PR00275; GLUCAGON.
 DR SMART: SM00070; GLUCA; 2.
 DR PROSITE: PS00260; GLUCAGON; 3.
 KW Glucagon family; Hormone; Cleavage on pair of basic residues; Signal;
 AMidation.
 FT SIGNAL 1 22
 FT CHAIN 23 151 PROGLUCAGON.
 FT PEPTIDE 55 83 GLUCAGON.
 FT PROPEP 86 118
 FT PEPTIDE 118 147 GLUCAGON-LIKE PEPTIDE.
 FT MOD RES 147 147 AMIDATION (G-148 PROVIDE AMIDE GROUP).
 SQ SEQUENCE 151 AA; 17520 MW; B6C0D87536C0AEB5 CRC64;

Query Match 85.8%; Score 121; DB 1; Length 151;
 Best Local Similarity 73.3%; Pred. No. 2.1e-12;
 Matches 22; Conservative 3; Mismatches 5; Indels 0; Gaps 0;

QY 1 HXEGFTSDVSSYLXGQAXXFIAMLVKGR 30
 DB 118 HAEGFTSDITSTYLEGQAKKEFIAMLVKGR 147

RESULT 10
 ID GLUM_ANGAN STANDARD; PRT: 30 AA.
 AC P41521;
 DT 01-NOV-1995 (Rel. 32, Created)
 DT 01-NOV-1995 (Rel. 32, Last sequence update)
 DT 01-NOV-1995 (Rel. 32, Last annotation update)
 DE Glucagon-like peptide (GLP).
 OS Anguilla anguilla (European freshwater eel), and
 OS Anguilla rostrata (American eel).
 CC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 CC Actinopterygii; Neopterygii; Teleostei; Anguilliformes; Anguillidae;
 CC Anguilla.
 OC NCBI_TaxID=7936, 7938;
 RN [1]
 RP SEQUENCE.
 RC TISSUE=Pancreas;
 RX MEDLINE=91340068; PubMed=1874385;
 RA Conlon J.M., Andrews P.C., Thim L., Moon T.W.;
 RT "The primary structure of glucagon-like peptide but not insulin has
 RT been conserved between the American eel, Anguilla rostrata and the
 RT European eel, Anguilla anguilla.";
 RL Gen. Comp. Endocrinol. 82:23-32(1991).
 CC -1- SIMILARITY: BELONGS TO THE GLUCAGON FAMILY.
 DR PIR: B61125; B61125.
 DR PIR: C61125; C61125.
 DR HSSP: P01275; IBDH.
 DR InterPro: IPR000532; Glucagon.
 DR Pfam: PF00123; hormone2; 1.
 DR PRINTS: PR00275; GLUCAGON.
 DR SMART: SM00070; GLUCA; 1.
 DR PROSITE: PS00260; GLUCAGON; 1.
 KW Glucagon family; Amidation.
 FT MOD RES 30 30 AMIDATION.
 SQ SEQUENCE 30 AA; 3376 MW; 592DA5EABD6E49D0 CRC64;

Query Match 75.9%; Score 107; DB 1; Length 30;
 Best Local Similarity 66.7%; Pred. No. 7.7e-11;
 Matches 20; Conservative 3; Mismatches 7; Indels 0; Gaps 0;

QY 1 HXEGFTSDVSSYLXGQAXXFIAMLVKGR 30

```

RT "Anglerfish islet pre-proglucagon II. Nucleotide and corresponding
RT amino acid sequence of the cDNA."
RL J. Biol. Chem. 258:3280-3284(1983).
RN [2]
RP PROCESSING.
RX MEDLINE=86286913; PubMed=3526301;
RA Noe B.D., Andrews P.C.;
RT "Specific glucagon-related peptides isolated from anglerfish islets
RT are metabolic cleavage products of (pre)proglucagon-II."
RL Peptides 7:331-339(1986).
CC -!- FUNCTION: PROMOTES HYDROLYSIS OF GLUCOGEN AND LIPIDS, AND RAISES
CC THE BLOOD SUGAR LEVEL.
CC -!- INDUCTION: PRODUCED IN THE A CELLS OF THE ISLETS OF LANGERHANS
CC IN RESPONSE TO A DROP IN BLOOD SUGAR CONCENTRATION.
CC -!- SIMILARITY: BELONGS TO THE GLUCAGON FAMILY.
-----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb.ch/announce/sib.ch).
CC or send an email to license@sib-stb.ch).
-----
CC EMBL: V00632; GAA23905.1; -.
CC PIR: A05150; GCAR2.
CC HSSP: P01274; IGCN.
CC InterPro: IPR000532; Glucagon.
DR Pfam: PF001123; hormone2; 2.
DR PRINTS: PR00275; GLUCAGON.
DR SMART: SM00070; GLUCA; 2.
DR PROSITE: PS00260; GLUCAGON; 2.
KW Glucagon family; Hormone; Cleavage on pair of basic residues; Signal.
FT SIGNAL 1 21
FT PEPTIDE 22 49 GLICENTIN-RELATED POLYPEPTIDE.
FT PEPTIDE 52 80 GLUCAGON II.
FT PROPEP 83 86
FT PEPTIDE 89 119 GLUCAGON-LIKE PEPTIDE II.
SQ SEQUENCE 122 AA; 14171 MW; 5140AC47EF915519 CRC64;

Query Match 73.8%; Score 104; DB 1; Length 122;
Best Local Similarity 63.3%; Pred. No. 9.3e-10;
Matches 19; Conservative 4; Mismatches 7; Indels 0; Gaps 0;

Qy 1 HXEGFETSDVSSYLKGOAAXXFIATLVNCR 30
Db 89 HADGTTSDVSSYLDQAKDFVSWLKAGR 118
|.:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|

RESULT 13
GLUC_CARAU
ID GLUC_CARAU STANDARD; PRT: 121 AA.
AC P79695;
DT 01-NOV-1997 (Rel. 35, Created)
DT 01-NOV-1997 (Rel. 35, Last sequence update)
DT 16-OCT-2001 (Rel. 40, Last annotation update)
DE Glucagon precursor [Contains: Glucocentin-related polypeptide (GRPP);
DE Glucagon; Glucagon-like peptide].
OS Carassius auratus (Goldfish).
CC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
CC Actinopterygii; Neopterygii; Teleostei; Ostariophysi; Cypriniformes;
CC Cyprinidae; Carassius.
CC NCB1_TaxID=7957;
CC [1]
RP SEQUENCE FROM N.A.
RA Yuen T.T.H., Mok P.Y., Chow B.K.C.;
RL Submitted (FEB-1997) to the EMBL/GenBank/DBJ databases.
CC -!- FUNCTION: PROMOTES HYDROLYSIS OF GLUCOGEN AND LIPIDS, AND RAISES
CC THE BLOOD SUGAR LEVEL.
CC -!- SIMILARITY: BELONGS TO THE GLUCAGON FAMILY.
-----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -

```

the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See <http://www.isb-sib.ch/announce/> or send an email to license@isb-sib.ch).

CC EMBL: U65528; AAB39563.1; -
 DR HSSP: P01274; IGCN.
 DR InterPro: IPR000532; Glucagon.
 DR Pfam: PF00123; hormone2; 2.
 DR PRINTS: PR00275; GLUCAGON.
 DR SMART: SM00070; GLUCA; 2.
 DR PROSITE: PS00260; GLUCAGON; 2.
 KW Glucagon family; Hormone; Cleavage on pair of basic residues; Signal.
 FT SIGNAL 1 21 POTENTIAL.
 FT PEPTIDE 22 47 GLICENTIN-RELATED POLYPEPTIDE.
 FT PROPEP 50 78 GLUCAGON.
 FT PEPTIDE 80 85
 FT PEPTIDE 88 121
 SQ SEQUENCE 121 AA; 13527 MW; 5C1D4BEC1D26B9C6 CRC64;

Query Match 72.3%; Score 102; DB 1; Length 121;
 Best Local Similarity 60.0%; Pred. No. 1.9e-09;
 Matches 18; Conservative 5; Mismatches 7; Indels 0; Gaps 0;

Oy 1 HXEGFTSDVSSYLXGQAAXXFIAVLVYKGR 30
 Db 88 HAEGTYSDDISSFLRDQAQNFVWLKSGQ 117

RESULT 14
 GLUC_LEPSP
 ID GLUC_LEPSP STANDARD; PRT; 78 AA.

AC P09566; 01-MAR-1989 (Rel. 10, Created)
 DT 01-NOV-1990 (Rel. 16, Last sequence update)
 DT 16-OCT-2001 (Rel. 40, Last annotation update)
 DE Glucagon precursor [contains: Glucagon; Glucagon-36 (Oxyntomodulin); Glucagon-like peptide] (Fragment).
 OS Lepisosteus spatula (Alligator gar) (Atractosteus spatula).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Actinopterygii; Neopterygii; Semionotiformes; Lepisosteidae; Lepisosteus.
 OC NCBI_TaxID=7917;
 RN [1]
 RP SEQUENCE OF 1-36 AND 45-78.
 RC TISSUE=Pancreas;
 RX MEDLINE=88196798; PubMed=3282974;
 RA Pollock H.G., Kimmel J.R., Ebner K.E., Hamilton J.W., Rouse J.B., Lance V., Rawlitch A.B.;
 RT "Isolation and structures of alligator gar (Lepisosteus spatula) glucagon, oxyntomodulin, and glucagon-like peptide; amino acid sequences of oxyntomodulin and glucagon-like peptide.";
 RT Gen. Comp. Endocrinol. 69:133-140(1988).
 RL [2]
 RP PRELIMINARY SEQUENCE OF 1-29.
 RC TISSUE=Pancreas;
 RX MEDLINE=88030594; PubMed=3311873;
 RA Pollock H.G., Kimmel J.R., Hamilton J.W., Rouse J.B., Ebner K.E., Lance V., Rawlitch A.B.;
 RT "Isolation and structures of alligator gar (Lepisosteus spatula) insulin and pancreatic polypeptide.";
 RT Gen. Comp. Endocrinol. 67:375-382(1987).
 CC -1- FUNCTION: PROMOTES HYDROLYSIS OF GLUCOGEN AND LIPIDS, AND RAISES THE BLOOD SUGAR LEVEL.
 CC -1- INDUCTION: PRODUCED IN THE A CELLS OF THE ISLETS OF LANGERHANS
 CC -1- IN RESPONSE TO A DROP IN BLOOD SUGAR CONCENTRATION.
 CC -1- MISCELLANEOUS: X'S IN THE SEQUENCE WERE INCLUDED BY HOMOLOGY WITH AMERICAN GOOSEFISH SEQUENCES.
 CC -1- SIMILARITY: BELONGS TO THE GLUCAGON FAMILY.
 DR PIR: S06339; GCGA.
 DR HSSP: P01274; IGCN.
 DR InterPro: IPR000532; Glucagon.

DR Pfam: PF00123; hormone2; 2.
 DR SMART: SM00070; GLUCA; 2.
 DR PROSITE: PS00260; GLUCAGON; 2.
 KW Glucagon family; Hormone.

FT PEPTIDE 1 29 GLUCAGON.
 FT PEPTIDE 30 36 GLUCAGON-36.
 FT PEPTIDE 45 78 GLUCAGON-LIKE PEPTIDE.
 SQ SEQUENCE 78 AA; 8990 MW; 30106496271594E0 CRC64;

Query Match 71.6%; Score 101; DB 1; Length 78;
 Best Local Similarity 60.0%; Pred. No. 1.8e-09;
 Matches 18; Conservative 5; Mismatches 7; Indels 0; Gaps 0;

Oy 1 HXEGFTSDVSSYLXGQAAXXFIAVLVYKGR 30
 Db 45 HADGTYSDVSSYLQDAKFFVWLKSGQ 74

RESULT 15
 GLUC_ICTPU
 ID GLUC_ICTPU STANDARD; PRT; 71 AA.

AC P04093; 01-NOV-1986 (Rel. 03, Created)
 DT 01-MAR-1989 (Rel. 10, Last sequence update)
 DT 01-NOV-1990 (Rel. 16, Last annotation update)
 DE Glucagon precursor (Fragment).
 DE Ictalurus punctatus (Channel catfish).
 OS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Actinopterygii; Neopterygii; Teleostei; Ostariophysi; Siluriformes; Ictaluridae; Ictalurus.
 OC NCBI_TaxID=7998;
 RN [1]
 RP SEQUENCE.
 RC TISSUE=Pancreas;
 RX MEDLINE=87156787; PubMed=3030323;
 RA Hoesein N.M., Mahrenholz A.M., Andrews P.C., Gurd R.S.;
 RT "Biological activities of catfish glucagon and glucagon-like peptide.";
 RL Biochem. Biophys. Res. Commun. 143:87-92(1987).
 RN [2]
 RP SEQUENCE.
 RC TISSUE=Pancreas;
 RX MEDLINE=85157536; PubMed=3838546;
 RA Andrews P.C., Ronner P.;
 RT "Isolation and structures of glucagon and glucagon-like peptide from catfish pancreas.";
 RT J. Biol. Chem. 260:3910-3914(1985).
 RL J. Biol. Chem. 260:3910-3914(1985).
 CC -1- FUNCTION: PROMOTES HYDROLYSIS OF GLYCOGEN AND LIPIDS, AND RAISES THE BLOOD SUGAR LEVEL.
 CC -1- INDUCTION: PRODUCED IN THE A CELLS OF THE ISLETS OF LANGERHANS
 CC -1- IN RESPONSE TO A DROP IN BLOOD SUGAR CONCENTRATION.
 CC -1- MISCELLANEOUS: X'S IN THE SEQUENCE WERE INCLUDED BY HOMOLOGY WITH AMERICAN GOOSEFISH SEQUENCES.
 CC -1- SIMILARITY: BELONGS TO THE GLUCAGON FAMILY.
 DR PIR: A05166; GCIDC.
 DR HSSP: P01274; IGCN.
 DR InterPro: IPR000532; Glucagon.
 DR Pfam: PF00123; hormone2; 2.
 DR SMART: SM00070; GLUCA; 2.
 DR PROSITE: PS00260; GLUCAGON; 2.
 KW Glucagon family; Hormone.
 FT NON_TER 1 1
 FT PEPTIDE 1 29 GLUCAGON.
 FT PEPTIDE 30 36 GLUCAGON-LIKE PEPTIDE.
 FT PEPTIDE 38 53
 FT CONFLICT 53 53 E -> D (IN REF. 2).
 FT NON_TER 71 71
 SQ SEQUENCE 71 AA; 8173 MW; 24688E79AD981A8F CRC64;

Query Match 70.9%; Score 100; DB 1; Length 71;
 Best Local Similarity 63.3%; Pred. No. 2.4e-09;
 Matches 19; Conservative 3; Mismatches 8; Indels 0; Gaps 0;

Oy 1 HXEGFTSDVSSYLXGQAAXXFIAVLVYKGR 30

Thu Feb 27 13:12:18 2003

us-09-091-605-1.rsp

Page 9

Db | :||:||||| | | | | | :
38 HADGTYNSDVSSYLOEQAKDFITWLKSCQ 67

Search completed: February 13, 2003, 11:02:34
Job time : 12 secs

GenCore version 5.1.3
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: February 13, 2003, 11:00:06 ; Search time 29 Seconds
(without alignments)
220.257 Million cell updates/sec

Title: US-09-091-605-1

Perfect score: 141
Sequence: 1 HXEGFTSDVSYLXGQAAKXFTAMLVKGR 31

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 671580 seqs, 206047115 residues

Total number of hits satisfying chosen parameters: 671580

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

SPTREMBL.21:*
1: sp_archaea:*
2: sp_bacteria:*
3: sp_fungi:*
4: sp_human:*
5: sp_invertebrate:*
6: sp_mammal:*
7: sp_mhc:*
8: sp_organelle:*
9: sp_phage:*
10: sp_plant:*
11: sp_rodent:*
12: sp_virus:*
13: sp_vertebrate:*
14: sp_unclassified:*
15: sp_virus:*
16: sp_bacteriophage:*
17: sp_archaeap:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	133	94.3	180	6 Q95LGO	Q95LGO canis fami
2	121	85.8	206	13 Q91410	Q91410 gallus gall
3	115	81.6	204	13 Q12956	Q12956 heloderma s
4	107	75.9	220	13 Q8UWL9	Q8UWL9 hoplobatr
5	103	73.0	266	13 Q42143	Q42143 xenopus lae
6	102	72.3	72	13 Q91409	Q91409 oncorhynch
7	102	72.3	178	13 Q91971	Q91971 oncorhynch
8	98	69.5	219	13 Q42144	Q42144 xenopus lae
9	97	68.8	178	13 Q91189	Q91189 oncorhynch
10	93	66.0	121	13 Q9DD6	Q9DD6 brachydanio
11	89	63.1	160	13 Q9PURI	Q9PURI petromyzon
12	82	58.2	62	13 Q9PRW9	Q9PRW9 scyllorhinu
13	78	55.3	96	13 Q9DG43	Q9DG43 ambloplites
14	70	49.6	120	13 Q9PURI	Q9PURI petromyzon
15	53.5	37.9	426	16 P71006	P71006 bacillus su
16	52.5	37.2	285	17 Q8TPJ9	Q8TPJ9 methanosarc

17	51	36.2	810	4 Q9NTW8	Q9NTW8 homo sapien
18	51	36.2	867	4 Q9UEX9	Q9UEX9 homo sapien
19	49	34.8	130	11 Q9CVF1	Q9CVF1 mus musculu
20	49	34.8	144	11 Q9B887	Q9B887 mus musculu
21	49	34.8	236	16 Q9ZD11	Q9ZD11 listeria in
22	49	34.8	236	16 Q9ZD11	Q9ZD11 listeria in
23	48.5	34.4	221	16 Q916W5	Q916W5 pseudomonas
24	48	34.0	171	11 Q9D227	Q9D227 mus musculu
25	47.5	33.7	1100	16 Q8YAE8	Q8YAE8 listeria mo
26	47	33.3	302	16 Q9K3M4	Q9K3M4 streptomyce
27	46.5	33.0	328	16 Q9PM60	Q9PM60 campylobact
28	46.5	33.0	427	17 Q8TLY0	Q8TLY0 methanosarc
29	46	32.6	542	10 Q9LXH0	Q9LXH0 arabidopsis
30	46	32.6	815	5 Q9U1S7	Q9U1S7 caenorhabdi
31	45.5	32.3	372	10 Q9XEW9	Q9XEW9 cicer ariet
32	45	31.9	245	16 Q8X5X9	Q8X5X9 escherichia
33	45	31.9	389	2 Q931H2	Q931H2 wolfinella s
34	45	31.9	634	3 Q9HEE5	Q9HEE5 neosporea
35	45	31.9	3600	10 Q9SA64	Q9SA64 arabidopsis
36	44.5	31.6	210	5 Q95XL4	Q95XL4 caenorhabdi
37	44	31.2	136	17 Q8TLQ2	Q8TLQ2 methanosarc
38	44	31.2	268	16 Q9RS44	Q9RS44 deinococcus
39	44	31.2	287	4 Q9H5K2	Q9H5K2 homo sapien
40	44	31.2	334	16 Q8U9B9	Q8U9B9 agrobacteri
41	44	31.2	387	16 Q9BA97	Q9BA97 rhizobium l
42	44	31.2	390	4 Q9NXC2	Q9NXC2 homo sapien
43	44	31.2	478	16 Q9KV20	Q9KV20 vibrio chol
44	44	31.2	575	9 Q98545	Q98545 bacterioph
45	44	31.2	893	3 Q99222	Q99222 saccharomyc

ALIGNMENTS

RESULT 1

ID Q95LGO PRELIMINARY: PRT: 180 AA.
AC Q95LGO;
DT 01-DEC-2001 (TREMBLrel. 19, Created)
DT 01-DEC-2001 (TREMBLrel. 19, Last sequence update)
DT 01-MAR-2002 (TREMBLrel. 20, Last annotation update)
DE Preproglucagon.
OS Canis familiaris (Dog).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Carnivora; Fissipedia; Canidae; Canis.
OX NCBI_TaxID=9615;
RN [1]
RP SEQUENCE FROM N.A.
RA Irwin D.M.;
RT "cDNA cloning of proglucagon from the stomach and pancreas of the
RT dog.";
RL Submitted (SEP-2000) to the EMBL/GenBank/DBJ databases.
DR EMBL: AF308439; AAL09425.1; -
DR InterPro: IPR000532; Glucagon.
DR Pfam: PF00123; hormone2; 3
DR PROSITE: PS00260; GLUCAGON; UNKNOWN 3
DR PROSITE: PS00260; GLUCAGON; UNKNOWN 3
SQ SEQUENCE 180 AA: 2114 MM; 80F66941AFC324FD CRC64;

Query Match 94.3%; Score 133; DB 6; Length 180;
Best Local Similarity 86.7%; Pred. No. 6.8e-14;
Matches 26; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1 HXEGFTSDVSYLXGQAAKXFTAMLVKGR 30
Db 98 HXEGFTSDVSYLXGQAAKXFTAMLVKGR 127

RESULT 2

ID Q91410 PRELIMINARY: PRT: 206 AA.
AC Q91410;
DT 01-NOV-1996 (TREMBLrel. 01, Created)
DT 01-NOV-1996 (TREMBLrel. 01, Last sequence update)

FW	Alternative splicing,	20	BY SIMILARITY,
FT	STGNL	1	GRP (GLICENTINE RELATED POLYPEPTIDE),
FT	PEPTIDE	21	50
FT	PEPTIDE	53	81
FT	PEPTIDE	116	145
FT	PEPTIDE	144	196
FT	VARSPIC	149	149
FT	VARSPIC	150	204
SEQ	SEQUENCE	204 AA;	23553 MW; B132E3FE46873E72 CRC64;
Query Match			
Best Local Similarity		81.6%;	Score 115; DB 13; Length 204;
Matches 21; Conservative		3; Mismatches	6; Indels 0; Gaps 0
OY	1 HXEGFTSDVSYLXGQAAAXFTALVYGR	30	
DB	116 HADGRTSDISSYLEGQAAKEFTALVNGR	145	
RESULT 4			
O8UML9	PRELIMINARY;	220 AA.	
ID	O8UML9	PRELIMINARY;	220 AA.
AC	O8UML9;		
DT	01-MAR-2002 (TREMBLrel. 20, Created)		
DT	01-MAR-2002 (TREMBLrel. 20, Last sequence update)		
DT	01-JUN-2002 (TREMBLrel. 21, Last annotation update)		
DE	Proglucagon.		
OS	Hoplobatrachus rugulosus.		
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;		
OC	Amphibia; Batrachia; Anura; Neobatrachia; Ranoidae; Ranidae;		
OC	Hoplobatrachus.		
RN	NCBI_TaxID=110072;		
RP	SEQUENCE FROM N.A.		
RA	Yeung C.-M., Chow B.K.C.;		
RT	*Identification of a proglucagon cDNA from Rana tigrina rugulosa that		
RT	encodes two GLP-1s.;		
RL	Gen. Comp. Endocrinol. 124:0-0(2001).		
DR	EMBL; AF324209; AAL35758.1; -		
DR	InterPro; IPR000532; Glucagon.		
DR	Pfam; PF00123; hormone2; 4.		
DR	PRINTS; PR00275; GLUCAGON.		
DR	SMART; SM00070; GLUCA; 4.		
DR	PROSITE; PS00260; GLUCAGON; UNKNOWN.4.		
SEQ	SEQUENCE 220 AA; 25615 MW; C72D926E7F89E381 CRC64;		
Query Match			
Best Local Similarity		75.9%;	Score 107; DB 13; Length 220;
Matches 19; Conservative		5; Mismatches	6; Indels 0; Gaps 0;
OY	1 HXEGFTSDVSYLXGQAAAXFTALVYGR	30	
DB	135 HADGRTSDVSYLXGQAAKEFTALVNGR	164	
RESULT 5			
O42143	PRELIMINARY;	266 AA.	
ID	O42143	PRELIMINARY;	266 AA.
AC	O42143;		
DT	01-JAN-1998 (TREMBLrel. 05, Created)		
DT	01-JAN-1998 (TREMBLrel. 05, Last sequence update)		
DT	01-JUN-2001 (TREMBLrel. 17, Last annotation update)		
DE	Glucagon I precursor [contains: Glucagon; glucagon-like peptide 1A		
DE	(GLP-1A); glucagon-like peptide 1B (GLP-1B); glucagon-like peptide 1C		
DE	(GLP-1C); glucagon-like peptide 2 (GLP-2)].		
OS	Xenopus laevis (African clawed frog).		
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;		
OC	Amphibia; Batrachia; Anura; Mesobatrachia; Pipoidae; Pipidae;		
OC	Xenopodinae; Xenopus.		
OC	NCBI_TaxID=8355;		
RN	[1]		
RP	SEQUENCE FROM N.A. AND ALTERNATIVE SPLICING.		
CC	TISSUE=PANCREAS;		

RX MEDLINE=97368292; PubMed=9223287;
 RA Irwin D.M., Satkunarajah M., Wen Y., Brubaker P.L., Pederson R.A.,
 Wheeler M.B.;
 RT "The xenopus proglucagon gene encodes novel GIP-1-like peptides with
 insulinotropic properties";
 RL Proc. Natl. Acad. Sci. U.S.A. 94:7915-7920(1997).
 CC -1- FUNCTION: PROMOTES HYDROLYSIS OF GLYCOGEN AND LIPIDS, AND RAISES
 THE BLOOD SUGAR LEVEL.
 CC -1- ALTERNATIVE PRODUCTS: 2 ISOFORMS: 1 (SHOWN HERE) AND 2; ARE
 PRODUCED BY ALTERNATIVE SPLICING.
 CC -1- SIMILARITY: BELONGS TO THE GLUCAGON FAMILY.
 DR EMBL: AF004432; AAB65660.1; -.
 DR HSSP: P01274; IGCN.
 DR InterPro: IPR000532; Glucagon.
 DR Pfam: PF00123; hormone2; 5.
 DR PRINTS: PR00275; GLUCAGON.
 DR SMART: SM00070; GLUCA; 5.
 DR PROSITE: PS00260; GLUCAGON; 5.
 KW Glucagon family; Hormone; Signal; Cleavage on pair of basic residues;
 KM Multigene family; Alternative splicing.
 FT SIGNAL 1
 FT PEPTIDE 53 81
 FT PEPTIDE 97 133
 FT PEPTIDE 142 173
 FT PEPTIDE 180 211
 FT PEPTIDE 227 259
 FT VARSPLIC 214 261
 FT SEQUENCE 266 AA; 30951 MW; 544F7BDC20AF872C CRC64;

Query Match 73.08; Score 103; DB 13; Length 266;
 Best Local Similarity 56.7%; Pred. No. 9.2e-09;
 Matches 17; Conservative 7; Mismatches 6; Indels 0; Gaps 0;

OY 1 HXEGFTSDVSSYLXGQAAAXFIAVLVYKGR 30
 Db 180 HADGFTSDVSSYLXGQAAAXFIAVLVYKGR 209

RESULT 6
 ID 091409 PRELIMINARY; PRT; 72 AA.
 AC 091409; 091232;
 DT 01-NOV-1996 (TREMblrel. 01, Created)
 DT 01-NOV-1996 (TREMblrel. 01, Last sequence update)
 DT 01-DEC-2001 (TREMblrel. 19, Last annotation update)
 DE PROGLUCAGON (Fragment).
 OS Oncorhynchus tshawytscha (Chinook salmon) (King salmon).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Actinopterygii; Neopterygii; Teleostei; Euteleostei;
 OC Protacanthopterygii; Salmoniformes; Salmonidae; Oncorhynchus.
 NCBI_Taxid=74940;
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=95295739; PubMed=7776976;
 RA Irwin D.M., Wong J.;
 RT "Trout and chicken proglucagon: alternative splicing generates mRNA
 transcripts encoding glucagon-like peptide 2.";
 RL Mol. Endocrinol. 9:267-277(1995).
 DR EMBL: S78474; AAD14283.1; -.
 DR EMBL: U19920; AAC59670.1; -.
 DR HSSP: P01274; IGCN.
 DR InterPro: IPR000532; Glucagon.
 DR Pfam: PF00123; hormone2; 2.
 DR PRINTS: PR00275; GLUCAGON.
 DR SMART: SM00070; GLUCA; 2.
 DR PROSITE: PS00260; GLUCAGON; UNKNOWN_1.
 FT NON_TER 1 1
 FT SEQUENCE 72 AA; 8293 MW; 8584352B1C260A31 CRC64;

Query Match 72.3%; Score 102; DB 13; Length 72;
 Best Local Similarity 60.0%; Pred. No. 3.1e-09;
 Matches 18; Conservative 5; Mismatches 7; Indels 0; Gaps 0;

OY 1 HXEGFTSDVSSYLXGQAAAXFIAVLVYKGR 30
 Db 39 HADGFTSDVSSYLXGQAAAXFIAVLVYKGR 68

RESULT 7
 ID 091971 PRELIMINARY; PRT; 178 AA.
 AC 091971; 091408; 091188; 092169;
 DT 01-NOV-1996 (TREMblrel. 01, Created)
 DT 01-NOV-1996 (TREMblrel. 01, Last sequence update)
 DT 01-JUN-2001 (TREMblrel. 17, Last annotation update)
 DE Glucagon I precursor.
 OS Oncorhynchus mykiss (Rainbow trout) (Salmo gairdneri).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Actinopterygii; Neopterygii; Teleostei; Euteleostei;
 OC Protacanthopterygii; Salmoniformes; Salmonidae; Oncorhynchus.
 NCBI_Taxid=8022;
 RN [1]
 RP SEQUENCE FROM N.A., AND ALTERNATIVE SPLICING.
 RC TISSUE-DISTAL SMALL INTESTINE AND PANCREAS;
 RX MEDLINE=95295739; PubMed=7776976;
 RA Irwin D.M., Wong J.;
 RT "Trout and chicken proglucagon: alternative splicing generates mRNA
 transcripts encoding glucagon-like peptide 2.";
 RL Mol. Endocrinol. 9:267-277(1995).
 CC -1- FUNCTION: PROMOTES HYDROLYSIS OF GLYCOGEN AND LIPIDS, AND RAISES
 THE BLOOD SUGAR LEVEL. (BY SIMILARITY).
 CC -1- ALTERNATIVE PRODUCTS: 2 ISOFORMS: INTESTINAL (SHOWN HERE) AND
 PANCREATIC; ARE PRODUCED BY ALTERNATIVE SPLICING.
 CC -1- INDUCTION: PRODUCED IN THE A CELLS OF THE ISLETS OF LANGERHANS IN
 RESPONSE TO A DROP IN BLOOD SUGAR CONCENTRATION.
 CC -1- SIMILARITY: BELONGS TO THE GLUCAGON FAMILY.
 DR EMBL: U19913; AAC59667.1; -.
 DR EMBL: U19917; AAC59669.1; -.
 DR EMBL: U19918; AAC60212.1; -.
 DR EMBL: U19919; AAC60213.1; -.
 DR EMBL: U19918; AAC60213.1; JOINED.
 DR EMBL: S78475; AAB34505.1; -.
 DR EMBL: S78473; AAB34504.2; -.
 DR HSSP: P01274; IGCN.
 DR InterPro: IPR000532; Glucagon.
 DR Pfam: PF00123; hormone2; 3.
 DR PRINTS: PR00275; GLUCAGON.
 DR SMART: SM00070; GLUCA; 3.
 DR PROSITE: PS00260; GLUCAGON; 3.
 KW Glucagon family; Hormone; Cleavage on pair of basic residues; Signal;
 KM Alternative splicing; Multigene family.
 FT SIGNAL 1
 FT PEPTIDE 2 49
 FT PEPTIDE 52 80
 FT PEPTIDE 85 120
 FT PEPTIDE 137 169
 FT VARSPLIC 124 178
 FT SEQUENCE 178 AA; 20034 MW; 5CF6980CF2A9D58E CRC64;

Query Match 72.3%; Score 102; DB 13; Length 178;
 Best Local Similarity 60.0%; Pred. No. 8.6e-09;
 Matches 18; Conservative 5; Mismatches 7; Indels 0; Gaps 0;

RESULT 8
 ID 042144 PRELIMINARY; PRT; 219 AA.
 AC 042144;
 DT 01-JAN-1998 (TREMblrel. 05, Created)
 DT 01-JAN-1998 (TREMblrel. 05, Last sequence update)
 DT 01-JUN-2001 (TREMblrel. 17, Last annotation update)
 DE Glucagon II precursor (contains: Glucagon; glucagon-like peptide 1A

DE (GLP-1A); glucagon-like peptide 1B (GLP-1B); glucagon-like peptide 1C (GLP-1C)).

OS Xenopus laevis (African clawed frog).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Amphibia; Batrachia; Anura; Mesobatrachia; Pipidea; Pipidae;

OC Xenopodidae; Xenopus.

NCBI_TaxID=8355;

RN [1]

RP SEQUENCE FROM N.A.

RC TISSUE=PANCREAS;

RX MEDLINE=9368292; PubMed=9223287;

RA Irwin D.M., Satkunarajah M., Wen Y., Brubaker P.L., Pederson R.A., Wheeler M.B.;

RT "The Xenopus proglucagon gene encodes novel GLP-1-like peptides with insulinotropic properties";

RL Proc. Natl. Acad. Sci. U.S.A. 94:7915-7920(1997).

CC -1- FUNCTION: PROMOTES HYDROLYSIS OF GLYCOGEN AND LIPIDS, AND RAISES THE BLOOD SUGAR LEVEL.

CC -1- SIMILARITY: BELONGS TO THE GLUCAGON FAMILY.

DR EMBL: AF004433; AAB5661.1; -.

DR HSSP: P01274; IGCN.

DR InterPro: IPR000532; Glucagon.

DR Pfam: PF00123; hormone2; 4.

DR PRINTS: PR00275; GLUCAGON.

DR SMART: SM00070; GLUCA; 4.

DR PROSITE: PS00260; GLUCAGON; 3.

KW Glucagon family; Hormone; Signal; Cleavage on pair of basic residues; Multigene family.

FT SIGNAL 1

FT PEPTIDE 53 81 POTENTIAL.

FT PEPTIDE 97 133 GLUCAGON-LIKE PEPTIDE 1A.

FT PEPTIDE 142 173 GLUCAGON-LIKE PEPTIDE 1B.

FT PEPTIDE 180 211 GLUCAGON-LIKE PEPTIDE 1C.

SQ SEQUENCE 219 AA; 25271 MW; ACC69233C62C0 CRC64;

Query Match 69.5%; Score 98; DB 13; Length 219;

Best Local Similarity 53.3%; Pred. No. 5e-08;

Matches 16; Conservative 7; Mismatches 7; Indels 0; Gaps 0;

QY 1 HXEGFTSDVSSYLXGQAAAXFTIWLKGR 30

Db 180 HAEGFTNDMTNYLEKAKKEFVGLNGR 209

RESULT 9

Q91189 PRELIMINARY; PRT; 178 AA.

AC Q91189; Q92168;

DT 01-NOV-1996 (TREMblrel. 01, Created)

DT 01-NOV-1996 (TREMblrel. 01, Last sequence update)

DE 01-JUN-2001 (TREMblrel. 17, Last annotation update)

DE Glucagon II precursor.

OS Oncorhynchus mykiss (Rainbow trout) (Salmo gairdneri).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Actinopterygii; Neopterygii; Teleostei; Euteleostei;

OC Protacanthopterygii; Salmoniformes; Salmonidae; Oncorhynchus.

NCBI_TaxID=8022;

RN [1]

RP SEQUENCE FROM N.A. AND ALTERNATIVE SPLICING.

RX TISSUE=DISTAL SMALL INTESTINE, AND PANCREAS;

RX MEDLINE=95295739; PubMed=7776976;

RA Irwin D.M., Wong J.;

RT "Trout and chicken proglucagon: alternative splicing generates mRNA transcripts encoding glucagon-like peptide 2.4";

RL Mol. Endocrinol. 9:267-277(1995).

CC -1- FUNCTION: PROMOTES HYDROLYSIS OF GLYCOGEN AND LIPIDS, AND RAISES THE BLOOD SUGAR LEVEL. (BY SIMILARITY).

CC -1- ALTERNATIVE PRODUCTS: 2 ISOFORMS: INTESTINAL (SHOWN HERE) AND PANCREATIC; ARE PRODUCED BY ALTERNATIVE SPLICING.

CC -1- INDUCTION: PRODUCED IN THE A CELLS OF THE ISLETS OF LANGERHANS IN RESPONSE TO A DROP IN BLOOD SUGAR CONCENTRATION.

CC -1- SIMILARITY: BELONGS TO THE GLUCAGON FAMILY.

DR EMBL: U19914; AAC59668.1; -.

DR EMBL: U19916; AAC60210.1; -.

DR EMBL: U19915; AAC60210.1; JOINED.

DR EMBL: U19915; AAC60209.1; -.

DR HSSP: P01274; IGCN.

DR InterPro: IPR000532; Glucagon.

DR Pfam: PF00123; hormone2; 3.

DR PRINTS: PR00275; GLUCAGON.

DR SMART: SM00070; GLUCA; 3.

DR PROSITE: PS00260; GLUCAGON; UNKNOWN.2.

KW Glucagon family; Hormone; Cleavage on pair of basic residues; Signal; Alternative splicing; Multigene family.

FT SIGNAL 1

FT PEPTIDE 49 49 POTENTIAL.

FT PEPTIDE 52 80 GLUCAGON.

FT PEPTIDE 85 120 GLUCAGON-LIKE PEPTIDE 1.

FT PEPTIDE 137 169 GLUCAGON-LIKE PEPTIDE 2.

FT VAREPLIC 124 178 MISSING (IN PANCREATIC ISOFORM).

SQ SEQUENCE 178 AA; 19998 MW; E89D7386CD91C66 CRC64;

Query Match 68.8%; Score 97; DB 13; Length 178;

Best Local Similarity 58.6%; Pred. No. 5.7e-08;

Matches 17; Conservative 5; Mismatches 7; Indels 0; Gaps 0;

QY 1 HXEGFTSDVSSYLXGQAAAXFTIWLKGR 29

Db 90 HADGFTSDVSSYLXGQAAAXFTIWLKSG 118

RESULT 10

Q9DD6 PRELIMINARY; PRT; 121 AA.

AC Q9DD6;

DT 01-MAR-2001 (TREMblrel. 16, Created)

DT 01-MAR-2001 (TREMblrel. 16, Last sequence update)

DT 01-DEC-2001 (TREMblrel. 19, Last annotation update)

DE Glucagon polypeptide.

OS Brachydanio rerio (Zebrafish) (Zebra danio).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Actinopterygii; Neopterygii; Teleostei; Ostariophysi; Cypriniformes; Cyprinidae; Danio.

NCBI_TaxID=7955;

RN [1]

RP SEQUENCE FROM N.A.

RX MEDLINE=99425190; PubMed=10495291;

RA Argenton F., Zecchin E., Bortolussi M.;

RT "Early appearance of pancreatic hormone-expressing cells in the zebrafish embryo";

RL Mech. Dev. 87:217-221(1999).

DR EMBL: AJ133697; CAC20108.1; -.

DR HSSP: P01274; IGCN.

DR ZFIN: ZDB-GENE-010219-1; gcg.

DR InterPro: IPR000532; Glucagon.

DR Pfam: PF00123; hormone2; 2.

DR PRINTS: PR00275; GLUCAGON.

DR SMART: SM00070; GLUCA; 2.

DR PROSITE: PS00260; GLUCAGON; 1.

KW Polypeptide.

FT CHAIN 49 79 GLUCAGON.

FT CHAIN 88 121 GLUCAGON-LIKE PEPTIDE 1.

SQ SEQUENCE 121 AA; 13537 MW; A85385F690DA180F CRC64;

Query Match 66.0%; Score 93; DB 13; Length 121;

Best Local Similarity 63.3%; Pred. No. 1.7e-07;

Matches 19; Conservative 3; Mismatches 8; Indels 0; Gaps 0;

QY 1 HXEGFTSDVSSYLXGQAAAXFTIWLKGR 30

Db 88 HAEGTSDVSSYLXGQAAAXFTIWLKSG 117

RESULT 11

Q9PURI

```

ID 09PURI PRELIMINARY; PRT; 160 AA.
AC 09PR28; 09PR27;
DT 01-MAY-2000 (TREMblrel. 13, Created)
DT 01-MAY-2000 (TREMblrel. 13, Last sequence update)
DE 01-DEC-2001 (TREMblrel. 19, Last annotation update)
DE Glucagon I precursor [Contains: glucagon; glucagon-like peptide 1
  (GLP-1); glucagon-like peptide 2 (GLP-2)].
OS Petromyzon marinus (Sea lamprey).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Hyperoartia;
OC Petromyzontiformes; Petromyzontidae; Petromyzon.
OX NCBI_TaxId=757;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=INTESTINE;
RX MEDLINE=20022986; PubMed=10555286;
RA Irwin D.M., Hunter O., Youson J.H.;
RT "Lamprey proglucagon and the origin of glucagon-like peptides.";
RL Mol. Biol. Evol. 16:1548-1557(1999).
RN [2]
RP SEQUENCE OF 43-71 AND 82-113.
RC TISSUE=INTESTINE;
RX MEDLINE=94010172; PubMed=8405897;
RA Conlon J.M., Nielsen P.F., Youson J.H.;
RT "Primary structures of glucagon and glucagon-like peptide isolated
  from the intestine of the parasitic phase lamprey Petromyzon
  marinus.";
RL Gen. Comp. Endocrinol. 91:96-104(1993).
CC -1- FUNCTION: PROMOTES HYDROLYSIS OF GLYCOGEN AND LIPIDS, AND RAISES
  THE BLOOD SUGAR LEVEL.
CC -1- SIMILARITY: BELONGS TO THE GLUCAGON FAMILY.
DR EMBL; AF159707; AAF09186.1; -.
DR HSSP; P01275; 18H0.
DR InterPro; IPR000532; Glucagon.
DR Pfam; PF00123; hormone2; 2.
DR PRINTS; PR00275; GLUCAGON.
DR SMART; SM00070; GLUCA; 2.
DR PROSITE; PS00260; GLUCAGON; 2.
KW Glucagon family; Hormone; Signal; Cleavage on pair of basic residues;
KW Multimeric family.
FT SIGNAL 1 22 POTENTIAL.
FT PEPTIDE 43 71 GLUCAGON.
FT PEPTIDE 82 113 GLUCAGON-LIKE PEPTIDE 1.
FT PEPTIDE 130 160 GLUCAGON-LIKE PEPTIDE 2.
SQ SEQUENCE 160 AA; 18042 MW; 9A52C530D5A74072 CRC64;

Query Match 63.1%; Score 89; DB 13; Length 160;
Best Local Similarity 50.0%; Pred. No. 1.1e-06;
Matches 14; Conservative 8; Mismatches 6; Indels 0; Gaps 0;

QY 1 HXEGFTSDVSSYLXGQAXXXFIAMLVK 28
Db 82 HADGTFNDMTYLDAAKAAHDFVSWLAR 109

RESULT 12
Q9PRM9 PRELIMINARY; PRT; 62 AA.
AC 09PRM9; 09PRX0; 09PRM8;
DT 01-MAR-2000 (TREMblrel. 13, Created)
DT 01-MAR-2001 (TREMblrel. 16, Last sequence update)
DE 01-JUN-2002 (TREMblrel. 21, Last annotation update)
DE Glucagon precursor [Contains: glucagon-29; glucagon-33; glucagon-like
  peptide] (Fragments).
OS Scyliorhinus canicula (Spotted dogfish) (Spotted catshark).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Chondrichthyes;
OC Elasmobranchii; Galeomorphi; Galeoidea; Carcharhiniformes;
OC Scyliorhinidae; Scyliorhinus.
OX NCBI_TaxId=7830;
RN [1]
RP SEQUENCE.
RC TISSUE=PANCREAS;
RX MEDLINE=94286411; PubMed=8015974;
RA Conlon J.M., Hazon N., Thim L.;

```

```

RT "Primary structures of peptides derived from proglucagon isolated from
  the pancreas of the elasmobranch fish, scyliorhinus canicula.";
RL Peptides 15:163-167(1994).
CC -1- FUNCTION: PROMOTES HYDROLYSIS OF GLYCOGEN AND LIPIDS, AND RAISES
  THE BLOOD SUGAR LEVEL.
CC -1- SIMILARITY: BELONGS TO THE GLUCAGON FAMILY.
DR HSSP; P01274; 16GN.
DR InterPro; IPR000532; Glucagon.
DR PRINTS; PR00275; GLUCAGON.
DR SMART; SM00070; GLUCA; 2.
DR PROSITE; PS00260; GLUCAGON; 2.
KW Glucagon family; Hormone.
FT PEPTIDE 1 29 GLUCAGON-29.
FT PEPTIDE 30 33 GLUCAGON-33.
FT NON_CONS 33 34
FT PEPTIDE 34 62 GLUCAGON-LIKE PEPTIDE.
SQ SEQUENCE 62 AA; 7270 MW; C5F487C12C69CD1 CRC64;

Query Match 58.2%; Score 82; DB 13; Length 62;
Best Local Similarity 51.9%; Pred. No. 5.3e-06;
Matches 14; Conservative 4; Mismatches 9; Indels 0; Gaps 0;

QY 1 HXEGFTSDVSSYLXGQAXXXFIAMLV 27
Db 1 HSEGTFTSDYSKYMDNRKADFEVQWLM 27

RESULT 13
Q9DG43 PRELIMINARY; PRT; 96 AA.
AC 09DG43;
DT 01-MAR-2001 (TREMblrel. 16, Created)
DT 01-MAR-2001 (TREMblrel. 16, Last sequence update)
DE 01-DEC-2001 (TREMblrel. 19, Last annotation update)
DE Proglucagon (Fragment).
OS Ambloplites rupestris.
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;
OC Centrarchomorphi; Acanthopterygii; Percomorphi; Perciformes; Percoidae;
OC Centrarchidae; Ambloplites.
OX NCBI_TaxId=109273;
RN [1]
RP SEQUENCE FROM N.A.
RA Al-Mahrouki A.A., Irwin D.M., Youson J.H.;
RT "Rock Bass proglucagon.";
RL Submitted (SEP-1999) to the EMBL/Genbank/DBJ databases.
DR EMBL; AF190499; AAG16778.1; -.
DR HSSP; P01274; 16GN.
DR InterPro; IPR000532; Glucagon.
DR Pfam; PF00123; hormone2; 2.
DR PRINTS; PR00275; GLUCAGON.
DR SMART; SM00070; GLUCA; 2.
DR PROSITE; PS00260; GLUCAGON; UNKNOWN_1.
FT NON_TER 1 1
FT CHAIN 1 >29 GLUCAGON.
FT CHAIN 39 >70 GLUCAGON-LIKE PEPTIDE 1.
FT CHAIN 86 >96 GLUCAGON-LIKE PEPTIDE 2.
FT NON_TER 96 96
SQ SEQUENCE 96 AA; 11225 MW; 6435033EBDDC00CE CRC64;

Query Match 55.3%; Score 78; DB 13; Length 96;
Best Local Similarity 43.3%; Pred. No. 3.9e-05;
Matches 13; Conservative 7; Mismatches 10; Indels 0; Gaps 0;

QY 1 HXEGFTSDVSSYLXGQAXXXFIAMLVKGR 30
Db 1 HSGGFTNDYTYVLEDRQADPIRWLMNKK 30

RESULT 14
Q9PUB0 PRELIMINARY; PRT; 120 AA.
AC 09PUB0;

```


GenCore version 5.1.4.p5_4578
Copyright (c) 1993 - 2003 CompuGen Ltd.

OK nucleic - nucleic search, using sw model

Run on: February 14, 2003, 07:55:04 ; Search time 48 Seconds
(without alignments)
594.186 Million cell updates/sec

Title: US-09-091-605-2

Perfect score: 93
Sequence: 1 CATCTGAGGAGGACCTTTAC.....GGCTGTGAAGGCCGAGCA 93

Scoring table: IDENTITY NUC
Gapop 10.0, Gapext 1.0

Searched: 441362 seqs, 15338381 residues

Total number of hits satisfying chosen parameters: 882724

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database: Issued Patents, NA.*

1: /cgn2_6/ptodata/1/lna/5A.COMB.seq.*
2: /cgn2_6/ptodata/1/lna/5B.COMB.seq.*
3: /cgn2_6/ptodata/1/lna/6A.COMB.seq.*
4: /cgn2_6/ptodata/1/lna/6B.COMB.seq.*
5: /cgn2_6/ptodata/1/lna/PCUTS.COMB.seq.*
6: /cgn2_6/ptodata/1/lna/Backfiles1.seq.*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	93	100.0	528	2	US-08-835-231-8
2	93	100.0	528	4	US-09-108-661-8
3	93	100.0	955	3	US-08-784-582-57
4	93	100.0	955	3	US-08-784-582-60
5	93	100.0	2356	3	US-08-784-582-72
6	91.4	98.3	528	2	US-08-835-231-7
7	91.4	98.3	528	4	US-09-108-661-7
8	91.4	98.3	528	4	US-08-784-582-55
9	80.8	86.9	144	2	US-08-835-231-17
10	80.8	86.9	144	4	US-09-108-661-17
11	49.8	53.5	78	2	US-08-829-876-22
12	49.8	53.5	78	4	US-09-234-874A-22
13	37.8	40.6	57	4	US-08-811-028-43
14	35.8	38.5	48	2	US-08-811-028-44
15	32.8	35.3	53	2	US-08-811-028-46
16	32.2	34.6	73	2	US-08-829-876-24
17	32.2	34.6	73	4	US-09-234-874A-24
18	29.4	31.6	52	2	US-08-829-876-23
19	29.4	31.6	52	4	US-09-234-874A-23
20	28	30.1	2409	1	US-08-382-828C-1
21	28	30.1	2409	3	US-09-330-945-1
22	26.2	28.2	36	2	US-08-811-028-45
23	26.2	28.2	5558	4	US-08-961-527-103
24	25.8	27.7	144	2	US-08-835-231-17
25	25.8	27.7	144	4	US-09-108-661-17
26	25.4	27.3	1614	4	US-08-522-217-7
27	25.4	27.3	2665	3	US-09-040-005-1

28	25	26.9	725	4	US-09-221-017B-198	Sequence 198, App
29	24.6	26.5	516	1	US-08-532-828B-13	Sequence 13, Appl
30	24.6	26.5	1263	1	US-08-532-828B-11	Sequence 11, Appl
31	24.6	26.5	1643	1	US-08-532-828B-1	Sequence 1, Appl
32	24.6	26.5	1643	1	US-08-532-828B-7	Sequence 7, Appl
33	24.6	26.5	1643	1	US-08-532-828B-9	Sequence 9, Appl
34	24.6	26.5	1643	1	US-08-700-359-8	Sequence 8, Appl
35	24.6	26.5	1643	1	US-08-700-359-10	Sequence 10, Appl
36	24.6	26.5	1643	1	US-08-674-168-21	Sequence 21, Appl
37	24.6	26.5	1643	2	US-08-596-366-5	Sequence 5, Appl
38	24.6	26.5	1643	2	US-08-596-366-7	Sequence 7, Appl
39	24.6	26.5	1643	2	US-08-967-104-7	Sequence 5, Appl
40	24.6	26.5	1643	2	US-08-967-104-7	Sequence 7, Appl
41	24.6	26.5	1643	2	US-08-985-908-3	Sequence 3, Appl
42	24.6	26.5	1643	3	US-08-985-908-6	Sequence 4, Appl
43	24.6	26.5	1643	3	US-08-985-908-6	Sequence 6, Appl
44	24.6	26.5	1643	3	US-08-852-730-12	Sequence 12, Appl
45	24.6	26.5	1643	3	US-08-852-730-12	Sequence 12, Appl

ALIGNMENTS

RESULT 1
US-08-835-231-8
; Sequence 8, Application US/08835231
; Patent No. 5861284
GENERAL INFORMATION:
APPLICANT: NISHIMURA, Osamu
APPLICANT: KURIYAMA, Masato
APPLICANT: KOYAMA, No. 5861284yuk1
APPLICANT: FUKUDA, Tsunehiko
TITLE OF INVENTION: METHOD FOR PRODUCING A BIOLOGICALLY
TITLE OF INVENTION: ACTIVE RECOMBINANT CYSTEINE-FREE
NUMBER OF SEQUENCES: 37
CORRESPONDENCE ADDRESS:
ADDRESSEE: DIKE, BRONSTEIN, ROBERTS & CUSHMAN, LLP
STREET: 130 WATER STREET
CITY: BOSTON
STATE: MA
COUNTRY: USA
ZIP: 02109
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FASTSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/835,231
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/350,709
FILING DATE: 07-DEC-1994
APPLICATION NUMBER: 07/838,857
FILING DATE: 18-FEB-1992
APPLICATION NUMBER: JP 024841
FILING DATE: 19-FEB-1991
APPLICATION NUMBER: JP 0271438
FILING DATE: 18-OCT-1991
ATTORNEY/AGENT INFORMATION:
NAME: DAVID, RUSNICK S
REGISTRATION NUMBER: 34,235
REFERENCE/DOCKET INFORMATION: 41614-FWC
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617-523-3400
TELEFAX: 617-523-6440
TELEX: 200291 STRE
INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 528 base pairs
TYPE: nucleic acid
STRANDEDNESS: double

TOPOLOGY: linear
MOLECULE TYPE: Synthetic DNA
HYPOTHETICAL: NO
ANTI-SENSE: NO
FRAGMENT TYPE:
ORIGINAL SOURCE:
ORGANISM: Synthetic DNA
US-08-835-231-8

Query Match 100.0%; Score 93; DB 2; Length 528;
Best Local Similarity 100.0%; Pred. No. 5.9e-26;
Matches 93; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 CATCGTGAAGGACCTTTACCACTGATGATGTTCTATTGGAAGGCCAAGCTGCCAAG 60
DB 1 CATCGTGAAGGACCTTTACCACTGATGATGTTCTATTGGAAGGCCAAGCTGCCAAG 60
OY 61 GAATTCATGCTGCTGGCTGCTGTAAGGCCGAGGA 93
DB 61 GAATTCATGCTGCTGGCTGCTGTAAGGCCGAGGA 93

RESULT 2

US-09-108-661-8
Sequence 8, Application US/09108661
Patent No. 6287806

GENERAL INFORMATION:

APPLICANT: NISHIMURA, Osamu
APPLICANT: KURIYAMA, Masato
APPLICANT: Koyama, No. 6287806yuk1
APPLICANT: FUKUDA, Tsunehiko
TITLE OF INVENTION: METHOD FOR PRODUCING A BIOLOGICALLY
NUMBER OF SEQUENCES: 37
CORRESPONDENCE ADDRESS:
ADDRESSEE: DIKE, BRONSTEIN, ROBERTS & CUSHMAN, LLP
STREET: 130 WATER STREET
CITY: BOSTON
STATE: MA
COUNTRY: USA
ZIP: 02109
COMPUTER READABLE FORM:
MEDIUM TYPE: diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/108,661
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/350,709
FILING DATE: 07-DEC-1994
APPLICATION NUMBER: 07/838,857
FILING DATE: 18-FEB-1992
APPLICATION NUMBER: JP 024841
FILING DATE: 19-FEB-1991
APPLICATION NUMBER: JP 0271438
FILING DATE: 18-OCT-1991
ATTORNEY/AGENT INFORMATION:
NAME: DAVID, RESNICK S
REGISTRATION NUMBER: 34,235
REFERENCE/DOCKET NUMBER: 41614-FWC
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617-523-3400
TELEFAX: 617-523-6440
TELEX: 200291 STRE
INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 528 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear

MOLECULE TYPE: Synthetic DNA
HYPOTHETICAL: NO
ANTI-SENSE: NO
FRAGMENT TYPE:
ORIGINAL SOURCE:
ORGANISM: Synthetic DNA
US-09-108-661-8

Query Match 100.0%; Score 93; DB 4; Length 528;
Best Local Similarity 100.0%; Pred. No. 5.9e-26;
Matches 93; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 CATCGTGAAGGACCTTTACCACTGATGATGTTCTATTGGAAGGCCAAGCTGCCAAG 60
DB 1 CATCGTGAAGGACCTTTACCACTGATGATGTTCTATTGGAAGGCCAAGCTGCCAAG 60
OY 61 GAATTCATGCTGCTGGCTGCTGTAAGGCCGAGGA 93
DB 61 GAATTCATGCTGCTGGCTGCTGTAAGGCCGAGGA 93

RESULT 3

US-08-784-582-57
Sequence 57, Application US/08784582
Patent No. 6110707

GENERAL INFORMATION:

APPLICANT: Newgard, Christopher B.
APPLICANT: Halban, Philippe A.
APPLICANT: No. 6110707mington, Karl D.
APPLICANT: Clark, Samuel A.
APPLICANT: Thigpen, Anice E.
APPLICANT: Quaden, Christian
APPLICANT: Kruse, Fred
TITLE OF INVENTION: RECOMBINANT EXPRESSION OF PROTEINS FROM
NUMBER OF SEQUENCES: 79
CORRESPONDENCE ADDRESS:
ADDRESSEE: Arnold, White & Durkee
STREET: P.O. Box 4433
CITY: Houston
STATE: Texas
COUNTRY: USA
ZIP: 77210
COMPUTER READABLE FORM:
MEDIUM TYPE: floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/784,582
FILING DATE: Concurrently Herewith
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 60/028,427
FILING DATE: 15-OCT-1996
APPLICATION DATA:
APPLICATION NUMBER: US 08/589,028
FILING DATE: 19-JAN-1996
ATTORNEY/AGENT INFORMATION:
NAME: Highlander, Steven L.
REGISTRATION NUMBER: 37,642
REFERENCE/DOCKET NUMBER: UTSD:514
TELECOMMUNICATION INFORMATION:
TELEPHONE: 512/418-3000
TELEFAX: 512/474-7577
INFORMATION FOR SEQ ID NO: 57:
SEQUENCE CHARACTERISTICS:
LENGTH: 955 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-784-582-57

Query Match 100.0%; Score 93; DB 3; Length 955;
Best Local Similarity 100.0%; Pred. No. 7.4e-26;
Matches 93; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 CATGCTGAAGGACCTTTACAGATGATGTAAGTCTTATTGGAAAGCCCAAGCTGCCAAG 60
DB 318 CATGCTGAAGGACCTTTACAGATGATGTAAGTCTTATTGGAAAGCCCAAGCTGCCAAG 377
OY 61 GAATTCATTGCTTGGCTGTGTAAGGCCGAGGA 93
DB 378 GAATTCATTGCTTGGCTGTGTAAGGCCGAGGA 410

RESULT 4

US-08-784-582-60
Sequence 60, Application US/08784582
Patent No. 6110707
GENERAL INFORMATION:
APPLICANT: Newgard, Christopher B.
APPLICANT: Halban, Philippe A.
APPLICANT: No. 6110707mington, Karl D.
APPLICANT: Clark, Samuel A.
APPLICANT: Thigpen, Anice E.
APPLICANT: Quade, Christian
APPLICANT: Kruse, Fred
APPLICANT: Mcgarry, Dennis
TITLE OF INVENTION: RECOMBINANT EXPRESSION OF PROTEINS FROM
TITLE OF INVENTION: SECRETORY CELL LINES
NUMBER OF SEQUENCES: 79
CORRESPONDENCE ADDRESS:
ADDRESSEE: Arnold, White & Durkee
STREET: P.O. Box 4433
CITY: Houston
STATE: Texas
COUNTRY: USA
ZIP: 77210
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/784,582
FILING DATE: Concurrently Herewith
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 60/028,427
FILING DATE: 15-OCT-1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/589,028
FILING DATE: 19-JAN-1996
ATTORNEY/AGENT INFORMATION:
NAME: Highlander, Steven L.
REGISTRATION NUMBER: 37,642
REFERENCE/DOCKET NUMBER: UTSD:514
TELECOMMUNICATION INFORMATION:
TELEPHONE: 512/418-3000
TELEFAX: 512/474-7577
INFORMATION FOR SEQ ID NO: 60:
SEQUENCE CHARACTERISTICS:
LENGTH: 955 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-784-582-60

Query Match 100.0%; Score 93; DB 3; Length 955;
Best Local Similarity 100.0%; Pred. No. 7.4e-26;
Matches 93; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 CATGCTGAAGGACCTTTACAGATGATGTAAGTCTTATTGGAAAGCCCAAGCTGCCAAG 60
DB 318 CATGCTGAAGGACCTTTACAGATGATGTAAGTCTTATTGGAAAGCCCAAGCTGCCAAG 377

DB 318 CATGCTGAAGGACCTTTACAGATGATGTAAGTCTTATTGGAAAGCCCAAGCTGCCAAG 377
OY 61 GAATTCATTGCTTGGCTGTGTAAGGCCGAGGA 93
DB 378 GAATTCATTGCTTGGCTGTGTAAGGCCGAGGA 410

RESULT 5

US-08-784-582-72
Sequence 72, Application US/08784582
Patent No. 6110707
GENERAL INFORMATION:
APPLICANT: Newgard, Christopher B.
APPLICANT: Halban, Philippe A.
APPLICANT: No. 6110707mington, Karl D.
APPLICANT: Clark, Samuel A.
APPLICANT: Thigpen, Anice E.
APPLICANT: Quade, Christian
APPLICANT: Kruse, Fred
APPLICANT: Mcgarry, Dennis
TITLE OF INVENTION: RECOMBINANT EXPRESSION OF PROTEINS FROM
TITLE OF INVENTION: SECRETORY CELL LINES
NUMBER OF SEQUENCES: 79
CORRESPONDENCE ADDRESS:
ADDRESSEE: Arnold, White & Durkee
STREET: P.O. Box 4433
CITY: Houston
STATE: Texas
COUNTRY: USA
ZIP: 77210
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/784,582
FILING DATE: Concurrently Herewith
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 60/028,427
FILING DATE: 15-OCT-1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/589,028
FILING DATE: 19-JAN-1996
ATTORNEY/AGENT INFORMATION:
NAME: Highlander, Steven L.
REGISTRATION NUMBER: 37,642
REFERENCE/DOCKET NUMBER: UTSD:514
TELECOMMUNICATION INFORMATION:
TELEPHONE: 512/418-3000
TELEFAX: 512/474-7577
INFORMATION FOR SEQ ID NO: 72:
SEQUENCE CHARACTERISTICS:
LENGTH: 2356 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-784-582-72

Query Match 100.0%; Score 93; DB 3; Length 2356;
Best Local Similarity 100.0%; Pred. No. 1e-25;
Matches 93; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 CATGCTGAAGGACCTTTACAGATGATGTAAGTCTTATTGGAAAGCCCAAGCTGCCAAG 60
DB 1704 CATGCTGAAGGACCTTTACAGATGATGTAAGTCTTATTGGAAAGCCCAAGCTGCCAAG 1763
OY 61 GAATTCATTGCTTGGCTGTGTAAGGCCGAGGA 93
DB 1764 GAATTCATTGCTTGGCTGTGTAAGGCCGAGGA 1796

```
RESULT 6
US-08-835-231-7
; Sequence 7, Application US/08835231
; Patent No. 5861284
; GENERAL INFORMATION:
; APPLICANT: NISHIMURA, Osamu
; APPLICANT: KURIYAMA, Masato
; APPLICANT: KUYAMA, No. 5861284yuk1
; APPLICANT: FUKUDA, Tsunehiko
; TITLE OF INVENTION: METHOD FOR PRODUCING A BIOLOGICALLY
; NUMBER OF SEQUENCES: 37
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: DIKE, BRONSTEIN, ROBERTS & CUSHMAN, LLP
; STREET: 130 WATER STREET
; CITY: BOSTON
; STATE: MA
; COUNTRY: USA
; ZIP: 02109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/835,231
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/350,709
; FILING DATE: 07-DEC-1994
; APPLICATION NUMBER: 07/838,857
; FILING DATE: 18-FEB-1992
; APPLICATION NUMBER: JP 024841
; FILING DATE: 19-FEB-1991
; APPLICATION NUMBER: JP 0271438
; FILING DATE: 18-OCT-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: DAVID, RESNICK S
; REGISTRATION NUMBER: 34,235
; REFERENCE/DOCKET NUMBER: 41614-FWC
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-523-3400
; TELEFAX: 617-523-6440
; TELEX: 200291 STRE
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 528 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: Synthetic DNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; FRAGMENT TYPE:
; ORIGINAL SOURCE:
; ORGANISM: Synthetic DNA
US-08-835-231-7

Query Match          98.3%; Score 91.4; DB 2; Length 528;
Best Local Similarity 98.9%; Pred. No. 2.4e-25;
Matches 92; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

RESULT 7

```
US-09-108-661-7
; Sequence 7, Application US/09108661
; Patent No. 6287806
; GENERAL INFORMATION:
; APPLICANT: NISHIMURA, Osamu
; APPLICANT: KURIYAMA, Masato
; APPLICANT: KUYAMA, No. 6287806yuk1
; APPLICANT: FUKUDA, Tsunehiko
; TITLE OF INVENTION: METHOD FOR PRODUCING A BIOLOGICALLY
; NUMBER OF SEQUENCES: 37
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: DIKE, BRONSTEIN, ROBERTS & CUSHMAN, LLP
; STREET: 130 WATER STREET
; CITY: BOSTON
; STATE: MA
; COUNTRY: USA
; ZIP: 02109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/108,661
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/350,709
; FILING DATE: 07-DEC-1994
; APPLICATION NUMBER: 07/838,857
; FILING DATE: 18-FEB-1992
; APPLICATION NUMBER: JP 024841
; FILING DATE: 19-FEB-1991
; APPLICATION NUMBER: JP 0271438
; FILING DATE: 18-OCT-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: DAVID, RESNICK S
; REGISTRATION NUMBER: 34,235
; REFERENCE/DOCKET NUMBER: 41614-FWC
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-523-3400
; TELEFAX: 617-523-6440
; TELEX: 200291 STRE
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 528 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: Synthetic DNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; FRAGMENT TYPE:
; ORIGINAL SOURCE:
; ORGANISM: Synthetic DNA
US-09-108-661-7

Query Match          98.3%; Score 91.4; DB 4; Length 528;
Best Local Similarity 98.9%; Pred. No. 2.4e-25;
Matches 92; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

RESULT 8
US-08-784-582-55


```

; Sequence 55, Application US/08784582
; Patent No. 6110707
; GENERAL INFORMATION:
; APPLICANT: Newgard, Christopher B.
; APPLICANT: Halban, Philippe A.
; APPLICANT: No. 6110707mington, Karl D.
; APPLICANT: Clark, Samuel A.
; APPLICANT: Thigpen, Alice E.
; APPLICANT: Quade, Christian
; APPLICANT: Kruse, Fred
; APPLICANT: McGarry, Dennis
; TITLE OF INVENTION: RECOMBINANT EXPRESSION OF PROTEINS FROM
; TITLE OF INVENTION: SECRETORY CELL LINES
; NUMBER OF SEQUENCES: 79
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Arnold, White & Durkee
; STREET: P.O. Box 4433
; CITY: Houston
; STATE: Texas
; COUNTRY: USA
; ZIP: 77210
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/784,582
; FILING DATE: Concurrently Herewith
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/028,427
; FILING DATE: 15-OCT-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/589,028
; FILING DATE: 19-JAN-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Highlander, Steven L.
; REGISTRATION NUMBER: 37,642
; REFERENCE/DOCKET NUMBER: UTSD:514
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 512/418-3000
; TELEFAX: 512/474-7577
; INFORMATION FOR SEQ ID NO: 55:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 895 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-08-784-582-55
;
; Query Match 89.7%; Score 83.4; DB 3; Length 895;
; Best Local Similarity 93.5%; Pred. No. 3e-22;
; Matches 87; Conservative 0; Mismatches 6; Indels 0; Gaps 0;
;
QY 1 CATGCTGAAGGACCTTACGAGTGTAGTCTTATTGGAAGCCAGTCCCAAG 60
    |||||||
DB 343 CATGCTGAAGGACCTTACGAGTGTAGTCTTATTGGAAGCCAGTCCCAAG 402
;
QY 61 GAATTCATGCTTGGCTGTGTAAGGCGCAGGA 93
    |||||||
DB 403 GAATTCATGCTTGGCTGTGTAAGGCGCAGGA 435
;
; RESULT 9
; US-08-835-231-17
; Sequence 17, Application US/08835231
; Patent No. 5861284
; GENERAL INFORMATION:
; APPLICANT: NISHIMURA, Osamu
; APPLICANT: KURIYAMA, Masato
; APPLICANT: KOYAMA, No. 5861284uyuki
; APPLICANT: FUKUDA, Tsunehiko

```

```

; TITLE OF INVENTION: METHOD FOR PRODUCING A BIOLOGICALLY
; TITLE OF INVENTION: ACTIVE RECOMBINANT CYSTEINE-FREE
; NUMBER OF SEQUENCES: 37
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: DIKE, BRONSTEIN, ROBERTS & CUSHMAN, LLP
; STREET: 130 WATER STREET
; CITY: BOSTON
; STATE: MA
; COUNTRY: USA
; ZIP: 02109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FASTSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/835,231
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/350,709
; FILING DATE: 07-DEC-1994
; APPLICATION NUMBER: 07/838,857
; FILING DATE: 18-FEB-1992
; APPLICATION NUMBER: JP 024841
; FILING DATE: 19-FEB-1991
; APPLICATION NUMBER: JP 0271438
; FILING DATE: 18-OCT-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: DAVID, RESNICK S
; REGISTRATION NUMBER: 34,235
; REFERENCE/DOCKET NUMBER: 41614-FWC
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-523-3400
; TELEFAX: 617-523-6440
; TELEX: 200291 STRE
; INFORMATION FOR SEQ ID NO: 17:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 144 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; FRAGMENT TYPE:
; ORIGINAL SOURCE:
; FEATURE:
; NAME/KEY: Coding Sequence
; LOCATION: 22...144
;
US-08-835-231-17
;
; Query Match 86.9%; Score 80.8; DB 2; Length 144;
; Best Local Similarity 92.4%; Pred. No. 1.5e-21;
; Matches 85; Conservative 0; Mismatches 7; Indels 0; Gaps 0;
;
QY 1 CATGCTGAAGGACCTTACGAGTGTAGTCTTATTGGAAGCCAGTCCCAAG 60
    |||||||
DB 43 CATGCTGAAGGACCTTACGAGTGTAGTCTTATTGGAAGCCAGTCCCAAA 102
;
QY 61 GAATTCATGCTTGGCTGTGTAAGGCGCAGGA 92
    |||||||
DB 103 GAATTCATGCTTGGCTGTGTAAGGCGCAGGA 134
;
; RESULT 10
; US-09-108-661-17
; Sequence 17, Application US/09108661
; Patent No. 6287806
; GENERAL INFORMATION:
; APPLICANT: NISHIMURA, Osamu
; APPLICANT: KURIYAMA, Masato
; APPLICANT: KOYAMA, No. 6287806uyuki
; APPLICANT:

```

APPLICANT: FUKUDA, Tsunehiko
TITLE OF INVENTION: METHOD FOR PRODUCING A BIOLOGICALLY
TITLE OF INVENTION: ACTIVE RECOMBINANT CYSTEINE-FREE
NUMBER OF SEQUENCES: 37
CORRESPONDENCE ADDRESS:
ADDRESSEE: DIKE, BRONSTEIN, ROBERTS & CUSHMAN, LLP
STREET: 130 WATER STREET
CITY: BOSTON
STATE: MA
COUNTRY: USA
ZIP: 02109
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FASTSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/108,661
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/350,709
FILING DATE: 07-DEC-1994
APPLICATION NUMBER: 07/838,857
FILING DATE: 18-FEB-1992
APPLICATION NUMBER: JP 024841
FILING DATE: 19-FEB-1991
APPLICATION NUMBER: JP 0271438
FILING DATE: 18-OCT-1991
ATTORNEY/AGENT INFORMATION:
NAME: DAVID, RESNICK S
REGISTRATION NUMBER: 34,235
REFERENCE/DOCKET NUMBER: 41614-FWC
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617-523-3400
TELEFAX: 617-523-6440
TELEX: 200291 STRE
INFORMATION FOR SEQ ID NO: 17:
SEQUENCE CHARACTERISTICS:
LENGTH: 144 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: CDNA
HYPOTHETICAL: NO
ANTI-SENSE: NO
FRAGMENT TYPE:
ORIGINAL SOURCE:
FEATURE:
NAME/KEY: Coding Sequence
LOCATION: 22...144
US-09-108-661-17

Query Match
Best Local Similarity 86.9%; Score 80.8; DB 4; Length 144;
Matches 85; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

Qy 1 CATGCTGAGGAGCCTTACAGTGAAGTCTTATTTGGAAGGCAAGCTGCGCAG 60
Db 43 CATGCTGAGGAGCCTTACAGTGAAGTCTTATTTGGAAGGCAAGCTGCGCAG 60
Qy 61 GAATTCATTTGGTGGTGGTGAAGGCGGAGG 92
Db 103 GAATTCATTTGGTGGTGGTGAAGGCGGAGG 134

RESULT 11
US-08-829-876-22
Sequence 22, Application US/08829876
Patent No. 5962266
GENERAL INFORMATION:
APPLICANT: White, Tyler R.
APPLICANT: Damm, Deborah

APPLICANT: Lesikar, David D.
APPLICANT: McFadden, Kathleen
APPLICANT: Garrick, Brett L.
TITLE OF INVENTION: PROTEASE INHIBITOR PEPTIDES
NUMBER OF SEQUENCES: 228
CORRESPONDENCE ADDRESS:
ADDRESSEE: Foley & Lardner
STREET: 3000 K Street, N.W., Suite 500
CITY: Washington
STATE: D.C.
COUNTRY: USA
ZIP: 20007-5109
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/829,876
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/436,555
FILING DATE: 08-MAY-1995
ATTORNEY/AGENT INFORMATION:
NAME: Pelto, Don J.
REGISTRATION NUMBER: 33,754
REFERENCE/DOCKET NUMBER: 56324/106/SCNO
TELECOMMUNICATION INFORMATION:
TELEPHONE: (202)672-5300
TELEFAX: (202)672-5399
TELEX: 904136
INFORMATION FOR SEQ ID NO: 22:
SEQUENCE CHARACTERISTICS:
LENGTH: 78 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-829-876-22

Query Match
Best Local Similarity 53.5%; Score 49.8; DB 2; Length 78;
Matches 57; Conservative 0; Mismatches 12; Indels 0; Gaps 0;

Qy 24 TGATGTAGTCTTATTGGAAGGCGCAAGCTGCCAAGATTCATTCGCTGGGTGAA 83
Db 1 TGATGTCTTCTTACTTGAAGGTCAAGCTGCTAAGATTCATTCGCTGGGTGAA 60
Qy 84 AGGCGGAGG 92
Db 61 AGGTAGAGG 69

RESULT 12
US-09-234-874A-22
Sequence 22, Application US/09234874A
Patent No. 6376648
GENERAL INFORMATION:
APPLICANT: White, Tyler R.
APPLICANT: Damm, Deborah
APPLICANT: Lesikar, David D.
APPLICANT: McFadden, Kathleen
APPLICANT: Garrick, Brett L.
TITLE OF INVENTION: PROTEASE INHIBITOR PEPTIDES
NUMBER OF SEQUENCES: 228
CORRESPONDENCE ADDRESS:
ADDRESSEE: Foley & Lardner
STREET: 3000 K Street, N.W., Suite 500
CITY: Washington
STATE: D.C.
COUNTRY: USA
ZIP: 20007-5109

```
COMPUTER READABLE FORM:
MEDIUM TYPE: floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
  APPLICATION NUMBER: US/09/234, 874A
  FILING DATE: 11-Jun-2001
PRIOR APPLICATION DATA:
  APPLICATION NUMBER: 08/436, 555
  FILING DATE: 08-MAY-1995
ATTORNEY/AGENT INFORMATION:
  NAME: Bent, Stephen
  REGISTRATION NUMBER: 29, 768
REFERENCE/DOCKET NUMBER: 056324/0106
TELECOMMUNICATION INFORMATION:
  TELEPHONE: (202)672-5300
  TELEFAX: (202)672-5399
  TELEX: 904136
INFORMATION FOR SEQ ID NO: 22:
SEQUENCE CHARACTERISTICS:
  LENGTH: 78 base pairs
  TYPE: nucleic acid
  STRANDEDNESS: single
  TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
SEQUENCE DESCRIPTION: SEQ ID NO: 22:
US-09-234-874A-22

Query Match      53.5%; Score 49.8; DB 4; Length 78;
Best Local Similarity 82.6%; Pred. No. 3,9e-10;
Matches 57; Conservative 0; Mismatches 12; Indels 0; Gaps 0;

QY 24 TGAGTGAAGTCTTATTGGAGCCAGCTGCCAGATTCATTGCTGGCTGAA 83
DB 1 TGAGTCTCTTCTTACTTGAAGTCAAGCTGCTAGAGATTCATCGCTGGTGTCAA 60

QY 84 AGGCCGAGG 92
DB 61 AGGTAGAGG 69

RESULT 13
US-08-811-028-43
Sequence 43, Application US/08811028C
Patent No. 5891671
GENERAL INFORMATION:
  APPLICANT: SUZUKI, Yuji
  APPLICANT: MASUDA, Koji
  TITLE OF INVENTION: METHOD FOR CLEAVING CHIMERIC ENZYME USING PROCESSING
  FILE REFERENCE: 001560-294
  CURRENT FILING DATE: 1987-03-04
  EARLIER FILING DATE: 1996-03-04
  NUMBER OF SEQ ID NOS: 54
SOFTWARE: Patentin Ver. 2.0
SEQ ID NO 43
LENGTH: 57
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
  OTHER INFORMATION: Description of Artificial Sequence: oligonucleotide
  OTHER INFORMATION: GLP-1
US-08-811-028-43

Query Match      40.6%; Score 37.8; DB 2; Length 57;
Best Local Similarity 78.9%; Pred. No. 1,8e-05;
Matches 45; Conservative 0; Mismatches 12; Indels 0; Gaps 0;

QY 5 CTGAAGGACCTTTACCACTGATGTAAGTTCTTATTGGAGGCCAAGCTGCCAAG 61
```

```
DB 1 CGGAGGTAACCTTACCGAGCATGTGAGCTGTCTGGAAGGTCAAGCGGCAAAAG 57

RESULT 14
US-08-811-028-44/c
Sequence 44, Application US/08811028C
Patent No. 5891671
GENERAL INFORMATION:
  APPLICANT: SUZUKI, Yuji
  APPLICANT: MASUDA, Koji
  TITLE OF INVENTION: METHOD FOR CLEAVING CHIMERIC ENZYME USING PROCESSING
  FILE REFERENCE: 001560-294
  CURRENT FILING DATE: 1987-03-04
  EARLIER FILING DATE: 1996-03-04
  NUMBER OF SEQ ID NOS: 54
SOFTWARE: Patentin Ver. 2.0
SEQ ID NO 44
LENGTH: 48
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
  OTHER INFORMATION: Description of Artificial Sequence: oligonucleotide
  OTHER INFORMATION: GLP-2
US-08-811-028-44

Query Match      38.5%; Score 35.8; DB 2; Length 48;
Best Local Similarity 85.1%; Pred. No. 9,4e-05;
Matches 40; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 1 CATGCTGAAGGACCTTTACCACTGATGTAAGTTCTTATTGGAAG 47
DB 48 CATGCGGAAGTACTTACCAAGCATGTAGCTCCTATCTGGAAG 2

RESULT 15
US-08-811-028-46/c
Sequence 46, Application US/08811028C
Patent No. 5891671
GENERAL INFORMATION:
  APPLICANT: SUZUKI, Yuji
  APPLICANT: MASUDA, Koji
  TITLE OF INVENTION: METHOD FOR CLEAVING CHIMERIC ENZYME USING PROCESSING
  FILE REFERENCE: 001560-294
  CURRENT FILING DATE: 1987-03-04
  EARLIER FILING DATE: 1996-03-04
  NUMBER OF SEQ ID NOS: 54
SOFTWARE: Patentin Ver. 2.0
SEQ ID NO 46
LENGTH: 53
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
  OTHER INFORMATION: Description of Artificial Sequence: oligonucleotide
  OTHER INFORMATION: GLP-4
US-08-811-028-46

Query Match      35.3%; Score 32.8; DB 2; Length 53;
Best Local Similarity 84.1%; Pred. No. 0.0013;
Matches 37; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 49 CAAGCTGCCAAGAAATTCATTGGCTGGGGAAGGCGGAGG 92
DB 53 CAGCGCGCAAAAGAAATTCATCGCTGTGCTGTGAAGGCCCTGG 10
```

Thu Feb 27 13:12:08 2003

us-09-091-605-2.rni

Page 8

Search completed: February 14, 2003, 08:25:50
Job time : 50 secs

Tue Feb 27 13:12:17 2003

us-09-091-605-1.ra1

Page 1

GenCore version 5.1.3
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: February 13, 2003, 11:02:22 ; Search time 15 seconds
(without alignments)
60,807 Million cell updates/sec

Title: US-09-091-605-1

Perfect score: 141
Sequence: 1 HXECTFTSDVSTLXGQAAAXFTAWLVKGRX 31

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 262574 seqs, 29422922 residues

Total number of hits satisfying chosen parameters: 262574

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database: Issued Patents, AA:*

- 1: /cgn2_6/ptodata/1/1aa/5A.COMB.pep.*
- 2: /cgn2_6/ptodata/1/1aa/5B.COMB.pep.*
- 3: /cgn2_6/ptodata/1/1aa/6A.COMB.pep.*
- 4: /cgn2_6/ptodata/1/1aa/6B.COMB.pep.*
- 5: /cgn2_6/ptodata/1/1aa/6C.COMB.pep.*
- 6: /cgn2_6/ptodata/1/1aa/6D.COMB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	133	94.3	30	1	US-08-066-480-6
2	133	94.3	30	1	US-08-095-162-1
3	133	94.3	30	1	US-08-470-220A-1
4	133	94.3	30	2	US-08-927-327-1
5	133	94.3	30	3	US-08-967-374-1
6	133	94.3	30	4	US-08-961-405A-5
7	133	94.3	30	4	US-08-915-918A-5
8	133	94.3	30	4	US-08-302-596-4
9	133	94.3	30	4	US-08-472-349-3
10	133	94.3	30	4	US-09-333-415-4
11	133	94.3	30	4	US-09-585-181A-4
12	133	94.3	30	4	US-09-209-799D-10
13	133	94.3	30	4	US-09-975-905-1
14	133	94.3	30	4	US-09-505-991-1
15	133	94.3	30	4	US-09-573-809-1
16	133	94.3	30	4	US-09-303-016-4
17	133	94.3	30	4	US-09-212-663-4
18	133	94.3	30	5	PCR-US95-15800-27
19	133	94.3	30	5	US-09-025-951-1
20	133	94.3	30	1	US-08-095-162-3
21	133	94.3	30	1	US-08-295-913A-1
22	133	94.3	30	1	US-08-470-220A-3
23	133	94.3	30	1	US-08-807-263-3
24	133	94.3	30	2	US-08-967-374-3
25	133	94.3	30	4	US-08-961-405A-1
26	133	94.3	30	4	US-09-258-750-1
27	133	94.3	30	4	US-09-258-750-1

28	133	94.3	31	4	US-08-915-918A-1	Sequence 1, Appli
29	133	94.3	31	4	US-09-302-596-3	Sequence 3, Appli
30	133	94.3	31	4	US-08-472-349-2	Sequence 2, Appli
31	133	94.3	31	4	US-09-623-618B-2	Sequence 2, Appli
32	133	94.3	31	4	US-09-623-618B-17	Sequence 27, Appli
33	133	94.3	31	4	US-09-623-618B-27	Sequence 28, Appli
34	133	94.3	31	4	US-09-623-618B-28	Sequence 28, Appli
35	133	94.3	31	4	US-09-333-415-3	Sequence 1, Appli
36	133	94.3	31	4	US-09-209-799D-1	Sequence 29, Appli
37	133	94.3	31	4	US-09-209-799D-29	Sequence 1, Appli
38	133	94.3	31	4	US-09-265-141A-1	Sequence 3, Appli
39	133	94.3	31	4	US-09-505-991-3	Sequence 3, Appli
40	133	94.3	31	4	US-09-303-016-3	Sequence 1, Appli
41	133	94.3	31	4	US-09-398-111-1	Sequence 3, Appli
42	133	94.3	31	4	US-09-212-663-3	Sequence 2, Appli
43	133	94.3	31	5	PCR-US95-15800-28	Sequence 85, Appli
44	133	94.3	32	4	US-09-258-750-85	
45	133	94.3	32	4	US-09-398-111-85	

ALIGNMENTS

RESULT 1
US-08-066-480-6
Sequence 6, Application US/08066480

Patent No. 5424286

GENERAL INFORMATION:

APPLICANT: Eng, John

TITLE OF INVENTION: Pharmaceutical Compositions And Use of

NUMBER OF SEQUENCES: 7

CORRESPONDENCE ADDRESSES: Exendin-3 and Exendin-4 for Treatment of Diabetes Mellitus

ADDRESS: Allegrini & Wilcoff, Ltd.

STREET: 10 S. Wacker Drive

CITY: Chicago

STATE: Illinois

COUNTRY: USA

ZIP: 60606

COMPUTER READABLE FORM: disk

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: PatentIn Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/066,480

FILING DATE: 24-MAR-1993

CLASSIFICATION: 514

ATTORNEY/AGENT INFORMATION:

NAME: McDonnell, John J

REGISTRATION NUMBER: 26,949

REFERENCE/DOCKET NUMBER: 93,084

TELECOMMUNICATION INFORMATION:

TELEPHONE: 312-715-1234

INFORMATION FOR SEQ ID NO: 6:

SEQUENCE CHARACTERISTICS:

LENGTH: 30 amino acids

TYPE: amino acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: peptide

FEATURE:

NAME/KEY: Peptide

LOCATION: 1..30

OTHER INFORMATION: /note="GLP-1(7-36) fragment"

US-08-066-480-6

Query Match 94.3%; Score 133; DB 1; Length 30;
Best Match Similarity 86.7%; Pred. No. 1.3e-14;
Matches 26; Conservative 0; Mismatches 4; Gaps 0;

OY 1 HXEGFTSDVSSYLXGQAAKFIAMLVKGR 30
Db 1 HXEGFTSDVSSYLXGQAAKFIAMLVKGR 30

RESULT 2

US-08-095-162-1

; Sequence 1, Application US/08095162
; Patent No. 5512459
; GENERAL INFORMATION:
; APPLICANT: Wagner, Fred W.
; APPLICANT: Stout, Jay
; APPLICANT: Henriksen, Dennis
; APPLICANT: Partridge, Bruce
; APPLICANT: Manning, Shane
; TITLE OF INVENTION: Enzymatic Method for Modification of
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Merchant & Gould
; STREET: 3100 No. 5512459west Center
; CITY: Minneapolis
; STATE: MN
; COUNTRY: USA
; ZIP: 55402

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/095,162
FILING DATE: 20-JUL-1993
CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: Nelson, Albin J.
REGISTRATION NUMBER: 28,659
REFERENCE/DOCKET NUMBER: 8648.32-US01
TELECOMMUNICATION INFORMATION:
TELEPHONE: 612-332-5300
TELEFAX: 612-332-9081
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 30 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
IMMEDIATE SOURCE:
CLONE: GLP1 7-36-NH2 (glucagon-like Peptide)
US-08-095-162-1

Query Match 94.3%; Score 133; DB 1; Length 30;
Best Local Similarity 86.7%; Pred. No. 1.3e-14;
Matches 26; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

OY 1 HXEGFTSDVSSYLXGQAAKFIAMLVKGR 30
Db 1 HXEGFTSDVSSYLXGQAAKFIAMLVKGR 30

RESULT 3

US-08-470-220A-1
; Sequence 1, Application US/08470220A
; Patent No. 5707826
; GENERAL INFORMATION:

; APPLICANT: Wagner, Fred W.
; APPLICANT: Stout, Jay
; APPLICANT: Henriksen, Dennis
; APPLICANT: Partridge, Bruce
; APPLICANT: Manning, Shane
; TITLE OF INVENTION: Enzymatic Method for Modification of
; NUMBER OF SEQUENCES: 26

CORRESPONDENCE ADDRESS:
ADDRESSEE: Merchant & Gould
STREET: 3100 No. 5707826west Center
CITY: Minneapolis
STATE: MN
COUNTRY: USA
ZIP: 55402

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/470,220A
FILING DATE: 06-JUN-1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/095,162
FILING DATE: 20-JUL-1993
ATTORNEY/AGENT INFORMATION:
NAME: Nelson, Albin J.
REGISTRATION NUMBER: 28,659
REFERENCE/DOCKET NUMBER: 8648.32-US01
TELECOMMUNICATION INFORMATION:
TELEPHONE: 612-332-5300
TELEFAX: 612-332-9081
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 30 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
IMMEDIATE SOURCE:
CLONE: GLP1 7-36-NH2 (glucagon-like Peptide)
US-08-470-220A-1

Query Match 94.3%; Score 133; DB 1; Length 30;
Best Local Similarity 86.7%; Pred. No. 1.3e-14;
Matches 26; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

OY 1 HXEGFTSDVSSYLXGQAAKFIAMLVKGR 30
Db 1 HXEGFTSDVSSYLXGQAAKFIAMLVKGR 30

RESULT 4

US-08-927-227-1
; Sequence 1, Application US/08927227A
; Patent No. 5977071
; GENERAL INFORMATION:

; APPLICANT: Galloway, James A.
; APPLICANT: Hoffmann, James A.
; TITLE OF INVENTION: GLUCAGON-LIKE INSULINOTROPIC PEPTIDE ANALOGS,
; FILE REFERENCE: X-9332B
; CURRENT APPLICATION NUMBER: US/08/927,227A
; CURRENT FILING DATE: 1997-09-10
; NUMBER OF SEQ ID NOS: 1
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 1
; LENGTH: 30
; TYPE: PPT
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: The arginine residue at position 30 is modified so
; OTHER INFORMATION: as to replace the terminal carboxyl group with an
; OTHER INFORMATION: amine.
US-08-927-227-1

Query Match 94.3%; Score 133; DB 2; Length 30;
Best Local Similarity 86.7%; Pred. No. 1.3e-14;
Matches 26; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

```
QY      1 HXEGFTSDVSSYLXGQAAXFIAMLVKGR 30  
          | ||||| | | | | |  
Db      1 HAEGFTSDVSSYLEGAKEFIAMLVKGR 30
```

RESULT 5
US-08-967-374-1

1 Sequence 1, Application US/08967374
 2 Patent No. 6037143
 3
 4 GENERAL INFORMATION:
 5
 6 APPLICANT: Wagner, Fred W.
 7 APPLICANT: Stout, Jay
 8 APPLICANT: Henriksen, Dennis
 9 APPLICANT: Partridge, Bruce
 10 APPLICANT: Manning, Shane
 11
 12 TITLE OF INVENTION: Enzymatic Method for Modification of
 13
 14 TITLE OF INVENTION: Recombinant Polypeptides
 15
 16 NUMBER OF SEQUENCES: 26
 17
 18 CORRESPONDENCE ADDRESS:
 19
 20 ADDRESSEE: Merchant & Gould
 21 STREET: 3100 No. 6037143west Center
 22
 23 CITY: Minneapolis
 24
 25 STATE: MN
 26
 27 COUNTRY: USA
 28 ZIP: 55403

Query Match	94.3%	Score 133;	DB 3;	Length 30;
Best Local Similarity	86.7%	Pred	NO. 1.3e-14;	
Matches 26; Conservative	0;	Mismatches 4;	Indels 0;	Gaps 0

RESULT 6
US-09-348-136-1

```

: Sequence 1, Application US/09348136
: Patent No. 6133235
: GENERAL INFORMATION:
: APPLICANT: Calloway, James A.
: APPLICANT: Hoffmann, James A.
: TITLE OF INVENTION: GLUCAGON-LIKE INSULINOTROPIC PEPTIDE ANALOGS
: TITLE OF INVENTION: COMPOSITIONS AND METHODS
: FILE REFERENCE: X-9332P

```

```

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040

```

```

Query Match:      94.3%;   Score 133;   DB 4;   Length 30;
Best Local Similarity: 86.7%;   Pred. No. 1.3e-14;
Matches    26;   Conservative    0;   Mismatches    4;   Indels    0;   Gaps    0;

```

RESULT 7

```

: Sequence 5 Application US/08961405A
: Patent No. 6191102
:
: GENERAL INFORMATION:
: APPLICANT: Dimarchi, Richard D.
: APPLICANT: Efendić, Sued
: TITLE OF INVENTION: USE OF GLP-1 ANALOGS AND DERIVATIVES
: TITLE OF INVENTION: ADMINISTERED PERIPHERALLY IN REGULATION OF OBESITY
: NUMBER OF SEQUENCES: 9
: CORRESPONDENCE ADDRESS:
: ADDRESSEE: BARNES & THORNBURG
: STREET: 200 W. Madison, Suite 2601
:
: CITY: Chicago
: STATE: Illinois
: COUNTRY: USA
: ZIP: 60606
:
: COMPUTER READABLE FORM:
: MEDIUM TYPE: Floppy disk
: COMPUTER: IBM PC compatible
: OPERATING SYSTEM: PC-DOS/MS-DOS
: SOFTWARE: PatentIn Release #1.0, Version #1.30
:
: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/08/961,405A
: FILING DATE: 30-OCT-1997
:
: PRIOR APPLICATION DATA:
: APPLICATION NUMBER: US 60/030,213
: FILING DATE: 05-NOV-1996
: ATTORNEY/AGENT INFORMATION:
: NAME: Martin, Alice O.
: REGISTRATION NUMBER: 35,601
: REFERENCE/DOCKET NUMBER: 3051/90264
: TELECOMMUNICATION INFORMATION:
: TELEPHONE: 312-757-1313
: TELEFAX: 312-757-5646
: INFORMATION FOR SEQ ID NO: 5:
: SEQUENCE CHARACTERISTICS:
: LENGTH: 30 amino acids
: TYPE: amino acid
: STRANDEDNESS:
: TOPOLOGY: linear
: MOLECULE TYPE: peptide
:
: US-08-961-405A-5

```

Query Match	94.3%	Score 133	DB 4	Length 30
Best Local Similarity	86.7%	Pred No. 1.3e-14		
Matches 26	Conservative	0	Mismatches 4	Indels 0
			Gaps	0

QY 1 HXEGFTSDVSSYLXGQAAXXFIAVLVKGR 30
| | | | | | | | | | | |
Db 1 HAEGFTSDVSSYLEGQAKEFIAVLVKGR 30

RESULT 8
US-08-91

```

Sequence 5, Application US/08915918A
Patent No. 6277819
GENERAL INFORMATION:
APPLICANT: Etendic, Suad
TITLE OF INVENTION: USE OF GLP-1 OR ANALOGS IN TREATMENT OF
TITLE OF INVENTION: MYOCARDIAL INFARCTION
NUMBER OF SEQUENCES: 6
CORRESPONDENCE ADDRESS:
ADDRESSEE: BRINKS, HOFER, GILSON & LIONE
STREET: NBC Tower - Suite 3600, 455 N. Cityfront
STREET: Plaza Drive
CITY: Chicago
STATE: Illinois
COUNTRY: USA
ZIP: 60611-5599
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/915,918A
FILING DATE: 21-Aug-1997
CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: Martin, Alice O.
REGISTRATION NUMBER: 35,601
REFERENCE/DOCKET NUMBER: 8792/28
TELECOMMUNICATION INFORMATION:
TELEPHONE: 312-321-4200
TELEFAX: 312-321-4299
INFORMATION FOR SEQ ID NO: 5:
SEQUENCE CHARACTERISTICS:
LENGTH: 30 amino acids
TYPE: amino acid
STRANDEDNESS:
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-915-918A-5

Query Match          94.3%; Score 133; DB 4; Length 30;
Best Local Similarity 86.7%; Pred. No. 1,3e-14;
Matches    26; Conservative    0; Mismatches    4; Indels    0; Gaps    0;

QY      1 HXEGTFTSDVSYLKGQAAXXTAWLVKGR 30
        I | | | | | | | | | | | | | | | |
Db       1 HAECTFTSDVSYLEGQAAXXTAWLVKGR 30

RESULT 9
US-09-302-596-4
Sequence 4, Application US/09302596
Patent No. 6284725
GENERAL INFORMATION:
APPLICANT: Coolidge, Thomas R.
APPLICANT: Ehlers, Mario R.W.
TITLE OF INVENTION: Metabolic Intervention with GLP-1 to Improve the Function of
TITLE OF INVENTION: Ischemic and Repertused Tissue
FILE REFERENCE: P036600S1
CURRENT APPLICATION NUMBER: US/09/302,596
CURRENT FILING DATE: 1999-04-30
PRIOR APPLICATION NUMBER: 60/103,498
PRIOR FILING DATE: 1998-10-08
NUMBER OF SEQ ID NOS: 13
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 4
```

```

; LENGTH: 30
; TYPE: PRT
; ORGANISM: mammalian
US-09-302-596-4

```

Query Match	94.3%	Score 133;	DB 4;	Length 30;
Best Local Similarity	86.7%;	Pred. NO. 1.3e-14;		
Matches 26; Conservative	0;	Mismatches 4;	Indels 0;	Gaps 0;

QY 1 HXEGFTSDVSSYLXGQAAXFIAVLVKGR 30
 | | | | | | | | | | | | |
Dd 1 HAEGFTSDVSSYLEGAKEFIAMLVKGR 30

RESULT 10
ME-09-473

Sequence 3, Application US/08472349
Patent No. 6284727

GENERAL INFORMATION:

APPLICANT: Kim, Yesook
APPLICANT: Lambert, William J.
APPLICANT: Qi, Hong
APPLICANT: Gelfand, Robert A.
APPLICANT: Geoghegan, Kieran F.
APPLICANT: Danley, Dennis E.
TITLE OF INVENTION: Prolonged Delivery of Peptides
NUMBER OF SEQUENCES: 7
CORRESPONDENCE ADDRESS:
ADDRESSEE: Pfizer Inc
STREET: 235 East 42nd Street, 20th Floor
CITY: New York
STATE: New York
COUNTRY: U.S.A.
ZIP: 10017-5755

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/472,349
FILING DATE:
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/181,655
FILING DATE:

ATTORNEY/AGENT INFORMATION:
NAME: Sheyka, Robert F.
REGISTRATION NUMBER: 31,304
REFERENCE/DOCKET NUMBER: PC8391
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212)573-1189
TELEFAX: (212)573-1939
TELEX: N/A

INFORMATION FOR SEQ ID NO: 3:
SEQUENCE CHARACTERISTICS:
LENGTH: 30 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHEICAL: NO
ANTI-SENSE: NO
FRAGMENT TYPE: N-terminal
ORIGINAL SOURCE:
ORGANISM: N/A
STRAIN: N/A
INDIVIDUAL ISOLATE: N/A
HAPLOTYPE: N/A
CELL LINE: N/A
IMMEDIATE SOURCE:
LIBRARY: N/A
CLONE: N/A


```
; Sequence 1, Application US/09505991
; Patent No. 6403361
; GENERAL INFORMATION:
; APPLICANT: Wagner, Fred W.
; Stout, Jay
; Henriksen, Dennis
; Partridge, Bruce
; Manning, Shane
; TITLE OF INVENTION: Enzymatic Method for Modification of
; Recombinant Polypeptides
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Merchant & Gould
; STREET: 3100 No. 640361west Center
; CITY: Minneapolis
; STATE: MN
; COUNTRY: USA
; ZIP: 55402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/505,991
; FILING DATE: 17-Feb-2000
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/520,485
; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: Carter, Charles G.
; REGISTRATION NUMBER: 35,093
; REFERENCE/DOCKET NUMBER: 8648.32-USD1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 612-332-5300
; TELEFAX: 612-332-9081
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 30 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; IMMEDIATE SOURCE:
; CLONE: GLP1 7-36-NH2 (Glucagon-like Peptide)
; SEQUENCE DESCRIPTION: SEQ ID NO: 1:
; US-09-505-991-1
;
Query Match 94.3%; Score 133; DB 4; Length 30;
Best Local Similarity 86.7%; Pred.No.1.3e-14;
Matches 26; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
QY 1 HXEGTFTSDVSYLXGQAAXXFIATLWKGR 30
I | | | | | | | | | | | | | | | | | |
Db 1 HXEGTFTSDVSYLXGQAAXXFIATLWKGR 30
```

Search completed: February 13, 2003, 11:03:53
Job time : 16 secs

GenCore version 5.1.3
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: February 13, 2003, 10:57:11 ; Search time 35 Seconds
(without alignments)
118.022 Million cell updates/sec

Title: US-09-091-605-1
Perfect score: 141
Sequence: 1 HXKGFPSDVSSYLKQAAAXFIAMLVKGRX 31

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 908470 seqs, 133250620 residues

Total number of hits satisfying chosen parameters: 908470

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :
1: /SID52/gcgdata/geneseq/geneseq-emb1/AA1980.DAT:*
2: /SID52/gcgdata/geneseq/geneseq-emb1/AA1981.DAT:*
3: /SID52/gcgdata/geneseq/geneseq-emb1/AA1982.DAT:*
4: /SID52/gcgdata/geneseq/geneseq-emb1/AA1983.DAT:*
5: /SID52/gcgdata/geneseq/geneseq-emb1/AA1984.DAT:*
6: /SID52/gcgdata/geneseq/geneseq-emb1/AA1985.DAT:*
7: /SID52/gcgdata/geneseq/geneseq-emb1/AA1986.DAT:*
8: /SID52/gcgdata/geneseq/geneseq-emb1/AA1987.DAT:*
9: /SID52/gcgdata/geneseq/geneseq-emb1/AA1988.DAT:*
10: /SID52/gcgdata/geneseq/geneseq-emb1/AA1989.DAT:*
11: /SID52/gcgdata/geneseq/geneseq-emb1/AA1990.DAT:*
12: /SID52/gcgdata/geneseq/geneseq-emb1/AA1991.DAT:*
13: /SID52/gcgdata/geneseq/geneseq-emb1/AA1992.DAT:*
14: /SID52/gcgdata/geneseq/geneseq-emb1/AA1993.DAT:*
15: /SID52/gcgdata/geneseq/geneseq-emb1/AA1994.DAT:*
16: /SID52/gcgdata/geneseq/geneseq-emb1/AA1995.DAT:*
17: /SID52/gcgdata/geneseq/geneseq-emb1/AA1996.DAT:*
18: /SID52/gcgdata/geneseq/geneseq-emb1/AA1997.DAT:*
19: /SID52/gcgdata/geneseq/geneseq-emb1/AA1998.DAT:*
20: /SID52/gcgdata/geneseq/geneseq-emb1/AA1999.DAT:*
21: /SID52/gcgdata/geneseq/geneseq-emb1/AA2000.DAT:*
22: /SID52/gcgdata/geneseq/geneseq-emb1/AA2001.DAT:*
23: /SID52/gcgdata/geneseq/geneseq-emb1/AA2002.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	134	95.0	31	17	AAW03901
2	134	95.0	31	17	AAW03902
3	133	94.3	30	15	AAW45435
4	133	94.3	30	15	AAW63247
5	133	94.3	30	16	AAW69063
6	133	94.3	30	16	AAW79809
7	133	94.3	30	16	AAW80548
8	133	94.3	30	17	AAW8956
9	133	94.3	30	17	AAW8956
10	133	94.3	30	18	AAW16383

11	133	94.3	30	19	AAW29555
12	133	94.3	30	19	AAW63288
13	133	94.3	30	19	AAW63182
14	133	94.3	30	19	AAW50906
15	133	94.3	30	20	AAW42935
16	133	94.3	30	20	AAW42937
17	133	94.3	30	20	AAW27374
18	133	94.3	30	20	AAW39773
19	133	94.3	30	20	AAW34198
20	133	94.3	30	20	AAW31503
21	133	94.3	30	20	AAW22166
22	133	94.3	30	20	AAW03719
23	133	94.3	30	21	AAW11283
24	133	94.3	30	21	AAW21336
25	133	94.3	30	21	AAW21340
26	133	94.3	30	21	AAW21352
27	133	94.3	30	21	AAW21108
28	133	94.3	30	21	AAW07294
29	133	94.3	30	21	AAW07313
30	133	94.3	30	21	AAW53280
31	133	94.3	30	21	AAW78949
32	133	94.3	30	22	AAW07375
33	133	94.3	30	22	AAW09260
34	133	94.3	30	22	AAW63287
35	133	94.3	30	22	AAW63289
36	133	94.3	30	22	AAW63303
37	133	94.3	30	22	AAW82336
38	133	94.3	30	22	AAW83291
39	133	94.3	30	22	AAW70461
40	133	94.3	30	22	AAW91170
41	133	94.3	30	22	AAW81181
42	133	94.3	30	22	AAW60124
43	133	94.3	30	22	AAW60127
44	133	94.3	30	22	AAW60127
45	133	94.3	30	22	AAW60249

ALIGNMENTS

RESULT 1					
AAW03901	standard; peptide; 31 AA.				
XX	AAW03901:				
XX	15-APR-1997	(first entry)			
XX	Glucagon like peptide 1 (7-37) analogue Ser26.				
DE	Human: glucagon like peptide; GLP-1; analogue; stimulation;				
KW	pancreas; insulin; islet cell; treatment; type II diabetes.				
XX	Homo sapiens.				
OS					
XX					
FH	Key	Location/Qualifiers			
FT	Misc-difference 20	/note- "wild type Lys substituted with Ser"			
FT	Misc-difference 29	/note- "optionally absent when Arg30 and Gly31 are absent"			
FT	Misc-difference 30	/note- "optionally absent when Gly31 is absent"			
FT	Misc-difference 31	/note- "optionally absent"			
FT	Misc-difference 31	/note- "optionally absent"			
XX	US5545618-A.				
XX	13-AUG-1996.				
XX	Human glucagon like peptide				
XX	Target peptide (GL				
PF	GLP1(7-35)-NH2.				
XX	20-SEP-1991;				
PR	91US-0762768.				

Thr 8 GLP-1(7-36)-
Glucagon-like pept
GLP-1(7-36). Homo
Glucagon-like pept
Glucagon-like pept
Arg26-GLP-1(7-36).
Glucagon-like pept
Glucagon-like pept
GLP-1 mutant pept
Glucagon-like pept
GLP-1-like peptide
Amino acid sequence
GLP-1 peptide SEQ
GLP-1 analogue Thr
GLP-1 peptide GLP-
GLP-1 analogue #12
Human glucagon-lik
Modified Glucagon
Modified Glucagon
Modified Glucagon
Glucagon-like pept
Glucagon-like pept
Mammalian glucagon
Human glucagon-lik
An insoluble gluc
An insoluble gluc
An insoluble gluc
Glucagon-like pept
GLP-1 peptide #2.
GLP-1. Unidentifi
Pancreatic hormone
Human glucagon-lik
Human glucagon-lik
Human glucagon-lik
Glucagon-like pept

PR 24-JAN-1990; 90US-0468736.
 PR 10-DEC-1993; 93US-0165516.
 XX
 PA (BUCK/) BUCKLEY D I.
 PA (HABE/) HABENER J F.
 PA (MALL/) MALLORY J B.
 PA (MOJS/) MOJSOV S.
 XX
 PI Buckley DI, Habener JF, Mallory JB, Mojsov S;
 DR WPI: 1996-383697/38.
 XX
 PT New modified glucagon-like peptide I fragments - have higher
 PT activity than glucagon or have improved plasma stability, useful for
 PT treating type II diabetes
 XX
 PS Example 1; page -: 16pp; English.
 XX
 CC The present peptide is a specific example of a claimed human
 CC glucagon like peptide I (GLP-1) analogue, which is useful for
 CC stimulating insulin release from pancreatic islet cells, especially
 CC in the treatment of type II diabetes at doses of 1 pg/kg to
 CC 1 mg/kg.
 CC
 XX
 SQ Sequence 31 AA;
 Query Match 95.0%; Score 134; DB 17; Length 31;
 Best Local Similarity 86.7%; Pred. No. 5.7e-15;
 Matches 26; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
 QY 1 HXEGFTSDVSSYLXGQAAAXFIAWLVKGR 30
 Db 1 HXEGFTSDVSSYLXGQAAAXFIAWLVKGR 30
 ID AAR45435
 AC AAR45435;
 XX
 DT 27-JUN-1994 (first entry)
 DE Insulinotropic derivative.
 XX
 KW Insulinotropic; activity; enhancing insulin activity; treatment;
 KW Type II diabetes.
 XX
 OS Synthetic.
 XX
 PN WO9325579-A.
 PD 23-DEC-1993.
 XX
 PF 14-APR-1993; 93WO-0503388.
 XX
 PR 15-JUN-1992; 92US-0899073.
 XX
 PA (PFIZ) PFIZER INC.
 XX
 PI Andrews GC, Daumy GO, Francoeur ML, Larson ER;
 DR WPI: 1994-007457/01.
 XX
 PT New derivs. of glucagon-like peptide I and insulinotropic - used for
 PT enhancing insulin action in a mammal, partic. by iontophoretic admin.
 XX
 PS Claim 3; Page 20; 32pp; English.
 XX
 CC The sequence is that of a derivative of insulinotropic which
 CC has insulinotropic activity and is useful for enhancing insulin
 CC action in a mammal, partic. for treating Type II diabetes
 CC (claimed). It is partic. suited for delivery to a mammal by
 CC iontophoresis.
 CC
 XX
 SQ Sequence 30 AA;
 Query Match 94.3%; Score 133; DB 15; Length 30;
 RESULT 2
 ID AAW03902 standard; peptide; 31 AA.
 AC AAW03902;
 XX
 DT 15-APR-1997 (first entry)
 DE Glucagon like peptide I (7-37) analogue Ala26.
 XX
 KW Human; glucagon like peptide; GLP-1; analogue; stimulation;
 KW pancreas; insulin; islet cell; treatment; type II diabetes.
 XX
 OS Homo sapiens.
 XX
 PN Key Location/Qualifiers
 FT Misc-difference 20 /note= "wild type Lys substituted with Ala"
 FT Misc-difference 29 /note= "optionally absent when Arg30 and Gly31 are
 FT Misc-difference 30 absent"
 FT Misc-difference 31 /note= "optionally absent when Gly31 is absent"
 FT Misc-difference 31 /note= "optionally absent"
 XX
 PN US5545618-A.
 XX
 PD 13-AUG-1996.
 XX
 PF 24-JAN-1990; 90US-0468736.
 XX
 PR 20-SEP-1991; 91US-0762768.
 PR 24-JAN-1990; 90US-0468736.
 PR 10-DEC-1993; 93US-0165516.
 XX
 PA (BUCK/) BUCKLEY D I.
 PA (HABE/) HABENER J F.

PA (MALL/) MALLORY J B.
 PA (MOJS/) MOJSOV S.
 XX
 PI Buckley DI, Habener JF, Mallory JB, Mojsov S;
 DR WPI: 1996-383697/38.
 XX
 PT New modified glucagon-like peptide I fragments - have higher
 PT activity than glucagon or have improved plasma stability, useful for
 PT treating type II diabetes
 XX
 PS Example 1; page -: 16pp; English.
 XX
 CC The present peptide is a specific example of a claimed human
 CC glucagon like peptide I (GLP-1) analogue, which is useful for
 CC stimulating insulin release from pancreatic islet cells, especially
 CC in the treatment of type II diabetes at doses of 1 pg/kg to
 CC 1 mg/kg.
 CC
 XX
 SQ Sequence 31 AA;
 Query Match 95.0%; Score 134; DB 17; Length 31;
 Best Local Similarity 86.7%; Pred. No. 5.7e-15;
 Matches 26; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
 QY 1 HXEGFTSDVSSYLXGQAAAXFIAWLVKGR 30
 Db 1 HXEGFTSDVSSYLXGQAAAXFIAWLVKGR 30
 ID AAR45435
 AC AAR45435;
 XX
 DT 27-JUN-1994 (first entry)
 DE Insulinotropic derivative.
 XX
 KW Insulinotropic; activity; enhancing insulin activity; treatment;
 KW Type II diabetes.
 XX
 OS Synthetic.
 XX
 PN WO9325579-A.
 PD 23-DEC-1993.
 XX
 PF 14-APR-1993; 93WO-0503388.
 XX
 PR 15-JUN-1992; 92US-0899073.
 XX
 PA (PFIZ) PFIZER INC.
 XX
 PI Andrews GC, Daumy GO, Francoeur ML, Larson ER;
 DR WPI: 1994-007457/01.
 XX
 PT New derivs. of glucagon-like peptide I and insulinotropic - used for
 PT enhancing insulin action in a mammal, partic. by iontophoretic admin.
 XX
 PS Claim 3; Page 20; 32pp; English.
 XX
 CC The sequence is that of a derivative of insulinotropic which
 CC has insulinotropic activity and is useful for enhancing insulin
 CC action in a mammal, partic. for treating Type II diabetes
 CC (claimed). It is partic. suited for delivery to a mammal by
 CC iontophoresis.
 CC
 XX
 SQ Sequence 30 AA;
 Query Match 94.3%; Score 133; DB 15; Length 30;

Best Local Similarity 86.7%; Pred. No. 8.1e-15;
Matches 26; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1 HXEGFTSDVSSYLKGOAAXXTIAMLVKGR 30
1 HXEGFTSDVSSYLKGOAAXXTIAMLVKGR 30
DB 1 HXEGFTSDVSSYLKGOAAXXTIAMLVKGR 30

RESULT 4
AAR63247
ID AAR63247 standard; peptide; 30 AA.

AC AAR63247;
XX
XX 02-MAY-1995 (first entry)

DE Insulinotropan (GLP-1(7-36)) for use in treating NIDDM.

XX Insulinotropic activity; GLP-1; glucagon-like protein 1; NIDDM;
KW non-Insulin dependent diabetes mellitus; Insulinotropan; truncated.

XX Synthetic.

PN Epe19322-A.

PD 12-OCT-1994.

PF 10-FEB-1994; 94EP-0300981.

PR 07-APR-1993; 93US-0044133.

PA (PFIZ) PEIZER INC.
PT (PFIZ) PEIZER CORP.

PI Danley DE, Gelfand RA, Geoghegan KF, Kim Y, Lambert WJ;
PI Qi H, Oih, Hong Q, Yesook K;

DR WPI; 1994-311774/39.

PT Treatment of non-Insulin dependent diabetes mellitus - using a
PT glucagon-like peptide 1 or deriv. with prolonged action for
PT sustained glycaemic control

PS Claim 2; Page 46; 70pp; English.

XX This peptide is GLP-1(7-36) [GLP = glucagon-like peptide], a truncated
XX deriv. of GLP-1. GLP-1 and its deriv.s are useful in the treatment of
CC Non-Insulin Dependent Diabetes Mellitus (NIDDM). During processing in
CC the pancreas and intestine, GLP-1 (AAR63245) is converted to a 31 amino
CC acid peptide having amino acids 7-37 of GLP-1, alternatively referred
CC to as insulinotropan. GLP-1(7-37) has insulinotropic activity, ie. it
CC is able to stimulate, or cause to be stimulated, the synthesis of the
CC hormone insulin. Other derivs. of GLP-1 are shown in AAR63246-51. It
CC has been discovered that prolonged plasma elevations of GLP-1, and
CC related polypeptides, are necessary during the meal and beyond to
CC achieve sustained glycaemic control in patients with NIDDM. The invention
CC provides a compsn. that has prolonged action after each administration.

SO Sequence 30 AA;

Query Match 94.3%; Score 133; DB 15; Length 30;
Best Local Similarity 86.7%; Pred. No. 8.1e-15;

Matches 26; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1 HXEGFTSDVSSYLKGOAAXXTIAMLVKGR 30
1 HXEGFTSDVSSYLKGOAAXXTIAMLVKGR 30
DB 1 HXEGFTSDVSSYLKGOAAXXTIAMLVKGR 30

RESULT 5
AAR69063
ID AAR69063 standard; peptide; 30 AA.

AC AAR69063;

XX 23-AUG-1995 (first entry)

DE Amidated Glucagon like peptide 1 (GLP1) (7-36)-NH2.

XX Glucagon like peptide; GLP; transpeptidation; endopeptidase;
KW trypsin; thrombin; cleavage.

XX Synthetic.

XX Key Location/Qualifiers
XX Modified-site 30
XX /Label= Arg-NH2

XX W09503405-A.

PD 02-FEB-1995.

PF 19-JUL-1994; 94WO-US08125.

PR 20-JUL-1993; 93US-0095162.

PA (BION) BIONEERASKA INC.

PI Henriksen D, Manning S, Partridge B, Stout J, Wagner FW;

PI WPI; 1995-075233/10.

PT Transpeptidation of recombinant polypeptides - using
PT endopeptidase such as trypsin or thrombin to modify C-terminal
PT residue.

PS Claim 33; Page 50; 69pp; English.

XX The naturally occurring sequence of Glucagon like peptide 1 (GLP1)
XX is AAR69072. It is a 36 AA peptide that has been recombinantly
CC produced but without a mechanism for providing for the amidation of
CC the C-terminal Arg residue. Amidated recombinant GLP1 (7-36)NH2
CC (AAR69063) was prepd. from a multicopy fusion protein contg. four
CC copies of a modified truncated GLP peptide having AA residues 7-34
CC of the native polypeptide and the terminal AA residues A-F-A at
CC residues 35-37 (GLP1 (7-34)-A-F-A) (AAR69064). The recombinant GLP1 (7-
CC 34)-A-F-A can be transpeptidated to yield the modified recombinant
CC native GLP1 (7-36) (AAR69063) as follows. Trypsin was used to
CC cleave the peptide at the Lys-Ala bond in the presence of either
CC Gly-Arg-NH2 or Gly-Arg-Gly addition units so that the cleavage of
CC the Ala-Phe-Arg leaving unit is followed by the addition of either
CC Gly-Arg-NH2 or Gly-Arg-Gly to the core GLP1 (7-34) to yield either
CC amidated 7-36 GLP1-NH2 or GLP1 7-36 with a terminal Gly (AAR69063).

SO Sequence 30 AA;

Query Match 94.3%; Score 133; DB 16; Length 30;
Best Local Similarity 86.7%; Pred. No. 8.1e-15;

Matches 26; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1 HXEGFTSDVSSYLKGOAAXXTIAMLVKGR 30
1 HXEGFTSDVSSYLKGOAAXXTIAMLVKGR 30
DB 1 HXEGFTSDVSSYLKGOAAXXTIAMLVKGR 30

RESULT 6
AAR79809
ID AAR79809 standard; peptide; 30 AA.

AC AAR79809;

XX 01-FEB-1996 (first entry)

DE Glucagon like peptide GLP-1 (7-36)amide.

KW Glucagon like peptide; GLP-1 (7-36)amide; type II diabetes;

KW non-insulin dependent; divalent metal cation; zinc.
 XX Synthetic.
 OS

Key Location/Qualifiers
 30
 Modified-site /note="amidated"

EP658568-A1.

21-JUN-1995.

02-DEC-1994; 94EP-0308950.

09-DEC-1993; 93US-0164277.

(ELIL) LILLY & CO ELI.

Galloway JA, Hoffmann JA;

WPI; 1995-217011/29.

New divalent metal complexes of glucagon-like peptide 1 - useful for treating type II diabetes

Claim 4; Page 4; 10pp; English.

AA79809 is the glucagon like peptide GLP-1 (7-36)amide. When complexed to a divalent metal cation (pref. zinc) it can be used to treat type II (non-insulin dependent) diabetes.

Sequence 30 AA;

Query Match 94.3%; Score 133; DB 16; Length 30;
 Best Local Similarity 86.7%; Pred. No. 8.1e-15;
 Matches 26; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1 HXEGFTSDVSSYLXGQAAAXFIAMLVKGR 30
 1 HXEGFTSDVSSYLXGQAAKEFIAMLVKGR 30

AA80548
 ID AA80548 standard; peptide; 30 AA.
 AC
 AA80548;

28-FEB-1996 (first entry)

Human glucagon like peptide (GLP-1).

Exendin-4; diabetes mellitus; hyperglycaemia;
 insulinotropic peptide; glucagon like peptide; GLP-1.

Homo sapiens.

US5424286-A.

13-JUN-1995.

24-MAY-1993; 93US-0066480.

24-MAY-1993; 93US-0066480.

(ENGJ/) ENG J.

Eng J;

WPI; 1995-262627/34.

Stimulating/inhibiting insulin release with exendin polypeptide(s) -
 for treating diabetes mellitus and preventing hyperglycaemia.

XX Disclosure; Columns 5-6; 17pp; English.
 PS
 XX
 XX AA80548 is the human glucagon like peptide (GLP-1), to which the

CC Heloderma horridum/suspectum exendin-3/-4 peptides are analogous.
 CC The exendin peptides are insulinotropic, and can therefore be used
 CC in the treatment of diabetes mellitus (types I or II), and for the
 CC prevention of hyperglycaemia.

Sequence 30 AA;

Query Match 94.3%; Score 133; DB 16; Length 30;
 Best Local Similarity 86.7%; Pred. No. 8.1e-15;
 Matches 26; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1 HXEGFTSDVSSYLXGQAAAXFIAMLVKGR 30
 1 HXEGFTSDVSSYLXGQAAKEFIAMLVKGR 30

AA898956
 ID AA898956 standard; peptide; 30 AA.
 AC
 AA898956;

15-JAN-1997 (first entry)

Target peptide (GLP1(7-36)) used in fusion protein construct.

Fusion protein construct; isolation; purification;

growth hormone releasing factor; glucagon-like peptide 1;
 parathyroid hormone; inclusion body; carbonic anhydrase.

Synthetic.

W09617942-A1.

13-JUN-1996.

07-DEC-1995; 95WO-US15800.

07-DEC-1994; 94US-0350530.

(BION-) BIONEERASKA INC.

De LA MOTTE RS, Henriksen DB, Holmquist B, Manning SD;
 Partridge BE, Stout JS, Wagner FW;

WPI; 1996-287186/29.

Isolation and purification of peptide(s) from fusion protein constructs
 PT - which include a carbonic anhydrase and a variable fused
 PT polypeptide

Claim 58; Page 50; 67pp; English.

A new method for the isolation and/or purification of a recombinant
 CC peptide employs a fusion protein construct (FPC) comprising a
 CC carbonic anhydrase and a variable fused polypeptide containing a
 CC target peptide. The method comprises precipitating either the FPC or
 CC a fragment of the FPC including the carbonic anhydrase. An
 CC alternative method of producing the peptide comprises expressing the
 CC FPC as part of an inclusion body. The target peptide of the FPC are
 CC derived from growth hormone releasing factor (GRF), glucagon-like
 CC peptide 1 (GLP1) or parathyroid hormone (PTH). This sequence
 CC corresponds to amino acids 7-36 of GLP1.

Sequence 30 AA;

Query Match 94.3%; Score 133; DB 17; Length 30;
 Best Local Similarity 86.7%; Pred. No. 8.1e-15;
 Matches 26; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1 HXEGFTSDVSYLXGQAXXFIAMLVKGR 30
 |||||
 DB 1 HAEGETSDVSYLXGQAKKEFIAMLVKGR 30

RESULT 9

AAW98975
 ID AAW98975 standard; Peptide: 30 AA.

AC AAW98975;

DT 03-DEC-1996 (first entry)

XX GLP1(7-35)-NH2.

DE GLP1: C-amide; C-amidated peptide; alpha-carboxamide;
 KW recombinant protein; fusion protein; transpeptidation.

XX Synthetic.

OS Key Location/Qualifiers

FT Modified-site 30 /note= "C-terminal amide"

XX W09617941-A2.

PN 13-JUN-1996.

XX 07-DEC-1995; 95WO-US15799.

PF 07-DEC-1994; 94US-0350528.

PR (BION-) BIONEERASKA INC.

XX Heriksen DB, Holmquist B, Patridge BE, Stout JS;

PI Wagner FW;

XX WPI; 1996-287185/29.

DR Production of C-terminal alpha-carboxamidated peptide(s) - by

PT cleavage and transpeptidation of recombinant multicopy peptide(s) or

FT fusion constructs

XX Example 16; Page 69; 93pp; English.

PS Amidated recombinant GLP1(7-36)-NH2 (AAW98975) may be prep'd. from

CC a recombinant multicopy fusion peptide by cleavage, transamidation

CC and photochemical rearrangement. A DNA construct is formed by

CC joining 4 copies of the coding sequence for GLP1(7-36)-Met

CC (AAW98976) and a linker peptide including a thrombin cleavage site.

CC Expression in E. coli, followed by thrombin and CMR digestion yields

CC GLP1(7-36)-Hse (AAW98977), which is subjected to transamidation and

CC UV irradiation to yield GLP1(7-36)-NH2. The amidated peptide may also

CC be produced via GLP1(7-35)-Met (AAW98978) using a transpeptidation

CC reaction.

XX SQ Sequence 30 AA;

XX Query Match 94.3%; Score 133; DB 17; Length 30;

XX Best Local Similarity 86.7%; Pred. No. 8.1e-15;

XX Matches 26; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

XX 01-OCT-1997 (first entry)

XX Glucagon-like peptide-1(7-36).

XX Glucagon-like peptide-1(7-36); GLP-1 (7-36); insulin secretagogue;

XX Insulinotropic hormone; type II diabetes mellitus; therapy.

XX Rattus sp.

XX US5614492-A.

XX 25-MAR-1997.

XX 05-MAY-1986; 86US-0859928.

XX 05-SEP-1991; 91US-0756215.

XX 05-MAY-1986; 86US-0859928.

XX 26-JAN-1988; 88US-0148517.

XX 01-JUN-1990; 90US-0532111.

XX 23-NOV-1993; 93US-0156800.

XX (GENO) GEN HOSPITAL CORP.

XX Habener JF;

XX WPI; 1997-201513/18.

XX Glucagon-like peptide-1 fragment comprising amino acids 7-36 -

XX useful for enhancing insulin production in pancreatic islet cells,

XX especially for treating type II diabetes mellitus.

XX Claim 1; Column 34; 37pp; English.

XX Glucagon-like peptide-1 (7-36) (AAW16383) comprises amino acid

XX residues 7-36 of rat glucagon-like peptide-1 (GLP-1) (see also

XX AAW16384). It is naturally produced from GLP-1 in the intestine

XX and to a lesser extent in the pancreas. GLP-1(7-36) has

XX insulinotropic activity, being able to stimulate the synthesis

XX and secretion of insulin from the pancreas. It can be produced

XX by chemical synthesis or by proteolytic digestion of GLP-1 for use

XX as an insulin secretagogue or for the treatment of type II diabetes

XX mellitus.

XX SQ Sequence 30 AA;

XX Query Match 94.3%; Score 133; DB 18; Length 30;

XX Best Local Similarity 86.7%; Pred. No. 8.1e-15;

XX Matches 26; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

XX QY 1 HXEGFTSDVSYLXGQAXXFIAMLVKGR 30

XX 1 HAEGETSDVSYLXGQAKKEFIAMLVKGR 30

XX DB 1 HAEGETSDVSYLXGQAKKEFIAMLVKGR 30

RESULT 11

AAW29555

ID AAW29555 standard; peptide: 30 AA.

AC AAW29555;

DT 02-FEB-1999 (first entry)

XX Thr-8 GLP-1(7-36)-NH2, a new glucagon-like peptide-1 analogue.

XX Glucagon-like peptide-1; GLP-1; analogue; diabetes mellitus; insulin.

XX Synthetic.

OS Key Location/Qualifiers

FT Modified-site 30 /note= "Arg-NH2"

XX

PN W09843658-A1.
 PD 08-OCT-1998.
 PF 25-MAR-1998; 98WO-US05945.
 PR 31-MAR-1997; 97US-0041167.
 PA (ELIL) LILLY & CO ELI.
 PI Hoffmann JA;
 DR WPI; 1998-568263/48.
 PT New glucagon-like peptides for stimulating insulin secretion - have
 PT long-lasting action without risk of inducing hypoglycaemia, useful
 PT for treatment of diabetes
 PS Claim 8; Page 23; 26pp; English.
 CC The sequence represents a specifically claimed example of new
 CC GLP-1 (7-37) analogues (GLP = glucagon-like peptide) which stimulate
 CC insulin release and so are useful for treating diabetes mellitus.
 CC The analogues have a longer-lasting action than known GLP-1 peptides
 CC (they are more resistant to peptidases) and can provide overnight
 CC glycaemic control without the risk of inducing hypoglycaemia.
 CC (N.B. This sequence is not shown explicitly in the patent but was
 CC constructed using the generic sequence of AAW29551 as a template.)
 SQ Sequence 30 AA;
 Query Match 94.3%; Score 133; DB 19; Length 30;
 Best Local Similarity 86.7%; Pred. No. 8.1e-15;
 Matches 26; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
 Oy 1 HXEGFTSDVSSYLYGQAAXXFIAMLYKGR 30
 Db 1 HTEGFTSDVSSYLEGQAAXFIAMLYKGR 30
 RESULT 12
 AAW63288 standard; peptide; 30 AA.
 ID AAW63288;
 AC AAW63288;
 DT 29-SEP-1998 (first entry)
 DE Glucagon-like peptide-1 (7-36) amide.
 DE Glucagon-like peptide; obesity.
 KW GLP-1; glucagon-like peptide; obesity.
 OS Homo sapiens.
 OS Homo sapiens.
 FH Key Location/Qualifiers
 FT Modified-site 30 /note="C-terminal amide"
 FT Modified-site 30 /note="C-terminal amide"
 PN W09819698-A1.
 PD 14-MAY-1998.
 PF 04-NOV-1997; 97WO-US20114.
 PR 30-OCT-1997; 97US-0961405.
 PR 05-NOV-1996; 96US-0030213.
 PA (ELIL) LILLY & CO ELI.
 PI DiMarchi RD, Efendic S;
 DR WPI; 1998-286595/25.

PT Use of glucagon-like peptide-1 and analogues and derivatives - to
 PT reduce body weight, e.g., in treatment of obesity
 PS Claim 12; Page 18; 42pp; English.
 CC The patent describes a new method of reducing body weight which
 CC comprises administration of a composition comprising: (i) glucagon-
 CC like peptide-1 (GLP-1); (ii) a GLP-1 analogue; (iii) a GLP-1 derivative;
 CC (iv) an agonist of the GLP-1 receptor; (v) an agonist of the GLP-1
 CC signal transduction cascade; (vi) a compound which stimulates synthesis
 CC of endogenous GLP-1; (vii) a compound that stimulates release of
 CC endogenous GLP-1; or (viii) a salt of a material described in (i)-(vii).
 CC The method may be used for treatment of obesity. The present sequence,
 CC GLP-1 (7-36) amide, represents a preferred GLP-1 compound which can be
 CC used in the method.
 SQ Sequence 30 AA;
 Query Match 94.3%; Score 133; DB 19; Length 30;
 Best Local Similarity 86.7%; Pred. No. 8.1e-15;
 Matches 26; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
 Oy 1 HXEGFTSDVSSYLYGQAAXXFIAMLYKGR 30
 Db 1 HTEGFTSDVSSYLEGQAAXFIAMLYKGR 30
 RESULT 13
 AAW63182 standard; peptide; 30 AA.
 ID AAW63182;
 AC AAW63182;
 DT 16-SEP-1998 (first entry)
 DE GLP-1(7-36).
 DE GLP-1(7-36).
 KW Glucagon-like peptide-1; GLP-1; diabetes; lipophilic; tetradecanoyl;
 KW carboxynonadecanoyl; deoxychoyl; choleyl; lithocholoyl.
 OS Homo sapiens.
 OS Homo sapiens.
 FH Key Location/Qualifiers
 FT Modified-site 30 /note="optionally the C-terminal is in amide form"
 FT Modified-site 30 /note="optionally the C-terminal is in amide form"
 PN W09808871-A1.
 PD 05-MAR-1998.
 PF 22-AUG-1997; 97WO-DK00340.
 PR 20-DEC-1996; 96DK-0001470.
 PR 30-AUG-1996; 96DK-0000931.
 PR 08-NOV-1996; 96DK-0001259.
 PA (NOVO) NOVO-NORDISK AS.
 PI Knudsen LB, Nielsen PF, Sorensen PO;
 DR WPI; 1998-239721/21.
 PT Glucagon-like peptide-1 derivatives which have lipophilic
 PT substituent - exhibit protracted profiles of action relative to
 PT known glucagon-like peptide-1 compounds and are useful in
 PT treatment of diabetes
 PS Claim 36; Page -: 76pp; English.
 CC New derivatives of glucagon-like peptide-1 (GLP-1) and its fragments
 CC and their analogues are disclosed in which at least one amino acid
 CC residue of the parent peptide has a lipophilic substituent attached
 CC to it. The GLP-1 fragment is preferably GLP-1(A-C) where A is 1-7 and

CC C is 35-45. The lipophilic substituent is typically tetradecanoyl,
 CC carboxyundecanoyl, deoxychoyl, choleyl or lithocholoyl, and it
 CC is attached e.g. to the epsilon-amino group of a lys residue in the
 CC peptide. The present sequence represents a preferred parent GLP-1
 CC fragment to which the lipophilic substituent is to be attached.
 CC GLP-1 and its analogues and fragments may be used in treatment of
 CC type 1 and type 2 diabetes. Prior art analogues exhibit a high
 CC clearance rate from the body, which limits their usefulness. The
 CC new lipophilically substituted compounds have a protracted profile
 CC of action compared with known analogues, e.g. GLP-1(7-37).
 CC (N.B. The present sequence is described by name in the patent
 CC specification but is not explicitly shown. It is deduced from the
 CC protein sequence shown in Swiss-Prot entry P01275 using information
 CC given in the patent.)
 CC
 XX SQ Sequence 30 AA:
 Query Match 94.3%; Score 133; DB 19; Length 30;
 Best Local Similarity 86.7%; Pred. No. 8.1e-15;
 Matches 26; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
 QY 1 HXEGFTSDVSSYLKGQAAXXFIAMLVKGR 30
 1 HXEGFTSDVSSYLKGQAAKEFIAMLVKGR 30
 DB 1 HXEGFTSDVSSYLKGQAAKEFIAMLVKGR 30
 RESULT 14
 AAM50906
 ID AAM50906 standard; peptide: 30 AA.
 XX
 AC AAM50906;
 DT 17-AUG-1998 (first entry)
 XX
 DE Glucagon-like peptide-1 analogue SEQ ID NO:5.
 XX
 KW Glucagon-like peptide-1; GLP-1 (7-37); GLP-1 analogue; surgical trauma;
 KW stress; hormonal response; insulin resistance; catabolic reaction;
 KW human; incretin hormone.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT Modified-site 30
 FT /note="amiated"
 XX
 WO9808873-A1.
 XX
 PD 05-MAR-1998.
 XX
 PF 26-AUG-1997; 97WO-US15042.
 XX
 PR 21-AUG-1997; 97US-0024982.
 PR 30-AUG-1996; 96US-0024982.
 XX
 PA (ELIL) LILLY & CO ELI.
 XX
 PI Efendic S;
 DR WPI: 1998-239722/21.
 XX
 PT Use of glucagon-like peptide-1 and analogues and their derivatives
 PT - to attenuate post-surgical catabolic changes, insulin resistance
 PT and hormonal responses to stress
 PS Claim 1; Page 13; 42pp; English.
 CC The present sequence represents a glucagon-like peptide-1 (GLP-1)
 CC analogue, which is used in the methods of the invention. The methods
 CC are: (1) for attenuating post-surgical catabolic changes and insulin
 CC resistance, comprising administering glucagon-like peptide-1 (GLP-1), a
 CC GLP-1 analogue, a GLP-1 derivative, or a salt of this compound; (2) for

CC attenuating post-surgical catabolic changes and hormonal responses to
 CC stress, comprising administering a compound which exerts insulinotropic
 CC activity by interacting with the same receptor (or receptors) with which
 CC GLP-1, GLP-1 analogues and GLP-1 derivatives interact in exerting their
 CC insulinotropic activity, and (3) for attenuating post-surgical catabolic
 CC changes and hormonal responses to stress, comprising administering a
 CC compound which enhances insulin sensitivity by interacting with the same
 CC receptor (or receptors) with which GLP-1, GLP-1 analogues and GLP-1
 CC derivatives interact to enhance insulin sensitivity. The processes are
 CC useful for improving recovery after surgery by preventing the catabolic
 CC reaction and insulin resistance caused by surgical trauma and
 CC exacerbated by pre-operative fasting. GLP-1's short half-life, and hence
 CC the need for continuous administration, are not disadvantages, as the
 CC patient is usually hospitalised before surgery, and fluids are
 CC continuously administered parenterally, before, during and after surgery.
 CC
 XX SQ Sequence 30 AA:
 Query Match 94.3%; Score 133; DB 19; Length 30;
 Best Local Similarity 86.7%; Pred. No. 8.1e-15;
 Matches 26; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
 QY 1 HXEGFTSDVSSYLKGQAAXXFIAMLVKGR 30
 1 HXEGFTSDVSSYLKGQAAKEFIAMLVKGR 30
 DB 1 HXEGFTSDVSSYLKGQAAKEFIAMLVKGR 30
 RESULT 15
 AA42935
 ID AA42935 standard; peptide: 30 AA.
 XX
 AC AA42935;
 DT 20-DEC-1999 (first entry)
 XX
 DE Glucagon-like peptide GLP-1 (7-36).
 XX
 KW Glucagon-like peptide; GLP-1; antidiabetic; anti-obesity;
 KW insulinotropic; appetite suppressant.
 XX
 OS Homo sapiens.
 OS
 PN WO9943707-A1.
 XX
 PD 02-SEP-1999.
 XX
 PF 25-FEB-1999; 99WO-DK00085.
 XX
 PR 27-FEB-1998; 98DK-0000263.
 PR 27-FEB-1998; 98DK-0000268.
 PR 08-APR-1998; 98DK-0000508.
 XX
 PA (NOVO) NOVO-NORDISK AS.
 XX
 PI Knudsen LB, Huusfeldt PO, Nielsen PF, Madsen K;
 DR WPI: 1999-540561/45.
 XX
 PT New N-modified peptide derivatives, useful for treating diabetes,
 PT insulin resistance and obesity
 PS Disclosure: Page 1; 62pp; English.
 CC New glucagon-like peptide-1 (GLP-1) derivatives are disclosed which
 CC comprise residues 7-45 of GLP-1 or a fragment thereof, preferably
 CC residues 7-36, 7-37 or 7-38 or their analogues, in which (a) a
 CC lipophilic substituent is attached to at least one amino acid and (b)
 CC the N-terminal is substituted with a group containing an optionally
 CC substituted 5- or 6-membered N-heterocycle, e.g. imidazolyl. The
 CC compounds stimulate secretion of insulin, suppress secretion of
 CC glucagon, suppress gastric motility and/or restore glucose compliance
 CC to beta-cells. They are used to treat insulin-dependent or non-insulin-
 CC dependent diabetes mellitus, insulin resistance and obesity. They have

Thu Feb 27 13:12:17 2003

us-09-091-605-1.rag

Page 8

CC a longer-lasting action than GLP-1 derivatives that lack the lipophilic
CC substituent. Some of them also exist as partially structured micelle-
CC like aggregates, so have improved solubility and stability. The present
CC sequence is a specifically preferred example of a GLP-1 analogue on
XX which the derivatives are based.

SQ Sequence 30 AA;

Query Match	94.3%	Score 133	DB 20	Length 30
Best Local Similarity	86.7%	Pred. No. 8.1e-15		
Matches 26	Conservative	0	Mismatches 4	Indels 0
				Gaps 0

```
QY      1 HXEGFTSDVSSYLXGQAAXXFIAWLVKGR   30
          | ||||| ||||| ||||| |||||
Db       1 HAEGFTSDVSSYLEGQAKEFIAWLVKGR   30
```

Search completed: February 13, 2003, 11:02:17
Job time : 36 secs

1

GenCore version 5.1.4.p5.4578
Copyright (c) 1993 - 2003 CompuGen Ltd.

OW nucleic - nucleic search, using sw model

Run on: February 14, 2003, 07:10:09 ; Search time 174.5 Seconds
(without alignments)
1200.205 Million cell updates/sec

Title: US-09-091-605-4

Perfect score: 93
Sequence: 1 CATGTCGAAGGACCTTAC.....GCCTGCTGAAGGCCAGGA 93

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 2185239 seqs, 112599159 residues

Total number of hits satisfying chosen parameters: 4370478

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :

N.Geneseq_101002:*

- 1: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1980.DAT:*
- 2: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1981.DAT:*
- 3: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1982.DAT:*
- 4: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1983.DAT:*
- 5: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1984.DAT:*
- 6: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1985.DAT:*
- 7: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1986.DAT:*
- 8: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1987.DAT:*
- 9: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1988.DAT:*
- 10: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1989.DAT:*
- 11: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1990.DAT:*
- 12: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1991.DAT:*
- 13: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1992.DAT:*
- 14: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1993.DAT:*
- 15: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1994.DAT:*
- 16: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1995.DAT:*
- 17: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1996.DAT:*
- 18: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1997.DAT:*
- 19: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1998.DAT:*
- 20: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1999.DAT:*
- 21: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA2000.DAT:*
- 22: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA2001A.DAT:*
- 23: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA2001B.DAT:*
- 24: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA2002.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	93	100.0	93	18	AAAT77297
2	91.4	98.3	93	18	AAAT77296
3	91.4	98.3	96	13	AAO27605
4	91.4	98.3	955	18	AAAT75672
5	91.4	98.3	955	18	AAAT75673
6	91.4	98.3	955	21	AAAC55763
7	91.4	98.3	955	21	AAAC55765
8	91.4	98.3	2356	21	AAAC55775
9	91.4	98.3	3798	23	ABV25306

10	89.8	96.6	396	22	AAAF30989
11	86.4	92.9	626	24	AAO58859
12	81.8	88.0	895	18	AAAT75669
13	81.8	88.0	895	21	AAAC55762
14	81.8	88.0	1034	11	AAO06255
15	81.8	88.0	1034	18	AAAT73216
16	81.8	88.0	1034	18	AAZ20678
17	80.2	86.2	387	21	AAAS1462
18	80.2	86.2	390	21	AAAS1461
19	80.2	86.2	390	21	AAAS1464
20	80.2	86.2	393	21	AAAS1463
21	79.2	85.2	144	13	AAO27607
22	78.8	84.7	387	21	AAAS1466
23	74.8	80.4	95	22	AAFE29136
24	70.6	75.9	1576	13	AAO25339
25	66.4	71.4	627	20	AAAX9247
26	63.2	68.0	395	21	AAAS1465
27	63.2	68.0	398	21	AAAS1466
28	61.6	66.2	315	11	AAO04767
29	57	61.3	110	16	AAO91253
30	57	61.3	112	16	AAO91251
31	57	61.3	384	16	AAO91259
32	56.6	60.9	516	17	AAAT07347
33	55.4	59.6	279	17	AAAT34870
34	53.8	57.8	174	17	AAAT34869
35	53	57.0	1134	22	AAAC86599
36	53	57.0	1158	22	AAAC86600
37	49.8	53.5	78	21	AAZ57465
38	49.8	53.5	78	22	AAAS14247
39	47	50.5	108	16	AAO91252
40	45.8	49.2	112	16	AAO91254
41	37.8	40.6	65	24	ABN56946
42	37.4	40.2	57	18	AAV02282
43	35	37.6	70	22	AAAC86514
44	34.2	36.8	48	18	AAV02283
45	34	36.6	492	19	AAV33163

ALIGNMENTS

RESULT 1					
AAAT77297					
ID	AAAT77297	standard;	DNA;	93	bp.
XX	AAAT77297:				
AC	AAAT77297:				
XX					
DT	14-JAN-1998	(first entry)			
XX					
DE	DNA encoding glucagon-like peptide GLP-1(7-37)	Val8 analogue.			
XX					
KW	Diabetes; non-insulin dependent diabetes mellitus; NIDDM;				
KW	Insulin dependent diabetes mellitus; IDDM; gene therapy;				
KW	glucagon-like peptide; GLP; ss.				
XX					
OS	Synthetic.				
XX					
FT	key	Location/Qualifiers			
FT	mal_peptide	1..93			
FT		/tag= a			
FT		/product= Val8-GLP-1(7-37)			
XX					
PN	W09729180-A1.				
XX					
PD	14-AUG-1997.				
XX					
PF	06-FEB-1997;	97WO-US01978.			
XX					
PR	23-FEB-1996;	96GB-0003847.			
XX					
PR	06-FEB-1996;	96US-0012111.			
XX					
PA	(ELIL) LILLY & CO ELI.				
XX					

Prepro-somatostatin
Human colon cancer
Rat preproglucagon
Rat preproglucagon
Glucagon-like peptide
Rat prepro-glucagon
Preproglucagon cod
PCPB-RR-GLIP (R26)
PCPB-RVR-GLIP (R26)
PCPB-0AR-GLIP (R26)
PCPB-BGR-GLIP (R26)
PCPB-1(7-37)-hbrGF
PCPB-AM-GLIP (R26)
Glucagon-like peptide
Chicken glucagon c
Nucleotide sequenc
PCPB-0AR-V8-GLIP f
PCPB-LVPR-V8-GLIP
Sequence encoding
Glucagon like peptide
Glucagon like peptide
Glucagon like peptide
pAK623 fragment.
Plasmid pBN4:GLP(7
Plasmid pBN4:GLP(7
DNA encoding a Bac
DNA encoding a Bac
Kunitz protease in
Oligonucleotide 62
Glucagon like peptide
Glucagon like peptide
Mouse spliced tran
Oligonucleotide GL
PCR primer used to
Oligonucleotide GL
Heloderma suspectu

PI Borts TL, Broderick CL, Dimarchi RD, Grinnell BW;
PI Miller AR;

XX
XX
XX WPI: 1997-415336/38.

DR P-PSDB; AAMW24390.

XX
XX
XX Gene therapy of type I and type II diabetes - by in vivo expression
PT of glucagon like peptide GLP-1(7-37) analogue

PS
XX
XX Claim 8; Page 24; 31pp; English.

CC This DNA sequence encodes an analogue of a glucagon-like peptide
CC GLP-1(7-37). This peptide provides a means of delivering long term
CC amounts of a GLP-1(7-37)-based protein, which is useful in treating type
CC I and type II diabetes. A stable mammalian cell line, which is
CC immunologically isolated from the mammal's immune system, is transformed
CC with a vector expressing a protein of the above sequence. This
CC transformed cell line is then implanted into the individual needing
CC treatment. Once implanted, the GLP-1(7-37) analogue, in conjunction with
CC high serum glucose levels, causes pancreatic cells to produce insulin in
CC non-insulin dependent diabetes mellitus (NIDDM) and delays gastric
CC emptying in both NIDDM and insulin dependent diabetes mellitus (IDDM)
CC patients. An expression vector coding for a protein of the above
CC sequence can also be directly injected into the mammal, such that the
CC vector is incorporated into a cell and secretes the protein. This method
CC overcomes the problems of the short serum half life of GLP-1(7-37),
CC allowing delivery of effective long term amounts for diabetes treatment.

XX
XX Sequence 93 BP; 24 A; 16 C; 28 G; 25 T; 0 other;

Query Match 100.0%; Score 93; DB 18; Length 93;
Best Local Similarity 100.0%; Pred. No. 1.5e-23;

Matches 93; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CATGTTGAAGGACCTTACCAAGTATGATCTTATTTGGAAGGCCAAGTCCCAAG 60
DB 1 CATGTTGAAGGACCTTACCAAGTATGATCTTATTTGGAAGGCCAAGTCCCAAG 60

QY 61 GAATTCATTGCTTGGCTGGTGAAGGCCGAGA 93
DB 61 GAATTCATTGCTTGGCTGGTGAAGGCCGAGA 93

RESULT 2

AAQ77296
ID AAQ77296 standard; DNA; 93 BP.

XX
XX
XX AAT77296;

DT 14-JAN-1998 (first entry)

XX
XX
XX DNA encoding glucagon-like peptide GLP-1(7-37) Ala8 analogue.

XX
XX
XX Diabetes; non-insulin dependent diabetes mellitus; NIDDM;

KW insulin dependent diabetes mellitus; IDDM; gene therapy;

KW glucagon-like peptide; GLP; ss.

XX
XX
XX Synthetic.

OS
XX
XX Key Location/Qualifiers

FT met_peptide

FT 1..93

FT /tag= a

PN MO9729180-A1.

XX
XX
XX 14-AUG-1997.

PF 06-FEB-1997; 97MO-US01978.

XX
XX
XX 23-FEB-1996; 96GB-0003847.

PR 06-FEB-1996; 96US-0012111.

PA (ELIL) LILLY & CO ELIL.

PI Borts TL, Broderick CL, Dimarchi RD, Grinnell BW;

PI Miller AR;

XX
XX
XX WPI: 1997-415336/38.

DR P-PSDB; AAMW24389.

XX
XX
XX Gene therapy of type I and type II diabetes - by in vivo expression
PT of glucagon like peptide GLP-1(7-37) analogue

PS
XX
XX Claim 8; Page 24; 31pp; English.

CC This DNA sequence encodes an analogue of a glucagon-like peptide
CC GLP-1(7-37). This peptide provides a means of delivering long term
CC amounts of a GLP-1(7-37)-based protein, which is useful in treating type
CC I and type II diabetes. A stable mammalian cell line, which is
CC immunologically isolated from the mammal's immune system, is transformed
CC with a vector expressing a protein of the above sequence. This
CC transformed cell line is then implanted into the individual needing
CC treatment. Once implanted, the GLP-1(7-37) analogue, in conjunction with
CC high serum glucose levels, causes pancreatic cells to produce insulin in
CC non-insulin dependent diabetes mellitus (NIDDM) and delays gastric
CC emptying in both NIDDM and insulin dependent diabetes mellitus (IDDM)
CC patients. An expression vector coding for a protein of the above
CC sequence can also be directly injected into the mammal, such that the
CC vector is incorporated into a cell and secretes the protein. This method
CC overcomes the problems of the short serum half life of GLP-1(7-37),
CC allowing delivery of effective long term amounts for diabetes treatment.

XX
XX Sequence 93 BP; 24 A; 17 C; 28 G; 24 T; 0 other;

Query Match 98.3%; Score 91.4; DB 18; Length 93;
Best Local Similarity 98.9%; Pred. No. 5.4e-23;

Matches 92; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 CATGTTGAAGGACCTTACCAAGTATGATCTTATTTGGAAGGCCAAGTCCCAAG 60
DB 1 CATGTTGAAGGACCTTACCAAGTATGATCTTATTTGGAAGGCCAAGTCCCAAG 60

QY 61 GAATTCATTGCTTGGCTGGTGAAGGCCGAGA 93
DB 61 GAATTCATTGCTTGGCTGGTGAAGGCCGAGA 93

RESULT 3

AAQ27605
ID AAQ27605 standard; DNA; 96 BP.

XX
XX
XX AAQ27605;

DT 04-FEB-1993 (first entry)

XX
XX
XX DNA encoding glucagon-like peptide I (7-37).

XX
XX
XX Human parathyroid hormone production; osteoporosis; GLP-I (7-37);

KW hypoparathyroidism; hypertension; insulinotropin; ss.

XX
XX
XX Synthetic.

OS
XX
XX EP499990-A.

PN 26-AUG-1992.

XX
XX
XX 15-FEB-1992; 92EP-0102543.

PF 19-FEB-1991; 91JP-0024841.

XX
XX
XX 18-OCT-1991; 91JP-0271438.

PR 24-OCT-1991; 91JP-0277724.

XX
XX
XX (TAKE) TAKEDA CHEM IND LTD.

PA Fukuda T, Koyama N, Kuriyama M, Nishimura O;

```

XX      WPI: 1992-286114/35.
DR
XX      Cysteine-free peptide prodn., e.g. human parathyroid hormone
XX      deriv. - by culturing transformant to produce a fusion protein
XX      comprising the cysteine-free peptide fused to a cysteine at its
XX      N-terminus where cleavage can occur
XX
XX      Disclosure; Page 5; 60pp; English.
XX
XX      The DNA codes for glucagon-like peptide I (7-37) [GIP-1 (7-37)]
XX      (Insulinotropic). PTH (1-34), it may be used in a method of culturing
XX      a transformant to produce a fusion protein comprising a cysteine-free
XX      peptide fused to a cysteine at its N-terminus where cleavage can occur.
XX      This method can be used to produce peptides which can be used as a
XX      pharmaceutical or industry in general. See also AAQ27603-Q27622.
XX
XX      Sequence 96 BP; 24 A; 18 C; 29 G; 25 T; 0 other;
SQ
XX
XX      Query Match          98.3%; Score 91.4; DB 13; Length 96;
XX      Best Local Similarity 98.9%; Pred. No. 5.5e-23;
XX      Matches 92; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX      1 CATGTTGAAGGACCTTTACCAAGTATGATCTCTATTGGAAGGCCAAGCTGCCAAG 60
XX      ||| |||||||||||||||||||||||||||||||||||||||||||||||||||
XX      1 CATGCTGAAGGACCTTTACCAAGTATGATCTCTATTGGAAGGCCAAGCTGCCAAG 60
XX
XX      61 GAATTCATTGCTTGGCTGCTGTAAGAGCCGAGGA 93
XX      |||||||||||||||||||||||||||||||||||||||
XX      61 GAATTCATTGCTTGGCTGCTGTAAGAGCCGAGGA 93
XX
XX      Db
XX
XX      RESULT 4
XX      AAT75672
XX      ID AAT75672 standard; DNA; 955 BP.
XX
XX      AAT75672;
XX
XX      03-FEB-1998 (first entry)
XX
XX      Human preproglucagon cDNA.
XX
XX      Recombinant protein; expression; secretory cell line; human;
XX      glucagon; peptide hormone; amidation; insulinoma; RIN; rat;
XX      diabetes; gene therapy; ss.
XX
XX      Homo sapiens.
XX
XX      OS
XX      FH Key Location/Qualifiers
XX      FT CDS 27..569
XX      FT /*tag= a
XX
XX      WO9726321-A2.
XX
XX      24-JUL-1997.
XX
XX      17-JAN-1997; 97WO-US00761.
XX
XX      15-OCT-1996; 96US-0028427.
XX      19-JAN-1996; 96US-0589028.
XX
XX      (BETA-) BETAGENE INC.
XX      (TEXA) UNIV TEXAS SYSTEM.
XX
XX      Clark SA, Halban PA, Kruse F, McGarry D, Newgard CB;
XX      Northington KD, Quade C, Thigpen AE;
XX      WPI: 1997-385326/35.
XX      P-PSDB: AAM22080.
XX
XX      Recombinant cell engineered to provide amylin to a mammal - useful
XX      to treat e.g. angiogenesis, anorexia, obesity, hypertension,
XX      osteoporosis etc.
XX

```

```

XX      Example 10; Page 283-284; 336pp; English.
XX
XX      This cDNA sequence includes a coding sequence for human
XX      preproglucagon (see AAM22080). It was produced from pancreatic
XX      cDNA by PCR amplification (see AAT75670-71), and has been ligated
XX      into pNotI/77, generating pNotA77/h-glucagon. A mutated human
XX      preproglucagon cDNA (see AAT75673) has also been produced. Rat
XX      insulinoma RIN cell lines expressing preproglucagon demonstrated
XX      efficient amidation of a secreted, processed polypeptide. The
XX      invention provides methods for production of heterologous
XX      polypeptides using recombinantly engineered cell lines. Also
XX      described are methods of engineering cells for high level
XX      expression, methods of large-scale heterologous protein production,
XX      and methods for treatment of disease in vivo using viral delivery
XX      systems and recombinant cell lines.
XX
XX      Sequence 955 BP; 301 A; 181 C; 203 G; 270 T; 0 other;
SQ
XX
XX      Query Match          98.3%; Score 91.4; DB 18; Length 955;
XX      Best Local Similarity 98.9%; Pred. No. 1.1e-22;
XX      Matches 92; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX      1 CATGTTGAAGGACCTTTACCAAGTATGATCTCTATTGGAAGGCCAAGCTGCCAAG 60
XX      ||| |||||||||||||||||||||||||||||||||||||||||||||||||||
XX      318 CATGCTGAAGGACCTTTACCAAGTATGATCTCTATTGGAAGGCCAAGCTGCCAAG 377
XX
XX      61 GAATTCATTGCTTGGCTGCTGTAAGAGCCGAGGA 93
XX      |||||||||||||||||||||||||||||||||||||||
XX      378 GAATTCATTGCTTGGCTGCTGTAAGAGCCGAGGA 410
XX
XX      Db
XX
XX      RESULT 5
XX      AAT75673
XX      ID AAT75673 standard; DNA; 955 BP.
XX
XX      AAT75673;
XX
XX      03-FEB-1998 (first entry)
XX
XX      Human mutated preproglucagon cDNA.
XX
XX      Recombinant protein; expression; secretory cell line; human;
XX      glucagon; peptide hormone; amidation; insulinoma; RIN; rat;
XX      diabetes; gene therapy; ss.
XX
XX      Homo sapiens.
XX
XX      OS
XX      FH Key Location/Qualifiers
XX      FT CDS 27..569
XX      FT /*tag= a
XX      FT mutation 181
XX      FT /*tag= b
XX      FT /*note= "C at position 181 creates an Ala-52 codon"
XX      FT /*tag= b
XX      FT /*note= "T at position 204 creates an SpeI site"
XX
XX      WO9726321-A2.
XX
XX      24-JUL-1997.
XX
XX      17-JAN-1997; 97WO-US00761.
XX
XX      15-OCT-1996; 96US-0028427.
XX      19-JAN-1996; 96US-0589028.
XX
XX      (BETA-) BETAGENE INC.
XX      (TEXA) UNIV TEXAS SYSTEM.
XX
XX      Clark SA, Halban PA, Kruse F, McGarry D, Newgard CB;
XX      Northington KD, Quade C, Thigpen AE;
XX

```

XX WPI: 1997-385326/35.
 DR P-PSDB: AAM22081.
 XX
 PT Recombinant cell engineered to provide amylin to a mammal - useful
 PT to treat e.g. angiodenesis, anorexia, obesity, hypertension,
 XX osteoporosis etc.
 PS Example 10; Page 285-286; 336pp; English.
 XX
 CC This CDNA sequence includes a coding sequence for a mutated human
 CC preproglucagon (see AAM22081). It was produced from plasmid
 CC pN1A77/h.glucagon (see AAT756/2) using mutagenic primers. 2
 CC Mutations were created, one altering the native Arg-52 codon to an
 CC Ala codon, and one creating an SpeI site, with no change in the
 CC deduced amino acid sequence. The mutated sequence has been used
 CC to construct plasmid pN1A77/mut.glucagon. Rat insulinoma RIN cell
 CC lines expressing preproglucagon demonstrated efficient amideation of
 CC a secreted, processed polypeptide. The invention provides methods
 CC for production of heterologous polypeptides using recombinantly
 CC engineered cell lines. Also described are methods of engineering
 CC cells for high level expression, methods of large-scale
 CC heterologous protein production, and methods for treatment of
 CC disease in vivo using viral delivery systems and recombinant cell
 CC lines.
 XX
 SQ Sequence 955 BP; 302 A; 180 C; 202 G; 271 T; 0 other;
 Query Match 98.3%; Score 91.4; DB 18; Length 955;
 Best Local Similarity 98.9%; Pred. No. 1,1e-22;
 Matches 92; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 OY 1 CATGTTGAAGGACCTTTACAGTGTGTAAGTCTTATTGGAAGGCCAAGTGCACG 60
 DB 318 CATGCTGAAGGGACCTTTACAGTGTGTAAGTCTTATTGGAAGGCCAAGTGCACG 377
 OY 61 GAATTCATTGCTTGGCTGTGTAAGGCCGAGGA 93
 DB 378 GAATTCATTGCTTGGCTGTGTAAGGCCGAGGA 410
 RESULT 6
 AAC55763
 ID AAC55763 standard; cDNA; 955 BP.
 XX
 AC AAC55763;
 XX
 DT 17-JAN-2001 (first entry)
 XX
 DE Human preproglucagon encoding cDNA.
 XX
 KW Amylin; production; secretory cell; blood glucose level regulation;
 KW diabetes mellitus; hypoglycaemia; osteoporosis; Paget's disease;
 KW hypercalcaemia; obesity; hypertension; ss.
 XX
 OS Homo sapiens.
 XX
 PN US6110707-A.
 XX
 PD 29-AUG-2000.
 XX
 PF 17-JAN-1997; 97US-0784582.
 XX
 PR 11-OCT-1996; 96US-0028279.
 PR 19-JAN-1996; 96US-0589028.
 XX
 PA (TEXA) UNIV TEXAS SYSTEM.
 PA (BETA-) BETAGENE INC.
 XX
 PI Newgard CB, Halban P, Normington KD, Thigpen AE, Quade C;
 PI Kruse F, McGarry D, Clark SA;
 XX WPI: 2000-586352/55.
 DR

DR P-PSDB: AAB26774.
 XX
 PT Producing mammalian amylin, useful for regulating blood glucose and
 PT insulin levels, e.g. for treating diabetes mellitus or hypoglycaemia, by
 PT employing recombinantly engineered secretory cell lines -
 XX
 PS Example 10; Column 175-178; 136pp; English.
 XX
 CC This invention relates to a method for producing mammalian amylin. The
 CC method relies on the use of a recombinantly engineered secretory cell
 CC line. The method comprises:
 CC (a) providing a starting secretory cell that has a regulated secretory
 CC pathway;
 CC (b) introducing, into the starting secretory cell, an amylin-encoding
 CC gene operatively linked to a first promoter;
 CC (c) selecting a secretory cell of (b) that exhibits increased production
 CC of biologically active amylin as compared to the starting secretory
 CC cell; and (d) culturing the selected secretory cell.
 CC Amylin is an insulin modulator, and the method results in antidiabetic,
 CC hypotensive and osteopathic activity. The amylin produced are useful
 CC for regulating blood glucose levels, as well as in modulating the
 CC circulating levels of insulin in a mammal. The amylin produced may be
 CC used in treating diabetes mellitus, hypoglycaemia, osteoporosis, Paget's
 CC disease, hypercalcaemia, obesity, hypertension, or any other disorder
 CC requiring amylin regulation. The invention includes cDNA and protein
 CC sequences (AAC55760 and AAB26771) representing human amylin. Sequences
 CC AAC55776-C55681 and AAB26765-B26777 are used in examples of the method of
 CC the invention for the production of mammalian amylin.
 XX
 SQ Sequence 955 BP; 301 A; 181 C; 203 G; 270 T; 0 other;
 Query Match 98.3%; Score 91.4; DB 21; Length 955;
 Best Local Similarity 98.9%; Pred. No. 1,1e-22;
 Matches 92; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 OY 1 CATGTTGAAGGACCTTTACAGTGTGTAAGTCTTATTGGAAGGCCAAGTGCACG 60
 DB 318 CATGCTGAAGGGACCTTTACAGTGTGTAAGTCTTATTGGAAGGCCAAGTGCACG 377
 OY 61 GAATTCATTGCTTGGCTGTGTAAGGCCGAGGA 93
 DB 378 GAATTCATTGCTTGGCTGTGTAAGGCCGAGGA 410
 RESULT 7
 AAC55765
 ID AAC55765 standard; cDNA; 955 BP.
 XX
 AC AAC55765;
 XX
 DT 17-JAN-2001 (first entry)
 XX
 DE Mutant human preproglucagon cDNA.
 XX
 KW Amylin; production; secretory cell; blood glucose level regulation;
 KW diabetes mellitus; hypoglycaemia; osteoporosis; Paget's disease;
 KW hypercalcaemia; obesity; hypertension; ss.
 XX
 OS Homo sapiens.
 XX
 PN US6110707-A.
 XX
 PD 29-AUG-2000.
 XX
 PF 17-JAN-1997; 97US-0784582.
 XX
 PR 11-OCT-1996; 96US-0028279.
 PR 19-JAN-1996; 96US-0589028.
 XX
 PA (TEXA) UNIV TEXAS SYSTEM.
 PA (BETA-) BETAGENE INC.
 XX
 PI Newgard CB, Halban P, Normington KD, Thigpen AE, Quade C;
 PI Kruse F, McGarry D, Clark SA;
 XX WPI: 2000-586352/55.
 DR

PI Kruse F, McGarry D, Clark SA;
XX WPI: 2000-586352/55.
DR P-PSDB: AAB26775.

XX Producing mammalian amylin, useful for regulating blood glucose and
XX insulin levels, e.g. for treating diabetes mellitus or hypoglycemia, by
XX employing recombinantly engineered secretory cell lines -
XX Example 10; Column 179-180; 136pp; English.

XX This invention relates to a method for producing mammalian amylin. The
XX method relies on the use of a recombinantly engineered secretory cell
XX line. The method comprises:
XX (a) providing a starting secretory cell that has a regulated secretory
XX pathway;
XX (b) introducing, into the starting secretory cell, an amylin-encoding
XX gene operatively linked to a first promoter;
XX (c) selecting a secretory cell of (b) that exhibits increased production
XX of biologically active amylin as compared to the starting secretory
XX cell; and (d) culturing the selected secretory cell.
XX Amylin is an insulin modulator, and the method results in antidiabetic,
XX hypotensive and osteopathic activity. The amylin produced are useful
XX for regulating blood glucose levels, as well as in modulating the
XX circulating levels of insulin in a mammal. The amylin produced maybe
XX used in treating diabetes mellitus, hypoglycemia, osteoporosis, Paget's
XX disease, hypercalcaemia, obesity, hypertension, or any other disorder
XX requiring amylin regulation. The invention includes cDNA and protein
XX sequences (AAC55716 and AAB26771) representing human amylin. Sequences
XX CC AAC55716-C55681 and AAB26775-B26777 are used in examples of the method of
XX the invention for the production of mammalian amylin.
XX Sequence 955 BP; 302 A; 180 C; 202 G; 271 T; 0 other:

Query Match 98.3%; Score 91.4; DB 21; Length 955;
Best Local Similarity 98.9%; Pred. No. 1.1e-22;
Matches 92; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 CATGTTGAAGGACCTTTACAGTGAATGTTCTTATTGGAAGGCCAACCTGCCAAG 60
DB 318 CATGCTGAAGGACCTTTACAGTGAATGTTCTTATTGGAAGGCCAACCTGCCAAG 377
QY 61 GAATTCATGCTGCTGCTGTTGAAGGCCGAGGA 93
DB 378 GAATTCATGCTGCTGCTGTTGAAGGCCGAGGA 410

RESULT 8
AAC55775
ID AAC55775 standard; DNA: 2356 BP.

AC AAC55775;
AT 17-JAN-2001 (first entry)

XX Human growth hormone and mutated proglucagon fusion DNA sequence.
XX DE Amylin: production; secretory cell; blood glucose level regulation;
XX KW diabetes mellitus; hypoglycemia; osteoporosis; Paget's disease;
XX KW hypercalcaemia; obesity; hypertension; ss.

OS Homo sapiens.

PN US6110707-A.

PD 29-AUG-2000.

PF 17-JAN-1997; 97US-0784582.

PR 11-OCT-1996; 96US-0028279.

PA 19-JAN-1996; 96US-0589028.
(TEXA) UNIV TEXAS SYSTEM.

PA (BETA-) BETAGENE INC.

XX Newgard CB, Halban P, Normington KD, Thippen AE, Quaade C;
PI Kruse F, McGarry D, Clark SA;

XX WPI: 2000-586352/55.
DR P-PSDB: AAB26777.

XX Producing mammalian amylin, useful for regulating blood glucose and
XX insulin levels, e.g. for treating diabetes mellitus or hypoglycemia, by
XX employing recombinantly engineered secretory cell lines -
XX Example 12; Column 187-190; 136pp; English.

XX This invention relates to a method for producing mammalian amylin. The
XX method relies on the use of a recombinantly engineered secretory cell
XX line. The method comprises:
XX (a) providing a starting secretory cell that has a regulated secretory
XX pathway;
XX (b) introducing, into the starting secretory cell, an amylin-encoding
XX gene operatively linked to a first promoter;
XX (c) selecting a secretory cell of (b) that exhibits increased production
XX of biologically active amylin as compared to the starting secretory
XX cell; and (d) culturing the selected secretory cell.
XX Amylin is an insulin modulator, and the method results in antidiabetic,
XX hypotensive and osteopathic activity. The amylin produced are useful
XX for regulating blood glucose levels, as well as in modulating the
XX circulating levels of insulin in a mammal. The amylin produced maybe
XX used in treating diabetes mellitus, hypoglycemia, osteoporosis, Paget's
XX disease, hypercalcaemia, obesity, hypertension, or any other disorder
XX requiring amylin regulation. The invention includes cDNA and protein
XX sequences (AAC55716 and AAB26771) representing human amylin. Sequences
XX CC AAC55716-C55681 and AAB26775-B26777 are used in examples of the method of
XX the invention for the production of mammalian amylin.
XX Sequence 2356 BP; 614 A; 600 C; 581 G; 561 T; 0 other:

Query Match 98.3%; Score 91.4; DB 21; Length 2356;
Best Local Similarity 98.9%; Pred. No. 1.4e-22;
Matches 92; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 CATGTTGAAGGACCTTTACAGTGAATGTTCTTATTGGAAGGCCAACCTGCCAAG 60
DB 1704 CATGCTGAAGGACCTTTACAGTGAATGTTCTTATTGGAAGGCCAACCTGCCAAG 1763
QY 61 GAATTCATGCTGCTGCTGTTGAAGGCCGAGGA 93
DB 1764 GAATTCATGCTGCTGCTGTTGAAGGCCGAGGA 1796

RESULT 9
ABV25306
ID ABV25306 standard; cDNA: 3798 BP.

AC ABV25306;

AT 16-SEP-2002 (first entry)

XX Human prostate expression marker cDNA 25297.
XX DE Human: prostate cancer; cytostatic; carcinogen; pharmacodynamic marker;
XX KW pharmacogenomic marker; gene; ss.

OS Homo sapiens.

PN WO200160860-A2.

PD 23-AUG-2001.

PF 20-FEB-2001; 2001WO-US05171.

PR 17-FEB-2000; 2000US-183119P.

PA 16-MAR-2000; 2000US-189862P.

PR 25-MAY-2000; 2000US-207454P.
PR 09-JUN-2000; 2000US-211314P.
PR 18-JUL-2000; 2000US-219007P.
PR 13-DEC-2000; 2000US-255281P.
XX
PA (MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.
PI Schlegel R, Endege WO, Monahan JE;
XX
DR WPI: 2001-662795/76.
XX
PT Novel isolated nucleic acid molecule associated with cancerous state of
PT prostate cells and correlating with presence of prostate cancer, useful
XX for detecting presence of prostate cancer, stage of prostate cancer
PS
XX Claim 1: Page 4978-4979; 11750pp; English.
XX
CC The invention relates to an isolated nucleic acid molecule (I) comprising
CC a nucleotide sequence given in Tables 1-9 (ABV00010-ABV62213) of the
CC specification or its complement. (I) is useful for:
CC (a) assessing whether a patient is afflicted with prostate cancer;
CC (b) monitoring the progression of prostate cancer in a patient;
CC (c) assessing the efficacy of a test compound to inhibit prostate
CC cancer in a patient;
CC (d) assessing the efficacy of a therapy for inhibiting prostate cancer
CC in a patient;
CC (e) selecting a composition for inhibiting prostate cancer in a patient;
CC (f) assessing the prostate cell carcinogenic potential of a compound;
CC (g) determining whether prostate cancer has metastasized in a patient;
CC (h) assessing the aggressiveness or indolence of prostate cancer in a
CC patient;
CC (i) is also useful as a pharmacodynamic or pharmacogenomic marker.
SQ
Sequence 3798 BP; 1166 A; 563 C; 616 G; 1364 T; 89 other;
Query Match 98.3%; Score 91.4; DB 23; Length 3798;
Best Local Similarity 98.9%; Pred. No. 1.6e-22;
Matches 92; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1 CATGTTGAGGACCTTACCAAGATGATGTTATTGGAAGCCCAAGCTGCCAAG 60
DB 3411 CATCTGAGGAGGACCTTACCAAGATGATGTTATTGGAAGCCCAAGCTGCCAAG 3470
QY 61 GAATTCATTGCTTGCTGTGTAAGAGCCGAGGA 93
DB 3471 GAATTCATTGCTTGCTGTGTAAGAGCCGAGGA 3503
RESULT 10
AAF30989
ID AAF30989 standard; DNA; 396 BP.
XX
AC AAF30989;
XX
DT 23-JUL-2001 (first entry)
XX
DE Prepro-somatostatin/GLP-1 coding sequence of pXIT-39.
XX
KW Somatostatin; glucagon-like peptide 1; GLP-1; antidiabetic;
KW drug delivery; diabetes; gene therapy; pXIT-39; ss.
XX
OS Chimeric - Homo sapiens.
OS Chimeric - Synthetic.
XX
FH Key Location/Qualifiers
FT CDS 7..390
FT /tag= a
FT /product= "prepro-somatostatin/cleavage site/GLP-1
XX fusion"
XX
PN WO200136643-A1.
XX
PD 25-MAY-2001.

XX
PF 17-NOV-2000; 2000MO-US31634.
XX
XX
PR 19-NOV-1999; 99US-0166508.
XX
XX
PA (TRAN-) TRANSKARYOTIC THERAPIES INC.
XX
PI Treco DA, Concino MF, Duguay SJ;
XX
DR WPI: 2001-355636/37.
XX
PT New nucleic acid constructs useful for transforming cells useful as a
PT drug delivery vehicle
XX
XX
PS Example 1: Fig 3; 89pp; English.
XX
CC The present sequence is that of a DNA sequence encoding a
CC prepro-somatostatin-glucagon-like peptide 1 (GLP-1) fusion protein.
CC The coding region is flanked by a 5' BamHI site and a 3' XhoI site.
CC A multibasic cleavage site separates the prepro-somatostatin and
CC GLP-1 moieties of the fusion protein. The DNA sequence in plasmid
CC pXIT-39 was designed for the fusion protein. The DNA sequence of
CC GLP-1 (7-37) in human cells. This is an example of nucleic acid
CC constructs of the invention designed for the expression of small
CC peptides. The small peptides are especially therapeutic peptides
CC such as small hormones and antidiabetic peptides such as GLP-1,
CC exendin-4 and gastric inhibitory polypeptide. Claimed methods
CC of treating a subject having diabetes involve administering the
CC nucleic acid construct or a cell capable of expressing the small
CC peptide. Transfected primary or secondary cells or cell strains
CC have wide applicability as vehicles or delivery systems for
CC therapeutic proteins. By controlling the number of cells introduced
CC into an individual, one can control the amount of the protein
CC delivered to the body. In addition, in some cases, it is possible
CC to remove the transfected cells if there is no longer a need for
CC the product. Human fibroblasts transfected with pXIT-39 secreted
CC human GLP-1(7-37) and GLP-1(3-36) (see AAB82335-36).
XX
SQ
Sequence 396 BP; 80 A; 112 C; 121 G; 83 T; 0 other;
Query Match 96.6%; Score 89.8; DB 22; Length 396;
Best Local Similarity 97.8%; Pred. No. 3.1e-22;
Matches 91; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1 CATGTTGAGGACCTTACCAAGATGATGTTATTGGAAGCCCAAGCTGCCAAG 60
DB 286 CATGCTGAGGAGGACCTTACCAAGATGATGTTATTGGAAGCCCAAGCTGCCAAG 345
QY 61 GAATTCATTGCTTGCTGTGTAAGAGCCGAGGA 93
DB 346 GAATTCATTGCTTGCTGTGTAAGAGCCGAGGA 378
RESULT 11
ABO58859
ID ABO58859 standard; CDNA; 626 BP.
XX
AC ABO58859;
XX
DT 02-AUG-2002 (first entry)
XX
DE Human colon cancer related nucleotide sequence SEQ ID NO:2554.
XX
KW Human; colon cancer; cancer; tissue profiling; forensic; mapping;
KW genetic analysis; diagnostic; antisense therapy; gene; ss.
XX
OS Homo sapiens.
OS
XX
FH Homo sapiens.
FT CDS 11..490
FT /tag= a
FT /product= "Human colon cancer related nucleotide sequence SEQ ID NO:2554."
XX
PN WO200229086-A2.
XX
PD 11-APR-2002.
XX
PF 02-OCT-2001; 2001MO-US30732.


```

XX 02-OCT-2000; 2000US-23721P.
XX (FARB ) BAYER CORP.
XX Burgess C, Astle JH, Carroll E, Catino TJ, Dwivedi P, Molino GA;
XX Thiaqlingam A, Lewis ME;
XX WPI: 2002-426115/45.
XX New isolated nucleic acid that is differentially expressed in cancer
XX tissues useful for determining the presence of colon cancer in a cell
XX or tissue type, and in antisense therapy
XX Claim 1; Fig 1; 796pp; English.
XX ABO6306 to ABO60787 represent isolated nucleic acids (I) differentially
XX expressed in cancer tissues. ABB7893 to ABB7904 represent proteins
XX encoded by the ABO60776 to ABO60787 nucleic acid sequences. (I) can be
XX used in antisense therapy. An antibody immunoreactive with a polypeptide
XX encoded by (I) is useful for detecting cancer in a patient sample, and
XX for detecting the presence or absence of a polynucleotide encoded by a
XX nucleic acid which hybridizes to (I) in a cell. A probe/primer derived
XX from (I) can be used for determining the phenotype of cells in a sample
XX of cells from a patient. (I) is useful for determining the presence of
XX colon cancer in a cell or tissue type, for determining the presence or
XX state of other type of cancer, in antisense therapy, to generate
XX macroarrays on a solid surface, to identify a chromosome on which the
XX corresponding gene resides, and in tissue profiling, forensics, genetic
XX analysis, mapping and diagnostic applications. (I) can be used to raise
XX antibodies, and to screen for peptide analogues and antagonists.
XX
XX Sequence 626 BP; 170 A; 134 C; 143 G; 159 T; 20 other:
XX
XX Query Match 92.9%; Score 86.4; DB 24; Length 626;
XX Best Local Similarity 98.9%; Pred. No. 5.8e-21;
XX Matches 87; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 1 CATGTGAAGGACCTTACAGTGATGATGTTCTTATTGGAGGCCAAGCTGCCAAG 60
XX ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
XX Db 253 CATCTGAAGGACCTTACAGTGATGATGTTCTTATTGGAGGCCAAGCTGCCAAG 312
XX
XX QY 61 GAATTCATTCGCTGGCTGTGTAAGGCC 88
XX ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
XX Db 313 GAATTCATTCGCTGGCTGTGTAAGGCC 340
XX
XX RESULT 12
XX AAT75669
XX ID AAT75669 standard; DNA: 895 BP.
XX
XX AC AAT75669;
XX
XX DT 03-FEB-1998 (first entry)
XX
XX DE Rat preproglucagon cDNA.
XX
XX KW Recombinant protein; expression; secretory cell line; rat;
XX glucagon; peptide hormone; amidation; insulinoma; RIN; diabetes;
XX gene therapy; ss.
XX
XX OS Rattus sp.
XX
XX FH Key Location/Qualifiers
XX FT CDS 52..594
XX FT /tag= a
XX
XX PN M09726321-A2.
XX PD 24-JUL-1997.
XX
XX PF 17-JAN-1997; 97WO-US00761.

```

```

XX 15-OCT-1996; 96US-0028427.
XX 19-JAN-1996; 96US-0589028.
XX
XX (BETA-) BETAGENE INC.
XX (TEXA ) UNIV TEXAS SYSTEM.
XX
XX PA Clark SA, Halban PA, Kruse F, McGarry D, Newgard CB;
XX PI Northington KD, Quade C, Thigpen AE;
XX
XX WPI: 1997-385326/35.
XX P-PSDB: AAM22079.
XX
XX Recombinant cell engineered to provide amylin to a mammal - useful
XX to treat e.g. angiogenesis, anorexia, obesity, hypertension,
XX osteoporosis etc.
XX
XX Example 10; Page 281-282; 336pp; English.
XX
XX This cDNA sequence includes a coding sequence for rat
XX preproglucagon (see AAM22079). It was produced from pancreatic
XX cDNA by PCR amplification (see AAT75667-68), and has been ligated
XX into pNO1A/T7, generating pNO1A/T7/r. Glucagon. Rat insulinoma RIN
XX cell lines expressing preproglucagon demonstrated efficient
XX amilation of a secreted, processed polypeptide. The invention
XX provides methods for production of heterologous polypeptides using
XX recombinant cells for high level expression, methods of large-scale
XX engineering cells for protein production, and methods for treatment of
XX heterologous protein production, and methods for treatment of
XX disease in vivo using viral delivery systems and recombinant cell
XX lines.
XX
XX Sequence 895 BP; 266 A; 211 C; 200 G; 218 T; 0 other:
XX
XX Query Match 88.0%; Score 81.8; DB 18; Length 895;
XX Best Local Similarity 92.5%; Pred. No. 2.8e-19;
XX Matches 86; Conservative 0; Mismatches 7; Indels 0; Gaps 0;
XX
XX QY 1 CATGTGAAGGACCTTACAGTGATGATGTTCTTATTGGAGGCCAAGCTGCCAAG 60
XX ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
XX Db 343 CATCTGAAGGACCTTACAGTGATGATGTTCTTATTGGAGGCCAAGCTGCCAAG 402
XX
XX QY 61 GAATTCATTCGCTGGCTGTGTAAGGCCGAGGA 93
XX ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
XX Db 403 GAATTCATTCGCTGGCTGTGTAAGGCCGAGGA 435
XX
XX RESULT 13
XX AAC55762
XX ID AAC55762 standard; cDNA; 895 BP.
XX
XX AC AAC55762;
XX
XX DT 17-JAN-2001 (first entry)
XX
XX DE Rat preproglucagon encoding cDNA.
XX
XX KW Amylin; production; secretory cell; blood glucose level regulation;
XX diabetes mellitus; hypoglycaemia; osteoporosis; Paget's disease;
XX hypercalcaemia; obesity; hypertension; ss.
XX
XX OS Rattus sp.
XX
XX PN US6110707-A.
XX PD 29-AUG-2000.
XX
XX PF 17-JAN-1997; 97US-0784582.
XX
XX PR 11-OCT-1996; 96US-0028279.
XX PR 19-JAN-1996; 96US-0589028.
XX
XX PA (TEXA ) UNIV TEXAS SYSTEM.

```

PA (BETA-) BETAGENE INC.

PI Newgard CB, Halban P, Normington KD, Thigpen AE, Qunaad C;
PI Kruse F, McGarry D, Clark SA;
XX WPI; 2000-586352/55.
DR P-PSDB; AAB26773.

XX Producing mammalian amylin, useful for regulating blood glucose and
PT insulin levels, e.g. for treating diabetes mellitus or hypoglycemia, by
PT employing recombinantly engineered secretory cell lines -
XX

PS Example 10; Column 173-174; 136pp; English.

XX This invention relates to a method for producing mammalian amylin. The
CC method relies on the use of a recombinantly engineered secretory cell
CC line. The method comprises:
CC (a) providing a starting secretory cell that has a regulated secretory
CC pathway;
CC (b) introducing, into the starting secretory cell, an amylin-encoding
CC gene operatively linked to a first promoter;
CC (c) selecting a secretory cell of (b) that exhibits increased production
CC of biologically active amylin as compared to the starting secretory
CC cell; and (d) culturing the selected secretory cell.
CC Amylin is an insulin modulator, and the method results in antidiabetic,
CC hypotensive and osteopathic activity. The method results in antidiabetic,
CC for regulating blood glucose levels, as well as in modulating the
CC circulating levels of insulin in a mammal. The amylin produced are useful
CC in treating diabetes mellitus, hypoglycemia, osteoporosis, Paget's
CC disease, hypercalcaemia, obesity, hypertension, or any other disorder
CC requiring amylin regulation. The invention includes human amylin. Sequences
CC AAC55716-C55681 and AAB26773-82677 are used in examples of the method of
CC the invention for the production of mammalian amylin.
XX

SQ Sequence 895 BP; 266 A; 212 C; 199 G; 218 T; 0 other;

Query Match 88.0%; Score 81.8; DB 21; Length 895;
Best Local Similarity 92.5%; Pred. No. 2,8e-19;

Matches 86; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 1 CATGTGAAGGACCTTACCATGATGTTCTTATTGGAAGCCAGCTGCCAAG 60
DB 343 CATGCTGAAGGACCTTACCATGATGTTCTTATTGGAAGCCAGCTGCCAAG 60
QY 61 GAATTCATTGCTTGGCTGTGAAGCCGAGGA 93
DB 403 GAATTCATTGCTTGGCTGTGAAGCCGAGGA 435

RESULT 14

ID AA006255 standard; DNA; 1034 BP.

AC AA006255;

DT 29-JAN-1991 (first entry)

DE Glucagon-like peptide, GLP-1 (7-37).

KW Insulin; diabetes mellitus; insulinotropic; pancreatic beta cells.

OS Synthetic.

XX Key Location/Qualifiers

FT CDS 61..603

FT sig_peptide /*tag= a

FT 61..120

FT /*tag= b

PN W09011296-A.

PD 04-OCT-1990.

XX

PE 20-MAR-1989; 89WO-US01121.

PR 20-MAR-1989; 89WO-US01121.

XX (GENO-) GEN HOSPITAL CORP.

PI Habener JF;

XX WPI; 1990-320226/42.

PT New glucagon-like peptide (GLP-1) - having insulin
PT formation-stimulating activity and useful in treating diabetes
PT mellitus.

PS Claim 6; Page 39; 52pp; English.

XX The peptide has insulinotropic activity specifically for pancreatic
CC beta cells. The peptide is derived from glucagon which, after
CC synthesis is cleaved into three peptides: glucagon, glucagon-like
CC peptide 1 (GLP-1) and GLP-2. GLP-1 has 37 AAs in its unprocessed
CC form and is unable to mediate the induction of insulin biosynthesis.
CC It is, however, naturally converted to a 31 AA-long peptide having
CC AAs 7-37 of GLP-1. Preferred derivs. have an H2 gp at the
CC N-terminal and an OH, OM, or NR R' gp at the C-terminal where M = a
CC cation or lower alkyl gp, and R' = H or a lower alkyl gp.
CC The pathogenesis of maturity onset of diabetes mellitus and also in
CC therapy.
XX See also AAR07398.

SQ Sequence 1034 BP; 315 A; 238 C; 226 G; 255 T; 0 other;

Query Match 88.0%; Score 81.8; DB 11; Length 1034;
Best Local Similarity 92.5%; Pred. No. 2,9e-19;

Matches 86; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 1 CATGTGAAGGACCTTACCATGATGTTCTTATTGGAAGCCAGCTGCCAAG 60
DB 352 CATGCTGAAGGACCTTACCATGATGTTCTTATTGGAAGCCAGCTGCCAAG 60
QY 61 GAATTCATTGCTTGGCTGTGAAGCCGAGGA 93
DB 412 GAATTCATTGCTTGGCTGTGAAGCCGAGGA 444

RESULT 15

ID AAT73216 standard; DNA; 1034 BP.

AC AAT73216;

DT 01-OCT-1997 (first entry)

DE Rat prepro-glucagon DNA.

KW Glucagon-like peptide-1(7-36); GLP-1; insulin secretagogue;
KW insulinotropic hormone; type II diabetes mellitus; therapy; ss.

OS Ratus sp.

OS

XX

XX

XX

XX

XX

XX

XX

XX

Key Location/Qualifiers

FT CDS 61..603

FT sig_peptide /*tag= a

FT 61..120

FT mat_peptide /*tag= b

FT 121..600

FT /*tag= c

PN US5614492-A.

PD 25-MAR-1997.

```

PF 05-MAY-1986; 86US-0859928.
XX
PR 05-SEP-1991; 91US-0756215.
PR 05-MAY-1986; 86US-0859928.
PR 26-JAN-1988; 88US-0148517.
PR 01-JUN-1990; 90US-0532111.
PR 23-NOV-1993; 93US-0156800.
XX
PA (GENO ) GEN HOSPITAL CORP.
XX
PI Habener JF;
XX
DR WPI: 1997-201513/18.
DR P-PSDB: AAW16384.
XX
XX Glucagon-like peptide-1 fragment comprising amino acids 7-36 -
PT useful for enhancing insulin production in pancreatic islet cells,
PT especially for treating type II diabetes mellitus
XX
PS Disclosure: Fig 1-1A: 37pp: English.
XX
CC A DNA molecule (AA73216) codes for rat preproglucagon (AAW16384), a
CC polypeptide that is processed by proteolytic cleavage to glucagon,
CC glucagon-like peptide-1 (GLP-1) and GLP-2. A peptide fragment
CC of GLP-1, GLP-1(7-36) (see also AAW16363), has been shown to possess
CC hormonal activity and can be used as an insulin secretagogue and
CC for the treatment of type II diabetes mellitus.
XX
SQ Sequence 1034 BP; 316 A; 237 C; 226 G; 255 T; 0 other;

```

Query Match 88.0%; Score 81.8; DB 18; Length 1034;
 Best Local Similarity 92.5%; Pred. No. 2.9e-19;
 Matches 86; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

```

QY 1 CATGTTGAAGGAGCCTTTACAGATGTAAGTCTTATTGGAAGCCAGCTGCCAAG 60
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 352 CATGCTGAAGGAGCCTTTACAGATGTAAGTCTTATTGGAAGCCAGCTGCCAAG 411
QY 61 GAATTCATTGCTTGCTGGTGAAGGCCGAGGA 93
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 412 GAATTCATTGCTTGCTGGTGAAGGCCGAGGA 444

```

Search completed: February 14, 2003, 08:03:04
 Job time : 175.5 secs

GenCore version 5.1.4-p5.4578
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: February 14, 2003, 07:55:04 ; Search time 48 Seconds
(without alignments)
594.186 Million cell updates/sec

Title: US-09-091-605-4

Perfect score: 93

Sequence: 1 CATGTTGAAGGACCTTTAC.....GGCTGTGAAGGCCGANGCA 93

Scoring table: IDENTITY-NUC
Gapop 10.0 , Gapext 1.0

Searched: 441362 seqs, 153338381 residues

Total number of hits satisfying chosen parameters: 882724

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 08
Maximum Match 1008
Listing first 45 summaries

Database :
1: /cgn2_6/prodata/1/ina/5A.COMB.seq:*
2: /cgn2_6/prodata/1/ina/5B.COMB.seq:*
3: /cgn2_6/prodata/1/ina/5A.COMB.seq:*
4: /cgn2_6/prodata/1/ina/5B.COMB.seq:*
5: /cgn2_6/prodata/1/ina/PCTUS.COMB.seq:*
6: /cgn2_6/prodata/1/ina/backfiles1.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	91.4	98.3	528	2	US-08-835-231-8
2	91.4	98.3	528	4	US-09-108-661-8
3	91.4	98.3	955	3	US-08-784-582-57
4	91.4	98.3	955	3	US-08-784-582-60
5	91.4	98.3	2356	3	US-08-835-231-7
6	89.8	96.6	528	2	US-08-784-582-72
7	89.8	96.6	528	4	US-09-108-661-7
8	81.8	88.0	895	3	US-08-784-582-55
9	79.2	85.2	144	4	US-08-835-231-17
10	79.2	85.2	144	4	US-09-108-661-17
11	49.8	53.5	78	2	US-08-829-876-22
12	49.8	53.5	78	2	US-09-234-874A-22
13	37.4	40.2	57	2	US-08-811-028-43
14	34.2	36.8	48	2	US-08-811-028-44
15	32.8	35.3	53	2	US-08-829-876-24
16	30.6	32.9	73	4	US-08-829-876-24
17	30.6	32.9	73	4	US-09-234-874A-24
18	29.4	31.6	52	2	US-08-829-876-23
19	29.4	31.6	52	2	US-09-234-874A-23
20	28	30.1	2409	4	US-08-392-828C-1
21	28	30.1	2409	3	US-09-330-945-1
22	27.8	29.9	5558	4	US-08-961-527-103
23	26.2	28.2	36	2	US-08-811-028-45
24	25.8	27.7	144	4	US-08-835-231-17
25	25.8	27.7	144	4	US-09-108-661-17
26	25.4	27.3	3416	3	US-08-701-240-3
27	25.4	27.3	3416	3	US-09-138-236-3

28	25	26.9	725	4	US-09-221-017B-198	Sequence 198, Appl
29	24.8	26.7	16998	4	US-09-676-610B-24	Sequence 24, Appl
30	24.2	26.0	516	1	US-08-532-828B-13	Sequence 13, Appl
31	24.2	26.0	1263	1	US-08-532-828B-11	Sequence 11, Appl
32	24.2	26.0	1643	1	US-08-532-828B-1	Sequence 1, Appl
33	24.2	26.0	1643	1	US-08-532-828B-7	Sequence 7, Appl
34	24.2	26.0	1643	1	US-08-532-828B-9	Sequence 9, Appl
35	24.2	26.0	1643	1	US-08-700-359-8	Sequence 8, Appl
36	24.2	26.0	1643	1	US-08-700-359-10	Sequence 10, Appl
37	24.2	26.0	1643	1	US-08-674-168-21	Sequence 21, Appl
38	24.2	26.0	1643	2	US-08-596-366-5	Sequence 5, Appl
39	24.2	26.0	1643	2	US-08-596-366-7	Sequence 7, Appl
40	24.2	26.0	1643	2	US-08-967-104-5	Sequence 5, Appl
41	24.2	26.0	1643	2	US-08-967-104-7	Sequence 7, Appl
42	24.2	26.0	1643	2	US-08-985-908-3	Sequence 3, Appl
43	24.2	26.0	1643	3	US-08-985-908-4	Sequence 4, Appl
44	24.2	26.0	1643	3	US-08-985-908-6	Sequence 6, Appl
45	24.2	26.0	1643	3	US-08-985-908-6	Sequence 6, Appl

ALIGNMENTS

RESULT 1
US-08-835-231-8
Sequence 8, Application US/08835231
Patent No. 5861284
GENERAL INFORMATION:
APPLICANT: NISHIMURA, Osamu
APPLICANT: KURIYAMA, Masato
APPLICANT: KOYAMA, No. 5861284yuyuki
APPLICANT: FUKUDA, Tsunehiko
TITLE OF INVENTION: METHOD FOR PRODUCING A BIOLOGICALLY
TITLE OF INVENTION: ACTIVE RECOMBINANT CYSTEINE-FREE
NUMBER OF SEQUENCES: 37
CORRESPONDENCE ADDRESSES:
ADDRESSEE: DIKE, BRONSTEIN, ROBERTS & CUSHMAN, LLP
STREET: 130 WATER STREET
CITY: BOSTON
STATE: MA
COUNTRY: USA
ZIP: 02109
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FASTSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/835,231
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/350,709
FILING DATE: 07-DEC-1994
APPLICATION NUMBER: 07/838,857
FILING DATE: 18-FEB-1992
APPLICATION NUMBER: JP 024841
FILING DATE: 19-FEB-1991
APPLICATION NUMBER: JP 0271438
FILING DATE: 18-OCT-1991
ATTORNEY/AGENT INFORMATION:
NAME: DAVID, RESNICK S
REGISTRATION NUMBER: 34,235
REFERENCE/DOCKET NUMBER: 41614-FWC
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617-523-3400
TELEFAX: 617-523-6440
TELEX: 200291 STRE
INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 528 base pairs
TYPE: nucleic acid
STRANDEDNESS: double

TOPOLOGY: linear
MOLECULE TYPE: Synthetic DNA
HYPOTHETICAL: NO
ANTI-SENSE: NO
FRAGMENT TYPE:
ORIGINAL SOURCE:
ORGANISM: Synthetic DNA
US-08-835-231-8

Query Match 98.3%; Score 91.4; DB 2; Length 528;
Best Local Similarity 98.9%; Pred. No. 3.6e-25;
Matches 92; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1 CATGTTGAAGGAGACCTTTACCACTGATGTAAGTTCTTATTGGAAAGCCCAAGTCCCAAG 60
DB 1 CATGCTGAAGGAGACCTTTACCACTGATGTAAGTTCTTATTGGAAAGCCCAAGTCCCAAG 60
OY 61 GAATTCATTGCTTGGCTGGTGGTAAGGCCGAGGA 93
DB 61 GAATTCATTGCTTGGCTGGTGGTAAGGCCGAGGA 93

RESULT 2

US-09-108-661-8
Sequence 8, Application US/09108661
Patent No. 6287806

GENERAL INFORMATION:

APPLICANT: NISHIMURA, Osamu
APPLICANT: KURIYAMA, Masato
APPLICANT: KOYAMA, No. 6287806uyuk1
APPLICANT: FUKUDA, Tsunehiko
TITLE OF INVENTION: METHOD FOR PRODUCING A BIOLOGICALLY
ACTIVE RECOMBINANT CYSTEINE-FREE
NUMBER OF SEQUENCES: 37
CORRESPONDENCE ADDRESS:

ADDRESSEE: DIKE, BRONSTEIN, ROBERTS & CUSHMAN, LLP
STREET: 130 WATER STREET
CITY: BOSTON
STATE: MA
COUNTRY: USA
ZIP: 02109

COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/108,661
FILING DATE:

CLASSIFICATION: 435

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/350,709
FILING DATE: 07-DEC-1994
APPLICATION NUMBER: 07/838,857
FILING DATE: 18-FEB-1992
APPLICATION NUMBER: JP 024841
FILING DATE: 19-FEB-1991
APPLICATION NUMBER: JP 0271438
FILING DATE: 18-OCT-1991
ATTORNEY/AGENT INFORMATION:

NAME: DAVID, RESNICK S
REGISTRATION NUMBER: 34,235
REFERENCE/DOCKET NUMBER: 41614-FWC
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617-523-3400
TELEFAX: 617-523-6440
TELEX: 200291 STRE

INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 528 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear

MOLECULE TYPE: Synthetic DNA
HYPOTHETICAL: NO
ANTI-SENSE: NO
FRAGMENT TYPE:
ORIGINAL SOURCE:
ORGANISM: Synthetic DNA
US-09-108-661-8

Query Match 98.3%; Score 91.4; DB 4; Length 528;
Best Local Similarity 98.9%; Pred. No. 3.6e-25;
Matches 92; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1 CATGTTGAAGGAGACCTTTACCACTGATGTAAGTTCTTATTGGAAAGCCCAAGTCCCAAG 60
DB 1 CATGCTGAAGGAGACCTTTACCACTGATGTAAGTTCTTATTGGAAAGCCCAAGTCCCAAG 60
OY 61 GAATTCATTGCTTGGCTGGTGGTAAGGCCGAGGA 93
DB 61 GAATTCATTGCTTGGCTGGTGGTAAGGCCGAGGA 93

RESULT 3

US-08-784-582-57
Sequence 57, Application US/08784582
Patent No. 6110707

GENERAL INFORMATION:

APPLICANT: Newgard, Christopher B.
APPLICANT: Halban, Philippe A.
APPLICANT: No. 6110707mnglon, Karl D.
APPLICANT: Clark, Samuel A.
APPLICANT: Thigpen, Anice E.
APPLICANT: Quade, Christian
APPLICANT: Kruse, Fred
APPLICANT: McGarry, Dennis
TITLE OF INVENTION: RECOMBINANT EXPRESSION OF PROTEINS FROM
NUMBER OF SEQUENCES: 79
CORRESPONDENCE ADDRESS:

ADDRESSEE: Arnold, White & Durkee
STREET: P.O. Box 4433
CITY: Houston
STATE: Texas
COUNTRY: USA
ZIP: 77210

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/784,582
FILING DATE: Concurrently Herewith
CLASSIFICATION: 435

PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 60/028,427
FILING DATE: 15-OCT-1996
APPLICATION NUMBER: US 08/589,028
FILING DATE: 19-JAN-1996
ATTORNEY/AGENT INFORMATION:

NAME: Highlander, Steven L.
REGISTRATION NUMBER: 37,642
REFERENCE/DOCKET NUMBER: UTS2,514
TELECOMMUNICATION INFORMATION:
TELEPHONE: 512/418-3000
TELEFAX: 512/474-7577

INFORMATION FOR SEQ ID NO: 57:
SEQUENCE CHARACTERISTICS:
LENGTH: 955 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-784-582-57

RESULT 6

US-08-835-231-7
Sequence 7, Application us/08835231
Patent No. 5861284
GENERAL INFORMATION:
APPLICANT: NISHIMURA, Osamu
APPLICANT: KURIYAMA, Masato
APPLICANT: KOTAWA, No. 5861284uyuk1
APPLICANT: FUKUDA, Tsunehiko
TITLE OF INVENTION: METHOD FOR PRODUCING A BIOLOGICALLY
NUMBER OF SEQUENCES: ACTIVE RECOMBINANT CYSTEINE-FREE
CORRESPONDENCE ADDRESS: 37
ADDRESSEE: DIKE, BRONSTEIN, ROBERTS & CUSHMAN, LLP
STREET: 130 WATER STREET
CITY: BOSTON
STATE: MA
COUNTRY: USA
ZIP: 02109
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FASTSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/835,231
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/350,709
FILING DATE: 07-DEC-1994
APPLICATION NUMBER: 07/838,857
FILING DATE: 18-FEB-1992
APPLICATION NUMBER: JP 024841
FILING DATE: 19-FEB-1991
APPLICATION NUMBER: JP 0271438
FILING DATE: 18-OCT-1991
ATTORNEY/AGENT INFORMATION:
NAME: DAVID, RESNICK S
REGISTRATION NUMBER: 34,235
REFERENCE/DOCKET NUMBER: 41614-FWC
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617-523-3400
TELEFAX: 617-523-6440
TELEX: 200291 STRE
INFORMATION FOR SEQ ID NO: 7:
SEQUENCE CHARACTERISTICS:
LENGTH: 528 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: Synthetic DNA
HYPOTHETICAL: NO
ANTI-SENSE: NO
FRAGMENT TYPE:
ORIGINAL SOURCE:
ORGANISM: Synthetic DNA
US-08-835-231-7

Query Match 96.6%; Score 89.8; DB 2; Length 528;
Best Local Similarity 97.8%; Pred. No. 1,4e-24;

Matches 91; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 1 CATGTTGAAGGACCTTTACAGTGATGTAAGTTCTTATTGGAGGCCAAGCTGCCAAG 60
DB 1 CATGCTGAAGGACCTTTACAGTGATGTAAGTTCTTATTGGAGGCCAAGCTGCCAAG 60
OY 61 GAATTCATTCGCTGGCTGGTGAAGGCCGAGGA 93
DB 61 GAATTCATTCGCTGGCTGGTGAAGGCCGAGGA 93

RESULT 7

US-09-108-661-7
Sequence 7, Application us/09108661
Patent No. 6287806
GENERAL INFORMATION:
APPLICANT: NISHIMURA, Osamu
APPLICANT: KURIYAMA, Masato
APPLICANT: KOTAWA, No. 6287806uyuk1
APPLICANT: FUKUDA, Tsunehiko
TITLE OF INVENTION: METHOD FOR PRODUCING A BIOLOGICALLY
NUMBER OF SEQUENCES: ACTIVE RECOMBINANT CYSTEINE-FREE
CORRESPONDENCE ADDRESS: 37
ADDRESSEE: DIKE, BRONSTEIN, ROBERTS & CUSHMAN, LLP
STREET: 130 WATER STREET
CITY: BOSTON
STATE: MA
COUNTRY: USA
ZIP: 02109
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FASTSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/108,661
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/350,709
FILING DATE: 07-DEC-1994
APPLICATION NUMBER: 07/838,857
FILING DATE: 18-FEB-1992
APPLICATION NUMBER: JP 024841
FILING DATE: 19-FEB-1991
APPLICATION NUMBER: JP 0271438
FILING DATE: 18-OCT-1991
ATTORNEY/AGENT INFORMATION:
NAME: DAVID, RESNICK S
REGISTRATION NUMBER: 34,235
REFERENCE/DOCKET NUMBER: 41614-FWC
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617-523-3400
TELEFAX: 617-523-6440
TELEX: 200291 STRE
INFORMATION FOR SEQ ID NO: 7:
SEQUENCE CHARACTERISTICS:
LENGTH: 528 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: Synthetic DNA
HYPOTHETICAL: NO
ANTI-SENSE: NO
FRAGMENT TYPE:
ORIGINAL SOURCE:
ORGANISM: Synthetic DNA
US-09-108-661-7

Query Match 96.6%; Score 89.8; DB 4; Length 528;
Best Local Similarity 97.8%; Pred. No. 1,4e-24;

Matches 91; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 1 CATGTTGAAGGACCTTTACAGTGATGTAAGTTCTTATTGGAGGCCAAGCTGCCAAG 60
DB 1 CATGCTGAAGGACCTTTACAGTGATGTAAGTTCTTATTGGAGGCCAAGCTGCCAAG 60
OY 61 GAATTCATTCGCTGGCTGGTGAAGGCCGAGGA 93
DB 61 GAATTCATTCGCTGGCTGGTGAAGGCCGAGGA 93

RESULT 8

US-08-784-582-55


```

TITLE OF INVENTION: METHOD FOR PRODUCING A BIOLOGICALLY
TITLE OF INVENTION: ACTIVE RECOMBINANT CYSTEINE-FREE
NUMBER OF SEQUENCES: 37
CORRESPONDENCE ADDRESS:
ADDRESSEE: DIKE, BRONSTEIN, ROBERTS & CUSHMAN, LLP
STREET: 130 WATER STREET
CITY: BOSTON
STATE: MA
COUNTRY: USA
ZIP: 02109
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FASTSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/835,231
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/350,709
FILING DATE: 07-DEC-1994
APPLICATION NUMBER: 07/838,857
FILING DATE: 18-FEB-1992
APPLICATION NUMBER: JP 024841
FILING DATE: 19-FEB-1991
APPLICATION NUMBER: JP 0271438
FILING DATE: 18-OCT-1991
ATTORNEY/AGENT INFORMATION:
NAME: DAVID, RESNICK S
REGISTRATION NUMBER: 34,235
REFERENCE/DOCKET NUMBER: 46164-FWC
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617-523-3400
TELEFAX: 617-523-6440
TELEX: 200291 STRE
INFORMATION FOR SEQ ID NO: 17:
SEQUENCE CHARACTERISTICS:
LENGTH: 144 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: CDNA
HYPOTHETICAL: NO
ANTI-SENSE: NO
FRAGMENT TYPE:
ORIGINAL SOURCE:
FEATURE:
NAME/KEY: Coding Sequence
LOCATION: 22...144
US-08-835-231-17

Query Match 85.2%; Score 79.2; DB 2; Length 144;
Best Local Similarity 91.3%; Pred. No. 8.3e-21;
Matches 84; Conservative 0; Mismatches 8; Indels 0; Gaps 0.

QY 1 CATGTGAAGGAGCCTTACCACTGATGTAAAGTTCTTATTTGGAAGCCAGCTGCAG 60
    ||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 43 CATGCTGAAGGACCTTACCAGGAGTAAGCTTATCTGGAAGCCAGGCTGCCAAA 102
    ||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

QY 61 GAATTCATTTGGCTGGTGGTGAAGAGCCGCGAG 92
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 103 GAATTCATTTGCTTGGCTGGTGAAGAGCCGCTG 134

RESULT 10
US-09-108-661-17
Sequence 17, Application US/09108661
Patent No. 6287806
GENERAL INFORMATION:
APPLICANT: NISHIMURA, Osamu
APPLICANT: KURIYAMA, Masato
APPLICANT: KOYAMA, No. 6287806uyuki

```

APPLICANT: FUKUDA, Tsunehiko
TITLE OF INVENTION: METHOD FOR PRODUCING A BIOLOGICALLY
TITLE OF INVENTION: ACTIVE RECOMBINANT CYSTEINE-FREE
NUMBER OF SEQUENCES: 37
CORRESPONDENCE ADDRESS:
ADDRESSEE: DIKE, BRONSTEIN, ROBERTS & CUSHMAN, LLP
STREET: 130 WATER STREET
CITY: BOSTON
STATE: MA
COUNTRY: USA
ZIP: 02109
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/108,661
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/350,709
FILING DATE: 07-DEC-1994
APPLICATION NUMBER: 07/838,857
FILING DATE: 18-FEB-1992
APPLICATION NUMBER: JP 024841
FILING DATE: 19-FEB-1991
APPLICATION NUMBER: JP 0271438
FILING DATE: 18-OCT-1991
ATTORNEY/AGENT INFORMATION:
NAME: DAVID, RESNICK S
REGISTRATION NUMBER: 34,235
REFERENCE/DOCKET NUMBER: 41614-FWC
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617-523-3400
TELEFAX: 617-523-6440
TELEX: 200291 STRE
INFORMATION FOR SEQ ID NO: 17:
SEQUENCE CHARACTERISTICS:
LENGTH: 144 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: CDNA
HYPOTHETICAL: NO
ANTI-SENSE: NO
FRAGMENT TYPE: NO
ORIGINAL SOURCE:
FEATURE:
NAME/KEY: Coding Sequence
LOCATION: 22...144
US-09-108-661-17

Query Match 85.2%; Score 79.2; DB 4; Length 144;
Best Local Similarity 91.3%; Pred. No. 8.3e-21;
Matches 84; Conservative 0; Mismatches 8; Indels 0; Gaps 0;
QY 1 CATGTGAAGGACCTTACACAGTAGTAGTCTTATTTGGAAGCCAGCTGCCAG 60
DB 43 CATGCTGAAGGACCTTACACAGTAGTAGTCTTATCTGGAAGCCAGCTGCCAAA 102
QY 61 GAATTCATTTGCTGGTGGTGAAGGCGCGAG 92
DB 103 GAATTCATTTGCTGGTGGTGAAGGCGCGTGG 134

RESULT 11
US-08-829-876-22
Sequence 22, Application US/08829876
Patent No. 5962266
GENERAL INFORMATION:
APPLICANT: White, Tyler R.
ADDRESSEE: Damu, Deborah
CITY: Washington
STATE: D.C.
COUNTRY: USA
ZIP: 20007-5109

APPLICANT: Lesikar, David D.
APPLICANT: McFadden, Kathleen
APPLICANT: Garrick, Brett L.
TITLE OF INVENTION: PROTEASE INHIBITOR PEPTIDES
NUMBER OF SEQUENCES: 228
CORRESPONDENCE ADDRESS:
ADDRESSEE: Foley & Lardner
STREET: 3000 K Street, N.W., Suite 500
CITY: Washington
STATE: D.C.
COUNTRY: USA
ZIP: 20007-5109
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/829,876
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/436,555
FILING DATE: 08-MAY-1995
ATTORNEY/AGENT INFORMATION:
NAME: Pelto, Don J.
REGISTRATION NUMBER: 33,754
REFERENCE/DOCKET NUMBER: 56324/106/SCNO
TELECOMMUNICATION INFORMATION:
TELEPHONE: (202)672-5300
TELEFAX: (202)672-5399
TELEX: 904136
INFORMATION FOR SEQ ID NO: 22:
SEQUENCE CHARACTERISTICS:
LENGTH: 78 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-829-876-22

Query Match 53.5%; Score 49.8; DB 2; Length 78;
Best Local Similarity 82.6%; Pred. No. 7.2e-10;
Matches 57; Conservative 0; Mismatches 12; Indels 0; Gaps 0;
QY 24 TGATGTAGTCTTATTGGAGCCAGCTGCCAGGAATTCATTGCTGGCTGTGA 83
DB 1 TGACGCTCTCTTACTTGAAGGCTCAAGCTGAAGATTCATCGCTTGGTGTCAA 60
QY 84 AGCGCGAGG 92
DB 61 AGGTAGAGG 69

RESULT 12
US-09-234-874A-22
Sequence 22, Application US/09234874A
Patent No. 6376648
GENERAL INFORMATION:
APPLICANT: White, Tyler R.
ADDRESSEE: Damu, Deborah
LESIKAR, David D.
MCFADDEN, Kathleen
GARRICK, Brett L.
TITLE OF INVENTION: PROTEASE INHIBITOR PEPTIDES
NUMBER OF SEQUENCES: 228
CORRESPONDENCE ADDRESS:
ADDRESSEE: Foley & Lardner
STREET: 3000 K Street, N.W., Suite 500
CITY: Washington
STATE: D.C.
COUNTRY: USA
ZIP: 20007-5109

```
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
  APPLICATION NUMBER: US/09/234,874A
  FILING DATE: 11-Jun-2001
  PRIORITY APPLICATION DATA:
    APPLICATION NUMBER: 08/436,555
    FILING DATE: 08-MAY-1995
  ATTORNEY/AGENT INFORMATION:
    NAME: Bent, Stephen
    REGISTRATION NUMBER: 29,768
    REFERENCE/DOCKET NUMBER: 056324/0106
  TELECOMMUNICATION INFORMATION:
    TELEPHONE: (202)672-5300
    TELEFAX: (202)672-5399
    TELEX: 904136
  INFORMATION FOR SEQ ID NO: 22:
    SEQUENCE CHARACTERISTICS:
      LENGTH: 78 base pairs
      TYPE: nucleic acid
      STRANDEDNESS: single
      TOPOLOGY: linear
    MOLECULE TYPE: DNA (genomic)
    SEQUENCE DESCRIPTION: SEQ ID NO: 22:
US-09-234-874A-22

Query Match
Best Local Similarity 82.6%; Score 49.8; DB 4; Length 78;
Matches 57; Conservative 0; Mismatches 12; Indels 0; Gaps 0;

QY 24 TGAGTGAAGTCTTATTGGAAGCCCAAGCTGCCAAGCAATTCATCTGCGTGGGAA 83
DB 1 TGAGCTCTCTTACTTGAAGGCTCAAGCTGCTAAGCAATTCATCTGCGTGGGAA 60
QY 84 AGCCGAGG 92
DB 61 AGGTAGAG 69

RESULT 13
US-08-811-028-43
  Sequence 43, Application US/08811028C
  Patent No. 5891671
  GENERAL INFORMATION:
    APPLICANT: SUZUKI, Yuji
    APPLICANT: MASUDA, Koji
    APPLICANT: MASUDA, Toyofumi
  TITLE OF INVENTION: METHOD FOR CLEAVING CHIMERIC ENZYME USING PROCESSING
  FILE REFERENCE: 001560-294
  CURRENT APPLICATION NUMBER: US/08/811,028C
  CURRENT FILING DATE: 1987-03-04
  EARLIER APPLICATION NUMBER: JP 8-70906
  EARLIER FILING DATE: 1996-03-04
  NUMBER OF SEQ ID NOS: 54
  SOFTWARE: Patentin Ver. 2.0
  SEQ ID NO 43
  LENGTH: 57
  TYPE: DNA
  ORGANISM: Artificial Sequence
  FEATURE:
    OTHER INFORMATION: Description of Artificial Sequence:oligonucleotide
  OTHER INFORMATION: GLP-1
US-08-811-028-43

Query Match
Best Local Similarity 80.0%; Score 37.4; DB 2; Length 57;
Matches 44; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 7 GAAGGACCTTACAGTGAATGATTCCTATTGGAAGCCCAAGCTGCCAAG 61
```

```
DB 3 GAAGTACCTTTACCAAGCATGTGAGCTCTGATTCGGAAGGCGGCAAAAG 57
RESULT 14
US-08-811-028-44/C
  Sequence 44, Application US/08811028C
  Patent No. 5891671
  GENERAL INFORMATION:
    APPLICANT: SUZUKI, Yuji
    APPLICANT: MASUDA, Koji
    APPLICANT: MASUDA, Toyofumi
  TITLE OF INVENTION: METHOD FOR CLEAVING CHIMERIC ENZYME USING PROCESSING
  FILE REFERENCE: 001560-294
  CURRENT APPLICATION NUMBER: US/08/811,028C
  CURRENT FILING DATE: 1987-03-04
  EARLIER APPLICATION NUMBER: JP 8-70906
  EARLIER FILING DATE: 1996-03-04
  NUMBER OF SEQ ID NOS: 54
  SOFTWARE: Patentin Ver. 2.0
  SEQ ID NO 44
  LENGTH: 48
  TYPE: DNA
  ORGANISM: Artificial Sequence
  FEATURE:
    OTHER INFORMATION: Description of Artificial Sequence:oligonucleotide
  OTHER INFORMATION: GLP-2
US-08-811-028-44

Query Match
Best Local Similarity 83.0%; Score 34.2; DB 2; Length 48;
Matches 39; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 1 CATGTTGAAGGACCTTTACCAAGTGAATGATTCCTATTGGAAG 47
DB 48 CATGCGGAAGTACCTTTACCAAGCATGTGAGCTCTGATTCGGAAG 2

RESULT 15
US-08-811-028-46/C
  Sequence 46, Application US/08811028C
  Patent No. 5891671
  GENERAL INFORMATION:
    APPLICANT: SUZUKI, Yuji
    APPLICANT: MASUDA, Koji
    APPLICANT: MASUDA, Toyofumi
  TITLE OF INVENTION: METHOD FOR CLEAVING CHIMERIC ENZYME USING PROCESSING
  FILE REFERENCE: 001560-294
  CURRENT APPLICATION NUMBER: US/08/811,028C
  CURRENT FILING DATE: 1987-03-04
  EARLIER APPLICATION NUMBER: JP 8-70906
  EARLIER FILING DATE: 1996-03-04
  NUMBER OF SEQ ID NOS: 54
  SOFTWARE: Patentin Ver. 2.0
  SEQ ID NO 46
  LENGTH: 53
  TYPE: DNA
  ORGANISM: Artificial Sequence
  FEATURE:
    OTHER INFORMATION: Description of Artificial Sequence:oligonucleotide
  OTHER INFORMATION: GLP-4
US-08-811-028-46

Query Match
Best Local Similarity 84.1%; Score 32.8; DB 2; Length 53;
Matches 37; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 49 CAAGCTGCCAAGCAATTCATCTGCGTGGGGAAGCCGAGG 92
DB 53 CAAGCGCAAAAGCAATTCATCTGCGTGGGGAAGCCGAGG 10
```

Thu Feb 27 13:12:09 2003

us-09-091-605-4.rml

Page 8

Search completed: February 14, 2003, 08:25:51
Job time : 49 secs

GenCore version 5.1.4-p5_4578
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: February 14, 2003, 07:57:09 : Search time 1184 Seconds
(without alignments)
1272.112 Million cell updates/sec

Title: US-09-091-605-4

Perfect score: 93
Sequence: 1 CACCTGAGGACGCTTAC.....GGCTGGTGAAGGCCGAGA 93

Scoring table: IDENTITY_NUC
Gapop 10.0, Gapext 1.0

Searched: 16154066 seqs, 8097743376 residues

Total number of hits satisfying chosen parameters: 32308132

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :
EST:
1: em_estba:*
2: em_esthm:*
3: em_esthm:*
4: em_esthm:*
5: em_esthm:*
6: em_esthm:*
7: em_esthm:*
8: em_esthm:*
9: em_esthm:*
10: em_esthm:*
11: em_esthm:*
12: em_esthm:*
13: em_esthm:*
14: em_esthm:*
15: em_esthm:*
16: em_esthm:*
17: em_esthm:*
18: em_esthm:*
19: em_esthm:*
20: em_esthm:*
21: em_esthm:*
22: em_esthm:*
23: em_esthm:*
24: em_esthm:*
25: em_esthm:*
26: em_esthm:*
27: em_esthm:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	91.4	98.3	359	BI715164	BI715164 ic29g03.y
2	91.4	98.3	382	BM313323	BM313323 1982f07.y
3	91.4	98.3	389	BM313323	BM313323 1127e09.y
4	91.4	98.3	394	BM313323	BM313323 1044a12.y
5	91.4	98.3	419	BM313323	BM313323 K-EST0111
6	91.4	98.3	427	BI466966	BI466966 ic17d08.y

7	91.4	98.3	443	14	BQ271272	BQ271272	1K11904.y
8	91.4	98.3	451	13	BM503895	BM503895	1997b05.y
9	91.4	98.3	451	14	BQ776591	BQ776591	1134g04.x
10	91.4	98.3	459	12	BG656237	BG656237	1b38g04.y
11	91.4	98.3	459	14	BQ286311	BQ286311	1K28e04.y
12	91.4	98.3	461	13	BM312520	BM312520	1675e12.y
13	91.4	98.3	463	14	BQ271456	BQ271456	1K44b08.y
14	91.4	98.3	466	14	BQ416911	BQ416911	1K39c06.y
15	91.4	98.3	471	12	BQ271361	BQ271361	1K12h07.y
16	91.4	98.3	471	12	BG655087	BG655087	1b45h03.y
17	91.4	98.3	471	14	BQ269449	BQ269449	1K25g03.y
18	91.4	98.3	472	14	BQ777016	BQ777016	1142c09.y
19	91.4	98.3	472	14	BQ787174	BQ787174	1151c09.y
20	91.4	98.3	474	13	BI467273	BI467273	1c22c02.x
21	91.4	98.3	476	14	BQ777432	BQ777432	1K11h07.y
22	91.4	98.3	476	14	BQ271282	BQ271282	1K14b03.y
23	91.4	98.3	479	13	BQ272090	BQ272090	1K18b09.y
24	91.4	98.3	479	13	BM312257	BM312257	1941b09.y
25	91.4	98.3	481	13	BM313155	BM313155	1K12c06.y
26	91.4	98.3	481	13	BQ776373	BQ776373	1131d12.y
27	91.4	98.3	483	13	BI715416	BI715416	1G32f01.y
28	91.4	98.3	483	14	BQ269264	BQ269264	1K23d04.y
29	91.4	98.3	484	14	BQ271926	BQ271926	1K16b09.y
30	91.4	98.3	484	14	BQ417049	BQ417049	1K41b03.y
31	91.4	98.3	484	14	BQ776874	BQ776874	1134d03.y
32	91.4	98.3	485	14	BQ631915	BQ631915	1124e04.y
33	91.4	98.3	485	14	BQ777960	BQ777960	1139c04.y
34	91.4	98.3	486	14	BQ778021	BQ778021	1140e04.y
35	91.4	98.3	487	13	BM312448	BM312448	1978f12.x
36	91.4	98.3	487	14	BQ269028	BQ269028	1K20d03.y
37	91.4	98.3	487	14	BQ269433	BQ269433	1K25e08.y
38	91.4	98.3	490	13	BM309838	BM309838	1944f02.y
39	91.4	98.3	492	13	BM312759	BM312759	1978g03.y
40	91.4	98.3	494	13	BI791789	BI791789	1604e11.y
41	91.4	98.3	497	12	BG654541	BG654541	1B41n07.y
42	91.4	98.3	497	13	BI438781	BI438781	1c26f01.x
43	91.4	98.3	497	13	BI792098	BI792098	1606f11.y
44	91.4	98.3	501	12	BE970164	BE970164	601680194
45	91.4	98.3	501	12	BE970164	BE970164	601680194

ALIGNMENTS

RESULT 1
BI715164 359 bp mRNA linear EST 19-SEP-2001
ic29g03.y1 HR85 islet Homo sapiens CDNA 5' similar to SW:GLUC_HUMAN
P01275 GLUCAGON PRECURSOR. [1] ; mRNA sequence.

ACCESSION
BI715164
VERSION
KEYWORDS
SOURCE
ORGANISM
human.
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
EST.
REFERENCE
AUTHORS
Melton, D., Brown, J., Kenty, G., Permut, A., Lee, C., Kaestner, K.,
Lemstra, L., Marra, M., Pape, D., Wille, T., Martin, J., Blisstein, A.,
Schmitt, A., Theising, B., Ritzer, E., Ronko, I., Bennett, J., Cardenas,
M., Gibbons, M., McCann, R., Cole, R., Tsagaris, W., Williams, T.,
Jackson, Y., and Bowers, Y.
Endocrine Pancreas Consortium
Unpublished (2000)

TITLE
JOURNAL
COMMENT
Contact: Douglas Melton, Klaus H. Kaestner, & Hiroshi Inoue
Endocrine Pancreas Consortium
Harvard University, Howard Hughes Medical Institute
Dept of Molecular and Cellular Biology, 7 Divinity Ave, Cambridge,
MA 02138

Tel: 617-495-1812
Fax: 617-495-8557
Email: dmelton@biohp.harvard.edu

Library was constructed by Dr. Hiroshi Inoue DNA sequencing by:
Washington University Genome Sequencing Center For information on
obtaining a clone please contact: Dr. Hiroshi Inoue
(hinoue@im.wustl.edu)
Seq primer: -40RP from Glibco

High quality sequence stop: 277.
Location/Qualifiers

FEATURES

source

/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone_lib="HR85 islet"
/tissue_type="Purified pancreatic islet"
/lab_host="DH10B"
/note="Organ: Pancreas; Vector: pBluescript SK(-); Site_1:
NotI; Site_2: XhoI; cDNA made by oligo-dT priming.
Size-selected on agarose gel. Average insert size ~1kb. 5'
XhoI site was destroyed after directional cloning.
Amplified once. Contact information: Hiroshi Inoue, MD,
Metabolism Div. (Alan Permut Lab), Washington University
School of Medicine, Box 8127, 660 South Euclid Ave., St.
Louis, MO 63110, E-mail: hinoue@imgate.wustl.edu, Tel:
314-362-1916, Fax: 314-747-2692."

BASE COUNT 103 a 74 c 92 g 90 t

ORIGIN

Query Match 98.3%; Score 91.4; DB 13; Length 359;
Best Local Similarity 98.9%; Pred. No. 1.6e-20;
Matches 92; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1 CATGTTGAAGGACCTTTACAGTGATGTAAGTTCTTATTGGAAGGCCAAGTCCCAAG 60
|||||
Db 126 CATGCTGAAGGACCTTTACAGTGATGTAAGTTCTTATTGGAAGGCCAAGTCCCAAG 185

OY 61 GAATTCATTGCTTGGCTGCTGTGAAGCCGAGGA 93
|||||
Db 186 GAATTCATTGCTTGGCTGCTGTGAAGCCGAGGA 218

RESULT 2 382 bp mRNA linear EST 03-JAN-2002
LOCUS BMJ13323

DEFINITION 1982f07.y1 HR85 islet Homo sapiens cDNA 5' similar to SW:GLUC_HUMAN
P01275 GLUCAGON PRECURSOR. [1]; mRNA sequence.

ACCESSION BMJ13323
VERSION BMJ13323.1 GI:18047668
KEYWORDS EST.

SOURCE human.

ORGANISM Homo sapiens

REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
1 (bases 1 to 382)
Melton,D., Brown,J., Kenly,G., Permut,A., Lee,C., Kaestner,K.,
Lemishka,I., Searce,M., Brestelli,J., Gradwohl,G., Clifton,S.,
Hillier,L., Marra,M., Pape,D., Wylie,T., Martin,J., Bliscain,A.,
Schmitt,A., Theising,B., Rilter,E., Ronko,I., Bennett,J., Cardenas
,M., Gibbons,M., McCann,R., Cole,R., Tsagarelisvill,R., Williams,T.,
Jackson,Y. and Bowers,Y.

AUTHORS

TITLE Endocrine Pancreas Consortium
JOURNAL Unpublished (2000)
COMMENT Other-ESTs: 1982f07.x1

CONTACT: Douglas Melton, Klaus H. Kaestner, & Hiroshi Inoue
Endocrine Pancreas Consortium
Harvard University, Howard Hughes Medical Institute
Dept of Molecular and Cellular Biology, 7 Divinity Ave, Cambridge,
MA 02138
Tel: 617-495-1812
Fax: 617-495-8557
Email: dmelton@bioh.harvard.edu
Library was constructed by Dr. Hiroshi Inoue DNA sequencing by:
Washington University Genome Sequencing Center For information on
obtaining a clone please contact: Dr. Hiroshi Inoue
(hinoue@im.wustl.edu)
Seq primer: -40RP from Glibco.

FEATURES

source

Location/Qualifiers
1..382
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone_lib="HR85 islet"
/tissue_type="Purified pancreatic islet"
/lab_host="DH10B"
/note="Organ: Pancreas; Vector: pBluescript SK(-); Site_1:
NotI; Site_2: XhoI; cDNA made by oligo-dT priming.
Size-selected on agarose gel. Average insert size ~1kb. 5'
XhoI site was destroyed after directional cloning.
Amplified once. Contact information: Hiroshi Inoue, MD,
Metabolism Div. (Alan Permut Lab), Washington University
School of Medicine, Box 8127, 660 South Euclid Ave., St.
Louis, MO 63110, E-mail: hinoue@imgate.wustl.edu, Tel:
314-362-1916, Fax: 314-747-2692."

BASE COUNT 110 a 79 c 98 g 95 t

ORIGIN

Query Match 98.3%; Score 91.4; DB 13; Length 382;
Best Local Similarity 98.9%; Pred. No. 1.7e-20;
Matches 92; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1 CATGTTGAAGGACCTTTACAGTGATGTAAGTTCTTATTGGAAGGCCAAGTCCCAAG 60
|||||
Db 135 CATGCTGAAGGACCTTTACAGTGATGTAAGTTCTTATTGGAAGGCCAAGTCCCAAG 194

OY 61 GAATTCATTGCTTGGCTGCTGTGAAGCCGAGGA 93
|||||
Db 195 GAATTCATTGCTTGGCTGCTGTGAAGCCGAGGA 227

RESULT 3 389 bp mRNA linear EST 02-JUL-2002
LOCUS B0632756

DEFINITION 1127e09.y1 HR85 islet Homo sapiens cDNA clone IMAGE:6031216 5'
similar to SW:GLUC_HUMAN P01275 GLUCAGON PRECURSOR. [1]; mRNA
sequence.

ACCESSION B0632756
VERSION B0632756.1 GI:21684274
KEYWORDS EST.

SOURCE human.

ORGANISM Homo sapiens

REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
1 (bases 1 to 389)
Melton,D., Brown,J., Kenly,G., Permut,A., Lee,C., Kaestner,K.,
Lemishka,I., Searce,M., Brestelli,J., Gradwohl,G., Clifton,S.,
Hillier,L., Marra,M., Pape,D., Wylie,T., Martin,J., Bliscain,A.,
Schmitt,A., Theising,B., Rilter,E., Ronko,I., Bennett,J., Cardenas
,M., Gibbons,M., McCann,R., Cole,R., Tsagarelisvill,R., Williams,T.,
Jackson,Y. and Bowers,Y.

AUTHORS

TITLE Endocrine Pancreas Consortium
JOURNAL Unpublished (2000)
COMMENT Other-ESTs: 1127e09.x1

CONTACT: Douglas Melton, Klaus H. Kaestner, & Hiroshi Inoue
Endocrine Pancreas Consortium
Harvard University, Howard Hughes Medical Institute
Dept of Molecular and Cellular Biology, 7 Divinity Ave, Cambridge,
MA 02138
Tel: 617-495-1812
Fax: 617-495-8557
Email: dmelton@bioh.harvard.edu
Library was constructed by Dr. Hiroshi Inoue DNA sequencing by:
Washington University Genome Sequencing Center For information on
obtaining a clone please contact: Dr. Hiroshi Inoue
(hinoue@im.wustl.edu)
Seq primer: -40RP from Glibco
High quality sequence stop: 361.
Location/Qualifiers
1..389
/organism="Homo sapiens"
/db_xref="taxon:9606"

/clone="IMAGE:6031216"
/clone_lib="HR85 islet"
/tissue_type="Purified pancreatic islet"
/lab_host="DH10B"
/note="Organ: Pancreas; Vector: pBluescript SK(-); Site: 1;
NOTI; Site: 2; XhoI; CDNA made by oligo-dT priming.
Size selected on agarose gel. Average insert size ~1kb. 5'
XhoI site was destroyed after directional cloning.
Amplified once. Contact information: Hiroshi Inoue, MD,
Metabolism Div. (Alan Permut Lab), Washington University
School of Medicine, Box 8127, 660 South Euclid Ave., St.
Louis, MO 63110, E-mail: hinoue@imgate.wustl.edu, Tel:
314-362-1916, Fax: 314-747-2692."

BASE COUNT 116 a 76 c 94 g 103 t

ORIGIN

Query Match 98.3%; Score 91.4; DB 14; Length 389;
Best Local Similarity 98.9%; Pred. No. 1.7e-20;
Matches 92; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 CATGTTGAGGACCTTACCAAGTATGATCTTATTGGAAGGCCAAGTCCCAAG 60
|||||
DB 72 CATGCTGAAGGACCTTACCAAGTATGATCTTATTGGAAGGCCAAGTCCCAAG 131
|||||
QY 61 GAATTCATTGCTTGGCTGTGTAAGGCCGAGGA 93
|||||
DB 132 GAATTCATTGCTTGGCTGTGTAAGGCCGAGGA 164
|||||

RESULT 4
BG654963 394 bp mRNA linear EST 05-JUN-2001
LOCUS BG654963
DEFINITION B64412.Y1 HR85 islet Homo sapiens CDNA 5' similar to SW:GLUC_HUMAN
P01275 GLUCAGON PRECURSOR. [1]; mRNA sequence.
ACCESSION BG654963
VERSION BG654963.1 GI:13792372
KEYWORDS EST.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1 (bases 1 to 394)
Melton, D., Brown, J., Kenty, G., Permut, A., Lee, C., Kaestner, K.,
Lemishka, I., Scearce, M., Brestelli, J., Gradwohl, G., Clifton, S.,
Hillier, L., Marra, M., Pape, D., Wille, T., Martin, J., Bistrain, A.,
Schmitt, A., Theising, B., Ritzer, E., Ronko, I., Bennett, J., Cardenas
, M., Gibbons, M., McCann, R., Cole, R., Tsagaris, V., Williams, T.,
, Jackson, Y. and Bowers, Y.
, Endocrine Pancreas Consortium
Unpublished (2000)
CONTACT: Douglas Melton, Klaus H. Kaestner, & Hiroshi Inoue
Endocrine Pancreas Consortium
Harvard University, Howard Hughes Medical Institute
Dept of Molecular and Cellular Biology, 7 Divinity Ave, Cambridge,
MA 02138
Tel: 617-495-1812
Fax: 617-495-8557
Email: dmelton@iuhp.harvard.edu

Library was constructed by Dr. Hiroshi Inoue DNA sequencing by:
Washington University Genome Sequencing Center For information on
obtaining a clone please contact: Dr. Hiroshi Inoue
(hinoue@imgate.wustl.edu)
Seq primer: -40RP from Gibco
High quality sequence stop: 350.
Location/Qualifiers

FEATURES
source
1..394
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone_lib="HR85 islet"
/tissue_type="Purified pancreatic islet"
/lab_host="DH10B"
/note="Organ: Pancreas; Vector: pBluescript SK(-); Site: 1;
NOTI; Site: 2; XhoI; CDNA made by oligo-dT priming.

Size selected on agarose gel. Average insert size ~1kb. 5'
XhoI site was destroyed after directional cloning.
Amplified once. Contact information: Hiroshi Inoue, MD,
Metabolism Div. (Alan Permut Lab), Washington University
School of Medicine, Box 8127, 660 South Euclid Ave., St.
Louis, MO 63110, E-mail: hinoue@imgate.wustl.edu, Tel:
314-362-1916, Fax: 314-747-2692."

BASE COUNT 119 a 74 c 90 g 110 t 1 others

ORIGIN

Query Match 98.3%; Score 91.4; DB 12; Length 394;
Best Local Similarity 98.9%; Pred. No. 1.7e-20;
Matches 92; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 CATGTTGAGGACCTTACCAAGTATGATCTTATTGGAAGGCCAAGTCCCAAG 60
|||||
DB 58 CATGCTGAAGGACCTTACCAAGTATGATCTTATTGGAAGGCCAAGTCCCAAG 117
|||||
QY 61 GAATTCATTGCTTGGCTGTGTAAGGCCGAGGA 93
|||||
DB 118 GAATTCATTGCTTGGCTGTGTAAGGCCGAGGA 150
|||||

RESULT 5
BM836042 419 bp mRNA linear EST 06-MAR-2002
LOCUS BM836042
DEFINITION K-EST0111434 S5SNU484s1 Homo sapiens CDNA clone S5SNU484s1-18-C08
5', mRNA sequence.
ACCESSION BM836042
VERSION BM836042.1 GI:19192451
KEYWORDS EST.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1 (bases 1 to 419)
Kim, N.S., Hahn, Y., Oh, J.H., Lee, J.Y., Ahn, H.Y., Chu, M.Y., Kim, M.R.,
Oh, K.J., Cheong, J.E., Sohn, H.Y., Kim, J.M., Park, H.S., Kim, S. and
Kim, Y.S.
21C Frontier Korean EST Project 2001
Unpublished (2002)
CONTACT: Kim YS
Genome Research Center
Korea Research Institute of Bioscience & Biotechnology
52 Eoeun-dong Yuseong-gu, Daejeon 305-333, South Korea
Tel: +82-42-860-4470
Fax: +82-42-860-4409
Email: yongsung@kribb.re.kr
Plate: 18 row: G column: 08
High quality sequence stop: 419.
Location/Qualifiers

FEATURES
source
1..419
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="S5SNU484s1-18-C08"
/clone_lib="S5SNU484s1"
/sex="M"
/tissue_type="Stomach"
/cell_type="Epithelial"
/lab_host="Top10F"
/note="Organ: Stomach; Vector: pTZ19RP1; Site: 1; EcoRI;
Site: 2; NOTI; The poly (A)+ RNA was decapped with tobacco
acid pyrophosphatase (TAP) and ligated with DNA-RNA linker
including EcoRI site by treatment of T4 RNA ligase. The
first strand cDNA was synthesized from oligo dT-selected
mRNA by priming with dr-tailed vector. The dr-tailed
vector was circularized with E. coli DNA ligase after digestion
of EcoRI which site is also included in vector. An RNA
strand converted to a DNA strand by Okayama-Berg method.
The obtained cDNA vectors were used for transformation of
competent cells E. coli Top10F by electroporation method.

After analyzing and sequencing about 2,000 - 3,000 colonies in original cDNA library, the abundant cDNAs were selected and amplified by PCR reaction using vector region primer including 17 promoter as 5' primer and N(dn)14 as 3' primer. The PCR products were used as template for synthesis of biotinylated single stranded RNA probes by in vitro transcription reaction. The synthesized RNA probes were hybridized with antisense single stranded cDNAs prepared from original library and incubated with avidin-gel. After removing DNA-RNA hybrids by centrifuge, the subtracted cDNA libraries were constructed by transformation of the remaining DNA into competent cells *E. coli* Top10[®] with electroporation method."

BASE COUNT 122 a 82 c 94 g 121 t

ORIGIN

Query Match 98.3%; Score 91.4; DB 14; Length 419;
Best Local Similarity 98.9%; Pred. No. 1.7e-20;
Matches 92; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 CAGTTGAGGACCTTTACAGTGTAGTCTTATTGGAAGCCAGCTGCCAG 60
DB 30 CAGCTGAAGGACCTTTACAGTGTAGTCTTATTGGAAGCCAGCTGCCAG 89
QY 61 GAATTCATTGCTTGGCTGTGTAAGGCCGAGGA 93
DB 90 GAATTCATTGCTTGGCTGTGTAAGGCCGAGGA 122

RESULT 6 427 bp mRNA linear EST 22-AUG-2001
LOCUS B1466966
DEFINITION ic17d08.y3 HR85 islet Homo sapiens cDNA 5' similar to SW:GLUC_HUMAN
ACCESSION P01275 GLUCAGON PRECURSOR. [1] ; mRNA sequence.
VERSION B1466966
KEYWORDS EST.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
1 (bases 1 to 427)

REFERENCE
AUTHORS Melton D., Brown J., Kenty G., Permutt A., Lee C., Kaestner K., Hillier L., Marra M., Pape D., Wylie T., Martin J., Blistain A., Schmitt A., Theising B., Rittler E., Ronko I., Bennett J., Cardenas M., Gibbons M., McCann R., Cole R., Tsagarishvili R., Williams T., Jackson Y. and Bowers Y.
Endocrine Pancreas Consortium
Unpublished (2000)
Other ESTs: ic17d08.x3
Contact: Douglas Melton, Klaus H. Kaestner, & Hiroshi Inoue
Endocrine Pancreas Consortium
Harvard University, Howard Hughes Medical Institute
Dept of Molecular and Cellular Biology, 7 Divinity Ave, Cambridge, MA 02138
Tel: 617-495-1812
Fax: 617-495-8557
Email: dmelton@hlp.harvard.edu
Library was constructed by Dr. Hiroshi Inoue DNA sequencing by: Washington University Genome Sequencing Center for information on (hinoue@im.wustl.edu)
High quality sequence overall poor quality
Location/Qualifiers
1. 427

FEATURES

source
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone_lib="HR85 islet"
/tissue_type="Purified pancreatic islet"
/lab_host="DH10B"
/note="Organ: Pancreas; Vector: pBluescript SK(-); Site_1:

NOT: Site_2: XhoI; cDNA made by oligo-dt priming.
Size-selected on agarose gel. Average insert size ~1kb. 5' XhoI site was destroyed after directional cloning.
Amplified once. Contact information: Hiroshi Inoue, MD, Metabolism Div. (Alan Permutt Lab), Washington University School of Medicine, Box 8127, 660 South Euclid Ave., St. Louis, MO 63110, E-mail: hinoue@imgate.wustl.edu, Tel: 314-362-1916, Fax: 314-747-2692."

BASE COUNT 123 a 94 c 111 g 99 t

ORIGIN

Query Match 98.3%; Score 91.4; DB 13; Length 427;
Best Local Similarity 98.9%; Pred. No. 1.8e-20;
Matches 92; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 CAGTTGAGGACCTTTACAGTGTAGTCTTATTGGAAGCCAGCTGCCAG 60
DB 290 CAGCTGAAGGACCTTTACAGTGTAGTCTTATTGGAAGCCAGCTGCCAG 349
QY 61 GAATTCATTGCTTGGCTGTGTAAGGCCGAGGA 93
DB 350 GAATTCATTGCTTGGCTGTGTAAGGCCGAGGA 382

RESULT 7 443 bp mRNA linear EST 07-MAY-2002
LOCUS BQ271272
DEFINITION ik11g04.y1 HR85 islet Homo sapiens cDNA clone IMAGE: 5780910 5' similar to SW:GLUC_HUMAN P01275 GLUCAGON PRECURSOR. [1] ; mRNA sequence.
ACCESSION BQ271272
VERSION BQ271272.1 GI:20496338
KEYWORDS EST.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
1 (bases 1 to 443)

REFERENCE
AUTHORS Melton D., Brown J., Kenty G., Permutt A., Lee C., Kaestner K., Hillier L., Marra M., Pape D., Wylie T., Martin J., Blistain A., Schmitt A., Theising B., Rittler E., Ronko I., Bennett J., Cardenas M., Gibbons M., McCann R., Cole R., Tsagarishvili R., Williams T., Jackson Y. and Bowers Y.
Endocrine Pancreas Consortium
Unpublished (2000)
Contact: Douglas Melton, Klaus H. Kaestner, & Hiroshi Inoue
Endocrine Pancreas Consortium
Harvard University, Howard Hughes Medical Institute
Dept of Molecular and Cellular Biology, 7 Divinity Ave, Cambridge, MA 02138
Tel: 617-495-1812
Fax: 617-495-8557
Email: dmelton@hlp.harvard.edu
Library was constructed by Dr. Hiroshi Inoue DNA sequencing by: Washington University Genome Sequencing Center for information on (hinoue@im.wustl.edu)
Seq primer: -40RP from Glibco.
Location/Qualifiers
1. 443

FEATURES

source
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone_lib="IMAGE: 5780910"
/clone_lib="HR85 islet"
/tissue_type="Purified pancreatic islet"
/lab_host="DH10B"
/note="Organ: Pancreas; Vector: pBluescript SK(-); Site_1: NotI; Site_2: XhoI; cDNA made by oligo-dt priming. Size-selected on agarose gel. Average insert size ~1kb. 5' XhoI site was destroyed after directional cloning. Amplified once. Contact information: Hiroshi Inoue, MD, Metabolism Div. (Alan Permutt Lab), Washington University

School of Medicine, Box 8127, 660 South Euclid Ave., St. Louis, MO 63110, E-mail: hinoe@imgate.wustl.edu, Tel: 314-362-1916, Fax: 314-747-2692."

BASE COUNT 132 a 99 c 110 g 101 t 1 others

Query Match 98.3%; Score 91.4; DB 14; Length 443;
Best Local Similarity 98.9%; Pred. No. 1.8e-20;
Matches 92; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 CATGTTGAAGGACCTTTACAGTATGATCTTATTGGAAGGCCAAGCTGCCAAG 60
|||||
Db 335 CATGCTGAAGGACCTTTACAGTATGATCTTATTGGAAGGCCAAGCTGCCAAG 394

Qy 61 GAATTCATTGCTTGGCTGGTGAAGGCCGAGGA 93
|||||
Db 395 GAATTCATTGCTTGGCTGGTGAAGGCCGAGGA 427

RESULT 8
BM503895 451 bp mRNA linear EST 14-FEB-2002
LOCUS 1997b05.y1 HR85 islet Homo sapiens cDNA 5' similar to SW:GLUC_HUMAN

ACCESSION P01275 GLUCAGON PRECURSOR. [1] ; mRNA sequence.
VERSION BM503895
KEYWORDS EST.

SOURCE human.
ORGANISM Homo sapiens

REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
AUTHORS 1 (bases 1 to 451)

Melton, D., Brown, J., Kenty, G., Permutt, A., Lee, C., Kaestner, K., Lemishka, I., Searce, M., Brestelli, J., Gradwohl, G., Clifton, S., Hillier, L., Marra, M., Pape, D., Wylie, T., Martin, J., Blistain, A., Schmitt, A., Theising, B., Ritter, E., Ronko, I., Bennett, J., Cardenas, M., Gibbons, M., McCann, R., Cole, R., Tsagarisvilli, R., Williams, T., Jackson, Y. and Bowers, Y.
TITLE Endocrine Pancreas Consortium
JOURNAL Unpublished (2000)
COMMENT Other-ESTs: 1997b05.x1
Contact: Douglas Melton, Klaus H. Kaestner, & Hiroshi Inoue
Endocrine Pancreas Consortium
Harvard University, Howard Hughes Medical Institute
Dept of Molecular and Cellular Biology, 7 Divinity Ave, Cambridge, MA 02138
Tel: 617-495-1812
Fax: 617-495-8557
Email: dmelton@hdp.harvard.edu
Library was constructed by Dr. Hiroshi Inoue DNA sequencing by:
Washington University Genome Sequencing Center For information on
obtaining a clone please contact: Dr. Hiroshi Inoue
(hinoe@imgate.wustl.edu)
Seq primer: -40RP from Gibco
High quality sequence stop: 440.

FEATURES

location/Qualifiers
1..451
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone_lib="HR85 islet"
/tissue_type="Purified pancreatic islet"
/lab_host="DH10B"
/note="Organ: Pancreas; Vector: pBluescript SK(-); Site_1: NotI; Site_2: XhoI; cDNA made by oligo-dT priming. Size-selected on agarose gel. Average insert size ~1kb. 5' XhoI site was destroyed after directional cloning. Amplified once. Contact information: Hiroshi Inoue, MD, Metabolism Div. (Alan Permutt Lab), Washington University School of Medicine, Box 8127, 660 South Euclid Ave., St. Louis, MO 63110, E-mail: hinoe@imgate.wustl.edu, Tel: 314-362-1916, Fax: 314-747-2692."

BASE COUNT 135 a 86 c 106 g 123 t 1 others

Query Match 98.3%; Score 91.4; DB 13; Length 451;
Best Local Similarity 98.9%; Pred. No. 1.8e-20;
Matches 92; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 CATGTTGAAGGACCTTTACAGTATGATCTTATTGGAAGGCCAAGCTGCCAAG 60
|||||
Db 74 CATGCTGAAGGACCTTTACAGTATGATCTTATTGGAAGGCCAAGCTGCCAAG 133

Qy 61 GAATTCATTGCTTGGCTGGTGAAGGCCGAGGA 93
|||||
Db 134 GAATTCATTGCTTGGCTGGTGAAGGCCGAGGA 166

RESULT 9
B0776591/c 451 bp mRNA linear EST 26-JUL-2002
LOCUS 1134g04.x1 HR85 islet Homo sapiens cDNA clone IMAGE:6032047 3'

DEFINITION similar to SW:GLUC_HUMAN P01275 GLUCAGON PRECURSOR. [1] ; mRNA sequence.
ACCESSION B0776591
VERSION B0776591.1 GI:21985063
KEYWORDS EST.

SOURCE human.
ORGANISM Homo sapiens

REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
AUTHORS 1 (bases 1 to 451)

Melton, D., Brown, J., Kenty, G., Permutt, A., Lee, C., Kaestner, K., Lemishka, I., Searce, M., Brestelli, J., Gradwohl, G., Clifton, S., Hillier, L., Marra, M., Pape, D., Wylie, T., Martin, J., Blistain, A., Schmitt, A., Theising, B., Ritter, E., Ronko, I., Bennett, J., Cardenas, M., Gibbons, M., McCann, R., Cole, R., Tsagarisvilli, R., Williams, T., Jackson, Y. and Bowers, Y.
TITLE Endocrine Pancreas Consortium
JOURNAL Unpublished (2000)
COMMENT Other-ESTs: 1997b05.x1
Contact: Douglas Melton, Klaus H. Kaestner, & Hiroshi Inoue
Endocrine Pancreas Consortium
Harvard University, Howard Hughes Medical Institute
Dept of Molecular and Cellular Biology, 7 Divinity Ave, Cambridge, MA 02138
Tel: 617-495-1812
Fax: 617-495-8557
Email: dmelton@hdp.harvard.edu
Library was constructed by Dr. Hiroshi Inoue DNA sequencing by:
Washington University Genome Sequencing Center For information on
obtaining a clone please contact: Dr. Hiroshi Inoue
(hinoe@imgate.wustl.edu)
Seq primer: -40UP from Gibco.

FEATURES

location/Qualifiers
1..451
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone_lib="IMAGE:6032047"
/tissue_type="Purified pancreatic islet"
/lab_host="DH10B"
/note="Organ: Pancreas; Vector: pBluescript SK(-); Site_1: NotI; Site_2: XhoI; cDNA made by oligo-dT priming. Size-selected on agarose gel. Average insert size ~1kb. 5' XhoI site was destroyed after directional cloning. Amplified once. Contact information: Hiroshi Inoue, MD, Metabolism Div. (Alan Permutt Lab), Washington University School of Medicine, Box 8127, 660 South Euclid Ave., St. Louis, MO 63110, E-mail: hinoe@imgate.wustl.edu, Tel: 314-362-1916, Fax: 314-747-2692."

BASE COUNT 132 a 96 c 82 g 141 t

Query Match 98.3%; Score 91.4; DB 14; Length 451;
Best Local Similarity 98.9%; Pred. No. 1.8e-20;
Matches 92; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY	1	CATGTTGAAGGACCTTTCACCATGTATGAATTCTTATTGGAAAGCCCAACTGCCAAG	60
Db	451	CATGCTGAAGGACCTTTCACCATGTATGAATTCTTATTGGAAAGCCCAACTGCCAAG	392
QY	61	GAATTCATTGCTTGCGCTGCTGAAGAAGCCGAGCA	93
Db	391	GAATTCATTGCTTGCGCTGCTGAAGAAGCCGAGCA	359
RESULT 10			
BG656237			
LOCUS	BG656237	458 bp	mRNA linear EST 05-JUN-2001
DEFINITION	IB38904.y1 HR85 islet Homo sapiens cDNA 5' similar to SW:GLUC_HUMAN		
ACCESSION	P01275 GLUCAGON PRECURSOR. [1] ; mRNA sequence.		
VERSION	BG656237		
KEYWORDS	BG656237.1 GI:13793646		
SOURCE	EST.		
ORGANISM	human.		
TAXID	Homo sapiens		
REFERENCE	Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.		
AUTHORS	Melton,D., Brown,J., Kenty,G., Permutt,A., Lee,C., Kraesner,K., Lemisha,I., Scarce,M., Brestelli,T., Gradwohl,G., Clifton,S., Hillier,L., Watta,M., Page,D., Wyle,T., Martin,U., Blistain,A., Schmitt,A., Theising,B., Riltter,E., Ronko,I., Bennett,J., Cardenas ,M., Gibbons,M., McCann,R., Cole,R., Tsagarelshvili,R., Williams,T., Jackson,Y., and Bowers,Y.		
JOURNAL	Endocrine Pancreas Consortium		
COMMENT	Unpublished (2000)		
	Contact: Douglas Melton, Klaus H. Kaestner, & Hiroshi Inoue		
	Endocrine Pancreas Consortium		
	Harvard University, Howard Hughes Medical Institute		
	Dept of Molecular and Cellular Biology, 7 Divinity Ave, Cambridge,		
	MA 02138		
	Tel: 617-495-1812		
	Fax: 617-495-8557		
	Email: dmelton@biohp.harvard.edu		
	Llibrary was constructed by Dr. Hiroshi Inoue DNA sequencing by:		
	Washington University Genome Sequencing Center For information on		
	obtaining a clone please contact: Dr. Hiroshi Inoue		
	(hinoue@im.wustl.edu)		
	Seq primer: -40RP from GIBCO		
	High quality sequence stop: 452.		
FEATURES			
SOURCE	Location/Qualifiers		
	1..458		
	/organism="Homo sapiens"		
	/db_xref="taxon:9606"		
	/clone_id="HR85 islet"		
	/tissue_type="Purified pancreatic islet"		
	/lab_host="DH10B"		
	/note="Organ: Pancreas; Vector: pBluescript SK(-); Site:1:		
	Note: Site:2: XhoI; cDNA made by oligo-dT priming.		
	Size-selected on agarose gel. Average insert size ~1kb. 5'		
	XhoI site was destroyed after directional cloning.		
	Amplified once. Contact information: Hiroshi Inoue, MD,		
	Metabolism Div. (Alan Permutt lab), Washington University		
	School of Medicine, Box 8127, 660 South Euclid Ave., St.		
	Louis, MO 63110, Email: hinoue@lmgate.wustl.edu, Tel:		
	314-366-1916, Fax: 314-747-2692."		
BASE COUNT	134 a 106 c 111 g 107 t		
ORIGIN			
Query Match	98.3%; Score 91.4; DB 12;	Length 458;	
Best Local Similarity	98.9%; Pred. No. 1.8e-20;		
Matches 92; Conservative 0;	Mismatches 1;	Indels 0;	Gaps 0;
QY	1	CATGTTGAAGGACCTTTCACCATGTATGAATTCTTATTGGAAAGCCCAAGTCCAAG	60
Db	348	CATGCTGAAGGACCTTTCACCATGTATGAATTCTTATTGGAAAGCCCAAGTCCAAG	407
QY	61	GAATTCATTGCTTGCGCTGCTGAAGAAGCCGAGCA	93
Db	391	GAATTCATTGCTTGCGCTGCTGAAGAAGCCGAGCA	359

DB	408	GAATTCATTGCTTGGCTGCTGTAAGAGCCAGCA	440
RESULT 11			
BQ286311			
LOCUS			
DEFINITION	BQ286311	459 bp	mRNA linear EST 14-MAY-2002
ACCESSION	1k28e04.y1	HR85 islet Homo sapiens cDNA clone IMAGE:5782351 5'	
VERSION		similar to SW:GLUC_HUMAN P01275 GLUCAGON PRECURSOR. [1] ;, mRNA	
KEYWORDS	BQ286311.1	GI:20655687	
SOURCE	EST.		
ORGANISM	human.		
REFERENCE	Homo sapiens		
AUTHORS	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.		
	1 (bases 1 to 459)		
	Melton,D., Brown,J., Kenty,G., Permutt,A., Lee,C., Kaestner,K., Lemishka,I., Searce,M., Brestelli,J., Gradwohl,G., Clifton,S., Hillier,L., Marra,M., Page,D., Wylie,T., Martin,J., Blistahn,A., Schmitt,A., Theising,B., Ritter,E., Ronko,T., Bennett,J., Cardenas , M., Gibbons,M., McCann,R., Cole,R., Tsagarashvili,R., Williams,T., Jackson,Y. and Bowers,Y.		
TITLE	Endocrine Pancreas Consortium		
JOURNAL	Unpublished (2000)		
COMMENT	Contact: Douglas Melton, Klaus H. Kaestner, & Hiroshi Inoue		
	Endocrine Pancreas Consortium		
	Harvard University, Howard Hughes Medical Institute		
	Dept of Molecular and Cellular Biology, 7 Divinity Ave, Cambridge, MA 02138		
	Tel: 617-495-1812		
	Fax: 617-495-8557		
	Email: dmelton@biohp.harvard.edu		
	Library was constructed by Dr. Hiroshi Inoue DNA sequencing by: Washington University Genome Sequencing Center For information on obtaining a clone please contact: Dr. Hiroshi Inoue (hinoue@im.wustl.edu)		
	Seq primer: -40RP from Gibco		
	High quality sequence stop: 440.		
FEATURES	Location/Qualifiers		
source	1..459		
	/organism="Homo sapiens"		
	/db_xref="taxon:9606"		
	/clone="IMAGE:5782351"		
	/clone_lib="HR85 islet"		
	/tissue_type="Purified pancreatic islet"		
	/lib_host="DH10B"		
	/note="Organ: Pancreas; Vector: pBluescript SK(-); Site_1: NotI; Site_2: XhoI; cDNA made by oligo-dT priming. Size-selected on agarose gel. Average insert size ~1kb. 5' XhoI site was destroyed after directional cloning. Amplified once. Contact Information: Hiroshi Inoue, MD, Metabolism Div. (Alan Permutt Lab), Washington University School of Medicine, Box 8127, 660 South Euclid Ave., St. Louis, MO 63110, E-mail: hinoue@im.wustl.edu, Tel: 314-362-1916, Fax: 314-747-2692."		
BASE COUNT	135 a 105 c 109 g 110 t		
ORIGIN			
Query Match	98.3%;	Score 91.4;	DB 14;
Best Local Similarity	98.9%;	Pred. No. 1.8e-20;	
Matches 92;	Conservative 0;	Mismatches 1;	Indels 0;
		Gaps 0;	
OY	1	CATGTTGAAGGACCTTACACATGATCTAGTCTTATTGGGAAGCCCAAGCTGCCAAG	60
DB	366	CATGCTGAAGGACCTTATACCAATGATAGTCTTATTGGGAAGCCCAAGCTGCCAAG	425
OY	61	GAATTCATTGCTTGGCTGCTGTAAGAGCCGAGAGA	93
DB	426	GAATTCATTGCTTGGCTGCTGTAAGAGCCGAGAGA	458
RESULT 12			

Accession	LOCUS	DEFINITION	VERSION	KEYWORDS	ORGANISM	REFERENCE	AUTHORS	TITLE	JOURNAL	COMMENT
BM312520	461 bp	mRNA	linear	EST 03-JAN-2002						
1675612.y1	HR85 islet	Homo sapiens cDNA 5' similar to SW:GLUC_HUMAN								
P01275	GLUCAGON	PRECURSOR. [1] ; mRNA sequence.								
BM312520										
BM312520.1	GI:18046865									
EST.										
human.										
Homo sapiens										
Eukaryota: Metazoa: Chordata: Craniata: Vertebrata: Euteleostomi;										
Mammalia: Eutheria: Primates: Catarrhini: Homiidae: Homo.										
1 (bases 1 to 461)										
Melton,D., Brown,J., Kenty,G., Permutt,A., Lee,C., Kaestner,K.,										
Lemishka,I., Searce,M., Brestelli,J., Gradwohl,G., Clifton,S.,										
Hillier,L., Marra,M., Pape,D., Wylie,T., Martin,J., Bistrah,A.,										
Schmitt,A., Theising,B., Ritter,E., Ronko,I., Bennett,J., Gardnas										
,M., Gibbons,M., McCann,R., Cole,R., Tsagarisvill,R., Williams,T.,										
Jackson,Y. and Bowers,Y.										
Endocrine Pancreas Consortium										
Unpublished (2000)										
Contact: Douglas Melton, Klaus H. Kaestner, & Hiroshi Inoue										
Endocrine Pancreas Consortium										
Harvard University, Howard Hughes Medical Institute										
Dept of Molecular and Cellular Biology, 7 Divinity Ave, Cambridge,										
MA 02138										
Tel: 617-495-1812										
Fax: 617-495-8557										
Email: dmelton@chp.harvard.edu										
Library was constructed by Dr. Hiroshi Inoue DNA sequencing by:										
Washington University Genome Sequencing Center For information on										
obtaining a clone please contact: Dr. Hiroshi Inoue										
(hinoue@im.wustl.edu)										
Seq primer: -40RP from Gibco										
High quality sequence stop: 401.										
Location/Qualifiers										
1..461										
/organism="Homo sapiens"										
/db_xref="taxon:9606"										
/clone_lib="HR85 islet"										
/tissue_type="Purified pancreatic islet"										
/lab_host="DH10B"										
/note="Organ: Pancreas; Vector: pBluescript SK(-); site:1;										
Note: Site:2: XhoI; CDNA made by oligo-dT priming. Inset size										
Size-selected on agarose gel. Average insert size ~1kb. 5'										
XhoI site was destroyed after directional cloning.										
Amplified once. Contact information: Hiroshi Inoue, MD,										
Metabolism Div. (Alan Permutt lab), Washington University										
School of Medicine, Box 8127, 660 South Euclid Ave., St.										
Louis, MO 63110, E-mail: hinoue@imgate.wustl.edu, Tel:										
314-362-1916, Fax: 314-747-2692."										
BASE COUNT	128 a	102 c	118 g	113 t						
ORIGIN										
Query Match	98.3%;	Score 91.4;	DB 13;	Length 461;						

VERSION	BO271456.1	GI:20496522
KEYWORDS	EST.	
SOURCE	human.	
ORGANISM	Homo sapiens	
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.	
AUTHORS	1 (bases 1 to 463) Melton,D., Brown,J., Kenly,G., Permutt,A., Lee,C., Kaestner,K., Lemishka,I., Searce,M., Brestelli,J., Gadowh,G., Clifton,S., Hillier,L., Marra,M., Pape,D., Wylie,T., Martin,J., Blisstein,A., Schmitt,A., Theising,B., Riter,E., Ronko,I., Bennett,J., Cardenas 'M., Gibbons,M., McCann,R., Cole,R., Tsagareishvili,R., Williams,T., Jackson,T. and Bowers,X.,	
TITLE	Endocrine Pancreas Consortium	
JOURNAL	Unpublished (2000)	
COMMENT	Other ESTs: ik14b08.x1 Contact: Douglas Melton, Klaus H. Kaestner, & Hiroshi Inoue Endocrine Pancreas Consortium Harvard University, Howard Hughes Medical Institute Dept of Molecular and Cellular Biology, 7 Divinity Ave, Cambridge, MA 02138 Tel: 617-495-1812 Fax: 617-495-8557 Email: dmelton@biohpc.harvard.edu Library was constructed by Dr. Hiroshi Inoue DNA sequencing by: Washington University Genome Sequencing Center For information on obtaining a clone please contact: Dr. Hiroshi Inoue (hinoue@um.wustl.edu) Seq primer: -40RP from Glibco.	
FEATURES	Location/Qualifiers	
source	1..463 /organism="Homo sapiens" /db_xref="taxon:9606" /clone="IMAGE: 5780703" /clone_1kb="HR85 islet" /tissue_type="Purified pancreatic islet" /lab_host="DH10B" /note="organ: Pancreas; Vector: pBluescript SK(-); Site_1: NotI; Site_2: XhoI; cDNA made by oligo-dT priming; -1kb. 5' Size-selected on agarose gel. Average insert size ~1kb. 5' XhoI site was destroyed after directional cloning. Amplified once. Contact information: Hiroshi Inoue, MD, Metabolism Div. (Alan Permutt Lab), Washington University School of Medicine, Box 8127, 660 South Euclid Ave., St. Louis, MO 63110, E-mail: hinoue@ingate.wustl.edu, Tel: 314-362-1916, Fax: 314-747-2692."	
BASE COUNT	135 a 107 c 115 g 106 t	
ORIGIN		
Query Match	98.3%;	Score 91.4; DB 14; Length 463;
Best Local Similarity	98.9%;	Pred No. 1.8e-20;
Matches 92; Conservative	0; Mismatches 1;	Indels 0; Gaps 0;
Oy	1 CATGTGAAGGACCTTTACCACTGATGTAAGTTATTATTTGGAAGGCCAACCTGCCAAG 60 Db 361 CATCTGAAGGACCTTTACCACTGATGTAAGTTATTATTTGGAAGGCCAACCTGCCAAG 420	
Oy	61 GAATTCATGCTGGCGCTGCGAAGGCCGAGGA 93 Db 421 GAATTCATGCTGGCGCTGCGAAGGCCGAGGA 453	
RESULT 14		
BO416911	466 bp	RNA linear
LOCUS	ik39c06.y1	HR85 islet Homo sapiens cDNA clone IMAGE: 5783410 5'
DEFINITION	similar to SW:GLOC_HUMAN P01275 GLOCACON PRECURSOR. [1] ;, mRNA	
ACCESSION	BO416911	
VERSION	BO416911.1	GI:21122112
KEYWORDS	EST.	
SOURCE	human.	
ORGANISM	Homo sapiens	

REFERENCE
AUTHORS
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
1 (bases 1 to 466)
Melton,D., Brown,J., Kenty,G., Permutt,A., Lee,C., Kaestner,K., Lemishka,I., Scaerac,M., Brestelli,J., Gradwohl,G., Clifton,S., Hillier,L., Marra,M., Pape,D., Wylie,T., Martin,J., Blistain,A., Schmitt,A., Theising,B., Ritzer,E., Ronko,I., Bennett,J., Cardenas,M., Gibbons,M., McCann,R., Cole,R., Tsagarisvill,R., Williams,T., Jackson,Y. and Bowers,Y.
Endocrine Pancreas Consortium
Unpublished (2000)
Other ESTs: ik39c06.x1

TITLE
JOURNAL
COMMENT
Contact: Douglas Melton, Klaus H. Kaestner, & Hiroshi Inoue
Endocrine Pancreas Consortium
Harvard University, Howard Hughes Medical Institute
Dept of Molecular and Cellular Biology, 7 Divinity Ave, Cambridge, MA 02138
Tel: 617-495-1812
Fax: 617-495-8557
Email: dmeltone@hmp.harvard.edu

Library was constructed by Dr. Hiroshi Inoue DNA sequencing by: Washington University Genome Sequencing Center For information on obtaining a clone please contact: Dr. Hiroshi Inoue (hinoue@im.wustl.edu)
Seq primer: -40RP from Gibco.
Location/Qualifiers
1. 466
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="IMAGE: 5783410"
/clone_lib="HR85 islet"
/tissue_type="Purified pancreatic islet"
/lab_host="DH10B"
/note="Organ: Pancreas; Vector: pBluescript SK(-); Site:1: NotI; Site:2: XhoI; CDNA made by oligo-dt priming. Size-selected on agarose gel. Average insert size ~1kb. 5' XhoI site was destroyed after directional cloning. Amplified once. Contact information: Hiroshi Inoue, MD, Metabolism Div. (Alan Permutt Lab), Washington University School of Medicine, Box 8127, 660 South Euclid Ave., St. Louis, MO 63110, E-mail: hinoue@ingate.wustl.edu, Tel: 314-362-1916, Fax: 314-747-2692."

FEATURES

SOURCE

BASE COUNT 139 a 108 c 113 g 106 t
ORIGIN

Query Match

Best Local Similarity 98.3%; Score 91.4; DB 14; Length 466;
Matches 92; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 CATGTTGAAGGACCTTTACAGTATGTAAGTCTTATTTGGAAGGCCAAGTCCCAAG 60
DB 370 CATGCTGAAGGACCTTTACAGTATGTAAGTCTTATTTGGAAGGCCAAGTCCCAAG 429
QY 61 GAATTCATTGCTTGGCTGGTGAAGGCCGAGGA 93
DB 430 GAATTCATTGCTTGGCTGGTGAAGGCCGAGGA 462

RESULT 15

LOCUS

BO271361 468 bp mRNA linear EST 07-MAY-2002
BO271361
DEFINITION
ik12h07.y1 HR85 islet Homo sapiens cDNA clone IMAGE: 5780965 5',
similar to SW:GLUC_HUMAN P01275 GLUCAGON PRECURSOR. [1], mRNA
sequence.

ACCESSION

BO271361
VERSION
BO271361.1 GI:20496427

KEYWORDS

SOURCE

ORGANISM

human.
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
1 (bases 1 to 466)
Melton,D., Brown,J., Kenty,G., Permutt,A., Lee,C., Kaestner,K.,

TITLE
JOURNAL
COMMENT
Contact: Douglas Melton, Klaus H. Kaestner, & Hiroshi Inoue
Endocrine Pancreas Consortium
Harvard University, Howard Hughes Medical Institute
Dept of Molecular and Cellular Biology, 7 Divinity Ave, Cambridge, MA 02138
Tel: 617-495-1812
Fax: 617-495-8557
Email: dmeltone@hmp.harvard.edu

Library was constructed by Dr. Hiroshi Inoue DNA sequencing by: Washington University Genome Sequencing Center For information on obtaining a clone please contact: Dr. Hiroshi Inoue (hinoue@im.wustl.edu)
Seq primer: -40RP from Gibco.
Location/Qualifiers
1. 468
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="IMAGE: 5780965"
/clone_lib="HR85 islet"
/tissue_type="Purified pancreatic islet"
/lab_host="DH10B"
/note="Organ: Pancreas; Vector: pBluescript SK(-); Site:1: NotI; Site:2: XhoI; CDNA made by oligo-dt priming. Size-selected on agarose gel. Average insert size ~1kb. 5' XhoI site was destroyed after directional cloning. Amplified once. Contact information: Hiroshi Inoue, MD, Metabolism Div. (Alan Permutt Lab), Washington University School of Medicine, Box 8127, 660 South Euclid Ave., St. Louis, MO 63110, E-mail: hinoue@ingate.wustl.edu, Tel: 314-362-1916, Fax: 314-747-2692."

FEATURES

SOURCE

BASE COUNT 140 a 108 c 114 g 106 t
ORIGIN

Query Match 98.3%; Score 91.4; DB 14; Length 468;
Matches 92; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 CATGTTGAAGGACCTTTACAGTATGTAAGTCTTATTTGGAAGGCCAAGTCCCAAG 60
DB 370 CATGCTGAAGGACCTTTACAGTATGTAAGTCTTATTTGGAAGGCCAAGTCCCAAG 429
QY 61 GAATTCATTGCTTGGCTGGTGAAGGCCGAGGA 93
DB 430 GAATTCATTGCTTGGCTGGTGAAGGCCGAGGA 462

Search completed: February 14, 2003, 09:05:35
Job time : 1185 secs

GenCore version 5.1.4-p5_4578
Copyright (c) 1993 - 2003 Compugen Ltd.

OM nucleic. - nucleic search, using sw model

Run on: February 14, 2003, 07:10:09 ; Search time 174.5 Seconds
(without alignments)
1200.205 Million cell updates/sec

Title: US-09-091-605-2

Perfect score: 93
Sequence: 1 CATGCTGAAGGACCTTAC.....GGCTGCTGAAGGCCGAGGA 93

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 2185239 seqs, 112599159 residues

Total number of hits satisfying chosen parameters: 4370478

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : N_Geneseq_101002.*

```
1: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1980.DAT:*
2: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1981.DAT:*
3: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1982.DAT:*
4: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1983.DAT:*
5: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1984.DAT:*
6: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1985.DAT:*
7: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1987.DAT:*
8: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1988.DAT:*
9: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1989.DAT:*
10: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1990.DAT:*
11: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1991.DAT:*
12: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1992.DAT:*
13: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1993.DAT:*
14: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1994.DAT:*
15: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1995.DAT:*
16: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1996.DAT:*
17: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1998.DAT:*
18: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1999.DAT:*
19: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA2000.DAT:*
20: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA2001A.DAT:*
21: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA2001B.DAT:*
22: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA2002.DAT:*
23: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA2002.DAT:*
24: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA2002.DAT:*
```

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	93	100.0	93	18	AAAT77296
2	93	100.0	96	13	AAQ27605
3	93	100.0	955	18	AAAT75672
4	93	100.0	955	21	AAAT75673
5	93	100.0	955	21	AAAC55763
6	93	100.0	955	21	AAAC55765
7	93	100.0	2356	21	AAAC55775
8	93	100.0	3798	23	ABY255106
9	91.4	98.3	93	18	AAAT77297

10	91.4	98.3	396	22	AAAF30989	Prepro-somatostati
11	88	94.6	626	24	ABO58859	Human colon cancer
12	83.4	89.7	895	18	AAAT75669	Rat preproglucagon
13	83.4	89.7	895	21	AAAC55762	Rat preproglucagon
14	83.4	89.7	1034	11	AAAO6255	Glucagon-like pept
15	83.4	89.7	1034	18	AAAT73216	Rat prepro-glucago
16	83.4	89.7	1034	20	AAAZ20678	Preproglucagon cod
17	81.8	88.0	387	21	AAAS1462	PCPB-RR-GLIP (R26)
18	81.8	88.0	390	21	AAAS1461	PCPB-RR-GLIP (R26)
19	81.8	88.0	390	21	AAAS1464	PCPB-RR-GLIP (R26)
20	81.8	88.0	393	21	AAAS1463	PCPB-RR-GLIP (R26)
21	80.8	86.9	144	13	AAO27607	PCPB-RR-GLIP (R26)
22	80.4	86.5	387	21	AAAS1460	PCPB-RR-GLIP (R26)
23	74.8	80.6	95	22	AAAF29136	PCPB-RR-GLIP (R26)
24	72.2	77.6	77.6	22	AAO25339	PCPB-RR-GLIP (R26)
25	68	73.1	627	20	AAAX9247	PCPB-RR-GLIP (R26)
26	63.2	68.0	315	11	AAAO9467	PCPB-RR-GLIP (R26)
27	61.6	66.2	335	21	AAAS1465	PCPB-RR-GLIP (R26)
28	61.6	66.2	335	21	AAAS1466	PCPB-RR-GLIP (R26)
29	58.6	63.0	110	16	AAO91253	PCPB-RR-GLIP (R26)
30	58.6	63.0	112	16	AAO91251	PCPB-RR-GLIP (R26)
31	58.6	63.0	384	16	AAO91259	PCPB-RR-GLIP (R26)
32	58.2	62.6	516	17	AAAT07347	PCPB-RR-GLIP (R26)
33	57	61.3	279	17	AAAT34870	PCPB-RR-GLIP (R26)
34	55.4	59.6	174	17	AAAT34869	PCPB-RR-GLIP (R26)
35	54.6	58.7	1134	22	AAAC86599	PCPB-RR-GLIP (R26)
36	54.6	58.7	1158	22	AAAC86600	PCPB-RR-GLIP (R26)
37	49.8	53.5	78	21	AAAZ57465	PCPB-RR-GLIP (R26)
38	49.8	53.5	78	21	AAAZ57465	PCPB-RR-GLIP (R26)
39	47.4	51.0	112	16	AAO91254	PCPB-RR-GLIP (R26)
40	47	50.6	108	16	AAO91252	PCPB-RR-GLIP (R26)
41	37.8	40.5	57	18	AAV02282	PCPB-RR-GLIP (R26)
42	37.8	40.6	65	24	ABNS6946	PCPB-RR-GLIP (R26)
43	35.8	38.5	48	18	AAV02283	PCPB-RR-GLIP (R26)
44	35	37.6	70	22	AAAC6614	PCPB-RR-GLIP (R26)
45	34	36.6	492	19	AAV33163	PCPB-RR-GLIP (R26)

ALIGNMENTS

RESULT 1
ID AAT77296 standard; DNA: 93 BP.

AC AAT77296;

DT 14-JAN-1998 (first entry)

DE DNA encoding glucagon-like peptide GLP-1(7-37) Ala8 analogue.

KW Diabetes: non-insulin dependent diabetes mellitus; NIDDM;

KW Insulin dependent diabetes mellitus; IDDM; gene therapy;

KW glucagon-like peptide; GLP; ss.

OS Synthetic.

FT Key Location/Qualifiers

FT mat_peptide I..93

FT /tag= a

FT /product= Ala8_GLP-1(7-37)

FT

FT

FT

FT

FT

FT

PI Borts TL, Broderick CL, Dimarchi RD, Grinnell BW;
 PI Miller AR;
 DR WPI: 1997-415336/38.
 DR P-PSDB: AAM24389.
 XX
 PI Gene therapy of type I and type II diabetes - by in vivo expression
 PT of glucagon like peptide GLP-1(7-37) analogue
 XX
 PS Claim 8; Page 24; 31pp; English.
 XX
 CC This DNA sequence encodes an analogue of a glucagon-like peptide
 CC GLP-1(7-37). This peptide provides a means of delivering long term
 CC amounts of a GLP-1(7-37)-based protein, which is useful in treating type
 CC I and type II diabetes. A stable mammalian cell line, which is
 CC immunologically isolated from the mammal's immune system, is transformed
 CC with a vector expressing a protein of the above sequence. This
 CC transformed cell line is then implanted into the individual needing
 CC treatment. Once implanted, the GLP-1(7-37) analogue, in conjunction with
 CC high serum glucose levels, causes pancreatic cells to produce insulin in
 CC non-insulin dependent diabetes mellitus (NIDDM) and delays gastric
 CC emptying in both NIDDM and insulin dependent diabetes mellitus (IDDM)
 CC patients. An expression vector coding for a protein of the above
 CC sequence can also be directly injected into the mammal, such that the
 CC vector is incorporated into a cell and secretes the protein. This method
 CC overcomes the problems of the short serum half life of GLP-1(7-37),
 CC allowing delivery of effective long term amounts for diabetes treatment.
 XX
 S0 Sequence 93 BP; 24 A; 17 C; 28 G; 24 T; 0 other;

Query Match 100.0%; Score 93; DB 18; Length 93;
 Best Local Similarity 100.0%; Pred. No. 1.6e-23;
 Matches 93; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 CATGCTGAAGGACCTTTACAGTGAATGTTATTGGAAGCCCAAGCTGCCAAG 60
 DB 1 CATGCTGAAGGACCTTTACAGTGAATGTTATTGGAAGCCCAAGCTGCCAAG 60
 OY 61 GAATTCATTGCTGGCTGGTGAAGGCCGAGGA 93
 DB 61 GAATTCATTGCTGGCTGGTGAAGGCCGAGGA 93

RESULT 2
 AAQ27605
 ID AAQ27605 standard; DNA; 96 BP.
 XX
 AC AAQ27605;
 XX
 DT 04-FEB-1993 (first entry)
 XX
 DE DNA encoding glucagon-like peptide I (7-37).
 XX
 KW Human parathyroid hormone production; osteoporosis; GLP-I (7-37);
 KW hypoparathyroidism; hypertension; insulinotropin; ss.
 XX
 OS Synthetic.
 XX
 PN EP499990-A.
 XX
 PD 26-AUG-1992.
 XX
 PF 15-FEB-1992; 92EP-0102543.
 XX
 PR 19-FEB-1991; 91JP-0024841.
 PR 18-OCT-1991; 91JP-0271438.
 PR 24-OCT-1991; 91JP-0277724.
 XX
 PA (TAKE) TAKEDA CHEM IND LTD.
 XX
 PI Fukuda T, Koyama N, Kuriyama M, Nishimura O;
 XX WPI: 1992-286114/35.

XX
 PT Cysteine-free peptide prodn., e.g. human parathyroid hormone
 PT deriv. - by culturing transformant to produce a fusion protein
 PT comprising the cysteine-free peptide fused to a cysteine at its
 PT N-terminus where cleavage can occur
 XX
 PS Disclosure; Page 5; 60pp; English.
 XX
 CC The DNA codes for glucagon-like peptide I (7-37) [GLP-I (7-37)]
 CC (insulinotropin). PTH (1-34), it may be used in a method of culturing
 CC a transformant to produce a fusion protein comprising a cysteine-free
 CC peptide fused to a cysteine at its N-terminus where cleavage can occur.
 CC This method can be used to produce peptides which can be used as a
 CC pharmaceutical or industry in general. See also AAQ27603-Q27622.
 XX
 S0 Sequence 96 BP; 24 A; 18 C; 29 G; 25 T; 0 other;

Query Match 100.0%; Score 93; DB 13; Length 96;
 Best Local Similarity 100.0%; Pred. No. 1.6e-23;
 Matches 93; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 CATGCTGAAGGACCTTTACAGTGAATGTTATTGGAAGCCCAAGCTGCCAAG 60
 DB 1 CATGCTGAAGGACCTTTACAGTGAATGTTATTGGAAGCCCAAGCTGCCAAG 60
 OY 61 GAATTCATTGCTGGCTGGTGAAGGCCGAGGA 93
 DB 61 GAATTCATTGCTGGCTGGTGAAGGCCGAGGA 93

RESULT 3
 AAT75672
 ID AAT75672 standard; DNA; 955 BP.
 XX
 AC AAT75672;
 XX
 DT 03-FEB-1998 (first entry)
 XX
 DE Human preproglucagon cDNA.
 XX
 KW Recombinant protein; expression; secretory cell line; human;
 KW glucagon; peptide hormone; amidation; insulinoma; RIN; rat;
 KW diabetes; gene therapy; ss.
 XX
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT CDS 27..569
 FT CDS /*tag= a
 XX
 XX WO9726321-A2.
 XX
 PD 24-JUL-1997.
 XX
 PF 17-JAN-1997; 97WO-US00761.
 XX
 PR 15-OCT-1996; 96US-0028427.
 PR 19-JAN-1996; 96US-0589028.
 XX
 PA (BETA-) BETAGENE INC.
 PA (TEXA) UNIV TEXAS SYSTEM.
 XX
 PI Clark SA, Halban PA, Kruse F, McGarry D, Newgard CB;
 PI Northington KD, Quade C, Thigpen AE;
 DR WPI: 1997-385326/35.
 DR P-PSDB: AAM22080.
 XX
 PT Recombinant cell engineered to provide amylin to a mammal - useful
 PT to treat e.g. angiogenesis, anorexia, obesity, hypertension,
 PT osteoporosis etc.
 XX
 PS Example 10; Page 283-284; 336pp; English.

XX This cDNA sequence includes a coding sequence for human
 CC preproglucagon (see AAW22080). It was produced from pancreatic
 CC cDNA by PCR amplification (see AAT75670-71), and has been ligated
 CC into pNOTA/17, generating pNOTA17/h.glucagon. A mutated human
 CC preproglucagon cDNA (see AAT75673) has also been produced. Rat
 CC insulinoma RIN cell lines expressing preproglucagon demonstrated
 CC efficient amidation of a secreted, processed polypeptide. The
 CC invention provides methods for production of heterologous
 CC polypeptides using recombinantly engineered cell lines. Also
 CC described are methods of engineering cells for high level
 CC expression, methods of large-scale heterologous protein production,
 CC and methods for treatment of disease in vivo using viral delivery
 CC systems and recombinant cell lines.

SQ Sequence 955 BP; 301 A; 181 C; 203 G; 270 T; 0 other;

Query Match 100.0%; Score 93; DB 18; Length 955;
 Best Local Similarity 100.0%; Pred. No. 3.2e-23;
 Matches 93; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CATGCTGAAGGACCTTACCAAGTACGTCTTATTGGAAAGCCAGCTGCCAAG 60
 Db 318 CATGCTGAAGGACCTTACCAAGTACGTCTTATTGGAAAGCCAGCTGCCAAG 377

Oy 61 GAATTCATTGCTGGCTGTAAGGCGGAGGA 93
 Db 378 GAATTCATTGCTGGCTGTAAGGCGGAGGA 410

RESULT 4
 AAT75673
 ID AAT75673 standard; DNA; 955 BP.

XX AAT75673;
 XX 03-FEB-1998 (first entry)

DE Human mutated preproglucagon cDNA.

XX
 KW Recombinant protein; expression; secretory cell line; human;
 KW glucagon; peptide hormone; amidation; insulinoma; RIN; rat;
 KW diabetes; gene therapy; ss.

OS Homo sapiens.
 OS Synthetic.

XX
 FT Key Location/Qualifiers
 FT CDS 27..569
 FT /*tag= a
 FT mutation 181
 FT /*tag= b
 FT /*note= "C at position 181 creates an Ala-52 codon"
 FT mutation 204
 FT /*tag= b
 FT /*note= "T at position 204 creates an SpeI site"

MO9726321-A2.
 PD 24-JUL-1997.
 XX
 XX 17-JAN-1997; 97WO-US00761.
 XX
 XX 15-OCT-1996; 96US-0028427.
 PR 19-JAN-1996; 96US-0589028.
 XX
 PA (BETA-) BETAGENE INC.
 PA (TEXA) UNIV TEXAS SYSTEM.
 XX
 PI Clark SA, Halban PA, Kruse F, McGarry D, Newgard CB;
 PI Normington KD, Quade C, Thigpen AE;
 XX
 DR WPI, 1997-385326/35.

DR P-PSDB; AAW22081.
 XX
 XX Recombinant cell engineered to provide amylin to a mammal - useful
 PT to treat e.g. angiogenesis, anorexia, obesity, hypertension,
 PT osteoporosis etc.
 XX
 XX Example 10; Page 285-286; 336pp; English.

CC This cDNA sequence includes a coding sequence for a mutated human
 CC preproglucagon (see AAW22081). It was produced from plasmid
 CC pNOTA17/h.glucagon (see AAT75672) using mutagenic primers. 2
 CC Mutations were created, one altering the native Arg-52 codon to an
 CC Ala codon, and one creating an SpeI site, with no change in the
 CC deduced amino acid sequence. The mutated sequence has been used
 CC to construct plasmid pNOTA17/mut.glucagon. Rat insulinoma RIN cell
 CC lines expressing preproglucagon demonstrated efficient amidation of
 CC a secreted, processed polypeptide. The invention provides methods
 CC for production of heterologous polypeptides using recombinantly
 CC engineered cell lines. Also described are methods of engineering
 CC cells for high level expression, methods of large-scale
 CC heterologous protein production, and methods for treatment of
 CC disease in vivo using viral delivery systems and recombinant cell
 CC lines.

SQ Sequence 955 BP; 302 A; 180 C; 202 G; 271 T; 0 other;

Query Match 100.0%; Score 93; DB 18; Length 955;
 Best Local Similarity 100.0%; Pred. No. 3.2e-23;
 Matches 93; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CATGCTGAAGGACCTTACCAAGTACGTCTTATTGGAAAGCCAGCTGCCAAG 60
 Db 318 CATGCTGAAGGACCTTACCAAGTACGTCTTATTGGAAAGCCAGCTGCCAAG 377

Oy 61 GAATTCATTGCTGGCTGTAAGGCGGAGGA 93
 Db 378 GAATTCATTGCTGGCTGTAAGGCGGAGGA 410

RESULT 5
 AAC55763
 ID AAC55763 standard; cDNA; 955 BP.

XX AAC55763;
 XX 17-JAN-2001 (first entry)

DE Human preproglucagon encoding cDNA.

XX
 KW Amylin; production; secretory cell; blood glucose level regulation;
 KW diabetes mellitus; hypoglycaemia; osteoporosis; Paget's disease;
 KW hypercalcaemia; obesity; hypertension; ss.

OS Homo sapiens.

XX
 FT US6110707-A.
 FT PN 29-AUG-2000.
 XX
 XX 17-JAN-1997; 97US-0784582.
 XX
 XX 11-OCT-1996; 96US-0028279.
 PR 19-JAN-1996; 96US-0589028.
 XX
 PA (TEXA) UNIV TEXAS SYSTEM.
 PA (BETA-) BETAGENE INC.
 XX
 PI Newgard CB, Halban P, Normington KD, Thigpen AE, Quade C;
 PI Kruse F, McGarry D, Clark SA;
 XX
 DR WPI, 2000-586352/55.
 DR P-PSDB; AAB26774.
 XX

PT Producing mammalian amylin, useful for regulating blood glucose and
 PT insulin levels, e.g. for treating diabetes mellitus or hypoglycemia, by
 PT employing recombinantly engineered secretory cell lines -
 XX
 XX Example 10; Column 175-178; 136pp; English.

CC This invention relates to a method for producing mammalian amylin. The
 CC method relies on the use of a recombinantly engineered secretory cell
 CC line. The method comprises:
 CC (a) providing a starting secretory cell that has a regulated secretory
 CC pathway;
 CC (b) introducing, into the starting secretory cell, an amylin-encoding
 CC gene operatively linked to a first promoter;
 CC (c) selecting a secretory cell of (b) that exhibits increased production
 CC of biologically active amylin as compared to the starting secretory
 CC cell; and (d) culturing the selected secretory cell.
 CC Amylin is an insulin modulator, and the method results in antidiabetic,
 CC hypotensive and osteopathic activity. The amylin produced are useful
 CC for regulating blood glucose levels, as well as in modulating the
 CC circulating levels of insulin in a mammal. The amylin produced maybe
 CC used in treating diabetes mellitus, hypoglycemia, osteoporosis, Paget's
 CC disease, hypercalcaemia, obesity, hypertension, or any other disorder
 CC requiring amylin regulation. The invention includes cDNA and protein
 CC sequences (AAC55760 and AAB26771) representing human amylin. Sequences
 CC AAC55716-C55681 and AAB26765-B26777 are used in examples of the method of
 CC the invention for the production of mammalian amylin.

CC Sequence 955 BP; 301 A; 181 C; 203 G; 270 T; 0 other;

Query Match

Best Local Similarity 100.0%; Score 93; DB 21; Length 955;
 Matches 93; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 CATGCTGAAGGACCTTACAGTATGATGTTCTTATTGGAAGGCCAAGTGCAG 60
 DB 318 CATGCTGAAGGACCTTACAGTATGATGTTCTTATTGGAAGGCCAAGTGCAG 377

OY 61 GAATTCATTGCTTGGCTGGTGAAGGCCGAGCA 93
 DB 378 GAATTCATTGCTTGGCTGGTGAAGGCCGAGCA 410

RESULT 6

AAC55765
 ID AAC55765 standard; cDNA; 955 BP.

AC AAC55765;

DT 17-JAN-2001 (first entry)

DE Mutant human preproglucagon cDNA.

KW Amylin; production; secretory cell; blood glucose level regulation;
 KW diabetes mellitus; hypoglycaemia; osteoporosis; Paget's disease;
 KW hypercalcaemia; obesity; hypertension; ss.

OS Homo sapiens.

PN US6110707-A.

PD 29-AUG-2000.

PF 17-JAN-1997; 97US-0784582.

PR 11-OCT-1996; 96US-0028279.

PR 19-JAN-1996; 96US-0589028.

PA (TEXA) UNIV TEXAS SYSTEM.

PA (BETA-) BETAGENE INC.

PI Newgard CB, Halban P, Normington KD, Thigpen AE, Quade C;
 PI Kruse F, McCarry D, Clark SA;

DR WPI: 2000-586352/55.
 DR P-PDB: AAB26775.

PT Producing mammalian amylin, useful for regulating blood glucose and
 PT insulin levels, e.g. for treating diabetes mellitus or hypoglycemia, by
 PT employing recombinantly engineered secretory cell lines -
 XX
 XX Example 10; Column 179-180; 136pp; English.

CC This invention relates to a method for producing mammalian amylin. The
 CC method relies on the use of a recombinantly engineered secretory cell
 CC line. The method comprises:
 CC (a) providing a starting secretory cell that has a regulated secretory
 CC pathway;
 CC (b) introducing, into the starting secretory cell, an amylin-encoding
 CC gene operatively linked to a first promoter;
 CC (c) selecting a secretory cell of (b) that exhibits increased production
 CC of biologically active amylin as compared to the starting secretory
 CC cell; and (d) culturing the selected secretory cell.
 CC Amylin is an insulin modulator, and the method results in antidiabetic,
 CC hypotensive and osteopathic activity. The amylin produced are useful
 CC for regulating blood glucose levels, as well as in modulating the
 CC circulating levels of insulin in a mammal. The amylin produced maybe
 CC used in treating diabetes mellitus, hypoglycemia, osteoporosis, Paget's
 CC disease, hypercalcaemia, obesity, hypertension, or any other disorder
 CC requiring amylin regulation. The invention includes cDNA and protein
 CC sequences (AAC55760 and AAB26771) representing human amylin. Sequences
 CC AAC55716-C55681 and AAB26765-B26777 are used in examples of the method of
 CC the invention for the production of mammalian amylin.

CC Sequence 955 BP; 302 A; 180 C; 202 G; 271 T; 0 other;

Query Match

Best Local Similarity 100.0%; Score 93; DB 21; Length 955;
 Matches 93; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 CATGCTGAAGGACCTTACAGTATGATGTTCTTATTGGAAGGCCAAGTGCAG 60
 DB 318 CATGCTGAAGGACCTTACAGTATGATGTTCTTATTGGAAGGCCAAGTGCAG 377

OY 61 GAATTCATTGCTTGGCTGGTGAAGGCCGAGCA 93
 DB 378 GAATTCATTGCTTGGCTGGTGAAGGCCGAGCA 410

RESULT 7

AAC55775
 ID AAC55775 standard; DNA; 2356 BP.

AC AAC55775;

DT 17-JAN-2001 (first entry)

DE Human growth hormone and mutated proglucagon fusion DNA sequence.

KW Amylin; production; secretory cell; blood glucose level regulation;
 KW diabetes mellitus; hypoglycaemia; osteoporosis; Paget's disease;
 KW hypercalcaemia; obesity; hypertension; ss.

OS Homo sapiens.

PN US6110707-A.

PD 29-AUG-2000.

PF 17-JAN-1997; 97US-0784582.

PR 11-OCT-1996; 96US-0028279.

PR 19-JAN-1996; 96US-0589028.

PA (TEXA) UNIV TEXAS SYSTEM.

PA (BETA-) BETAGENE INC.

PI Newgard CB, Halban P, Normington KD, Thigpen AE, Quade C;
PI Kruse F, McGarry D, Clark SA;
XX WPI: 2000-586352/55.
DR P-PSDB: AAB26777.
XX
XX producing mammalian amylin, useful for regulating blood glucose and
PT insulin levels, e.g. for treating diabetes mellitus or hypoglycemia, by
PT employing recombinantly engineered secretory cell lines -
XX
PS Example 12; Column 187-190; 136pp; English.
XX
XX This invention relates to a method for producing mammalian amylin. The
CC method relies on the use of a recombinantly engineered secretory cell
CC line. The method comprises:
CC (a) providing a starting secretory cell that has a regulated secretory
CC pathway;
CC (b) introducing, into the starting secretory cell, an amylin-encoding
CC gene operatively linked to a first promoter;
CC (c) selecting a secretory cell of (b) that exhibits increased production
CC of biologically active amylin as compared to the starting secretory
CC cell; and (d) culturing the selected secretory cell.
CC Amylin is an insulin modulator, and the method results in antidiabetic,
CC hypotensive and osteopathic activity. The amylin produced are useful
CC for regulating blood glucose levels, as well as in modulating the
CC circulating levels of insulin in a mammal. The amylin produced may be
CC used in treating diabetes mellitus, hypoglycemia, osteoporosis, Paget's
CC disease, hypercalcaemia, obesity, hypertension, or any other disorder
CC requiring amylin regulation. The invention includes cDNA and protein
CC sequences (AAC55760 and AAB26771) representing human amylin. Sequences
CC AAC55716-C55681 and AAB26765-B26777 are used in examples of the method of
CC the invention for the production of mammalian amylin.
XX
SQ Sequence 2356 BP; 614 A; 600 C; 581 G; 561 T; 0 other;
XX
Query Match 100.0%; Score 93; DB 21; Length 2356;
Best Local Similarity 100.0%; Pred. No. 4.1e-23;
Matches 93; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 1 CATGCTGAAGGACCTTACCGATGATGTAAGTCTTATTGGAAAGGCCAAGTCCCAAG 60
DB 1704 CATGCTGAAGGACCTTACCGATGATGTAAGTCTTATTGGAAAGGCCAAGTCCCAAG 1763
XX
QY 61 GAATTCATTGCTTGCTGGTGAAGGCCGAGGA 93
DB 1764 GAATTCATTGCTTGCTGGTGAAGGCCGAGGA 1796
XX
RESULT 8
ABV25306
ID ABV25306 standard; cDNA; 3798 BP.
XX
AC ABV25306;
XX
DT 16-SEP-2002 (first entry)
XX
DE Human prostate expression marker cDNA 25297.
XX
KW Human; prostate cancer; cytostatic; carcinogen; pharmacodynamic marker;
KW pharmacogenomic marker; gene; ss.
XX
OS Homo sapiens.
XX
PN WO200160860-A2.
XX
PD 23-AUG-2001.
XX
PF 20-FEB-2001; 2001WO-US05171.
XX
PR 17-FEB-2000; 2000US-183319P.
PR 16-MAR-2000; 2000US-189862P.
PR 25-MAY-2000; 2000US-207454P.
PR 09-JUN-2000; 2000US-211314P.
XX

PR 18-JUL-2000; 2000US-219007P.
PR 13-DEC-2000; 2000US-255281P.
XX
XX (MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.
XX
PI Schlegel R, Endege WO, Monahan JE;
XX
XX WPI: 2001-662795/76.
DR
XX
XX Novel isolated nucleic acid molecule associated with cancerous state of
PT prostate cells and correlating with presence of prostate cancer, useful
PT for detecting presence of prostate cancer, stage of prostate cancer -
XX
PS Claim 1; Page 4978-4979; 11750pp; English.
XX
XX The invention relates to an isolated nucleic acid molecule (I) comprising
CC a nucleotide sequence given in Tables 1-9 (ABV00010-ABV62213) of the
CC specification or its complement. (I) is useful for:
CC (a) assessing whether a patient is afflicted with prostate cancer;
CC (b) monitoring the progression of prostate cancer in a patient;
CC (c) assessing the efficacy of a test compound to inhibit prostate
CC cancer in a patient;
CC (d) assessing the efficacy of a therapy for inhibiting prostate cancer
CC in a patient;
CC (e) selecting a composition for inhibiting prostate cancer in a patient;
CC (f) determining the prostate cell carcinogenic potential of a compound;
CC (g) determining whether prostate cancer has metastasized in a patient;
CC (h) assessing the aggressiveness or indolence of prostate cancer in a
CC patient;
CC (I) is also useful as a pharmacodynamic or pharmacogenomic marker.
XX
SQ Sequence 3798 BP; 1166 A; 563 C; 616 G; 1364 T; 89 other;
XX
Query Match 100.0%; Score 93; DB 23; Length 3798;
Best Local Similarity 100.0%; Pred. No. 4.8e-23;
Matches 93; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 1 CATGCTGAAGGACCTTACCGATGATGTAAGTCTTATTGGAAAGGCCAAGTCCCAAG 60
DB 3411 CATGCTGAAGGACCTTACCGATGATGTAAGTCTTATTGGAAAGGCCAAGTCCCAAG 3470
XX
QY 61 GAATTCATTGCTTGCTGGTGAAGGCCGAGGA 93
DB 3471 GAATTCATTGCTTGCTGGTGAAGGCCGAGGA 3503
XX
RESULT 9
AAT77297
ID AAT77297 standard; DNA; 93 BP.
XX
AC AAT77297;
XX
DT 14-JAN-1998 (first entry)
XX
DE DNA encoding glucagon-like peptide GLP-1(7-37) Val8 analogue.
XX
KW Diabetes; non-insulin dependent diabetes mellitus; NIDDM;
KW insulin dependent diabetes mellitus; IDDM; gene therapy;
KW glucagon-like peptide; GLP; ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT mat_peptide 1..93
FT /tag= a
FT /product= Val8_GLP-1(7-37)
XX
PN WO9729180-A1.
XX
PD 14-AUG-1997.
XX
PF 06-FEB-1997; 97WO-US01978.
XX

PR 23-FEB-1996; 96GB-0003847.
 PR 06-FEB-1996; 96US-0012111.
 XX
 PA (ELIL) LILLY & CO ELI.
 XX
 PI Borts TL, Broderick CL, Dimarchi RD, Grinnell BW;
 PI Miller AR;
 XX
 DR WPI: 1997-415336/38.
 DR P-PSDB: AAM24390.
 XX
 PT Gene therapy of type I and type II diabetes - by in vivo expression
 PT of glucagon like peptide GLP-1(7-37) analogue
 XX
 PS Claim 8; Page 24; 31pp; English.
 XX
 CC This DNA sequence encodes an analogue of a glucagon-like peptide
 CC GLP-1(7-37). This peptide provides a means of delivering long term
 CC amounts of a GLP-1(7-37)-based protein, which is useful in treating type
 CC I and type II diabetes. A stable mammalian cell line, which is
 CC immunologically isolated from the mammal's immune system, is transformed
 CC with a vector expressing a protein of the above sequence. This
 CC transformed cell line is then implanted into the individual needing
 CC treatment. Once implanted, the GLP-1(7-37) analogue, in conjunction with
 CC high serum glucose levels, causes pancreatic cells to produce insulin in
 CC non-insulin dependent diabetes mellitus (NIDDM) and delays gastric
 CC emptying in both NIDDM and insulin dependent diabetes mellitus (IDDM)
 CC patients. An expression vector coding for a protein of the above
 CC sequence can also be directly injected into the mammal, such that the
 CC vector is incorporated into a cell and secretes the protein. This method
 CC overcomes the problems of the short serum half life of GLP-1(7-37),
 CC allowing delivery of effective long term amounts for diabetes treatment.
 XX
 SQ Sequence 93 BP; 24 A; 16 C; 28 G; 25 T; 0 other;
 Query Match 98.3%; Score 91.4; DB 18; Length 93;
 Best Local Similarity 98.9%; Pred. No. 6e-23;
 Matches 92; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1 CATGCTGAAGGACCTTACCACTGATGATCTTATTGGAAAGCCAAAGTCGCAAG 60
 Db 1 CATGTTGAAGGACCTTACCACTGATGATCTTATTGGAAAGCCAAAGTCGCAAG 60
 QY 61 GAATTCATTGCTTGGCTGTGAAGGCCGAGCA 93
 Db 61 GAATTCATTGCTTGGCTGTGAAGGCCGAGCA 93
 Db
 RESULT 10
 AAF30989
 ID AAF30989 standard; DNA: 396 BP.
 XX
 AC AAF30989;
 XX
 DT 23-JUL-2001 (first entry)
 XX
 DE Prepro-somatostatin/GLP-1 coding sequence of PXIT-39.
 XX
 KM Somatostatin; glucagon-like peptide 1; GLP-1; antidiabetic;
 KM drug delivery; diabetes; gene therapy; PXIT-39; ss.
 XX
 OS Chimeric - Homo sapiens.
 OS Chimeric - Synthetic.
 XX
 FT key Location/Qualifiers
 FT CDS 7..390
 FT /tag= a
 FT /product= "prepro-somatostatin/cleavage site/GLP-1
 fusion"
 XX
 PN WO200136643-A1.
 XX
 PD 25-MAY-2001.

XX
 PF 17-NOV-2000; 2000WO-US31634.
 XX
 PR 19-NOV-1999; 99US-0166508.
 XX
 PA (TRAN-) TRANSKARIOTIC THERAPIES INC.
 XX
 PI Treco DA, Concino MF, Duguay SJ;
 PI WPI: 2001-355636/37.
 DR
 XX
 PT New nucleic acid constructs useful for transforming cells useful as a
 PT drug delivery vehicle -
 XX
 PS Example 1; Fig 3; 89pp; English.
 XX
 CC The present sequence is that of a DNA sequence encoding a
 CC prepro-somatostatin-glucagon-like peptide 1 (GLP-1) fusion protein.
 CC The coding region is flanked by a 5' BamHI site and a 3' XhoI site.
 CC A multibasic cleavage site separates the prepro-somatostatin and
 CC GLP-1 moieties of the fusion protein. The DNA sequence in plasmid
 CC PXIT-39 was designed for the stable, constitutive expression of
 CC GLP-1 (7-37) in human cells. This is an example of nucleic acid
 CC constructs of the invention designed for the expression of small
 CC peptides. The small peptides are especially therapeutic peptides
 CC such as small hormones and antidiabetic peptides such as GLP-1,
 CC exendin-4 and gastric inhibitory polypeptide. Claimed methods
 CC of treating a subject having diabetes involve administering the
 CC nucleic acid construct or a cell capable of expressing the small
 CC peptide. Transfected primary or secondary cells or cell strains
 CC have wide applicability as vehicles or delivery systems for
 CC therapeutic proteins. By controlling the number of cells introduced
 CC into an individual, one can control the amount of the protein
 CC delivered to the body. In addition, in some cases, it is possible
 CC to remove the transfected cells if there is no longer a need for
 CC the product. Human fibroblasts transfected with PXIT-39 secreted
 CC human GLP-1(7-37) and GLP-1(3-36) (see AAB82335-36).
 XX
 SQ Sequence 396 BP; 80 A; 112 C; 121 G; 83 T; 0 other;
 Query Match 98.3%; Score 91.4; DB 22; Length 396;
 Best Local Similarity 98.9%; Pred. No. 9.2e-23;
 Matches 92; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1 CATGCTGAAGGACCTTACCACTGATGATCTTATTGGAAAGCCAAAGTCGCAAG 60
 Db 286 CATGCTGAAGGACCTTACCACTGATGATCTTATTGGAAAGCCAAAGTCGCAAG 345
 QY 61 GAATTCATTGCTTGGCTGTGAAGGCCGAGCA 93
 Db 346 GAATTCATTGCTTGGCTGTGAAGGCCGAGCA 378
 Db
 RESULT 11
 ABQ58859
 ID ABQ58859 standard; cDNA: 626 BP.
 XX
 AC ABQ58859;
 XX
 DT 02-ANG-2002 (first entry)
 XX
 DE Human colon cancer related nucleotide sequence SEQ ID NO:2554.
 XX
 KM Human: colon cancer; cancer; tissue profiling; forensic; mapping;
 KM genetic analysis; diagnostic; antisense therapy; gene; ss.
 XX
 OS Homo sapiens.
 OS
 XX
 PN WO200229086-A2.
 XX
 PD 11-APR-2002.
 XX
 PF 02-OCT-2001; 2001WO-US30732.

XX 02-OCT-2000: 2000US-237211P.
PR (FARB) BAYER CORP.
XX
XX
PI Burgess C, Astle JH, Carroll E, Catino TJ, Dwivedi P, Molino GA;
PI Thilagalingam A, Lewis ME;
XX
XX WPI: 2002-426115/45.
DR
XX
PT New isolated nucleic acid that is differentially expressed in cancer
PT tissues useful for determining the presence of colon cancer in a cell
PT or tissue type, and in antisense therapy
XX
XX
PS Claim 1: Fig 1, 796pp; English.
XX
XX ABO56306 to ABO60787 represent isolated nucleic acids (I) differentially
CC expressed in cancer tissues. ABB78993 to ABB79004 represent proteins
CC encoded by the ABO60776 to ABO60787 nucleic acid sequences. (I) can be
CC used in antisense therapy. An antibody immunoreactive with a polypeptide
CC encoded by (I) is useful for detecting cancer in a patient sample, and
CC for detecting the presence or absence of a polynucleotide encoded by a
CC nucleic acid which hybridises to (I) in a cell. A probe/primer derived
CC from (I) can be used for determining the presence of a nucleic acid which
CC hybridises to (I), and for determining the phenotype of cells in a sample
CC of cells from a patient. (I) is useful for determining the presence of
CC colon cancer in a cell or tissue type, for determining the presence or
CC state of other type of cancer, in antisense therapy, to generate
CC macroarrays on a solid surface, to identify a chromosome on which the
CC corresponding gene resides, and in tissue profiling, forensics, genetic
CC analysis, mapping and diagnostic applications. (I) can be used to raise
CC antibodies, and to screen for peptide analogues and antagonists.
XX
XX
SQ Sequence 626 BP; 170 A; 134 C; 143 G; 159 T; 20 other:
XX
Query Match 94.6%; Score 88; DB 24; Length 626;
Best Local Similarity 100.0%; Pred. No. 1.7e-21;
Matches 88; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 1 CATGCTGAAGGAGACCTTACCATGATGATGATTTATTTGGAAGGCCAAGCTGCCAAG 60
DB 253 CATGCTGAAGGAGACCTTACCATGATGATGATTTATTTGGAAGGCCAAGCTGCCAAG 312
QY 61 GAATTCATTGCTTGGCTGGTGAAGGCC 88
DB 313 GAATTCATTGCTTGGCTGGTGAAGGCC 340
XX
RESULT 12
AAT75669
ID AAT75669 standard; DNA; 895 BP.
XX
AC AAT75669;
XX
DT 03-FEB-1998 (first entry)
XX
DE Rat preproglucagon cDNA.
XX
XX Rat preproglucagon cDNA.
XX
KW Recombinant protein; expression; secretory cell line; rat;
KW glucagon; peptide hormone; amidation; insulinoma; RIN; diabetes;
KW gene therapy; ss.
XX
OS Rattus sp.
XX
XX
FH Key Location/Qualifiers
FT CDS 52..594
FT /*tag= a
XX
XX W09726321-A2.
XX
XX 24-JUL-1997.
XX
XX 17-JAN-1997; 97WO-US00761.

XX 15-OCT-1996; 96US-0028427.
PR 19-JAN-1996; 96US-0589028.
XX
XX
PA (BETA-) BETAGENE INC.
PA (TEXA-) UNIV TEXAS SYSTEM.
XX
XX Clark SA, Halban PA, Kruse F, McGarry D, Newgard CB;
PI Normington KD, Quaade C, Thigpen AE;
XX
XX WPI: 1997-385326/35.
DR P-PSDB; AAMW22079.
DR
XX
PT Recombinant cell engineered to provide amylin to a mammal - useful
PT to treat e.g. angiogenesis, anorexia, obesity, hypertension,
PT osteoporosis etc.
XX
XX Example 10; Page 281-282; 336pp; English.
XX
XX This cDNA sequence includes a coding sequence for rat
CC preproglucagon (see AAMW22079). It was produced from pancreatic
CC cDNA by PCR amplification (see AAT75667-68), and has been ligated
CC into pGTA/7, generating pGTA7/r-Glucagon. Rat Insulinoma RIN
CC cell lines expressing preproglucagon demonstrated efficient
CC amidation of a secreted, processed polypeptide. The invention
CC provides methods for production of heterologous polypeptides using
CC recombinantly engineered cell lines. Also described are methods of
CC engineering cells for high level expression, methods of large-scale
CC heterologous protein production, and methods for treatment of
CC disease in vivo using viral delivery systems and recombinant cell
CC lines.
XX
XX
SQ Sequence 895 BP; 266 A; 211 C; 200 G; 218 T; 0 other:
XX
Query Match 89.7%; Score 83.4; DB 18; Length 895;
Best Local Similarity 93.5%; Pred. No. 8.2e-20;
Matches 87; Conservative 0; Mismatches 6; Indels 0; Gaps 0;
XX
QY 1 CATGCTGAAGGAGACCTTACCATGATGATGATTTATTTGGAAGGCCAAGCTGCCAAG 60
DB 343 CATGCTGAAGGAGACCTTACCATGATGATGATTTATTTGGAAGGCCAAGCTGCCAAG 402
QY 61 GAATTCATTGCTTGGCTGGTGAAGGCCGAGGA 93
DB 403 GAATTCATTGCTTGGCTGGTGAAGGCCGAGGA 435
XX
RESULT 13
AAC55762
ID AAC55762 standard; cDNA; 895 BP.
XX
AC AAC55762;
XX
DT 17-JAN-2001 (first entry)
XX
DE Rat preproglucagon encoding cDNA.
XX
XX Amylin; production; secretory cell; blood glucose level regulation;
KW diabetes mellitus; hypoglycaemia; osteoporosis; Paget's disease;
KW hypercalcaemia; obesity; hypertension; ss.
XX
OS Rattus sp.
XX
XX
PN US6110707-A.
XX
XX 29-AUG-2000.
XX
XX 17-JAN-1997; 97US-0784582.
XX
XX 11-OCT-1996; 96US-0028279.
PR 19-JAN-1996; 96US-0589028.
XX
XX (TEXA-) UNIV TEXAS SYSTEM.

PA (BETA-) BETAGENE INC.
 XX Newgard CB, Halban P, Normington KD, Thigpen AE, Quade C;
 PI Kruse F, McGarry D, Clark SA;
 XX
 DR WPI: 2000-586352/55.
 DR P-PSDB: AAB26773.
 XX
 PT Producing mammalian amylin, useful for regulating blood glucose and
 PT insulin levels, e.g. for treating diabetes mellitus or hypoglycemia, by
 PT employing recombinantly engineered secretory cell lines
 XX
 PS Example 10; Column 173-174; 136pp; English.
 XX
 CC This invention relates to a method for producing mammalian amylin. The
 CC method relies on the use of a recombinantly engineered secretory cell
 CC line. The method comprises:
 CC (a) providing a starting secretory cell that has a regulated secretory
 CC pathway;
 CC (b) introducing, into the starting secretory cell, an amylin-encoding
 CC gene operatively linked to a first promoter;
 CC (c) selecting a secretory cell of (b) that exhibits increased production
 CC of biologically active amylin as compared to the starting secretory
 CC cell; and (d) culturing the selected secretory cell.
 CC Amylin is an insulin modulator, and the method results in antidiabetic,
 CC hypotensive and osteoporotic activity. The amylin produced are useful
 CC for regulating blood glucose levels, as well as in modulating the
 CC circulating levels of insulin in a mammal. The amylin produced maybe
 CC used in treating diabetes mellitus, hypoglycemia, osteoporosis, Paget's
 CC disease, hypercalcaemia, obesity, hypertension, or any other disorder
 CC requiring insulin regulation. The invention includes cDNA and protein
 CC sequences (AAC55760 and AAB26771) representing human amylin. Sequences
 CC AAC5716-C55681 and AAB26765-B26777 are used in examples of the method of
 CC the invention for the production of mammalian amylin.
 CC
 XX
 SQ Sequence 895 BP; 266 A; 212 C; 199 G; 218 T; 0 other;
 XX
 Query Match 89.7%; Score 83.4; DB 21; Length 895;
 Best Local Similarity 93.5%; Pred. No. 8.2e-20;
 Matches 87; Conservative 0; Mismatches 6; Indels 0; Gaps 0;
 XX
 QY 1 CATGCTGAAGGACCTTTACCATGATGAAGTTCTATTGGAAGGCCAAGCTGCCAAG 60
 Db 343 CATGCTGAAGGACCTTTACCATGATGAAGTTCTATTGGAAGGCCAAGCTGCCAAG 402
 XX
 QY 61 GAATTCATTGCTTGGCTGGTGAAGGCCGAGGA 93
 Db 403 GAATTCATTGCTTGGCTGGTGAAGGCCGAGGA 435
 XX
 RESULT 14
 AA006255
 ID AA006255 standard; DNA: 1034 BP.
 XX
 AC AA006255;
 XX
 DT 29-JAN-1991 (first entry)
 XX
 DE Glucagon-like peptide, GLP-1 (7-37).
 XX
 KW Insulin; diabetes mellitus; insulinotropic; pancreatic beta cells.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT CDS 61..603
 FT /*tag= a
 FT sig_peptide 61..120
 FT /*tag= b
 XX
 XX W09011296-A.
 XX
 XX 04-OCT-1990.

XX
 PF 20-MAR-1989; 89WO-US01121.
 XX
 PR 20-MAR-1989; 89WO-US01121.
 XX
 PA (GEHO-) GEN HOSPITAL CORP.
 XX
 PI Habener JF;
 XX
 DR WPI: 1990-320226/42.
 XX
 PT New glucagon-like peptide (GLP-1) - having insulin
 PT formation-stimulating activity and useful in treating diabetes
 PT mellitus.
 XX
 PS Claim 6; Page 39; 52pp; English.
 XX
 CC The peptide has insulinotropic activity specifically for pancreatic
 CC beta cells. The peptide is derived from glucagon which, after
 CC synthesis is cleaved into three peptides: glucagon, glucagon-like
 CC peptide 1 (GLP-1) and GLP-2. GLP-1 has 37 AAs in its unprocessed
 CC form and is unable to mediate the induction of insulin biosynthesis.
 CC It is, however, naturally converted to a 31 Aa-long peptide having
 CC AAs 7-37 of GLP-1. Preferred derivs. have an H2 gp at the
 CC N-terminal and an OH, OM, or NR/R' gp at the C-terminal where M= a
 CC cation or lower alkyl gp., and R' = H or a lower alkyl gp.
 CC preps. contg. the peptide or derivs. are useful in the study of
 CC the pathogenesis of maturity onset of diabetes mellitus and also in
 CC therapy.
 CC See also AAR07398.
 CC
 XX
 SQ Sequence 1034 BP; 315 A; 238 C; 226 G; 255 T; 0 other;
 XX
 Query Match 89.7%; Score 83.4; DB 11; Length 1034;
 Best Local Similarity 93.5%; Pred. No. 8.6e-20;
 Matches 87; Conservative 0; Mismatches 6; Indels 0; Gaps 0;
 XX
 QY 1 CATGCTGAAGGACCTTTACCATGATGAAGTTCTATTGGAAGGCCAAGCTGCCAAG 60
 Db 352 CATGCTGAAGGACCTTTACCATGATGAAGTTCTATTGGAAGGCCAAGCTGCCAAG 411
 XX
 QY 61 GAATTCATTGCTTGGCTGGTGAAGGCCGAGGA 93
 Db 412 GAATTCATTGCTTGGCTGGTGAAGGCCGAGGA 444
 XX
 RESULT 15
 AAT73216
 ID AAT73216 standard; DNA: 1034 BP.
 XX
 AC AAT73216;
 XX
 DT 01-OCT-1997 (first entry)
 XX
 DE Rat prepro-glucagon DNA.
 XX
 KW Glucagon-like peptide-1(7-36); GLP-1; insulin secretagogue;
 KW insulinotropic hormone; type II diabetes mellitus; therapy; ss.
 XX
 OS Rattus sp.
 XX
 FH Key Location/Qualifiers
 FT CDS 61..603
 FT /*tag= a
 FT sig_peptide 61..120
 FT /*tag= b
 FT mat_peptide 121..600
 FT /*tag= c
 XX
 XX US5614492-A.
 XX
 XX 25-MAR-1997.

